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ABSTRACT 
The human body contains approximately the same number of bacterial cells as human 
cells1. These communities of bacteria are termed the human microbiome2. One human 
microbial niche that has been previously overlooked is the bladder, because it has been 
considered a sterile. Recent discoveries, however, have shown that the female urinary bladder 
contains a unique microbiome3-6 and microbiota7 with distinct differences in healthy and 
disease states3,6,8,9. Because of the sterile bladder dogma, the bladder was overlooked in the 
initial characterization of the human microbiome10,11 and bacteria have not been considered to 
be a factor in most urogynecological conditions. By understanding the microbiome/microbiota 
of the female urinary bladder, we could develop better diagnostics, identify more effective 
treatments, and improve the quality of life for millions of women.  
The female urinary bladder contains a microbial community (the FUM) that can be 
distinguished from vulvo-vaginal contamination4. However, the female bladder is separated 
from the vagina, one of the highest biomass niches of the body, by the urethra, which is only a 
few centimeters in length. Furthermore, recent studies have shown that the most common 
organisms in the bladder are Lactobacillus, Gardnerella, Streptococcus, Corynebacterium, and a 
diverse group of anaerobes3,6-8,12-14. These genera are also found commonly in the vagina15-18. 
Thus, the bladder and vagina contain the same genera and often the same species. These 
 
 
xxvii 
 
observations beg the question, are these two adjacent anatomical sites microbiologically 
interconnected?  
Indeed, there is growing evidence for an interconnected urinary and vaginal 
microbiome. Most reproductive age women have a vaginal microbiome dominated by 
Lactobacillus15; however, this community often shifts to a more diverse community following 
menopause18-20. No one has directly compared the FUM of pre- to post-menopausal women, 
but our group has seen that younger, healthier, women have a FUM more dominated by 
Lactobacillus compared to older women suffering from urgency urinary incontinence (UUI), 
which is overactive bladder (OAB) accompanied by incontinence3,6. Menopause is a risk factor 
for urinary disorders, such as UUI/OAB and urinary tract infection (UTI). Treatment with vaginal 
estrogen improves symptoms of OAB21-23 and decreases the incidence of recurrent UTIs in this 
population24-26. It is thought that estrogen’s effect on the vagina is mediated by a shift toward a 
Lactobacillus-dominant microbiome, thereby protecting the bladder against a future ascending 
infection by uropathogens, such as E. coli24-26. Because urine was considered sterile, however, 
no one has ever looked to see if estrogen treatment results in corresponding changes to the 
FUM.  
Here, we observed that, within an individual, the vaginal and bladder microbiomes can 
contain similar organisms in similar community structures and that the two sites are more 
similar following estrogen treatment. Additionally, isolates from unrelated individuals are highly 
similar, indicating that certain species can survive in both niches. Finally, isolates taken from 
 
 
xxviii 
 
each site within an individual can have highly similar core genomes indicating a recent common 
ancestor. Many isolates taken from both sites at a given time point have identical CRISPR 
arrays, indicating that the strains have been exposed to identical recent phage infections. The 
implication is that these isolates are members of the same lineage and/or that they have been 
exposed to the same environment. Taken together, these data suggest that microbial sharing 
between these two anatomical sites is possible.   
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CHAPTER I 
INTRODUCTION AND LITERATURE REVIEW 
Historical Perspectives 
A single human being has the same number of bacterial cells as human cells 1, making 
the human body as complex an ecosystem as the rainforests or coral reefs.  Some of these 
bacteria are implicated in a wide range of acute and chronic diseases, while others are 
associated with health. Microbial communities are being studied in the gut 27, mouth 28, skin 29, 
reproductive organs 15, lung 30, and even the eye 31.  It is becoming more apparent that the 
future of individualized medicine will be based not only on the human genome, but also the 
human microbiome. However, in the rush to characterize every microbiological niche, one 
niche was overlooked, the bladder. This is because, traditionally, the bladder was considered 
sterile.  
The origin of the “urine is sterile” dogma dates to the mid-1800s and the attempt to 
understand germ theory by the earliest bacteriologists, including Louis Pasteur, Joseph Lister, 
and William Roberts 32-34, who showed that a vial of urine in a sealed container did not turn 
cloudy, in contrast to a vial of urine exposed to air or with added tap water. The conclusion was 
that “…fresh and healthy urine is perfectly free from bacteria or other minute organisms” 33,34. 
In other words, the dogma originated in an era when microbiology was in its infancy and all 
bacteria were considered pathogens. Yet, the dogma persists. 
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In the 1950s, Edward Kass, an infectious disease physician at Harvard Medical School, 
established a threshold for infection to detect patients with pyelonephritis 35. After analyzing 
the urine of symptomatic versus asymptomatic women in pregnancy or with diabetes or a 
cystocele, Kass determined that 105 colony forming units per milliliter (CFU/ml) was the dividing 
line between contamination and infection in most populations 36. This protocol was highly 
effective at identifying the at-risk population, which allowed for pre-treatment and resulted in 
greatly improved outcomes. Due to its efficacy in this situation, the test was adopted as the 
standard method for all urine culture tests, despite several studies that have since provided 
evidence that the ≥105 CFU/mL threshold is insufficient to detect significant bladder infections 
37-41. Our group has provided evidence that this protocol is highly effective at growing E. coli, 
but not much else 42,43. Therefore, a clinical urine culture report that reads “no growth” 
generally means, “no E. coli.” Over time, as patients with symptoms had positive urine cultures 
and asymptomatic patients were deemed “no growth,” the collective medical dogma decided 
that the urine of asymptomatic individuals must be sterile. This dogma persists today, but there 
were those that argued against it. 
Some in the medical establishment decided that, in some cases, going against this 
dogma would improve patient outcomes. In the mid-1800s, Lister developed “aseptic 
catheterization,” which requires the use of a sterile catheter, gloves, and disinfection of the 
insertion site. All these precautions were put into place to theoretically prevent contamination 
of a sterile body site. Aseptic catheterization soon became standard of practice for urethral 
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catheterization 33. In the 1960s, however, the urologist Jack Lapides suggested that intermittent 
catheterization did not have to be a sterile procedure performed exclusively by medical 
professionals. He hypothesized that patients with spinal cord injuries, who could not void 
normally, would retain urine and predispose them to recurrent urinary tract infections (UTIs). 
However, if they could intermittently catheterize themselves, they would decrease their rate of 
UTIs, even if the catheterization procedure was not sterile. He taught a “clean catheterization” 
technique in which a patient, after washing his or her hands, would insert a catheter for 
voiding, and immediately remove the catheter. Clean intermittent catheterization not only 
improved continence, but decreased rates of UTI and pyelonephritis in these patients 33,44. 
Thus, Lapides’ research in neurogenic bladder patients challenged the idea that UTIs were 
caused by instrumentation, and demonstrated that UTIs could be prevented by, rather than be 
the result of, catheterization. 
Another individual who questioned the “sterile bladder” dogma was Rosalind Maskell, a 
director of a clinical microbiology laboratory in England. In the late 1970s, Maskell noticed that 
patients with UTI-like symptoms, but negative standard urine cultures, contained slow-growing 
organisms that required growth conditions than differed from those of the standard method 
45,46. She concluded that standard urine culture was insufficient to diagnose many urinary 
disorders, and she urged general practitioners to collaborate with microbiologists to 
understand urinary disorders 45,46. Her advice was repudiated or ignored 47,48. It was not until 
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culture-independent DNA-based methods were developed that we began to understand that 
the slow-growing organisms revealed by Maskell’s experiments were just the tip of the iceberg. 
The Human Microbiome Project 
Only recently has it become accepted that most human body sites are colonized with 
bacteria, and that the vast majority of those bacteria are non-pathogenic. The first large-scale 
mapping of the human microbiome, using culture-independent methods, was the Human 
Microbiome Project (HMP) in the early 2000s. Even though the number of bacterial cells is 
equal to the number of human cells in the body 1, medical studies have traditionally focused on 
disease-causing bacteria. Therefore, very little was known about the natural residents, or 
commensals, of the human body. Initially, the HMP characterized the gut microbiome because 
samples from this heavily colonized (high biomass) environment were easy to collect, contained 
significant diversity between individuals 49, and had previously been observed to have 
differences in health and disease states 50. Following the initial phase, the project was expanded 
to sample the microbiome of 300 “normal” individuals at a total of five body sites: GI tract, 
mouth, vagina, skin and nasal cavity, using culture-independent methods, such as metagenomic 
and amplicon sequencing 2. Because the bladder was considered sterile, it was not included in 
either of these two early stages of the HMP study.  
Sequencing Technologies 
Most current high throughput DNA sequencing technologies can only produce relatively 
short sequence reads (~250-400 base pairs). These technologies (often called Next Generation 
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Sequencing or NGS) use massively parallel sequencing approaches and thus generate large 
numbers of sequences, thereby allowing for extensive coverage of a single genome or great 
depth of a single genomic site. Sequencing strategies fall into two categories: whole genome 
and metagenome. Whole genome sequencing (WGS) starts with an isolated pure culture; in 
contrast, metagenomics is performed on patient samples with mixed populations, such as a 
swab, fecal material, or urine. Each sequencing strategy uses a different technique to turn the 
large amounts of short sequences generated by NGS into useful information (Figure 1).  
Each sequencing method finds a way to use short read lengths to provide the desired 
information. In WGS, the bacterial genome of a pure isolate is fragmented, sequenced in short 
reads, and bioinformatically put back together again. There are two methods for re-assembling 
a genome: align to a reference strain or assemble de novo (like assembling the puzzle with or 
without the original picture as a guide).  
The most common technique to classify bacteria within a population is 16S rRNA gene 
amplicon sequencing (Figure 1B). The 16S rRNA gene is used because it is highly conserved 
among bacteria 51-53, a direct result of its critical cellular role, but is lacking in other domains of 
life. This gene is used as a molecular chronometer, with some highly conserved stretches and 
some hypervariable regions that change slowly over evolutionary time. These hypervariable 
regions contain specific polymorphisms that can be used for measuring evolutionary distance 
and thus phylogenetic relatedness 3,53. When all 9 known hypervariable regions (V1-V9) of the 
16S rRNA gene are sequenced (about 1,500 bases), there are sufficient polymorphisms for  
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species level classification. However, due to the short sequence length of NGS, only one to 
three hypervariable region(s) are covered. Typically, this is only sufficient to achieve taxonomic 
classification to the family or genus level. 
Lastly, metagenomic sequencing tries to reassemble larger regions of bacterial genomes 
(called contigs) from a mixed community. Overlapping regions of genomes are pieced together 
much in the same way as de novo WGS. These larger contigs can then be used to classify the 
organism, thereby providing population data as well as a snapshot of the overall genetic 
content of a sample.  
 
Figure 1. Comparison of Sequencing Technologies.  
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Much of the HMP research has relied on 16S rRNA amplicon sequencing to obtain a first 
glimpse of bacteria present in different niches, at different times, and between different 
disease states. Amplicon sequencing relies on polymerase chain reaction (PCR) amplification. 
This method is not quantitative; different sequences amplify at different rates; thus, the 
number of sequence reads obtained from different samples cannot be directly compared. 
Instead, researchers compare these data qualitatively, looking at the relative amounts of 
classified bacteria, rather than the numbers of raw sequences. 
A relative abundance graph (Figure 2) depicts the bacterial community structure in 
terms of percentage of total classified reads (y-axis) per sample collected (x-axis). Each color 
represents a different taxonomic classification. These graphs can be shown at any taxonomic 
level (Phylum, Class, Order, Family, or Genus) or combination of levels. For example, the 
Figure 1. Continued 
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previously published data in Figure 2 represents catheterized urines sequenced from women 
with urgency urinary incontinence (UUI) or from continent controls 3. Some urine samples were 
dominated by the genera Lactobacillus (blue) or Gardnerella (red) or by the family 
Enterobacteriaceae (green). The V4 region does not contain enough variability to distinguish 
genera of the Enterobacteriaceae family, which includes Escherichia, Klebsiella, and Proteus. In 
other samples, no bacterium dominated; these were termed “diverse.” In this way, one graph 
can display large amounts of taxonomic information concerning the qualitative differences 
between samples. 
 
Visualizing the Results of HMP 
Due to complex community structures, and variation between individuals, the data 
obtained through HMP was more complex than initially expected and ecological analysis tools 
Figure 2. Urinary Microbiome Profile by Cohort Based on 16S rRNA Gene V4 Sequencing.  
Stacked bar plots depict the sequence abundances of the 15 most abundant genus- or family-level taxa in the 
UUI and non-UUI cohorts. Taxa were ranked according to mean abundance across all samples. The y axis 
represents the percentage of sequences for a particular bacterial taxa; the x axis represents the study 
participants separated by cohort. The family Enterobacteriaceae could not be classified to the genus level. The 
remainder of sequences was combined in the category labeled “Other.” 
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had to be adopted, including community typing, principle component analysis, and 
measurements for diversity. One qualitative approach was the identification of community 
types; they are called enterotypes in the gut 54, community state types (CSTs) in the vagina 15, 
and urotypes in urine 3. To form community types, bacterial profiles are clustered together 
based on taxonomic similarity (as measured by Bray Curtis dissimilarity). Each specific clade in 
the tree contains similar community structures that can be grouped into types (for example see 
Figure 8-9). Those clusters can then be tested for their statistical association between 
individuals and diseases. Using this method, different enterotypes were found to be correlated 
to one’s diet, obesity, or Crohn’s disease 54-56.  
The HMP resulted in a significant increase in our understanding of the vaginal 
microbiome. It is well documented that the vagina of reproductive age women is highly 
colonized with bacteria (high biomass) and that the vaginal microbiome tends to fall into one of 
five CSTs: CST 1, 2, 3, and 5 are dominated by different species of Lactobacillus (L. crispatus, L. 
gasseri, L. iners, and L. jensenii, respectively)15. In contrast, CST 4 is dominated by a diverse 
group of anaerobes, including Anaerococcus, Peptoniphilus, Prevotella, Streptococcus, 
Atopobium, and Gardnerella 15.  
While community typing provides qualitative information on the types of bacteria 
present, principal component analysis (PCA) or discriminant analysis of principal components 
(DAPC) provides information on which samples resemble each other and which are distinct. 
Both methods rely on simplifying complex data to emphasize variation and highlight 
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associations in the data. Once the principal components have been calculated, each sample is 
represented as a single dot on either a two or three-dimensional plot. Similar samples will 
cluster together, while samples with greater variation will be farther apart. PCA includes the 
total variation, within and between groups 57, while DAPC highlights the variations between 
groups while minimizing the within-group variation 58.  
Finally, another method to compare complex community data is by calculating diversity. 
There are two main types of diversity, richness (the total number of organisms in a niche) and 
evenness (the distribution of those organisms).  Certain diversity measurements calculate 
richness only (species accumulation curves, species/OTU counts, Chao1), or evenness only 
(Peilou), but many diversity measurements take both into account (inverse Simpson, Shannon, 
Fisher’s alpha). The benefit to these types of measurements is that they provide a numerical 
value that can be compared to patient demographics or symptom scores for statistical analysis.  
The Bladder is not Sterile 
 Because the bladder was not originally tested in the original HMP, the study of the 
bladder microbiome is years behind the study of other human niches. As Maskell 
demonstrated, bacteria had not been detected in the bladder primarily because culture 
techniques were developed for fast growing aerobic uropathogens, such as uropathogenic E. 
coli. However, the paradigm is changing 59.  
Two major hurdles prevented the bladder microbiome field from moving forward: first, 
bacteria from the bladder had to be distinguished from vulvo-vaginal contamination; second, 
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the detected DNA had to be shown to originate from live bacteria (as opposed to free floating 
DNA or dead bacteria). To overcome the first hurdle, researchers from the Loyola Urinary 
Education and Research Collaborative (LUEREC) used suprapubic aspiration (SPA) to sample 
bladder urine directly 4. SPA collection uses a needle to collect urine directly through the lower 
abdomen, thereby bypassing the vagina. The SPA urine in these patients was compared to 
voided urine, a vaginal swab, a skin swab of the insertion site, and urine collected by 
transurethral catheter (TUC). Using 16S amplicon sequencing, they found that SPA and TUC 
urine had similar profiles, and were distinct from voided urine, vaginal swabs or skin swabs. 
Since SPA sampling bypasses the vagina, they concluded that the bladder contained bacterial 
DNA and additionally that TUC samples the bladder environment with minimal vulvo-vaginal 
contamination 4. Since TUC is a more feasible urine collection method, currently it is the 
sampling method of choice 3,6,14,60.  
To overcome the second hurdle, LUEREC researchers cultivated organisms from 
catheterized samples. The previous study had provided taxonomic identification of the 16S 
sequences detected in the bladder 4, and most of the detected bacteria were cultivatable, but 
not under standard urine culture conditions. Therefore, an enhanced quantitative urine culture 
(EQUC) protocol was developed. Unlike the standard urine culture (SUC) protocol, which plates 
1 l urine on blood and MacConkey agars with incubation in air for 24 hours, EQUC plates a 
greater amount of urine (100 l) on a greater variety of media with incubation under diverse 
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atmospheric conditions for 48 hours (Table 1) 7. The result is that many organisms detected by 
sequencing can be cultured.  
Table 1. Comparison between standard urine culture (SUC) and the expanded quantitative 
urine culture (EQUC) methods. 
Protocol Volume Media Atmospheric 
Conditions 
Time 
Standard Urine 
Culture (SUC)a 
1 µL  
 
Blood Agar  
MacConkey Agar  
Aerobic 24 hrs 
35° 
Enhanced 
Quantitative Urine 
Culture (EQUC)b 
100 µL 
  
Blood Agar 
CNA Agar  
Anaerobic Blood Agar  
Aerobic 
CO2 
Anaerobic 
48 hrs 
35° 
aFor standard urine culture, we struck 0.001 ml of urine onto 5% sheep blood (BAP) and MacConkey agars (BD BBL prepared 
plated media), which were incubated aerobically at 35°C for 24 hours. Each separate morphological colony type was counted 
and identified in any amount. The detection level was 1,000 colony-forming units per milliliter (CFU/ml), represented by 1 
colony of growth on either plate. If no growth was observed, the culture was reported as “no growth,” indicating no growth of 
bacteria at the lowest dilution, i.e., 1:1,000.  
bFor EQUC, we struck 0.1 ml of urine onto BAP, chocolate and colistin, naladixic acid (CNA) agars (BD BBL prepared plated 
media), which were incubated in 5% CO2 at 35°C for 48 hours. A second BAP plate and CDC anaerobe 5% sheep blood agar 
plate (BD BBL prepared plated media) were also inoculated with 0.1 ml of urine and incubated under anaerobic conditions at 
35°C for 48 hours. The detection level was 10 CFU/ml, represented by 1 colony of growth on any of the plates. Each 
morphologically distinct colony type was isolated on a different plate of the same medium to prepare a pure culture for 
identification. 
 
These first two studies showed that there was bacterial DNA present in the bladder (a 
microbiome) and that the DNA represented live, cultivatable bacteria (the microbiota) 14,61. Our 
research also shows that standard culture misses the vast majority of known and emerging 
uropathogens (Appendix H) 43,62. Throughout our studies, we have compared the results 
obtained by sequencing and EQUC and found that they are comparable but not identical, and 
are thus complementary (Figures C.7, D.7, and I.S1, for a full description, see the write up in the 
addendum for Appendix D. 
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The Female Urinary Microbiota in Relation to Health and Disease 
 Now that we know the female urinary microbiota (FUM) exist, the next obvious issue is 
whether the resident bacteria contribute to health and disease. A few key things are known. 
First, we know a bit about the microbiota and acute infectious diseases, such as urinary tract 
infections (UTIs). For example, patients undergoing pelvic organ prolapse and urinary 
incontinence (POP-UI) surgery were assessed by standard urine culture (SUC) on the day of 
surgery. We found that 8% had urinary microbes detectable by standard culture, but a further 
46% had a microbiome undetected by SUC, but identified via sequencing. On the day of 
surgery, the SUC-positive population tended to be dominated by Enterobacteriaceae (E. coli 
and relatives); 32% of these patients went on to develop a post-operative UTI. By contrast, the 
SUC-negative group had only a 3.7% post-operative UTI rate; those with sequencing-detectable 
microbiomes tended to be dominated by Lactobacillus instead of Enterobacteriaceae 
(Appendix I)63,64. This not only illustrates the poor detection of SUC methods, but also suggests 
that some microbiome profiles may pre-dispose the bladder to infection. 
Second, in a study of women undergoing instrumentation, it was found that detection of 
urinary bacteria correlated with greater symptom resolution and a decreased incidence of post-
instrumentation UTIs (Appendix B)65, suggesting that certain FUM profiles can be beneficial or 
protective. Third, our group and others have detected the presence of bacteria in kidney 
stones, often pathogenic bacteria, suggesting that some kidney stones may have a bacterial 
component (Appendix F)66.  
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 Fourth, we detect trends that correlate the microbiome with certain age-related 
disorders, specifically incontinence, which are traditionally not thought to have a bacterial 
etiology. We have seen that the FUM are distinct between overactive bladder (OAB) patients 
and continent controls (Appendices B-D)3,6. Overall, OAB cohorts tend to be more diverse by 
culture and sequencing, and have fewer Lactobacillus-dominant profiles. This is reminiscent of 
the vaginal microbiome story. However, it is unclear how much of the difference in diversity is 
due to the age, and therefore hormone status, of the individual versus the disease; part of this 
thesis was designed to address this concern. Furthermore, the FUM profile (urotype), or 
phenotype, of a patient’s bladder microbiome could be predictive of anticholinergic 
(solifenacin) treatment response (Appendix D)6. A less diverse FUM (with a mean of 3 unique 
organisms by EQUC) correlates with robust treatment response, whereas a FUM with more 
diverse cultivatable organisms (a mean of 5 or more per individual) tend to require either an 
increased dose of, or does not respond to, the medication. Finally, the evenness, or distribution 
of the microbiota within an environment, is correlated with symptoms of urgency incontinence 
but not stress incontinence (Appendix E)67.  
 Finally, notice that most of the organisms discussed so far are not commonly described 
as uropathogens. In fact, the most common genus, Lactobacillus, is considered beneficial in 
many other areas of the body, including the gut and vagina. But, not all Lactobacilli are created 
equal; L. gasseri has been correlated with symptoms of OAB, while L. crispatus is associated 
with continent controls (Appendix C, Figure C.6)3. Additionally, our lab has found urinary 
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isolates of L. crispatus that can kill uropathogenic E. coli (UPEC) more efficiently than lactic acid 
and H2O2 alone42,68,69.  
All of these data provide evidence for correlation between the FUM and important 
factors associated with health, incontinence, and infection; however, it is still unclear if these 
correlations are simple biomarkers or play a pivotal role in the etiology, progression, or 
resolution of each disease state.  
Similarities Between the FUM and Vaginal Microbiome, and Relationship to Estrogen 
 As we have previously described, the “normal” bladder microbiome is usually 
dominated by Lactobacillus, with another group dominated by one or more strict or facultative 
anaerobes, such as Gardnerella, Streptococcus, or Staphylococcus (Figure 1) 3. A list of the 
typical organisms residing in the vagina would be nearly identical to this list 15. However, from 
our first study using supra-pubic aspirates, we know that the bladder microbiome is distinct 
from vulvo-vaginal contamination 4. This led me to ask, is there any microbial link between the 
bladder and vaginal communities? 
There is preliminary evidence that the bladder and vaginal microbiomes are 
interconnected, at least in part. We know that certain uropathogens, such as UPEC, can live in 
both sites 70-72. What we do not know is if commensal organisms move between niches or are 
specific to a given niche. We do know from preliminary data that the female bladder and 
vaginal microbiomes are very similar in composition. In fact, early results in characterizing the 
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FUM showed that Gardnerella vaginalis, previously only known to live in the vagina, was also 
common in the bladder. 
Following menopause, the vaginal environment becomes more diverse and shifts away 
from Lactobacillus-dominant community state types 18. Following a few years of hormone 
replacement therapy (HRT), the vaginal microbiome has been shown to shift back toward low 
diversity and Lactobacillus dominance 73,74. As stated previously, we know that women with 
OAB tend to have increased microbial diversity 3,6. However, OAB is a disease associated with 
age and, in each of our previous studies, the OAB cohort was significantly older than the 
continent controls 3,6. Therefore, it is possible that the differences in diversity are associated 
with age and hormone status, rather than disease severity.  
Due to the close proximity of the urethra and the vaginal introitus, the clinical dogma 
connects urinary health to the health of the vagina. In the vagina, estrogen increases glycogen 
storage in vaginal epithelial tissues. Lactobacillus species use the glycogen as a carbon source. 
The result of glycogen metabolism by Lactobacillus is lactic acid, which decreases vaginal pH 
75,76. The resulting decrease in pH protects against colonization from acid-susceptible 
organisms, such as UPEC 77,78. This estrogen-to-pH relationship, and the production of H2O2 by 
Lactobacillus, is thought to be crucial for protection against UTIs. The reasoning is that the 
invading uropathogen first infects the vaginal tract and then ascends to the urinary tract 26,79. 
However, because the bladder was considered sterile, no one has determined if bladder 
bacteria also play a protective role.   
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This estrogen-to-urogenital-microbiome dogma is backed up by clinical observations. 
For example, treatment with topically applied HRT can improve symptoms of OAB 21-23, and 
decrease the incidence of recurrent UTIs 24-26. There is compelling evidence to suggest that 
vaginal estrogen therapy relieves symptoms of OAB, including urgency and frequency, in 
postmenopausal women 21,22,80-82. Estrogen therapy is currently used as a first line treatment 
for OAB in Europe. However, the data are inconclusive for treatment of UUI, a subset of OAB 
that includes all the symptoms of OAB with the addition of incontinence. For the treatment of 
UTIs, one study found that topical estrogen is as effective in decreasing recurrent UTI rates as 
the oral antibiotic nitrofurantoin macrocrystal (nitro), decreasing the rate of UTIs from 5.9 
episodes per year without estrogen to 0.5 episodes per year with vaginal estrogen cream 
compared to 0.8 episodes per year with nitro 24. The current dogma is that a healthy vagina will 
result in a healthy bladder, primarily due to the protective effects of Lactobacillus species in the 
vagina.  
It is known that estrogen affects the bladder epithelium. In studies of estrogen-deficient 
mouse models (ovariectomized vs sham-treated mice), decreases in uroepithelial cell-cell 
adhesion and in antimicrobial peptide (AMP) production were observed 83. When 
ovariectomized mice were infected with UPEC, bacterial levels increased, but both bacterial cell 
invasion and uroepithelium proliferation decreased compared to the sham-treated mice 72,83. 
All of these changes were reversed with HRT 72. This suggests that estrogen has a strong effect 
on the physiology of the bladder epithelium.  
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The bladder can be simply divided into two main parts, the trigone and the dome. The 
dome is the main body of the bladder and consists of all cells that lie above the ureter 
openings. It is the main portion of the bladder that expand and contracts during filling and 
voiding and therefore is very closely associated with the detrusor muscle. In contrast, the 
trigone is the triangular portion of tissue at the base of the bladder; two points of the triangle 
are the entry points of the ureters while the third is the urethra. Unlike the dome, the trigone 
does not stretch during filling84. The trigone and dome have been shown to have distinct gene 
expression profiles84, and originate from different embryonic lineages 85.  In fact, the trigone is 
derived from the same embryonic progenitors as the vagina 85, and the anterior vaginal wall 
and the trigone lie parallel to each other and are separated by the vesicovaginal space. Because 
of this shared lineage, about 50% of women contain “squamouse epithelium of the vaginal 
type” in the trigone area 86. Additionally, estradiol has been shown to bind to estrogen 
receptors in the trigone area but not in tissues collected from the dome of the bladder 85. 
Considering these numerous connections between the bladder and vaginal epithelium, it is 
reasonable to expect that estrogen treatment will have an effect on the bladder epithelium and 
this could result in alterations to the resident microbiota. 
Difficulties in Studying Niche Interconnectivity 
Are the bladder and vaginal microbiomes connected? On the surface, this is a simple 
question, but it encompasses some complex ideas and presents some unique challenges. Asking 
if the two niches are microbiologically linked suggests that the organisms have the ability to 
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migrate from one niche to another. However, other than known uropathogens (such as UPEC, 
Pseudomonas, Proteus, and some Klebsiella strains), none of the commensal organisms contain 
known motility genes. A rotation student under my supervision, Cesar Montelongo-Hernandez, 
tested at least one isolate of each species we isolated from bladders and, except for those listed 
above, none demonstrated motility in vitro (Appendix L). Some may be motile, but they would 
have to be novel methods of motility encoded by novel motility genes. Another way of 
detecting migration is to inoculate women or animal models and measure the progression from 
one niche to another over time. However, doing this in human subjects is infeasible and, due to 
differences in reproductive anatomy, it is not possible to do this in rats or mice 87,88. Therefore, 
we are left with finding specific examples where this does or does not happen in a community 
or within an individual.  
More than simple technical hurdles, the question of niche linkage is muddied by the 
intricacies of environmental and evolutionary factors. Each niche contains distinct 
environmental factors. For example, the vaginal environment contains a high biomass of 
bacteria living in complex vaginal communities 89. The environment can be highly acidic and 
there is an abundance of carbon sources both in the biofilm and on the epithelium. In 
comparison, the bladder environment seems much harsher. Unfortunately, due to the sterile 
bladder hypothesis, very few studies have been done regarding the bladder environment a 
bacterium may experience.  We have measured the biomass and found that is is substantially 
lower than the vaginal tract. Furthermore, the bacteria either would have to attach to the cell 
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wall, or live inside epithelial vesicles 90,91 to resist the shear forces of voiding. A few recent 
studies have shown that immune cells are present and the bladder epithelium creates 
antimicrobial peptides, but very little else is known about the bladder immune system 92-94. 
From preliminary data in our lab looking at E. coli and Lactobacillus grown in artificial urine, we 
know that urine is a poor culture medium and contains high amounts of urea, amines, and salt 
and no amount of sugar 95. Instead, we hypothesize that the bacteria are adhering to the 
uroepithelium.   
The bladder epithelium is coated in a quasi-crystalline array of uroplakin proteins that 
act as a permeability boundary 96. Three of the four uroplakin subtypes are highly glycosylated 
96. In addition to the uroplakins, there is a negatively charged glycosaminoglycan (GAG) layer 
that prevents bacterial attachment by E. coli 97-99. E. coli bypasses this charge deterrent by 
specifically binding to mannose on uroplakin subunit (UPIa) using type 1 pilus with a FimH tip92. 
We have been unsuccessful in finding FimH homologues in our bladder isolate genomes. This 
suggests that the attachment and adherence methods for UPEC are distinct from the 
commensal bacteria. If bladder bacteria have a novel method for attachment to the urothelium, 
then it would suggest that they are feeding off of the GAG layer and/or glycosylated uroplakins, 
but more research is needed to test this hypothesis. 
All of this illustrates that each niche represents a dramatically different environment 
with unique evolutionary pressures. But it is not unheard of for bacteria to survive, or even 
thrive, in different environments. Many bacteria can survive in our gut and in the soil and there 
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are many examples of opportunistic pathogens where the human is not the traditional host. 
However, in these cases there is usually something (nutrient sources, moisture, or an 
intracellular environment) that is similar between the two niches. If the same strains of bacteria 
can live in both the bladder and vaginal niches, we do not yet fully know which environmental 
factors are in common or even may be required for transmission between sites.  
Additionally, we have the issue of how we measure similarity between strains. Bacterial 
genomes contain two general sets of genes: the core and accessory genomes. The core genome 
contains all the genes required for life, such as genes involved in transcription, translation, 
replication, metabolism and DNA repair. A comparison of these genes will provide an accurate 
representation of the phylogenetic relatedness between organisms (see description of the 40-
core gene and average nucleotide identity approaches in Methods). In theory, the accessory 
genome contains genes that can be horizontally transferred, such as pathogenicity islands, and 
genes for attachment and adherence factors, and antibiotic resistance. We think of this set of 
genes as those required for adaptation to a given environment.  If two bacteria have the same 
core genome, we can conclude that they had a recent common ancestor, but without looking at 
the accessory genome, we cannot conclude anything about how identical they really are, or 
how adapted they are to a given niche. 
If we find two bacteria with the same core genomes, we have to accept the possibility of 
parallel evolution. If, at some point in the history of the host, say around birth, both niches 
were simultaneously inoculated with an ancestor strain, then that strain may have adapted to a 
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given niche but never left. We would have two strains of the same species, one that has 
evolved to inhabit the bladder and another that has evolved to inhabit the vagina. But, they are 
entirely different bacterial strains that have not migrated from one niche to another.  
Therefore, if we find evidence of the same species with the same core genome, we can 
only conclude that the strains share a recent common ancestor. To conclude that actual 
microbial sharing is happening, we would either need to observe the migration in real time, 
which is currently infeasible, or we would need to make an assessment of the accessory 
genome, which is a far more subtle and complex question. Even selecting target genes for 
analysis is not straightforward. As stated previously, with a few exceptions, we do not know 
enough about the bacterial physiology required in the bladder to make an educated guess 
about which genes would be adaptive in that niche. Additionally, due to the stochastic nature 
of horizontal gene transfer (HGT), we would have no way of knowing if a gene was recently 
added or removed from a genome. That, in combination with issues of overall genome 
coverage in first-pass whole genome sequencing (WGS), we do not know if the absence of a 
gene in a genome is indicative of the absence of the gene in that strain or our inability to 
sequence it. Therefore, is seems unlikely that we can currently use a single gene as a marker for 
the relatedness of any two accessory genomes. However, due to recent discoveries, we can ask 
about the recent environmental history of a given strain using CRISPR arrays.  
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Using CRISPR Arrays to Assess Recent Phage Exposure History 
The CRISPR/Cas system is a bacterial adaptive immune system. If a bacterium 
successfully evades infection by a bacteriophage (phage), it will store a short segment of the 
phage’s DNA in its own genome to better defend itself against future infections by that 
particular phage. The clustered regularly interspaced short palindromic repeats (CRISPR) array 
holds these short segments of phage DNA separated (spaced) by known repeated sequences 
100. If that bacterium encounters the same phage again, the Cas proteins will use these short 
segments to identify the foreign phage DNA and destroy it. The discovery of these systems has 
led to many exciting breakthroughs in genetic engineering, but here we will use the system as a 
chronologic log, because these arrays represent the recent infection history of a clonal 
population. In these arrays, the most recent viral infection is represented by the first insert 
followed by consecutively older inserts from older infections 101,102; thus, the array represents 
the clone’s recent exposure history.  
Phages are an integral part of any bacterial ecosystem and can represent one of the 
main evolutionary pressures within a bacterial community 103,104. Phages have been previously 
detected in bladder samples 105-107. Bladder phages have been detected as prophages in 
bacterial genomes (Appendix G) 105,107, and phages themselves also have been isolated from 
bladder cultures 106.  Therefore, we can conclude that phages do exist in the bladder 
environment, and if CRISPRs are present in our isolates they would reflect the recent history of 
phage infection for that bacterial population 108,109. If the arrays were identical between strains 
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isolated from each site, it would suggest that the bacteria were infected with the same phage. 
Achieving this result would occur for one of two reasons: either the isolates were completely 
identical strains, or the isolates were exposed to the same history of phages, which suggests 
exposure to identical environments. Either way, if the arrays were similar then it would be 
further evidence of a shared environmental history, which suggests movement between sites.  
Summary 
Because urine has long been considered sterile, the microbial content of the bladder 
(the FUM) has been ignored, and its role in female health has been overlooked. Previous work 
has shown us that the bladder and vagina contain similar organisms, and there seems to be an 
increase in diversity in both sites following menopause. We know that estrogen improves 
urinary symptoms and alters the community structure, by decreasing diversity, of the 
microbiome in the vagina. But, we do not know if there is a corresponding change in the 
bladder. In this thesis, I will show evidence that both niches respond similarly to estrogen and 
there are at least some organisms that are identical in both niches at any given time point.  
Many studies assume that the measured UTI, or OAB, symptom improvement is due 
entirely to a change in the vaginal community. However, none of these studies have directly 
captured the shift in vaginal community throughout treatment. Instead, these studies have 
compared hypoestrogenic women to pre-menopausal or women who have been on HRT for 5-
10 years. To my knowledge, this is the first study designed to capture the shift in community 
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structure in real time. Seeing the community response to an environmental shift will provide 
insight into the stability of the urogenital microbiome and could influence future treatments. 
In the next few chapters, I will present data that suggests that the bladder and vaginal 
microbiomes are connected, at least in part. Following the methods (Chapter II), we will look at 
global differences and similarities between the niches (Chapter III). The subsequent chapters 
will provide evidence that the community structures of the two sites are similar and respond 
similarly to change (Chapter IV), and that the species within a given individual at a given point in 
time are highly similar (Chapter V), suggesting that some bacteria may be able to reside in both 
niches.  
Due to the constraints discussed previously, we are unable to conclusively determine if 
the two microbiomes are interconnected, but this thesis is an important first step in 
understanding how these two microbiomes interact with each other. Additionally, the data 
presented here should be the foundation for new lines of research into niche boundaries, host-
bacterial interactions in the bladder, and bacterial adaptation. It is my hope that this work will 
lead to new discoveries and new therapies to treat lower urinary symptoms, such as therapies 
that treat the whole urogynecological microbiome, modulation of the bladder and vaginal 
communities prior to pharmacologic intervention, or inform the use of urogenital probiotics. 
We anticipate that this work will lead to better understanding and exciting new therapies for 
post-menopausal women that incorporate, modulate, or maintain the bacteria already present 
in an individual’s bladder.  
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CHAPTER II 
MATERIALS AND METHODS 
Clinical Study Design (The Estrogen Study) 
The data in this thesis were collected from a study designed by myself and Susanne 
Taege, a urogynecology fellow in LUEREC. We designed this study with three goals in mind. (1) 
To collect both vaginal and bladder samples at the same point in time from individual women. 
(2) To measure the changes of both the bladder and vaginal microbiomes in response to 
estrogen treatment. (3) Finally, Susanne wanted to assess microbiome changes as they 
correlate to estrogen’s treatment response for women with OAB.  
This protocol describes the samples collected for analysis in this study. In addition, I will 
describe additional samples that were collected for future work, but were not analyzed in this 
current study; these include perineal swabs, voided urine, and enriched culture samples. Dr. 
Taege and other members of the Loyola Urogynecology department were responsible for all 
recruitment and initial sample collection. This work would not have been possible without their 
help. The following is a description of the study design (and may include some language written 
by Dr. Taege).  
Study Design Overview. 
We recruited 40 post-menopausal women with OAB symptoms. Their menopausal 
status was determined clinically. From these recruits, we collected vaginal swabs, perineal 
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swabs, voided urine and urine obtained by transurethral catheter (TUC). The FUM was 
characterized using the EQUC protocol prior to, and following 12-weeks of, topical estrogen 
treatment. In this way, each patient acted as her own control, setting the baseline prior to 
estrogen treatment. This thesis will present data from the patients currently recruited (40 
baseline patients, 21 who have returned for their 12-week assessment). But, the study will 
continue until at least 40 patients have returned for their 12-week assessment. We will wait to 
run the symptoms and demographic assessments until at least 40 patients have returned for 
their 12-week visit. Therefore, this thesis will not include any symptom-to-microbiome 
assessment. This study was funded by the Urogynecology department research fund, an 
Investigator Initiated grant from the Kimberly Clark Corporation, two NIH awards to Drs. Wolfe 
and Brubaker (R01 DK104718 and R56DK104718) and the Arthur J Schmitt Dissertation 
Fellowship. 
Patient Recruitment and Clinical Assessment. 
Recruitment. Women were recruited from the ambulatory urogynecology clinic at 
Loyola University Medical Center. Informed research consent was obtained prior to enrollment. 
Visit 1 (Baseline). Following approved research consent, catheterized urine was 
collected for culturing by the EQUC and SUC protocols (see below). Voided urine, a perineal 
swab, and a vaginal swab also were collected for characterization by a modified EQUC protocol 
(see below). Perineal swabs and voided urine will not be the focus of work, but were collected 
and cultured so that the data is available for future analyses. Patients were asked to complete 
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the validated questionnaire, OAB-q, to measure OAB-related symptoms and quality of life 110. 
Demographic information and clinical characteristics were collected, including age, parity, 
medical illness, previous hysterectomy, previous incontinence surgery, and BMI.  
Physical examination was completed, including evaluation for pelvic organ prolapse with 
the POP-q examination. Patients were counseled on the evidence-based first-line options for 
the treatment of OAB, including behavioral modifications, physical therapy, and vaginal 
estrogen per standard practice in the Female Pelvic Medicine and Reproductive Surgery 
(FPMRS) clinic. All consented patients were prescribed vaginal estrogen, estradiol cream, 
provided by the study, based on the clinical practice guidelines for vaginal estrogen use in 
postmenopausal women with urogynecological complaints developed by the Society of 
Gynecological Surgeons Systematic Review Group 111. Patients received compensation with a 
parking voucher. 
Visit 2 (12-weeks). Patients were scheduled to return at twelve weeks from the initial 
visit for follow up. At this time, we collected catheterized and voided urine, a perineal swab, 
and a vaginal swab, and patients repeated the OAB-q to reassess symptoms and quality of life 
measures. Again, all samples were characterized using culture protocols. After collection of 
these samples, the patient’s participation in the study was concluded and the patient was 
compensated with a second parking voucher.  
30 
 
 
 
At this point, based on the patients’ response to treatment, continued clinical treatment 
may have included, but was not limited to, vaginal estrogen. The symptoms of OAB were 
reassessed and the next step in treatment was based on the clinician’s usual practice. 
Inclusion Criteria. Inclusion criteria were as follows: (1) Women who present with 
symptoms of OAB, defined as a condition characterized by urgency, with or without urgency 
incontinence, usually with frequency and nocturia in the absence of obvious pathology or 
infection, and who do not answer often to any of questions 10 – 15 on the Medical, 
Epidemiological and Social Aspects of Aging (MESA) urinary incontinence questionnaire 112,113, 
which the FPMRS clinicians give to all new patients as standard practice. (2) Postmenopausal by 
history, defined as twelve months or greater since last menstrual period or over the age of 55 if 
they have had a previous hysterectomy. (3) English language skills sufficient to complete 
questionnaires. (4) Clinical indication for vaginal estrogen use. (5) Patients not currently 
receiving vaginal estrogen therapy. 
Exclusion Criteria. The following were the exclusion criteria: (1) Patients currently on 
systemic hormone replacement therapy (HRT) or who have been on HRT within the past three 
months. (2) Patients with current diagnosis or history of estrogen dependent malignancies 
(breast, endometrial). (3) Contraindication or allergy to local estrogen therapy. (4) Insufficient 
language skills to complete study questionnaires. (5) Women with active, SUC-positive urinary 
tract infection at baseline assessment. (6) Patients who have received antibiotics within the 
past two weeks. (7) Advanced pelvic organ prolapse greater than stage II based on the pelvic 
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organ prolapse quantitation system (POP-q). (8) Patient not willing to use vaginal estrogen 
preparation. (9) Patients currently on anticholinergic medication or who have received 
anticholinergic medication within the past three months. (10) Patients wishing to start 
anticholinergic medication at the initial encounter. 
Clinical Sample Collection. 
The human subjects-certified research team personnel immediately de-identified each 
sample, removing all protected health information prior to submission to any non-clinical 
investigators. Only the study ID was available to individuals who were not involved in human 
subject recruitment, retention and oversight. All urine was collected in sterile blue cap-
collection cups (BD #364956), from which a dipstick test was preformed and a grey-top culture 
tube was filled, as is standard practice for clinical microbiology samples. The grey-top culture 
tubes contain a preservative that inhibits bacterial growth, but does not kill the cells. The grey-
top tubes were left at room temperature, and the blue-top collection cups were refrigerated, 
until processed by the Wolfe lab, in order to prevent bacterial growth. The swabs were 
collected using the BD ESwab (BD#220245), which contains a swab resting in 1 ml of bacterial 
preservative. Following collection, swabs were kept at room temperature. All samples were 
sent to the Wolfe lab for EQUC assessment within 4 hours of collection. 
Power Calculation and Sample Size.  
In a previous study, we observed that UUI women had a more diverse FUM than non-UI 
controls 3,6. The species accumulation analysis (Figure 3 also in Figure D.2) illustrates the 
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number of unique species cultured and identified (using EQUC) with each new patient sampled. 
When the curve plateaus, it indicates that the community is fully sampled and few, if any, new 
species will be identified. Therefore, it also measures the overall diversity of the population by 
total number of unique species isolated. The UUI group isolated 80 unique species at baseline 
and the control cohort isolated 36 unique species. Therefore, the species isolated from UUI was 
far more diverse than the species isolated from controls. There was statistical difference in the 
median number of isolates collected from each individual in each cohort [M=3 (IQR: 1-7) versus 
M=1 (IQR: 1-2), p<0.001].  
 
Figure 3. UUI Communities are More Diverse than Non-UI Controls. A rarefaction analysis 
showing the number of unique species of bacteria isolated (using EQUC) with each new 
patient sampled. More unique species of bacteria are seen in the UUI population than the 
non-UI controls. The median number of unique species isolated from each individual in the 
group is shown in the inset table. 
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Based on the difference in diversity between UUI and non-UI controls (Figure 3), we 
determined that a sample size of 40 will give us sufficient power (0.816), using the Wilcoxon-
Mann-Whitney test, to detect the difference between patients whose urinary microbiomes 
retain high diversity compared to those that change to a low diversity state. 
Laboratory Assessments 
Sample Processing and Storage. 
All samples were processed for culturing and stored for sequencing within 24 hours of 
arriving at the Wolfe Lab.  
Standard Urine Culture (SUC) and Enhanced Urinary Quantitative Culture (EQUC) Procedures. 
All cultures were set up in a biosafety cabinet in a room designated biosafety level 2 
(BSL2) to prevent cross contamination from any other bacterial experiments happening in the 
department.  
Grey-topped catheter samples were processed with SUC and EQUC methods. For SUC, 1 
µl of urine was inoculated onto 5% sheep blood agar plate (BAP) and MacConkey agar plate, 
incubated aerobically at 35°C for 24 h. EQUC uses 100 µl of urine grown under 5 conditions: (1) 
blood agar plates (BAP) in CO2 for 48 h, (2) chocolate agar (CHOC) in CO2 for 48 h, (3) colistin 
and nalidixic acid (CNA) agar in CO2 for 48 h, (4) CDC anaerobe BAP in an anaerobic jar for 48 h, 
and (5) BAP in aerobic conditions for 48 h (Table 2).  If the SUC contained high growth at 24 h, 
we read all the other plates, for all samples, for that patient and did not incubate the extra 24 
h. 
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We initially used the exact same protocol for all samples (urine obtained by TUC or void 
and vaginal and perineal swabs), but after the 10th patient, it was evident that the extra work 
involved for the high biomass samples (voided and both swabs) was not resulting in more data, 
and the overgrowth could be masking lower biomass organisms. We thus decided to pare down 
both the number of plates and the overall volume plated for the high biomass samples. From 
patient 11-30 we used 10 µl of urine onto BAP, CNA, and Anaerobic BAP (ABPA) for voided 
urine and both swabs. Between the 30th and 34th individual, we stopped culturing the perineal 
swab and voided urine all together. Then, we decided to continue culturing, but to bring the 
volume down even further to 1 µl for the perineal swab and voided urine (Table 2).  
Each morphologically distinct colony type in both SUC and EQUC procedures was 
counted and isolated onto a fresh plate of the same media to be used for identification with 
Matrix-Assisted Laser Desorption/Ionization Time-of Flight (MALDI-TOF) mass spectroscopy. 
This is the protocol used for our recent publications 3,6,7. Following identification, we stored 
down isolates in our collection in CryoSavr tubes pre-filled with Brucella medium and glycerol 
(Hardy Diagnostics CS100BNB) at -80°C. Because we use multiple media and conditions, we 
often isolate the same species on each plate. Initially, we isolated 2 clonal species from each 
species represented from each niche. However, this was a large burden on our storage facility, 
and following the 10th patient, we stepped down to 1 representative of each species from each 
niche. A full list of isolates collected can be found in the culture master list for this project 
(Share drive: WolfeLab\LUREC\EST_Effect of Estrogen_KTW_ST).  
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Table 2. Culture conditions for all Estrogen study samples  
 BAP in 
O2 for 
24 hr 
MAC in 
O2 for 
24 hr 
BAP in 
CO2 for 
48 hr 
CHOC in 
CO2 for 
48 hr 
CNA in 
CO2 for 
48 hr 
Anaerobic 
BAP for 
48hr 
BAP in 
O2 for 
48 hr 
Catheterized Urine        
     Standard 1 µl 1 µl      
     EQUC   100 µl 100 µl 100 µl 100 µl 100 µl 
Vaginal Swab*   10 µl  10 µl 10 µl  
Perineal Swab**   1 µl  1 µl 1 µl  
Voided Urine**   1 µl  1 µl 1 µl  
* Initially, all samples were process the same way as the catheterized samples. But, it was discovered that the high 
biomass made the plates difficult to read. Therefore, the volume plated and the overall conditions were decreased 
to what is shown in the chart. This decrease happened at the 11th baseline patient. See the first tab of the culture 
worksheet in the share drive for complete time point information: N:\WolfeLab\LUREC\EST_Effect of 
Estrogen_KTW_ST 
** The perineal swabs and voided urine underwent the same decrease in volume as the vaginal swabs, but it was 
still too much to cultivate. We decided to decrease the volume even further to 1 µl at patient EST35. 
 
Enriched Culture Samples. 
 In addition to storing down pure isolates, we also stored down “enriched culture” 
samples. There is the possibility of multiple strains of the same species residing in a given niche, 
and, by selecting only a single isolate, we could be missing species diversity in each location. 
Since storing down multiple isolates was cost-prohibitive, we decided to store down the entire 
plate instead. Following selection of individual morphologies for MALDI ID, the plates were 
swabbed and stored down in PBS with 10% AssayAssure. This storage media should be 
sufficient for preservation of the nucleic acids for future metagenomic sequencing, but not for 
future culturing. These samples represent the total biomass cultured on a given plate and are 
therefore not indicative of the overall biomass of the original sample. These samples were 
collected through the 16th baseline sample and the first 6 12-week samples.  
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16S rRNA Gene Sequencing. 
All samples were also stored down for future 16S rRNA gene sequencing. Each sample 
was processed under a PCR hood to prevent environmental contamination. Each sample was 
given a unique Wolfe-lab identifier, and overall volume was recorded. The general color, 
turbidity, and pH were recorded for all urine samples. 10% of the nucleic acid preservative 
AssayAssure (Sierra Molecular) was added to each sample prior to storage at -80°C. 
 The bladder is a low biomass niche and low biomass samples. High throughput 
sequencing technologies are susceptible to sequencing contamination 114. Therefore, we use a 
wide variety of methods (such as soaking materials in bleach, wiping down in DNA away, 
working in a PCR hood, and using extraction controls); however, there is still a low level of 
contamination. We estimate that the detection threshold for sequencing is about 1000 CFU/ml, 
and in our previous studies, only 50% of our populations could be characterized by sequencing 
3,6. On the other hand, EQUC can characterize 80-90% of our populations. For this reason, we 
chose to focus our analyses on EQUC data and not report our 16S analysis. See the methods 
sections for Appendices B-E and I-J for more information on the methods used for 16S 
sequencing.  
Statistical Analysis 
Statistical analyses of the EQUC data were performed using SAS software version 9.3. 
Wilcoxon rank sum tests were used to compare the median abundance for the most abundant 
sequenced taxa, and all cultured genera between groups. The frequency of detected genera 
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was compared between groups, using either Pearson chi-square or Fisher’s exact tests, 
depending on assumption validity. Each individual functioned as her own control, with the 
initial visit establishing the baseline profiles prior to estrogen treatment. Because we were not 
finished recruiting and collecting samples for this study, no analyses were be done comparing 
patient demographics and microbiome profiles. Appendix M lists scripts for creating relative 
abundance graphs, calculating diversity and generating dendrograms in RStudio 115. 
Microbial Whole Genome Sequencing and Analysis 
As described in the study design, we obtained paired urine samples and vaginal swabs 
from the same individual, isolated microbes from these paired samples, and used MALDI-TOF 
mass spec to obtain a putative classification to the species level. Additionally, a subset of 
organisms underwent whole genome sequencing to allow for more in-depth genome analysis. 
Here, I asked whether the same species were observed in both niches. The analysis was 
performed at multiple levels, species presence/absence, phylogeny, and genetic markers. I also 
performed genomic comparisons on samples collected from other studies, as well as publicly 
available genomes. I will go over each of these protocols in turn.  
Whole Genome Sequencing Library Prep.  
The isolates were grown in their preferred medium and pelleted. Genomic DNA was 
extracted from pelleted cells using a phenol-chloroform method 116. Genome sequencing was 
either completed at the Loyola core genomics facility, or with our collaborators in the Lawley 
lab at the Wellcome Trust Genome Campus in Hintxon, UK. Samples processed at either facility 
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underwent similar processing. The Illumina Nextera kit was used for whole genome library 
preparation, as described previously 117. Briefly, the bacterial genome was fragmented and 
tagged using a transposon system, and then Illumina sequencing adapters and dual-index 
barcodes were added to allow for multiplexing of samples. The resulting fragments were 
purified and size-selected using AMPure XP beads, quantified via the Qubit 2.0 Fluorometer and 
Agilent Bioanalyzer, normalized to equimolar concentrations, and sequenced using the Illumina 
MiSeq System. The concentrations of DNA loaded onto the sequencer were calculated based on 
the expected genome size and average fragment size to achieve 10X coverage of the entire 
genome. Quality control and de-multiplexing of sequence data was done with onboard MiSeq 
Control software and MiSeq Reporter (current version: 2.1.43).  
Whole Genome Assembly and Annotation.  
Annotated assemblies were produced using a pipeline, as previously described118. For 
each sample, sequence reads were used to create multiple assemblies using VelvetOptimiser 
v2.2.5119 and Velvet v1.2120. An assembly improvement step was applied to the assembly with 
the best N50 and contigs were scaffolded using SSPACE121 with sequence gaps filled using 
GapFiller122. Automated annotation was performed using PROKKA v1.11123 and genus-specific 
databases from RefSeq124. Genomes of good quality and with at least 10X coverage were used 
for further processing.  
If the genomes required modification, reprocessing was completed in Catherine 
Putonti’s lab. Briefly, the reads were run through Sickle for QC 125, using the standard 
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parameters from the Wellcome Trust and a minimum length of 100bp. The sequences were 
assembled with SPAdes 126, using the paired-end reads that passed QC and the non-paired end 
(singletons) reads. Five assemblies were generated (k=33,55,77,99, and 127) in the ‘only-
assembler’ option, and the best was chosen, as defined by Spades. The genomes were then 
filtered based on < 10x coverage and < 1kb per contigs. The genomes were filtered again, this 
time for low level contamination; if contamination was detected, the genomes were run 
through peasant (written by the Putonti lab) to exclude the lower abundance samples. These 
genomes were then annotated using the above specifications.  
To confirm accurate speciation, the 16S rRNA gene was extracted from the annotation 
using Artemis 127, and BLASTed for classficiation 128. For phylogenetic analysis of the 16S gene, 
alignments were generated using MAFFT 129 in Galaxy 62, RAxML 130 for bootstrapping and tree 
generation, and Figtree and ITOL 131 for tree visualization.  
Phylogenetic Analysis 
In bacteriology, phylogeny is typically determined using the 16S gene rRNA gene, which 
can be used to classify a bacterium to the species level. If the gene contains 100% to 97% 
similarity to a known species, then it is considered a member of that species. If the gene 
contains more variability, then it is a different species in the same genus. However, this method 
is not without flaws. It relies on measurement of just one gene, and does not account for 
potential horizontal gene transfer of the 16S gene. There are well-documented cases where the 
16S gene shares similarity between two divergent species (see Appendix K) 132,133. Therefore, 
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for our purposes, the 16S gene is insufficient to differentiate between related organisms. To 
overcome this, phylogenetic relatedness was measured in three separate ways: using the 16S 
gene, using 40 marker genes 134,135, and using average nucleotide identify (ANI) 136-138.  
Compared to the 16S-based phylogeny, fetchMG extracts 40 universal phylogenetic 
marker genes 135,139. Like the 16S gene, all 40 genes are essential for life; the genes include 
ribosomal subunits, tRNA synthetases, and RNA polymerases. All of the genes have been 
experimentally shown to have low horizontal transfer rates 134, and even if one gene was 
transferred, transfer of all 40 would be highly unlikely. In this way, we increase the 
informational input and, therefore, the accuracy of each tree.  
In contrast to choosing specific marker genes, with fetchMG, we can compare the 
average nucleotide identity (ANI) between the core, or conserved, genomes of any two given 
strains. The more closely related the two strains are, the greater amount of the genome is 
compared in this method. ANI is the bioinformatics equivalent of DNA-DNA hybridization 
(DDH), albeit more accurate, and as such is the new gold standard for speciation 136. Previously, 
the definition of a new species included at least one diagnostic phenotypic trait and a DDH 
score of at least 70% or less 140. This 70% DDH cutoff is equivalent to about 95% sequence 
identity 138. Although there is debate about the exact cutoff threshold, 96% seems to be the 
consensus. For our purposes, we will use ANI to detect overall phylogenetic differences 
between isolates from the vagina or bladder, and to determine whether or not these shifts 
correspond to distinct strains.  
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Synteny. 
 The percent identity obtained from ANI can give a relatively clear picture of the 
similarity between strains, but it is not complete. It is possible that the same genes are present, 
but in a completely different genomic orientation. To assess genomic orientation one must 
measure synteny, or the conservation of the order of genes within a genome. Using the Artemis 
Comparison Tool (ACT), we can visualize blocks of synteny between two genomes 141. 
Additionally, we can visualize the regions that might be present in one genome but missing 
from another. 
 To measure synteny, the contigs must be ordered; otherwise, very little information can 
be gained about the arrangement and position of the contigs. Ordering is normally done by 
aligning to a reference genome; but, as you can see in Chapter V, the reference genomes do not 
usually share a high percent identity with the bladder and vaginal isolates. Instead, I chose to 
use one of the isolate genomes as the reference and ordered the contigs from the other isolate 
genomes to it, using ABACAS 142. ABACAS uses MUMmer143 to align contigs and automatically 
generates a comparison file for use in ACT.  
Identifying Genomic Signatures (CDS, Domain, and CRISPR analysis). 
The previous methods all rely on phylogenetic differences between strains; however, it  
is very likely that a distinct niche-associated signature would not reside in the core genome but 
rather in the accessory genome. Therefore, we used other bioinformatics tools to analyze 
differences between the genomes. To explore differences in the genomes across a wide range 
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of individuals, my collaborators, Nitin Kumar and Sam Forster, post-doctoral fellows in the 
Lawley lab at the Sanger Institute, performed both the CDS and domain analyses. To explore 
differences in the genomes from isolates within a given individual, my collaborators in the 
Putonti lab at the Loyola Lake Shore Campus performed CRISPR array analysis.  
CDS analysis. The genome annotation process relies on comparisons to known genes. In 
a newly assembled genome, an open reading frame, otherwise known as a coding sequence 
(CDS), is identified based on the regions lacking stop codons. The CDSs are then compared to 
known genes. If the database contains a homologous gene, the CDS is given that label; if it does 
not, the CDS is labeled a “hypothetical protein” or “genes of unknown function”. CDS 
characterization can be a flawed process; ideally, each gene’s identification should be 
experimentally verified, but this is not practical. Using this method, however, many of the 
common genes involved in metabolism and basic cell functions can be easily and accurately 
identified.   
Domain analysis. Alternatively, many genes have no known function or are mis-
identified by either the annotation or COG method, but we can fairly accurately predict 
domains of proteins through homology. NCBI’s conserved domain database (CDD) is a 
repository of multiple sequence alignments representing conserved protein domains 144. The 
whole genome of each isolate was compared to the CDD database, resulting in a list of protein 
domains for each isolate. Using principle component analysis (PCA) and Discriminant Analysis of 
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Principal Components (DAPC), we determined how closely related each isolate’s list of domains 
is to any other list, and color-coded based on isolation location. 
CRISPR array analysis. CRISPR arrays were identified using CRISPRFinder 145. The 
upstream and downstream regions were identified using an in-house python script to read in 
the CRISPRFinder results (specifically the locations of the arrays in the contigs) and then parse 
out the upstream and downstream regions from the contigs. 
 
 
 
 
44 
 
 
CHAPTER III 
A GLOBAL COMPARISON OF BLADDER GENOMES TO GUT AND VAGINAL GENOMES 
Overview of the Study Design 
  This study was conducted in collaboration with Sam Forster and Nitin Kumar in Trevor 
Lawley’s lab at the Wellcome Trust Genome Campus in Hinxton, UK. To represent the total 
phylogenetic diversity of bacteria cultivated from the bladder, we chose to sequence 130 
isolates from species that spanned that diversity. Most of the sequenced isolates were 
collected as part of the Astellas study (Appendix C-D)3,6 or the maternal urinary microbiome 
study (Appendix I); two E. coli genomes from a UTI study were also included (one from a 
symptomatic woman and one from an asymptomatic woman, Appendix H)43. These genomes 
were compared to a collection of 209 previously published gut isolates collected by the Lawley 
lab 146, and a set of 135 publicly available vaginal isolates (the majority of which were collected 
by the HMP) 11. Vaginal genomes were only included if the metadata specifically stated that the 
isolate had been collected from the vagina (i.e., “urogenital” isolates were excluded). A full list 
of the isolates used are listed in Appendix N. As described below, these data show that bladder 
isolates closely resembles the vaginal isolates, but not the gut.  
Phylogenetic Diversity of Cultivated Bladder Isolates 
Figure 4 shows the complete phylogenetic diversity of the cultivatable organisms from 
bladder. Uropathogenic species, such as E. coli, Klebsiella, and Proteus (members of the 
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Enterobacteriaceae family) represent only a small portion of the phylogenetic diversity in the 
bladder. In fact, other than these uropathogens, very few Proteobacteria or even Gram-
negative organisms were found. Instead, the largest amount of phylogenetic diversity was 
found from the Gram-positive phyla Firmicutes and Actinomycetes, particularly the families 
Streptococcaceae, Lactobacilliaceae, and Bifidobacteriaceae.  
Comparison Functional Markers from the Bladder, Vaginal, and Gut Isolates 
The bladder isolate genomes were then compared to a dataset of vaginal and gut 
isolates cultivated from unrelated individuals. Using the genome annotations, we compared the 
CDSs that fall within given functional categories. Specifically, we used the categories 
standardized by the clusters of orthologous groups (COGs), which are organized into specific 
functional groups. We compared the number of genes in each COG functional group between 
niches (Figure 5A). Unsurprisingly, being the most diverse niche, the gut dataset contained the 
most CDS in every category measured. In contrast, the vaginal microbiome consistently had the 
fewest number of CDS in each category. The bladder dataset was consistently intermediate, 
having the same number of CDS with the gut in categories such as secondary metabolites 
biosynthesis, transport and catabolism, and lipid transport and metabolism. But, it had 
numbers of CDS similar to the vaginal dataset for categories such as cell cycle control, cell 
division, and chromosome partitioning. In all other categories, the bladder dataset fell directly 
between the vaginal and gut datasets (Figure 5A). We are currently unclear as to the underlying 
reason for this pattern. 
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Figure 4. Phylogenetic Diversity of Bladder Bacteria. A representation of the full diversity 
that can be isolated using the EQUC method from catheterized urine samples. A maximum 
likelihood tree generated from the 40 marker genes extracted from each genome. Each 
branch is labelled with the species ID from PROKKA. The inner grey ring labels the three 
phyla (Firmicutes, Actinobacteria and Proteobacteria) and the colored outer ring indicates 
the Families represented in the tree. 
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Figure 5. Comparing Functional Differences Between the Bladder, Vagina, and Gut Bacterial 
Genomes. Bladder data is represented in red, vaginal in yellow and gut in blue. (A) COG 
analysis of isolates and (B) DAPC of conserved proteins domains from the genomes collected 
from the three sites.  
A.  
B.  
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Table 3. A List of Isolates that are 100% identical Between the Bladder and Vagina by DAPC.  
Species Bladder Isolate ID Vaginal Isolate ID ANI (%) 
Actinomyces neuii 
16933_8#44 MJR8396A 98.4712 
16933_8#7 MJR8396A 98.5629 
Alloscardovia omnicolens 17957_1#65 CMW7705A 96.9694 
Lactobacillus crispatus 16933_8#46 Vmc8 98.4497 
Lactobacillus gasseri 16933_8#18 202-4 99.543 
Lactobacillus jensenii 
16933_8#49 SJ-7A-US 99.8639 
17957_1#81 SJ-7A-US 98.6966 
Lactobacillus rhamnosus 17957_1#9 51B 96.8512 
Streptococcus mitis 16933_8#21 CMW7705B 97.4119 
Two vaginal species (A. neuii and L. jensenii) pair with two separate bladder isolates 
 
Many genes have no known function or are misidentified by either the annotation or 
COG method, but homologous protein domains can be accurately predicted. The predicted 
protein domains were extracted from each genome and the list of these domains were  
compared between all isolates using DAPC, which highlights the variations between groups, 
minimizing the within-group variation (See Domain Analysis in the Methods chapter) 58. 
Isolates with similar domain profiles clustered together. When the DAPC plot was color-
coded based on niche, we observed strong clustering based on isolate collection location 
(Figure 5B). The cluster of gut isolates was distinct from the bladder and vaginal isolates, 
indicating that the bladder and gut isolates do not contain similar protein domains. This lack of 
overlap suggests that these niches share few of the same strains, and little to no functionality. 
About half of the bladder and vaginal isolates overlapped (Figure 5B), indicating that many 
isolates in each group contain the same functionality and suggesting that at least half of the 
organisms could be shared between sites. This result also indicates that a few isolates may be 
unique to each niche and do not share functionality.  
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Upon further analysis, we identified a few isolates whose protein domains are 100% 
identical between the bladder and vagina (Table 3). This is remarkable, considering that these 
isolates were collected at different times from completely unrelated individuals. This identity 
indicates that a bacterium isolated from the bladder of one individual has the same protein 
domain profile as a bacterium isolated from the vagina of another. In the case of two species 
(A. neuii and L. jensenii), one vaginal isolate matched two different bladder isolates (Table 3). 
From these observations, we infer that certain organisms with certain functionality profiles are 
highly conserved across humans. We further compared the isolates that had 100% identical 
protein domains using ANI (Table 3). Even though the protein domains profiles were 100% 
identical, ANI showed a decent amount of variability, from 96.8% to 99.5% identical. This 
difference suggests that even if the strains have the same function there might still be distinct 
differences between bladder and vaginal isolates.  
Summary 
These data highlight the possibility of an interconnected urogenital microbiome, one 
that has specific and highly conserved functions between humans. If we could understand the 
function of these shared genes, we would be closer to understanding how a single bacterium 
could live in both anatomical sites. These data also suggest that a bladder-specific genetic 
signature may be identifiable. About half of the isolates in both the bladder and vagina were 
distinct from each other and did not share a corresponding functional profile in the other site. 
Even if some bacteria can live in both sites, this observation suggests that some do not. 
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Additionally, even the bacteria whose protein domain profiles were 100% similar still showed 
some variation in their overall genomes. These data may be the first snapshot of niche-specific 
functionality and species. 
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CHAPTER IV 
THE BLADDER AND VAGINAL COMMUNITY STRUCTURE SHIFTS FOLLOWING 
ESTROGEN TREAMENT 
Overview 
 It is documented that estrogen therapy changes the vaginal community 26. Although 
some studies have assessed the vaginal microbiome of post-menopausal women 18,147, no one 
has tried to capture that change in real time, and no one has explored the effect of estrogen on 
the FUM. Here, we measured the bladder and vaginal communities at baseline and following 12 
weeks of estrogen treatment.  
This document describes 40 patients, 21 of whom have returned for their 12-week 
sample. Due to sample collection errors, we lack CFU/ml data for patients EST01 at the 12-week 
time point, and EST08 at the baseline time point. However, we do have the isolate identifiers 
for these samples; therefore, they are included in the species accumulation analysis, but must 
be excluded from the relative abundance and diversity measurements. Thus, there is a slight 
discrepancy between sample counts for each specific analysis.  
As stated in the study design, we collected perineal swabs and voided urine at each time 
point for each individual. Data for these samples will be presented for overall biomass and 
diversity, but will be excluded from figures and discussions of community structure data.  
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In this chapter,  I will present data describing the changes in the bladder and vaginal 
microbiomes prior to and following treatment. Based on previous literature, we expect the 
vaginal microbiome to decrease in diversity and transition to a more Lactobacillus-dominant 
community, without changing the overall biomass of the niche. If the two sites are 
microbiologically linked, and the FUM responds to estrogen, we would expect to see a 
corresponding decrease in diversity and shift towards Lactobacillus-dominance in the bladder. 
The data do follow these patterns, suggesting that estrogen modifies both pelvic floor niches.  
Diversity Decreases in the Bladder and Vagina Following Treatment 
Species accumulation curves were used to assess the diversity of the bladder and 
vaginal environments (Figure 6A), as well as the perineal and voided urine samples (Figure 6B). 
The curves represent the increase in the detection of additional unique species identified from 
each newly sampled participant in each group. Once the curve reaches a plateau, it represents 
the near total number of unique species found in that population. In Figure 6A, the vaginal 
samples are in red and the bladder samples are in blue; both darker lines represent baseline 
samples, while lighter lines represent 12-weeks samples. The baseline vaginal community was 
much more diverse than the baseline bladder community (80 versus 53 isolates, respectively). 
At 12-weeks, this relationship was retained. From baseline to 12 weeks, the vaginal microbiome 
showed a decrease in overall diversity, with a difference of 63 versus 55 isolates, at the same 
recruitment level (21 patients). A corresponding decrease was observed in the bladder 
community, with a difference of 40 versus 32 at the same recruitment level (21 patients) 
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(Figure 6A). In contrast, neither the perineum (yellow lines) nor the voided urine (green lines) 
had measurable decreases in diversity using this method (Figure 6B). 
In addition to species accumulation curves, different alpha diversity measurements 
were calculated, including measurements of richness (total number of species found) and 
evenness (the distribution of those species (Figure 6C and D). The vaginal community showed 
significant differences in 2 of the 5 diversity measurements, Fisher’s alpha (p=0.01) and overall 
richness (0.01). In contrast, the Peilou measurement of evenness alone is not significant 
(p=0.98) (Figure 6C). Since Fisher’s alpha takes into account both richness and evenness, but 
Peilou measures evenness, we can infer that the change in diversity is primarily driven by 
richness. This conclusion is supported by the species accumulation curve, which inherently 
measures species richness. Thus, both methods of measuring diversity demonstrate that the 
overall number of unique species is decreasing in the vagina following estrogen treatment. For 
the bladder environment, we saw no decrease in any diversity measurement (Figure 6C), a 
result that does not match those from the species accumulation curves.  
Voided urine showed an intermediate phenotype. By species accumulation curves, there 
was no decrease in diversity at 12 weeks (compare light to dark green lines in Figure 6B). This 
indicates that voided urine is not a measurement of the bladder environment, nor is it a 
combination of bladder and vaginal flora. Potentially, it also contains perineal, or skin, flora. 
However, empirical measurements of richness and evenness, specifically Fisher’s alpha (p= 
0.03), do show a significant decrease (Figure 6C). Additionally, the voided urine boxplots show a 
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trend toward a decrease in richness, but it was not significant (p=0.13) (Figure 6C). Overall, this 
suggests that voided urine is a poor measure of total diversity in the bladder. 
  
B.  
A.  
Figure 6. Diversity of the Microbiota in the Bladder, Vagina, Perineum and Voided Urine. 
Species accumulation curves are shown for (A) the bladder (blue) and vaginal swabs (red) and 
(B) perineal swabs (brown )and voided urine (green). (C) Five diversity measurements were 
calculated for each niche at each time point and compared with boxplots: Shannon diversity, 
inverse Simpson, overall richness, Peilou, and Fisher’s alpha diversity. 
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Figure 6. Continued… 
C.   
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The biomass does not change in response to estrogen. 
To check that the change in diversity was not associated with an overall decrease in 
biomass, we measured the total biomass of each sample at baseline and 12 weeks by total 
CFU/ml (Figure 7). The bladder had a consistently lower biomass than the vagina, the perineum, 
and voided urines, which all had similar biomasses. When the biomass at baseline was 
compared to the biomass at 12 weeks, the bladder and vagina did not show significant 
           Figure 7. The Biomass of Each Site Sampled at Baseline and 12-weeks. 
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differences (p=0.21 and 0.82, respectively). This illustrates that any decrease in diversity we 
measured in the bladder and vagina could not be due to overall decrease in biomass. However, 
the voided urine sample showed a significant elevation in total CFU/ml by 12 weeks (p=0.029), 
and the perineum seemed to show a trend towards increased biomass, suggesting that voided 
urine may be more closely related to the perineum because both sites did not stay stable, but 
increased following treatment.  
The Frequency of Lactobacillus-Dominant Profiles Increases by 12-weeks 
Measurements of diversity show that a change had occurred, but do not provide any 
information as to the identity of the organisms involved. We hypothesized that there would be 
an increase in the frequency of Lactobacillus dominance. To measure this, we compared the 
relative abundance of all baseline and 12-week samples from the vagina and bladder (Figure 8-
9). Each bar represents the percent of total CFU/ml with each color representing a different 
genus. For example, Lactobacillus is in blue. For each baseline and 12-week dataset, Bray-Curtis 
dissimilarity was used to group similar environments together. Relative abundance graphs were 
aligned with the corresponding Bray-Curtis derived dendrogram, and the Lactobacillus-
dominant clades were identified (Figure 8A-B, Figure 9A-B). Using this method, we measured 
the frequency of Lactobacillus-dominant profiles at baseline and 12 weeks for both the vagina 
(Figure 8) and bladder (Figure 9). To determine how many of the 12-week samples started as 
Lactobacillus, the 12-week samples were aligned with their corresponding baseline samples 
58 
 
 
 
(Figure 8C, Figure 9C). The frequency of Lactobacillus profiles for the vagina and bladder are 
listed in Figure 8D and 9D, respectively. 
In the vagina, 21% (8/38) of the patients were dominated by Lactobacillus at baseline, 
and that shifted to 40% (8/20) by 12 weeks (Figure 8A-B). This is a modest increase, but an 
increase nonetheless. Of the 8 12-week Lactobacillus-dominant profiles, 4 of them (50%) 
started out as Lactobacillus-dominant and 4 shifted towards Lactobacillus-dominance (Figure 
8C).  
In the bladder, 10% (4/38) of the patients were dominated by Lactobacillus at baseline. 
By 12 weeks, that number had increased to 35% (7/20). Of the 7 12-week Lactobacillus 
dominant samples, 2 of them started out as Lactobacillus-dominant, and 5 (71%) shifted 
towards Lactobacillus-dominant from a different background (Figure 9).  
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Figure 8. Vaginal Microbiome Community Structures at Baseline and 12 weeks. The vaginal 
microbiota from each individual are organized by the Bray-Curtis dendrogram groupings at 
(A) baseline and (B) 12-weeks. From the relative abundance graphs, it is clear that each 
group has a population of people dominated by Lactobacillus (blue). To determine which 
individuals shifted from a non-Lacto to a Lacto profile, (C) the 12-week samples were aligned 
with their corresponding baseline samples. Due to mix-ups in sample collection EST08 did 
not have CFU/ml for the baseline sample but did in the 12-week. Therefore, the last bar in 
figure C does not have a corresponding baseline sample. (D) The overall frequency of 
Lactobacillus-dominant individuals is listed. 
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The Bladder and Vaginal Microbiota Profiles are More Similar by 12-weeks 
 Thus far, we have looked at the patient data as a population, but not at an individual 
level. Here, we analyzed how an individual’s microbiota profile shifts following 12 weeks of 
Figure 9. Bladder Microbiome Community Structures at Baseline and 12 weeks. As in 
Figure 6, each baseline and 12-week sample is not only organized by dendrogram (A-B), 
but the 12-weeks are also aligned with their corresponding baseline sample (C). Due to 
mix-ups in sample collection EST08 did not have CFU/ml for the baseline sample but did 
in the 12-week. Therefore, the last bar in figure C does not have a corresponding 
baseline sample. The overall frequency of Lacto-dominant individuals is listed (D). 
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treatment. Of the 20 that have returned for their 12-week visit, two patient’s samples lacked 
CFU/ml count data, EST01_12w, and EST08_B; therefore, these two samples have been 
excluded from this analysis. Overall, eighteen patients have EQUC data from both the baseline 
and 12-week time points. In Figure 10, each patient was represented by two sets of bars, the 
first being the urine and vaginal swab collected at baseline (top graph), and the second being 
the same two samples collected at 12 weeks (bottom graph). We assessed each paired set for 
similarity between niches by grouping them into one of 4 classes: sets where both niches 
contain the same organisms in similar proportions are called Class 1; sets where each niche had 
the same dominant organism, but in different proportions are Class 2; sets where one sample 
was below the level of detection (culture negative, black bars) are Class 3; and sets where both 
niches were distinctly different are Class 4 (Table 4). I considered sample sets to be similar if 
they fell into Class 1 and Class 2, and different if they fell into Class 3 or 4.  
At baseline, 28% (5/18) of patients were Class 1 and another 28% (5/18) were Class 2. 
Also, at baseline, 11% (2/18) were Class 3, and 33% (6/18) were Class 4. Overall, at baseline, 
56% (10/18) were considered mostly similar, and 44% were considered mostly different (Figure 
10, Table 4). In contrast, at 12 weeks, 44% (8/18) were Class 1 and 33% are Class 2, while 17% 
were Class 3 and 6% are Class 4. Therefore, by 12 weeks, 77% of the samples were considered 
mostly similar (Figure 10, Table 4). 
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Table 4: Calculating the Number of Similar Bladder and Vaginal Pairs at Each Time Point. Sets 
where both niches contain the same organisms in similar proportions are called Class 1. Sets 
where each niche has the same dominant organism, but in different proportions are Class 2. 
Sets where one sample is below the level of detection (culture negative, black bars) are Class 3. 
And sets where both niches are distinctly different are Class 4. 
 Considered mostly similar Considered mostly different 
Timepoint Class 1 – Very similar Class 2 – Somewhat 
similar 
Class 3 –culture 
negative 
Class 4 – Not similar 
Baseline EST05, EST25, EST28, 
EST29, EST30 
EST06, EST10, 
EST16, EST19, EST20 
EST04, EST23 EST03, EST09, EST11, 
EST12, EST14, EST15,  
Proportion 28% (5/18) 28% (5/18) 11% (2/18) 33% (6/18) 
 56% (10/18) 44% (8/18) 
12 weeks EST05, EST06, EST09, 
EST14, EST15, EST16, 
EST28, EST30 
EST04, EST10, 
EST11, EST12, 
EST19, EST20, 
EST23, EST25, 
EST29 
EST03 
Proportion 44% (8/18) 33% (6/18) 17% (3/18) 6% (1/18) 
 77% (14/18) 22% (4/18) 
Figure 10. Comparison of the Bladder and Vaginal EQUC Data of Each Individual Prior to 
and Following 12-weeks of Estrogen Treatment. (A) The relative abundance graphs for 
each patient’s paired bladder and vaginal sample at baseline (top graph) and 12 weeks 
(bottom graph). Each bar represents the percent of total classified CFUs/ml with the color 
representing a unique species. 
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Summary 
We observed a decrease in overall diversity from baseline to 12 weeks; specifically, a 
decrease in species richness. Additionally, there was a modest increase in the frequency of 
Lactobacillus-dominant profiles by 12 weeks, but neither shift was as dramatic as anticipated. 
We think this can be attributed to the short treatment interval. All other studies measuring the 
effects of estrogen on the vaginal microbiome relied on cross-sectional analysis of cohorts of 
women. Some compared cohorts of premenopausal and post-menopausal women 18. Other 
studies compared groups of estrogen-negative postmenopausal women to those that have 
been on HRT for months or even years 73; the average for one was 13 years 74. Therefore, no 
other previous study has tracked the vaginal microbiome of individual women throughout 
estrogen therapy. This leads us to hypothesize that the changes we observe during this 12-week 
window are intermediate community states, and in some women the bacterial communities 
have not yet fully adapted to the estrogen-rich environment. We would anticipate that if we 
were to follow up with these patients at 6 months to 1 year, we might see the majority of them 
have become Lactobacillus-dominant.  
We also demonstrated that a given individual’s bladder and vaginal microbiome are 
more similar to each other following estrogen treatment. At baseline, about half of the women 
(56%) had similarities between the bladder and vaginal communities, but by 12 weeks that 
number increased to three-quarters of the population (77%) (Table 4). It is even more striking 
when you consider that the bladder and vagina have dramatically different biomasses (Figure 
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7), but by 12 weeks, 44% of the populations contained similar organisms in similar proportions 
(Table 4). This indicates that even with the discrepancies in environment, similar community 
structures can exist in each niche. This could be explained in one of two ways, either (1) the 
communities are responding similarly yet independently to treatment, or (2) that the two sites 
are microbially linked and therefore a change to one niche results in a corresponding change to 
the other. In the first scenario, we would expect the estrogen to affect the vaginal and bladder 
epithlium, increasing glycogen storage in both locations, which would in turn enrich for the 
same species of bacteria in each site. Alternatively, estrogen could be having an effect on 
glycogen storage only in the vagina or the bladder but because the microbiomes are shared, 
there is a community shift in both niches. Realistically, the truth may be somewhere in between 
and estrogen results in changes in both epithelial layers, but because the bacteria are shared, 
the community profiles change similarly in both niches.  
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CHAPTER V 
NICHE SPECIFICITY BETWEEN THE VAGINAL AND BLADDER MICROBIOMES 
WITHIN AN INDIVIDUAL 
Overview  
Our next goal was to determine if the bladder and vaginal communities within a given 
individual at a given point in time were similar or distinct. We already know from Chapter III 
that at least some organisms in the bladder and vagina are similar, even when they are isolated 
from different individuals. Additionally, from Chapter IV we know that the bladder and vaginal 
community structures look more similar to each other following estrogen treatment. However, 
it is possible that, even in individuals with similar dominant organisms in both sites, there can 
be less abundant bacteria that are distinct to a given niche. Hence, we wanted to know if there 
were any common species that were commonly isolated and specific to a given niche. We 
recognize that even if the same species are detected in each site, there could be distinct strains 
with distinct functionality. Therefore, we also went on to sequence specific species sets and 
compare each genome for strain similarity.  
Bladder and Vaginal Species Accounting within Individuals 
First, we asked if there is a species or set of species that is commonly and exclusively 
found in one site. I analyzed all the culture data from each individual in the estrogen study. 
Table 5 displays the number of species found in the bladder and vagina of 40 baseline samples 
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and 21 12-week samples. Columns 2 and 3 list the total number of isolates found in the bladder 
and vagina, respectively. It is important to note that the vagina consistently has a greater 
number of unique species when compared to the bladder, which correlates with the greater 
richness measured in Figure 4. The 4th column lists the number of species that are the same 
between both niches for a given individual. This number is consistently greater than half, or 
equal to, the number of isolates found in the bladder. Therefore, the species found in the 
bladder are usually also found in the vagina of the same individual.  
Next, I asked if there were any species that were unique to a given site. If a species was 
found in a single site of that individual, I checked to see if that species had ever been found in 
the other site in any other individual in this study, or in any previous study. Only 3 species were 
unique to the bladder of a given individual, i.e. never isolated in that patient’s vagina (Table 4, 
column 5). Of the 3, one of those species was isolated in the perineum of that individual at that 
time point, one had been isolated from vaginal swabs in a separate study (dark highlight), and 
the final one has only been isolated once. Therefore, using this method, we have not identified 
a subset of species that are frequently and uniquely isolated from the bladder.  
Of the species isolated from the vagina and not from the bladder, the majority has been 
isolated from a catheterized sample in previous studies (dark highlight). That leaves 5 
organisms that seem to be unique to the vaginal tract of these patients (Table 4, column 6). 
Again, these “unique” species are not frequently isolated, and would not constitute commonly 
detected isolates. These data suggest that most urogenital species can be detected in both 
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sites. However, this analysis was performed only at the species level and did not consider 
differences between strains of the same species. 
Table 5. Comparison of the Total Isolates Found in the Bladder Compared to the Vagina of 
Each Patient and Lists of Organisms Unique to Each Site.  
  
Total organisms 
found*     
  
Study ID Bladder Vagina 
# in 
common 
Organisms Not found in 
the Vagina**◊ 
Organisms Not found in 
the Bladder◊ 
EST01_B 7 8 5 Lacto amylovorus Ϯ Actinomyces radingae 
EST02_B 1 10 1 Bifido longum Actinomyces urogenitalis 
EST03_B 1 6 1 Coryne jeikeium Candida albicans 
EST04_B 0 7 0 
 
Comamonas kerstersii Ϯ Ϯ 
EST05_B 4 8 4 Dermabacter hominis 
EST06_B 1 7 1  Gemella morbillorium 
EST07_B 10 13 6 
 
Globicatella sulfidiciens 
EST08_B 4 3 3 
 
Lacto johnsonii 
EST09_B 5 7 3 
 
Lacto parabuchneri 
EST10_B 5 13 5 
 
Lacto vaginalis 
EST11_B 9 11 6 
 
Micrococcus luteus  
EST12_B 1 10 1 
 
Proteus mirabilis 
EST13_B 3 9 1 
 
Staph cohnii 
EST14_B 1 13 1  Strep vestibularis 
EST15_B 4 11 2  Staph pasteuri 
EST16_B 5 11 3 
 
Staph simulans 
EST17_B 0 15 0 Staph warneri 
EST18_B 11 9 6  Strept constellatus  
EST19_B 6 6 5  Strept lutetiensis 
EST20_B 1 5 1  Rosamonas mucosa Ϯ Ϯ 
EST21_B 1 8 1  Bacillus subtillus 
EST22_B 4 12 2  Lacto acidophilus 
EST23_B 0 1 0   
EST24_B 0 19 0   
EST25_B 1 1 1   
EST26_B 7 11 6   
EST27_B 2 16 1   
EST28_B 2 9 2   
EST29_B 7 8 5   
EST30_B 2 7 1   
EST32_B 7 13 3   
EST33_B 5 13 3   
68 
 
 
 
Table 5. Continued 
  
Total organisms 
found*      
Study ID Bladder Vagina 
# in 
common 
EST34_B 3 4 2 
EST35_B 2 9 1 
EST36_B 0 9 0 
EST37_B 5 8 3 
EST38_B 3 6 1 
EST39_B 4 12 2 
EST40_B 1 6 1 
EST01_12week 5 7 2 
EST03_12week 3 10 3 
EST04_12week 1 10 1 
EST05_12week 1 9 1 
EST06_12week 1 8 1 
EST08_12week 3 12 3 
EST09_12week 3 3 2 
EST10_12week 1 9 1 
EST11_12week 3 5 3 
EST12_12week 7 9 4 
EST14_12week 6 8 4 
EST15_12week 3 7 3 
EST16_12week 3 13 2 
EST19_12week 6 4 4 
EST20_12week 8 10 7 
EST23_12week 0 3 0 
EST25_12week 0 6 0 
EST28_12week 2 5 2 
EST29_12week 0 8 0 
EST30_12week 3 5 2 
EST32_12week 5 7 3 
*not including unknowns  
**From our entire study, each listed organism in this column has only been isolated once.  
Ϯ Found in the perineum of the same individual 
◊This list contains all organisms found in only one site in this study. Darkened organisms means it has been found in 
the opposite site in previous studies.  
Ϯ Ϯ Isolated only once from this, or any, study.  
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Genetic Analysis of Species Sets 
For this analysis, we selected patients in the estrogen study with the same isolate in 
both sites at both time points (sets of 4 isolates each) to test two related but unique 
hypotheses. First, we asked how stable a given niche was over time. If there were great stability 
over time, we would expect the strains within a given niche to be identical at baseline and 12 
weeks. If there was a great amount of transience, or the community contains a population of 
two or more strains of a species, the strains would be different at baseline and 12 weeks. We 
must understand this stability first, to draw any conclusions about the interconnectedness of 
the two sites. If a niche were not stable, then we could not conclude anything about the 
similarity or differences when comparing strains from another niche, because we would not 
know if the observed differences were due to niche interconnectivity or transient loss of an 
organisms from a volatile system. Therefore, in the sites with stable (and therefore 
hypothetically clonal) populations, we can compare the two sites with each other.  
The isolates chosen for WGS are listed in Table N.4A and Table 6, and the reference 
genomes, used to place these clinical isolates into phylogenetic context, are listed in Table 
N.4B. Isolates are organized into sets of four: a baseline bladder, a baseline vaginal, a 12-week 
bladder and a 12-week vaginal isolate. The only exception is G. vaginalis, which only contains 
two isolates. S. anginosus and C. coyleae have isolate sets from two individuals. Additionally, 
some patients have multiple sets of isolates represented (patient EST08 has an isolate set for A. 
urinae and E. coli and patient EST11 has an isolate set for C. amycolatum, G. vaginalis and C. 
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coyleae Table N.4A). In total, we have sequenced 36 genomes, representing 8 different species 
from 7 different individuals. To assess the quality of the genome sequence, the number of 
overall contigs, the N50 (or the contig that when summed with the larger contigs contains half 
of the total genome size), the median contig size, and the average sequencing coverage are 
listed in Table 6. To assess the dominance of that isolate in the original sample, we have listed 
the relative abundance of that isolate in Table 6. 
Table 6. Assembly statistics for all strains used in Each Species Set 
 Relative 
Abundance 
by EQUC 
Number of 
Contigs  
N50 Median 
Contig 
Length 
Average 
coverage 
C. amycolatum 
(EST11) 
     
   AW24_Cath_B 12.5% 70 111415 11146 84.3 
   AW12_Cath_12w 0.2% 45 160628 25270 182.4 
   AW06_Vag_B 0.3% 646 143372 355 165.5 
   AW10_Vag_12w 0.3% 707 146370 359 7.7 
E. coli (EST08)      
    AW04_Cath_B No info 169 115344 1355 66.8 
    AW14_Cath_12w 99.9% 201 247182 635 72.5 
    AW01_Vag_B No info 117 107673 9444 75.7 
    AW16_Vag_12w 28% 132 247226 978 72.3 
L. iners (EST16)      
    AW08_Cath_B 88% 10 99769 11783 412 
    AW18_Cath_12w 66% 380 22918 3021 134 
    AW09_Vag_B 43% 7 839239 99769 214.0 
    AW19_Vag_12w 80% 42 840074 1155 435.6 
L. crispatus (EST10)      
    AW22_Cath_B 100% 238 19090 4827 395.5 
    AW32_Cath_12w 32% 298 19460 2997 64 
    AW23_Vag_B 36% 286 20244 2877 291.8 
    AW33_Vag_12w 42% 1478 15241 325 56.2 
A. urinae (EST08)      
   AW03_Cath_B No info 99 200719 499 229.2 
   AW15_Cath_12w 0.005% 35 153022 22273 224.2 
   AW02_Vag_B No info 1254 14660 760 126.7 
   AW17_Vag_12w 16% 124 135785 3711 272.6 
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Table 6. Continued 
 Relative 
Abundance 
by EQUC 
Number of 
Contigs  
N50 Median 
Contig 
Length  
Average 
coverage 
G. vaginalis (EST11)      
   AW30_Cath_12w 99% 21 284146 23932 88.2 
   AW25_Vag_B 28% 25 234052 23933 64.0 
C. coyleae (EST11)      
   AW05_Cath_B 29% 6387 1185 585 42 
   AW11_Cath_12w 0.2% 86 97011 6107 163 
   AW07_Vag_B 5.6% 9499 1692 413 74.8 
   AW13_Vag_12w 7.4% 121 127535 896 171.3 
C. coyleae (EST05)      
   AW20_Cath_B 38% 97 131576 1827 95.2 
   AW28_Cath_12w 20% 3940 707 435 8.2 
   AW21_Vag_B 16% 115 131577 1047 125.8 
   AW29_Vag_12w 3.9% 182 33638 6091 31.6 
S. anginosus (EST14)      
   AW26_Cath_B 100% 53 116687 4011 47.5 
   AW34_Cath_12w 4.9% 82 55854 11798 60.8 
   AW27_Vag_B 100% 695 106465 265 34.9 
   AW35_Vag_12w 0.8% 44 116729 16118 680.6 
S. anginosus (EST15)      
   AW36_Cath_B 44% 59 107821 3192 788 
 
The sets of isolates were analyzed in multiple different ways: measuring phylogenetic 
relatedness using 40 core genes and ANI, overall synteny, and CRISPR array comparison. To 
prevent repetition, I will describe each test in detail once, then for each additional set, I will 
explain only the conclusions gained from that analysis. In the phylogenetic analysis, each clinical 
isolate will be color-coded in the trees based on its anatomical isolation location (red for vaginal 
isolates, and blue for bladder isolates). In the percent identity tables, if the percent identity 
suggests that the isolates are the same strains, it is colored green; if not, it is colored red, and 
all reference strains are in grey. Finally, the results of some species sets are more clear-cut than 
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others. The three most straightforward sets (C. amycolatum, E. coli, and L. iners) will be 
described first.  
Corynebacterium amycolatum. 
The four isolates of C. amycolatum collected from patient EST11 were compared using 
the 40-marker genes and ANI approaches. A maximum likelihood trees for 40 marker genes 
show 100% identity between all 4 clinical isolates, which are also distinct from the reference 
strains (Figure 11A). This indicates that the strains at least had a very recent common ancestor. 
ANI calculated that the genomes of all four isolates were greater than 99% similar to each other 
and only 94% similar to the reference strains (Figure 11B-C). The data show that the baseline 
and 12-week bladder samples are similar (blue boxes) and the baseline and 12-week vaginal 
samples are similar (red boxes), indicating that this organism was highly stable over time within 
each niche. Since each niche was highly stable, we can then compare the bacteria between 
niches and we see that they are highly similar (>99.4%) between sites.  
To assess the recent history of these bacterial lineages, we looked at the CRISPR arrays. 
Figure 12 shows a schematic of the CRISPR array analysis. Two strains contain the same array 
when they have the spacers in the same order (indicated in green, a unique spacer is indicated 
in blue). The 4 C. amycolatum strains contained identical arrays of 20 spacers each (Figure 13).  
Taken together, these data indicate that all 4 strains are identical. However, I cannot conclude 
that this is indicative of microbial sharing between sites. When we take the relative abundance 
into account (Table 6), we see that these 4 C. amycolatum strains were low abundance in each 
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of the samples (0.2% to 12.5%). Thus, it is possible that this particular organism may be a low 
abundance cross-contaminant, perhaps a urethral organism. An organism that lives on the 
urethral surface would theoretically be picked up by both a vaginal swab and catheter sample. 
Overall, we can conclude that these organisms are most likely the same strain, but it is not 
concrete evidence that this isolate can effectively live in each niche. 
 
B.  
Figure 11. Comparison of 4 strains of Corynebacterium amycolatum show 100% similarity 
The genomes of 4 isolates of C. amycolatum (baseline bladder, baseline vaginal, 12 week 
bladder, and 12-week vaginal) were compared (bladder isolates = blue, vaginal isolates = 
red). (A) Maximum likelihood tree of the 40 core genes, (B) average nucleotide identity (ANI), 
and (C) the percent identity calculated from ANI. All show great similarity between strains 
(99%) compared to the references strains (94%).  
C.  
A. 
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Figure 12. Schematic of CRISPR Array Comparison.  
Step 1: CRISPRFinder was used to identify the arrays in the bacterial genomes.  
Step 2: the output from CRISPRFinder was parsed into the individual phage genomic inserts. 
The metadata of each insert indicated the array number (if there were multiple in the 
genome) and the order of the spacers within the array.  
Step 3: Each spacer was compared to every other spacer from every other genome using 
USEARCH with a 70% identity threshold.  
Step 4: I went through these data and created diagrams for each spacer in each genome. If 
the spacer matched another array, the spacer was green. If the spacer was unique and 
didn’t match anything it was blue. To simplify the diagrams, I combined all spacers from one 
array into a single block. Some genomes contained spacers that only partially matched the 
full array from another genome. In this case, I listed the spacers in common by number. 
2. Isolate the spacers/inserts 
3. Compare the spacers in each isolate to every other isolate 
USEARCH clustering with 70% identity 
 Green = same spacer 
 Blue = unique spacer 
1. Find the CRISPR arrays using CRISPRFinder 
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Figure 13. CRISPR arrays for four C. amycolatum strains. 
Escherichia coli. 
 E. coli has well described motility genes and has been shown to ascend from the gut into 
the vagina and bladder 70-72. Therefore, we expect these isolates to migrate between sites, 
which would result in a highly transient community. Consistent with that theory, we see that 
baseline bladder and vaginal samples are 100% identical, 12-week bladder and vaginal samples 
are 100% identical, but the isolates from the two time points are only 97% identical by both the 
40 core gene analysis and ANI (Figure 14A-B). The 97% similarity between time points is 
comparable to the differences seen between reference genomes and clinical isolates.  
 Additionally, there is large amount of synteny between the two baseline strains and 
between the two 12-week strains, but little to no synteny when the baseline and 12-week 
samples are compared to each other (Figure 14C). Finally, CRISPR analysis shows that the 
baseline samples share an array with 17 spacers and identical 100pb flanking regions, none of 
which are seen in the 12-week samples. Additionally, the 12-week samples contain an array of 
23 spacers with identical 1000bp flanking regions (Figure 14D). 
These data demonstrate a lack of stability within a niche over time, but a high likelihood 
of microbial sharing between sites at any given time point. Again, this is consistent with the 
76 
 
 
 
theory that E. coli colonization is transient and two distinct populations of E. coli colonized this 
patient, one at baseline and another by 12-weeks.  
 
 
Figure 14. Genomic Analysis of E. coli Demonstrates Low Stability Within a Niche, but High 
Similarity Between Sites at Any Given Time Point. The genomes of 4 isolates of E. coli 
(baseline bladder, baseline vaginal, 12-week bladder, and 12-week vaginal) were compared 
(bladder isolates = blue, vaginal isolates = red). (A) A maximum likelihood tree of the 40 core 
genes, (B) a tree and table of the average nucleotide identity (ANI), (C) comparative 
genomic analysis using ACT, and (D) CRISPR array analysis 
B. 
A. 
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Figure 14. Continued 
C. 
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Lactobacillus iners. 
 Analysis by the 40 marker genes shows 100% identity between all four isolates, 
indicating that they at least share a recent common ancestor (Figure 15A). Of all the genomes 
sequenced, the L. iners baseline strains had some of the best assemblies: AW08_Cath_B had 
only 10 contigs with an N50 of 99769bp, and AW09_Vag_B had only 7 contigs with an N50 of 
839239bp (Table 6). Having fewer contigs with decently long lengths is ideal for comparing 
strains (Figure 15B). This is also well illustrated with the synteny results, where AW18 contains 
more dark lines (start and stop sites for the contigs) and more gaps than the other strains 
(Figure 15C). If we ignore AW18, we do see similarity between the bladder and vagina at ANI 
and synteny analysis. In comparison, the 12-week samples had more contigs with a much lower 
N50: AW18_Cath_12w had 380 contigs and N50 of 22918bp, AW19_Vag_12w had 42 with an 
N50 of 840074bp (Table 6). This means that the 12-week samples have more gaps, particularly 
where each contigs starts and stops. 
This discrepancy in assembly quality might account for the divergence seen with ANI 
and synteny analysis; particularly, that AW18 does not share a high percent identity with the  
Figure 14. Continued 
D.  
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baseline (AW08 and AW09) and within the vaginal niche over time (AW09 to AW19) by both 
ANI and Artemis Comparison Tool (ACT) (Figure 15 B-C). 
However, the CRISPR analysis shows a slightly different story. There is still great 
similarity between the two sites at baseline, where AW08 and AW09 share a six-spacer array 
with identical 1,000bp flanking regions (Figure 15D), indicating that the same strain was 
present in both sites at baseline. However, this strain does not appear to be maintained by 12 
weeks, as AW19 does not contain the baseline six-spacer array, but does contain a distinct six-
spacer array. Two of the spacers from the AW19 array are present in AW18, but due to the 
short contig lengths, there it is only a partial match (Figure 15D). It is possible that AW18 and 
AW19 do contain the baseline six-spacer array, but due to lack of genomic completeness, it is 
not detectable. I suggest this possibility because the ANI and synteny results seem to show that 
the rest of the AW19 genome is highly identical to both AW09 and AW08. To determine a 
difference, further sequencing may be required. Overall, these data show that the same strain 
is present in both sites at baseline, but we cannot make any conclusions about niche stability 
due to sequence coverage.   
80 
 
 
 
 
 
Figure 15. Genomic Analysis of L. iners Isolates Indicate that all Four Isolates Have a Close 
Common Ancestor, but a Potentially Different Recent History. The genomes of 4 isolates 
of L. iners (baseline bladder, baseline vaginal, 12-week bladder, and 12-week vaginal) were 
compared (bladder isolates = blue, vaginal isolates = red). (A) A maximum likelihood tree of 
the 40 core genes, (B) a tree and table of the average nucleotide identity (ANI), (C) 
comparative genomic analysis using ACT, and (D) CRISPR array analysis. 
A.  
B. 
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Figure 15. Continued 
C. 
D. 
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Lactobacillus crispatus. 
 Phylogeny of the 40 marker genes shows 100% similarity between all 4 strains (Figure 
16A), suggesting that all 4 strains share a recent common ancestor. Even though all 4 strains 
have a relatively large number of contigs (Table 5, Figure 16D), ANI shows between 99.7-99.9% 
similarity between all four strains (Figure 16B-D), and there is a great amount of synteny 
between all 4 strains (Figure 16D). This suggests that this organism was highly stable in both 
niches, and that the overall genomes are highly similar between sites.  
The CRISPR analysis confuses that data somewhat, for not all isolates are identical. The 
baseline samples (AW23 and AW22) do not contain any spacers in common, but those two 
strains are the only ones that lack a connection. The two 12-week samples and the baseline 
vaginal sample share an array of 4 spacers with identical 1,000bp flanking regions. Additionally, 
the baseline vaginal sample and the 12-week catheter sample share a six-spacer array, and the 
baseline catheter sample and 12-week vaginal sample share a separate 6-spacer array (Figure 
16E).  
There are potentially two explanations for these results: there is a problem with 
coverage, or we are working with mixed communities. As I stated previously, having a lot of 
small contigs can be problematic because, by definition, certain regions of the genome were 
not sequenced. Three of these genomes had about 200 contigs while one, AW33 had 1478 
contigs (Table 5). It is possible there were more than one clonal population of L. crispatus in 
that environment, we would have inadvertently sampled both of them. Even if we think we are 
83 
 
 
 
sequencing a pure colony of L. crispatus, we could be sequencing two populations. This might 
also account for the large number of contigs, if the genomes are distinct enough, there would 
be difficulty in piecing each genome together during de novo assembly. Due to these caveats, 
all we can conclude is that all 4 isolates share a recent common ancestor and contain a great 
amount of similarity, but may not be the same strains. 
 
Figure 16. Genomic Analysis of L. crispatus Isolates Indicate that All Four Isolates Have a 
Close Common Ancestor. The genomes of 4 isolates of L. crispatus (baseline bladder, 
baseline vaginal, 12-week bladder, and 12-week vaginal) were compared (bladder isolates = 
blue, vaginal isolates = red). (A) A maximum likelihood tree of the 40 core genes, (B) a tree 
and table of the average nucleotide identity (ANI), (C) Table of ANI results, (D) comparative 
genomic analysis using ACT, and (E) CRISPR array analysis. 
A. 
B. 
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Figure 16. Continued 
C. 
D.  
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Aerococcus urinae. 
 The 40-core gene phylogeny showed that three of the clinical isolates were similar to 
each other, but AW15 (the 12-week bladder sample) is distinct (Figure 17A).  ANI confirmed 
that the baseline bladder sample and both vaginal samples are greater than 99% similar (Figure 
17B). This suggests great stability within the vaginal tract, but not the bladder. The 12-week 
bladder sample was about 92% similar to the other clinical isolates, which is comparable to the 
percent similarity between the reference strains and clinical isolates. Additionally, a genome 
comparison by ACT shows very low synteny between AW15 and the rest of the genomes 
(Figure 17C). This suggests one of two things. Either the A. urinae community in the bladder 
shifted over time, or there are multiple clones of A. urinae in the bladder community, which we 
did not detect at baseline due to limits in sampling as described earlier.  
The CRISPR array analysis shows that the baseline catheterized sample (AW03) and the 
12-week vaginal sample (AW17) share two arrays. The baseline vaginal sample (AW02) only 
shares a partial array with the 12-week vaginal samples. AW15 did not have any detectable 
CRISPRs (Figure 17D). The differences in CRISPR arrays may also be explained by the mixture of 
Figure 16. Continued 
E.  
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two or more clonal A. urinae isolates. Overall, it is possible that the same strains are present in 
both niches at both time points, but we cannot make any conclusions until we decipher the 
number of distinct species in each population.  
 
Figure 17. Genomic Analysis of A. urinae Suggests Two Genetic Populations in Each Site. 
The genomes of 4 isolates of A. urinae (baseline bladder, baseline vaginal, 12-week bladder, 
and 12-week vaginal) were compared (bladder isolates = blue, vaginal isolates = red). (A) A 
maximum likelihood tree of the 40 core genes, (B) a tree and table of the average nucleotide 
identity (ANI), (C) comparative genomic analysis using ACT, and (D) CRISPR array analysis. 
A. 
B.  
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Figure 17. Continued 
*AW15 did not have any detectable spacers 
D.  
C.  
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Gardnerella vaginalis. 
 The G. vaginalis isolates were the only set with fewer than four isolates. As you can see 
in the relative abundance graphs (Figure 10), G. vaginalis (in red) was detected in the vagina of 
patient EST11 at baseline, but not the bladder. Then, at 12-weeks, both sites contained G. 
vaginalis, and it was highly dominant in the bladder. I wanted to know if the bladder isolate 
from the baseline vaginal sample was the same as the 12-week bladder sample, which would 
suggest migration of G. vaginalis to the bladder followed by the dominance of that organism. 
Alternatively, G. vaginalis could have been present but undetectable at baseline. Unfortunately, 
the 12-week vaginal sample was contaminated or incorrectly stored down, because the 16S 
gene extracted from the annotation blasted as L. crispatus; therefore, this sample was 
discarded. However, blast analysis of the 16S genes from the baseline vaginal sample and 12-
week bladder both identified as G. vaginalis.  
 Both sequences (AW25 and AW30) had few contigs with very high length and were, 
therefore, well suited for genomic analysis (Table 6). The baseline vaginal sample was 100% 
similar by 40 marker genes, and 99.88% similar by ANI to the 12-week bladder sample, 
compared with 88-94% similarity to the reference strains (Figure 18A-B). ACT analysis shows a 
high amount of synteny between the two genomes (Figure 18C). We did not detect any CRISPR 
arrays in these isolates, so we cannot make any conclusions about the recent history of these 
isolates. Although not definitive, these data do show that the two strains are highly similar, 
indicating that the baseline vaginal sample could have migrated to the bladder by 12-weeks.  
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Figure 18. Genomic Analysis of G. vaginalis Indicated that the Baseline Bladder Sample 
and 12-week Vaginal Sample Share a Recent Common Ancestor. The genomes of 2 
isolates of G.vaginalis (baseline vaginal and 12-week bladder) were compared (bladder 
isolates = blue, vaginal isolates = red). The 12-week vaginal sample was contaminated with 
L. crispatus, and was therefore excluded from further analysis. (A) A maximum likelihood 
tree of the 40 core genes, (B) a tree and table of the average nucleotide identity (ANI), and 
(C) comparative genomic analysis using ACT. No CRISPR arrays were found. 
C.  
A. 
B. 
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Streptococcus anginosus. 
 It was the original plan to sequence two sets of S. anginosus isolates, four from EST14 
and four from EST15. However, due to sequencing flow-cell capacity, we could only load one of 
the isolates from EST15. The other three are extracted and can be sequenced on a future 
sequencing run. Phylogenetic analysis of the 40 marker genes showed that all four samples 
from patient EST14 were 100% identical (Figure 19A) compared to 94% similarity to the 
reference strains, indicating that these 4 strains have a recent common ancestor. Surprisingly, 
the sample from patient EST15, AW36, was 99.8% similar to patient EST14’s strains. This 
suggests that, for S. anginosus, some urogenital isolates are more similar to each other than 
strains from other isolation sites.  
ANI presented a similar story (Figure 19B). All four isolates from EST14 were greater 
than 99.9% similar to each other, again suggesting high stability and similarity between sites. 
The bladder isolate from EST15 (AW36) was as similar as the reference strains to EST14. 
Therefore, even though the isolates from these two individuals have highly similar core genes, 
there are sufficient differences to distinguish isolates collected from different individuals. The 
reference strains all seem to be associated with virulence and were isolated from blood, oral, 
airway, and one (SA1) from the catheter of a quadriplegic suffering from a UTI. It is possible 
that the phylogenetic differences between the reference strains and study is due to virulence, 
and the less virulent strains of our study are clading separately from the more virulent 
reference strains. 
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Figure 19. Genomic Analysis of Streptococcus anginosus from Two Individuals. The 
genomes of 5 isolates of S. anginosus (4 from EST14 and 1 from EST15) were compared 
(bladder isolates = blue, vaginal isolates = red). (A) A maximum likelihood tree of the 40 
core genes, (B) a tree and table of the average nucleotide identity (ANI), and (C) 
comparative genomic analysis using ACT. No CRISPR arrays were found. 
A. 
B. 
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Figure 19. Continued 
C.  
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All 4 isolates from EST14 show a great amount of synteny (Figure 19C). Strain AW36 
from EST15 shows some synteny with the other clinical isolates, but also large and distinctive 
gaps, again indicating that isolates collected from different individuals have distinguishing 
features. No spacers were detected for any of these strains, which is apparently not uncommon. 
Previous publications have detected CRISPR arrays and/or genes in less than half the isolates 
sequenced (7/18). With the great amount of similarity between strains, I would conclude that 
the S. anginosus strains are stably colonized within a given niche and are highly similar between 
niches, which suggests that S. anginosus may be shared between sites.  
Corynebacterium coyleae. 
 In this final dataset, we isolated four stains of C. coyleae each from patient EST11 and 
patient EST05. As with S. anginosus, this dataset allows us to compare groups of isolates from 
different individuals to a reference strain. We found that, when comparing the 40 marker 
genes, isolates collected from within an individual were 100% similar (Figure 20A), but only 
99.2-99.1% similar between individuals or to the reference strain. ANI shows that samples 
within an individual were 99% similar to each other, but 96% similar between individuals or 
compared to the reference strain (Figure 20B). Additionally, comparison of the genomes shows 
a great amount of synteny between isolates collected from within a given individual, with the 
exception of AW28, which seems to be divergent (Figure 20C & E). The two baseline samples 
from patient EST11 (AW05 and AW07) contain a series of small contigs not present in the other 
genomes (Figure 20E). It is possible that if these genomes were cleaned up, then they would 
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show a greater similarity to the other genomes from that individual. Finally, if we compare a 
single genome from each individual, we see some synteny, but also rather large gaps (AW21 to 
AW11 in Figure 20D), suggesting that there is a great difference between strains collected from 
different individuals. 
 
 
Figure 20. Genomic Analysis of Corynebacterium coyleae From Two Individuals. The 
genomes of 8 isolates of C. coyleae (4 from ES11 and 4 from EST05) were compared (bladder 
isolates = blue, vaginal isolates = red). (A) A maximum likelihood tree of the 40 core genes, 
(B) a tree and table of the average nucleotide identity (ANI), and (C-E) comparative genomic 
analysis using ACT, and (F) CRISPR array analysis. 
A. 
B 
A. 
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D. Comparative genomics of the 4 strains collected from patient EST05.  
Figure 20. Continued 
C. Table of ANI results 
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E. Comparison of a strain from EST05 and EST11 
Figure 20. Continued 
F. Genome Comparison for strains from EST11 
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Even though the genomes are highly similar, the CRISPR analysis indicates a common 
recent history for the baseline samples in EST05 that is distinct from the 12-week samples 
(Figure 20G). The CRISPR analysis from EST11 is less clear-cut; the baseline of one niche is 
similar to the 12-week of another. This could mean that the strains swapped locations over 12 
weeks, or that each niche contained a mixed population of both strains, but by chance, we only 
sampled one. Overall, these data indicate that for at least two people, the C. coyleae present in 
each niche of a given individual is highly similar and stable over time. 
A Comparison of Multiple Strains Within an Individual. 
Multiple isolate sets were taken from a single patient. Both the A. urinae and E. coli 
isolate sets were taken from patient EST08, and C. amycolatum, G. vaginalis, and one set of C. 
Figure 20. Continued 
G. 
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coyleae were taken from patient EST11. I wanted to check that the similarity we detected 
between strains was not solely dependent on the patient’s niches. It is possible that, within one 
individual, a bladder isolate will always have greater similarity to other bladder isolates rather 
than vaginal isolates. Alternatively, it is possible that, within one individual, regaurdless of 
niche, all baseline samples will show greater similarity to other baseline samples rather than a 
12-week sample. To check for this, I compared all ANI trees from EST08 (Figure 21A) and EST11 
(Figure 21B). Neither set of trees elucidated a specific pattern. There did not seem to be a 
correlation of the patient’s isolation location and the relatedness of the samples. These data 
suggest that any similarity or differences we detect with phylogeny are the result of divergence 
within a specific species, not any one individual’s specific niche requirements. 
Here, I have shown that no single species is commonly and exclusively found in either 
the bladder or the vagina. Most species can be found in both sites. At the strain level of 
identification, isolates taken from the same individual at any given point in time tend to be 
closely related. Most have evidence of a recent common ancestor and some have evidence of 
great genetic synteny and recent enviromental history (as shown by analysis of CRISPR arrays). 
These data suggest that there is the potential for microbial sharing between sites within an 
individual. 
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Figure 21. Comparison of Isolate Sets Collected from the Same Individual. Comparing the 
ANI trees of (A) A. urinae and E. coli isolate sets from EST08 and (B) C. amycolatum, C. 
coyleae, and G. vaginalis isolate sets from EST11. For each tree, bladder isolates = blue, 
vaginal isolates = red. 
A. A. urinae and E. coli from EST08 
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Figure 21. Continued 
B. Isolate sets from EST11 
G. vaginalis 
C. coyleae 
C. amycolatum 
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Summary 
We analyzed 10 species sets, each collected from a single individual at baseline and 
following 12-weeks of treatment to determine if any of specific species has the potential for 
surviving in both the bladder and vaginal environments. Phylogenetic and genome comparison 
analysis show a high amount of similarity between most isolates. With the exception of E. coli 
(which seems to be a transient population), most isolate sets are highly similar phylogenetically. 
This tells us that the strains are stable over time within a niche and seem to be highly similar 
between niches. This could indicate that each site contains the same organism, or that the 
organisms share a very recent common ancestor.  
When we look at the recent phage history of these organisms, we often see that the 
baseline samples contain the same CRISPR arrays in both the bladder and vagina; this was true 
for C. amycolatum, E. coli, L. iners, and C. coyleae. However, for each of these sets, the 12-week 
arrays were distinct from the baseline arrays, indicating that there might have been a shift in 
the dominant clonal population by 12 weeks. For the strains that did not have similar CRISPRs 
at baseline (L. crispatus and A. urinae), their data suggests that two clonal populations were 
present at baseline and 12 weeks, but only one was sampled at any given time point. Overall, 
these data suggest that there is a high probably of microbial sharing of pathogenic (E. coli), 
commensal (Corynebacterium species, and L. iners), and even beneficial bacteria (L. crispatus). 
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CHAPTER VI 
DISCUSSION 
Summary of Data 
In this work, we attempted to acquire evidence to support or refute the idea that 
bacteria are shared between the bladder and the vagina. We tested this in three separate ways, 
comparing whole genomes of bacteria collected from unrelated individuals (Chapter III), 
comparing the community structure of both sites at a given point in time (Chapter IV), and 
comparing the genomes of bacteria collected from both sites of a woman at a given point in 
time (Chapter V).  
From previous work, we already knew that the same species of bacteria are often found 
in both the bladder and vagina. The data in Chapter III confirmed that the same species are not 
only collected from the bladder and vagina, but that these genomes have overlapping 
functionality. The DAPC of protein domains shows that the bladder and vaginal datasets overlap 
with each other, and are distinct from the gut dataset (Figure 5B). The DAPC also shows that 
not all the species from the bladder have overlapping functions in the vagina. About half of 
each dataset is distinct; therefore, it is possible that there are some organisms that share 
functionality and some that may have functionality specific to a given niche. For the 
overlapping section, some vaginal and bladder genomes have close to 100% identical protein 
domains on the DAPC, indicating that these bacteria have highly similar protein functions. 
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These data are intriguing because of the high similarity between strains isolated from unrelated 
individuals. These datasets were collected almost a decade apart, from different patient 
populations, in different areas of the world; thus, the similarity is striking. I would conclude that 
some strains of some organisms are specific for one niche or the other, but others possess the 
functionality to live in both sites. The fact that these highly similar bladder and vaginal isolates 
were collected from different individuals indicates that urogenital functionality is highly 
conserved in women.  
 Next, we looked at the microbiomes of the bladder and vagina within individual women. 
We found that about 50% of hypoestrogenic post-menopausal women have similar bladder and 
vaginal communities. That number increases to about 75% following estrogen treatment 
(Figure 10, Table 4). Therefore, at any time point, there are women whose samples are not just 
mostly similar, but are in similar proportions in each site. I find this remarkable, particularly 
considering that the biomass of each site does not appreciably change over time and that each 
site contains a vastly different biomass; as mentioned previously, the bladder contains many 
orders of magnitude fewer organisms than does the vagina. Even with this stability and 
discrepancy in biomass, we observed almost identical distributions of organisms in each site.  
There are a few caveats to this study and the resultant data. First, we cannot conclude 
that the observed changes are due to microbial sharing between sites. It is possible that each 
site is responding similarly yet independently from one another. Also, we have minimal data 
about the normal stability of the FUM of post-menopausal women. Our only other study 
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collecting longitudinal data included only UUI women as they took an anti-cholinergic 
medication 3,6. In that study, we observed some women remained stable throughout treatment, 
but many changed. However, we do not have any information to indicate if these changes were 
due to normal shifts over time or medication use. In this estrogen study, we do have the 
strength that each woman is her own control, so we could determine when a shift occurred 
regardless of the underlying reason and our data show that the bladder and vaginal 
microbiomes of several women experienced corresponding shifts over the 12-week estrogen 
treatment period.  
Finally, we took specific isolates from women in the estrogen study and compared their 
whole genomes (Chapter V). Here, we compared the same species cultured at baseline and 12 
weeks in the bladder and vagina, resulting in sets of 4 isolates each. The genomic data from 10 
species sets (8 different species across 7 different individuals) were analyzed. For the majority 
of species sets, (C. amycolatum, L. iners, L. crispatus, G. vaginalis, S. anginosus, and C. coyleae 
EST11 and EST05) marker gene analysis indicated that all strains within a species set were 
highly similar, and therefore shared a recent common ancestor. Comparison of the full genome 
by ANI and ACT concurred with the 40-marker gene analysis, indicating that these strains 
shared more than a common ancestor, but had very similar genomes and were therefore 
closely related.   
The recent phage history, as measured by CRISPR array analysis, showed that for some 
of the samples (L. iners, E. coli, C. coyleae EST05), baseline vaginal and bladder samples are 
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similar, and that the 12-week samples are similar, but each time point is distinct from each 
other. Two conclusions can be made. First, at any given time point, the same clonal population 
can be present in both sites, suggesting that that strain is shared between sites at a given point 
in time. Second, that something about the estrogen treatment causes a shift in the dominant 
population. Further data by Catherine Putonti showed that one isolate set (C. amycolatum) 
contained a variety of prophages in the baseline genomes, most of which had excised from the 
genome by 12 weeks (Putonti, unpublished data). Therefore, it is possible that estrogen hanges 
the expression of phages, which in turn would change the environment and could select for a 
population with a specific CRISPR profile.  
One strength of this analysis is the diversity of the datasets. We tested pathogenic 
species sets (E. coli, A. urinae), commensal species sets (L. iners, Corynebacterium species), and 
beneficial species sets (L. crispatus). The E. coli species set provides an example of a motile and 
transient population, with two distinct phylogenetic groups, one at baseline and one at 12 
weeks. The commensal and beneficial species sets are examples of much more stable 
phylogenetic populations over time, even considering the changes in estrogen levels. These 
data seem to suggest that a population of species within a given niche can be clonal.  
A limitation of this analysis is sampling bias. During initial culturing, if the colony is 
pinpoint, multiple colonies are picked up in order to ensure enough growth for identification 
and storage. This was the case for L. crispatus and A. urinae. Their genomes indicate a mixed 
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population, with multiple clones. If we had sequenced multiple individual colonies, we might 
have captured a mixed population at both time points.  
Implications and Discussion 
Throughout this analysis, we have tried to be very careful about what we can and 
cannot conclude from these data. We are trying to answer a very basic, yet nuanced, question: 
are the bladder and vaginal microbiomes interconnected or distinct? The current data provides 
evidence that the two sites are potentially connected microbiologically - that microbes might 
move between the two adjacent niches. This discovery should change the way we view the 
bacteria of the female pelvic floor and should inform research into UTIs, women’s health, and 
treatments moving forward.  
Medical dogma has always connected the health of the vagina to the health of the 
bladder, and the data shown here backs that up, with one important difference. Previously, it 
was thought that a healthy vaginal microbiota prevents ascending infections from migrating 
into a sterile bladder. Now, I would propose that the protection comes from the bacteria that 
reside in both the bladder and vagina, particularly in the presence of estrogen.  
To our knowledge, this is the first microbiome study to compare the strain similarity 
between close anatomical sites. Although the HMP dataset compared multiple human niches to 
each other, none of the datasets were as anatomically close as that vagina and bladder, and 
none of the analysis was completed at the species level11. There have been separate studies 
that compare regions of the mouth microbiome104, between sections of the gut microbiome of 
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mice148, or on areas of the skin149, but no other that has searched for strain specific connections 
from one human organ to another. 
Exploring the Implications of Interconnectivity. 
Considering that the bacteria are non-motile, how do the organisms move from one site 
to the other? Two options present themselves. First, both sites could be colonized soon after 
birth and two relatively stable environments are established, the low biomass of the bladder 
and the high biomass of the vagina. This would imply that the two sites started from a common 
ancestor but have had little connection over time. It would also imply that the two communities 
would eventually diverge from each other. The ANI and CRISPR data seem to refute this 
hypothesis. If it were true, we would not necessarily expect the genomes to be as similar as 
they are or to see that the CRISPR arrays are 100% identical between the two sites. Even if 
phages could migrate and bacteria could not, it still seems improbable that both niches would 
be exposed to the same phages in the same order. It is much more likely that the bacteria are 
moving between sites and bringing their phages and their CRISPR immunity with them.  
From the data presented here, it seems more likely that a second scenario is true - one 
site acts as a reservoir and periodically colonizes the other site. If this were the case, it is easy to 
imagine how the bladder could act as a reservoir for vaginal flora because it would re-seed the 
vagina following every void. In this case, we would expect to find low levels of the same 
organisms in the bladder all through life. Unfortunately, until we can properly interpret voided 
urine, this question cannot be answered.  
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Alternatively, the high biomass of the vagina could provide bacteria for ascending 
colonization. It is possible that even without motility, the mucosa between the vagina and 
bladder could transmit bacteria past the urethra. The data shown here even suggests that 
mechanical factors, such as the application of an estrogen cream, may be sufficient for 
movement. One can also imagine how any sort of pad (such as an infant diaper, menstrual pad, 
or continence diaper) could allow for a mechanical passage of vaginal organisms to the bladder. 
Physicians often recommend changing such pads frequently to decrease the risk of developing 
UTIs, but no significant research has been done on the subject in relation to commensal 
bacteria. This mechanical human intervention could also partially explain the increase in 
bladder diversity measured in incontinent patients and patients with increased BMI. If a patient 
continuously uses absorbent pads, those pads would provide vaginal flora, as well as those of 
the skin or gut, with a conduit for bladder colonization. Much in the same way, obesity could 
result in more friction, and therefore more movement of bacteria around the pelvic floor.  
If there is a stable bladder community, how does it survive? I would expect these 
organisms to live on the uroepithelium not in the urine itself. Lactobacillus species are known 
to feed off of glycogen produced by vaginal epithelium 75,76, so it would not be hard to imagine 
that they feed on something expressed on the surface of bladder cells, such as the 
glycosaminoglycan (GAG) layer. Even if that were true, it still would not explain why the bladder 
maintains a low biomass. It could be possible that the host actively regulates bacterial cell 
density through regulation of cell surface carbon sources. If there were limited nutritional 
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resources, then it would limit the overall bacteria cell density. Alternatively, the host could 
regulate the population through innate immunity, such as the use of antimicrobial peptides 
(AMPs). Finally, the composition of the urine itself, such as the presence of urea, salts, or 
amines, could be inhibitory to robust cell growth.  
Even if all of this were true, how could the bladder microbiome survive so long in such 
low density? The bladder epithelium is unique in that it can dramatically increase and decease 
its surface area as the bladder is filled and then voids. The luminal facing layer of the 
uroepithelium is comprised of umbrella cells 150. To increase their surface area, these cells keep 
a reserve of intracellular vesicles that provide additional membrane when needed 86. As the 
bladder is emptied, parts of the surface membrane bleb into the cell’s cytoplasm and are stored 
for later, therefore these vesicles contents contain both uroplakin and lumina contents and 
would not differ significantly from the surface of the bladder 86,150.  If bacteria are attached to 
the bladder epithelium, they too could be living in these intracellular vesicles and periodically 
be re-introduced into the bladder lumen. If this hypothesis were true, fluorescent microscopy 
could be used to detect bacterial cells in these vesicles. To my knowledge, no one has tried this 
experiment.  
Multiple mechanisms can be hypothesized that would explain how bacteria could 
migrate from one site to another or how the bladder bacteria are maintained in a low biomass 
state, but it is also important to explore an alternative hypothesis, i.e., we are simply collecting 
vaginal flora or urethral flora when we catheterize the bladder. In theory, the subsampling of 
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vaginal flora is possible, given the vastly different amounts of bacteria and the presence of 
similar species in both niches. However, in our group’s initial study, Wolfe and co-workers 4 
excluded the possibility of vulvo-vaginal contamination in the bladder. In surgical patients with 
and without urinary symptoms, voided urine, vaginal swabs, and catheterized urine were 
compared to suprapubic aspirates (SPA) 4. Aspirated urine was collected by a needle directly 
through the lower abdomen and therefore the collection method bypassed vulvo-vaginal 
contamination. In that study, the microbiome of aspirated urine was highly similar to 
catheterized urine and vastly different from voided urine and vaginal swabs. However, the 
samples size was very small (N=23), the samples did not undergo enhanced culturing (because 
it did not yet exist), and we have since learned a lot about sequencing low-biomass samples. 
The work from this thesis has shown that there can be connections between the bladder and 
vagina. Yet, this first study suggested that the vagina was distinct from the bladder. In light of 
the work from this thesis, I would recommend that the SPA-to-catheterized urine comparison 
study be repeated.  
Even given these concerns, the microbiome of catheterized samples has clearly provided 
useful information. As stated previously, we have identified associations between bladder 
microbiome characteristics and urgency symptoms3,6,65,151, response to UUI medication6, risk of 
post-operative63,64 and post-instrumentation UTIs65, and kidney stones152.  Additionally, the 
data presented here shows that the profiles of the bladder and vagina are not always similar, 
particularly in hypoestrogenic women. Thus, although it would be a good idea to repeat the 
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original SPA-to-catheterized urine comparison study, sufficient evidence links the bladder 
microbiome to bladder health and disease/disorder.  
The design of this study takes for granted the idea that topically applied estrogen will be 
delivered into the bladder, but how does this happen? Due to the proximity of the vagina and 
urethra, some estrogen cream will be delivered to the urethra during application, and it is 
possible that some hormone will be transmitted through the urethra at that time. However, we 
also know that the anterior vaginal wall lies parallel to the bladder trigone, separated only by 
the vesicovaginal space and connected by common blood supply. Additionally, we know that 
the trigone contains estrogen receptors, and it is known that estrogen can be absorbed through 
epithelial layers153, therefore, it is possible that estrogen could be absorbed and transmitted 
through the tissue. Not much is known about the vesicovaginal space, other than it is avascular 
and contains a layer of connective tissue154. It seems possible that estrogen could diffuse 
through the vaginal epithelium, vaginal lamina propria, through the vesicovaginal space and 
effect the bladder lamina propria beneath the trigone of the bladder. To distinguish between 
the possibility of the urethral exposure versus tissue diffusion, we could modify how the 
estrogen is delivered. Instead of a topical cream, an intravaginal delivery mechanisms (such as a 
tablet or pessury) could be used. These alternative mechanisms would have been found to be 
as effective at modulating symptoms, but would prevent urethral transmission of estrogen or 
mechanical spreading of organisms (as with the cream application).  
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Implications for Infection and Probiotics. 
UTIs, particularly those caused by UPEC, are the common bacterial infection in the US 
155. They are more prevalent in women, with 50% experiencing a UTI in her lifetime 155. 
Additionally, no specific genetic signature has been identified that is predictive of pathogenesis 
156.  Yet, the dogma persists that there are two types of E.coli: pathogenic strains (like UPEC) 
and asymptomatic bacteriuria (ABU) strains. ABU strains have even been used in women with 
UTIs to prevent recurrence 157. But the idea of ABU is flawed; an infection is more likely to be 
the result not just of the strain but also the environment in the host. The data presented here 
shows that E. coli colonization might be more transient than we first expected. After just 12 
weeks, the population of strains had completely changed (Figure 10). This suggests that the UTI 
field not only has to reconsider their definition of ASB and UPEC, but also begin to think about 
an E. coli infection as something highly dynamic. This raises a range of questions, where are 
these new strains coming from? How long do they stay? And, does the strain of UPEC change 
throughout the course of disease or treatment? 
 The findings are just as exciting from the probiotic standpoint. L. crispatus is the only 
species that we consistently find strongly associated with continent control patients, whereas 
other Lactobacillus species, especially L. gasseri, are associated with OAB patients (Figure C.6) 
3,6. Additionally, we have unpublished data that show that L. crispatus supernatants can kill E. 
coli cultures better than lactic acid and hydrogen peroxide alone42,68,69. All these data suggest 
that L. crispatus is a beneficial microbe in the bladder, and a potential probiotic for future 
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therapeutic use. These niche analysis data provide compelling evidence that a successful L. 
crispatus probiotic would not need to be administered directly into the bladder, which would 
increase cost and decrease patient comfort. Instead, a future therapy could use a L. crispatus 
inoculated in the vagina, much like the estrogen cream used in this study. A cream would be 
cheaper and easier to apply and there would still be high confidence that the probiotic could be 
transmitted into the bladder.  Additionally, my data suggest that adding L. crispatus to the 
estrogen cream may prime the vagina and bladder microbiota and epithelium for maintenance 
of the probiotic.  
In the age of antibiotic stewardship, I find it interesting that we were able to modify the 
urogenital microbiome with a non-antibiotic compound. If estrogen can be used to modify the 
microbiome, what else can be used? Are there small molecules, carbon sources, AMPs, host 
factors, or even bacterial signaling molecules that could be used to locally maintain a healthy 
urogenital environment? If another treatment could be found, particularly one that is effective 
in reproductive age women, we could dramatically reduce the amount of antibiotics used in this 
country.  
  Future Directions 
The data presented here should be a starting point for a wide variety of future studies 
exploring the bacterial and host components of the pelvic floor microbiome. I have already 
briefly covered a few future directions in the implications section; for example, repeating the 
SPA versus catheterized urine study, exploring the dynamics of E. coli infection, and trying to 
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inoculate L. crispatus in tandem with the estrogen cream. Here, I will address more immediate 
future directions, such as creating a reference genome database, continued longitudinal 
studies, interpretation of voided urine, and metagenomic analysis with the enriched culture 
samples.  
Reference Genome Database. 
 The genomic comparison data in Chapter V highlights just how different our urogenital 
strains are compared to GenBank reference strains. Future studies of urogenital isolates will 
need a reference dataset, and that is exactly what I have created here. The genomes sequenced 
with the Lawley Lab represent the breadth of phylogenetic diversity currently cultured from the 
bladder (Figure 4), and the isolates sequenced in Chapter V provide a direct comparison of 
bladder and vaginal isolates. These datasets will be turned into a publicly available reference 
genome database. Not only will these bladder genomes be a reference for future phylogenetic 
studies, but they can be used for functional studies as well. We need to mine these genomes to 
understand the functional requirements for surviving in the bladder, attaching to the 
urothelium, and promoting health and/or disease. 
Enriched Culture Samples.  
Many of these organisms cultured in Chapter V are very slow growers (e.g. Gardnerella 
and Lactobacillus). Therefore, during initial isolation, it was unrealistic to sub-culture a single 
colony. Instead, a group of colonies was collected, sub-cultured, and used for isolation and 
identification. Following identification using MALDI-TOF, all growth on the plate used for sub-
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culture was used to generate stored cultures (freezer stocks). Therefore, many of these 
genomes may in fact represent a consensus of multiple clonal populations within a given niche 
at a given time point. Additionally, for those isolates that do grow large enough colonies for 
clonal isolation (e.g. Aerococcus, Corynebacterium and Streptococcus), only a single colony was 
chosen for identification and storage. Therefore, it likely, that some genetic variation was not 
captured. This may account for the differences seen in A. urinae (Figure 17) and L. crispatus 
(Figure 16). It is possible that the bladder contained multiple clones of A. urinae, one 
represented by AW15 and the other by AW03, but both clones were not detected at both time 
points. Therefore, the data suggest an unstable environment when the reality might be bias in 
our sampling techniques.  
I had thought about this eventuality when designing this study. However, I had no way 
of knowing exactly how many colonies to store down, or whole genomes to sequence, to 
capture the full genetic potential. Instead, I opted for a storage protocol that would allow 
others to extend my work. After reading a plate and sub-culturing one of each unique colony, I 
used a sterile cotton swab to pick up all the colonies on the plate and inoculate into a storage 
media. These mixtures were frozen at -80C. I call these mixtures “enriched culture samples” 
(see Methods), and I performed this extra storage on all the plates from the first 20 patients. It 
would be possible to go back to these tubes, perform metagenomics, and measure species- or 
strain-specific sequences. Building from the work in this thesis and using the enriched cultured 
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samples, it might be possible to measure the total genomic diversity of a given species at a 
given time point. 
These samples could also be used for a variety of future studies. Unfortunately, the 
enriched samples cannot be re-cultured because they were stored down with nucleic acid 
preservative, not a culture preservative. However, I think metagenomic analysis would allow us 
to explore the genomic content in a mixed community, not just one genome at a time. Based on 
how our urinary isolates clade with reference genomes, it seems that the urogenital strains are 
dramatically different. It would be interesting to see if there is similar functionality between 
urogenital isolates that is absent in isolates from other collection sites. Metagenomic data from 
these samples may also be useful in exploring for prophages. As I mentioned earlier, C. 
amycolatum was found to lack the majority of its prophages by 12 weeks. Previous work in 
vaginally isolated Lactobacilli have shown that when the cell is stressed, it will release its 
prophages, and these phages can infect multiple Lactobacillus species 158. In addition, it is 
known that phage predation can change the gut community structure159,160, therefore, I think it 
would be very important to start understanding how phages interact with the bladder 
microbiome specifically in response to estrogen. Using these samples, we could test a wide 
variety of species before and after treatment. We have only explored the tip of the iceberg for 
bladder phages, and a metagenomic approach would allow us to see which phages have 
species-specific targets and which are able to infect multiple types of bacteria.  
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Interpreting Voided Urine. 
One consistent problem we face in the urinary microbiome field is interpreting voided 
urine. We want to be able to conduct long-term longitudinal studies, sample from biobanks, or 
do large population studies, yet all of this is infeasible if the participants must be catheterized. 
For example, we do not want to needlessly catheterize individuals, so we cannot study the 
urinary microbiome in infants and children, or in healthy reproductive aged women. Therefore, 
the next major step will be in interpreting voided urine. As I stated in Chapter III, we now have 
evidence that voided urine is a mixture not only of bladder and vaginal flora, but also potential 
skin flora (Figure 6). The estrogen study collected not only paired catheterized urine and vaginal 
swabs, but also voided urine and perineal swabs. It is imperative that these data be compared 
and explored to tease apart the composition of voided urine. Ideally, we would want to find a 
bladder-specific signature, but based on the data from this thesis, I think it would be more likely 
to find a urogenital-specific signature. If we can find that signature, we could at least be able to 
distinguish bladder/vaginal (urogenital) organisms from any other contaminant (e.g., skin or 
perineum).  
Long-term Estrogen Effects. 
 It would be in interesting to follow the women of the estrogen study for longer time 
frames, and capture longitudinal data as their symptoms improve. We would expect that, given 
enough time on estrogen therapy, most of the women would shift to a Lactobacillus-dominant 
community. However, we do not know if the observed changes are transient, stable, or stable 
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only for as long as estrogen is applied. It would be interesting in future studies to track 
hypoestrogenic women at baseline, 12 weeks, 6 months and 1 year of treatment.  
 It would also be interesting to follow women throughout their lifespans. A long-term or 
multi-cohort study would allow us to ask some important questions, e.g. what is the 
composition of the infant bladder microbiome? How does the bladder microbiome change after 
an infant’s first antibiotic exposure? How does the bladder and vaginal microbiome change 
throughout puberty? What is the change in the bladder microbiome following initiation of 
sexual activity? Do any of these things predispose individuals to recurrent UTIs or UUI later in 
life?  
As you can see, we are just beginning to explore the possibilities of this research. My 
hope is that this thesis is an important building block for future urogenital microbiome research 
that will improve women’s health.  
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INTRODUCTION TO THE APPENDICES: ADDITIONAL RESEARCH 
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This appendix provides the texts of all current publications that are not directly related 
to the dissertation. The thesis itself combined with this appendix represent the entirety of my 
graduate work. At the beginning of each appendix section, the manuscript citation will be listed, 
followed by a short summary of the work. The full manuscript text, all figures and tables, and 
complete methods are included. Please note that due to ongoing optimization and validation, 
the methods listed in each appendix section may vary from the methods listed in the main 
thesis. If there was any further work that did not make it into publication, such work will be 
listed in the adendum following each appendix section.  
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APPENDIX B 
THE FEMALE URINARY MICROBIOME IN URINARY URGENCY INCONTINENCE 
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Overview of Appendix B 
 In this study, catheter samples were collected from women with UUI who were 
participants in the Anticholinergic versus Botulinum Comparison (ABC) trail, a randomized trial 
investigating two alternative treatments for OAB161. All urines were negative by standard 
culture, but 16S rRNA gene sequencing showed that many contained bacterial DNA. 
Approximately half of the samples contained bacterial DNA above backgound levels. In these 
“sequence-positive” urines, we identified 8 major bacterial community structures (urotypes) 
where a single bacterial genus or family dominated most urotypes (i.e., >45% total sequence 
reads). This paper was the first publication descibing the urotype analysis and the distribution 
of those urotypes: nearly half were dominated by the genus Lactobacillus, followed by 
Gardnerella, Gardnerella/Prevotella, Enterobacteriaceae, Staphylococcus, Aerococcus and 
Bifidobacterium. The remaining urotype was called ‘Diverse’ to signify those without a 
dominant genus.  
All individuals in this study underwent instrumentation to inject either the botulinum 
toxin or a placebo into the detrusor muscle. Therefore, this paper analyzed the microbiomes of 
those individuals that developed a post-instrumentation UTI and those that did not. We found 
that sequence negative indivudals were at a greater risk for a post-instrumentation UTI. 
Therefore, this is the first piece of evidence that a protective microbiome might exist. 
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Abstract 
Objectives. To characterize the urinary microbiota in women planning treatment for 
urgency urinary incontinence and to describe clinical associations with urinary symptoms, 
urinary tract infection and treatment outcomes. 
Study Design. Catheterized urine samples were collected from female multi-site 
randomized trial participants without clinical evidence of urinary tract infection and 16S rRNA 
gene sequencing was used to dichotomize participants as either DNA sequence-positive or 
sequence negative. Associations with demographics, urinary symptoms, urinary tract infection 
risk, and treatment outcomes were determined. In sequence-positive samples, microbiota were 
characterized on the basis of their dominant microorganisms. 
Results. Over half [51.1% (93/182)] of the participants’ urine samples were sequence-
positive. Sequence-positive participants were younger (55.8 vs. 61.3, p=0.0007), had a higher 
body mass index (33.7 vs. 30.1, p=0.0009), had a higher mean baseline daily urgency urinary 
incontinence episodes (5.7 vs. 4.2, p<0.0001), responded better to treatment (decrease in 
urgency urinary incontinence episodes −4.4 vs. −3.3, p=0.0013) and were less likely to develop 
urinary tract infection (9% vs. 27%, p=0.0011). In sequence-positive samples, eight major 
bacterial clusters were identified; seven clusters were dominated by a single genus, most 
commonly Lactobacillus (45%) or Gardnerella (17%), but also other taxa (25%). The remaining 
cluster had no dominant genus (13%). 
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Conclusions. DNA sequencing confirmed urinary bacterial DNA in many women without 
signs of infection and with urgency urinary incontinence. Sequence status was associated with 
baseline urgency urinary incontinence episodes, treatment response and post-treatment 
urinary tract infection risk. 
Introduction 
Urgency urinary incontinence (UUI) is a heterogeneous condition usually attributed to 
abnormalities in detrusor neuro-muscular functioning and/or signaling. However, most 
incontinence experts suspect that UUI etiology is likely more complex. Current first line 
treatment for UUI is behavioral and/or pharmacologic, but many affected patients have 
persistent symptoms. Thus, the group of women affected by the generic symptom of UUI may 
have multiple, heterogeneous etiologies.  
The Anticholinergic Versus Botulinum Toxin A Comparison (ABC) Trial was a 10-center, 
double-blind, double-placebo-controlled randomized trial in which women received either one 
intra-detrusor injection of 100 U of onabotulinumtoxin A and daily oral placebo or daily oral 
anticholinergic medication and one intra-detrusor injection of saline161. The ABC study was 
designed and conducted prior to knowledge that the female lower urinary tract (bladder and/or 
urethra) contains bacterial communities (termed the female urinary microbiome).  
Growing evidence suggests that the female urinary microbiota may play a role in certain 
urinary disorders such as UUI162. Our research team previously described the female urinary 
microbiota of women with UUI163 using catheterized urine samples obtained at baseline from 
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patient-participants in a randomized clinical trial for the treatment of UUI who did not have 
clinical urinary tract infection (UTI)161. Previously, we also compared various techniques to 
verify that transurethral catheterization was an appropriate method to collect urine samples 
with minimal vulvo-vaginal contamination4. This current analysis goes beyond the initial testing 
of the prior samples to formally characterize the female urinary microbiota by 16S rRNA gene 
sequence analysis. Relationships between sequence status, microbiota characteristics and 
clinical variables of interest, including treatment response and post-treatment UTI risk, were 
also assessed.   
Materials and Methods 
Subjects and Specimen Acquisition. 
The full methods of the trial and the primary outcome of the ABC trial have been 
published161,164. Briefly, the trial randomized women without neurologic disease with 
moderate-to-severe UUI, defined as having ≥5 episodes of UUI per 3-day period. Participants 
were anticholinergic drug naïve or had previously used ≤2 anticholinergic medications other 
than the study drugs. Exclusion criteria included a post-void residual volume ≥150 mL or 
previous therapy with oral study medications or onabotulinumtoxin A. 
The primary outcome was reduction from baseline in mean episodes of urgency urinary 
incontinence (UUIE) per day over the 6-month period, as recorded in 3-day diaries submitted 
monthly. Secondary outcomes included resolution of UUI symptoms, quality of life, use of 
catheters, and adverse events including UTI, which was defined as a positive standard urine 
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culture with >105 colony-forming units of a known uropathogen or treatment with antibiotic for 
UTI within 6 months of randomization. Following treatment, intermittent catheterization was 
recommended if post-void residual was either >300mL or >150mL with “moderate” to “quite a 
bit” of bother associated with incomplete voiding.  
  All subjects were free of clinical UTI prior to study injection, as determined by a negative 
nitrite and leukocyte esterase result on a urine dipstick evaluation of a catheterized specimen. 
Urine culture was not required. Following baseline assessment and prior to injection, subjects 
provided a baseline catheterized urine sample, which was placed at -80°C within 1 hour; the 
frozen samples were batch-shipped on dry ice to Loyola University Chicago for 16S rRNA gene 
sequence analysis. Staff and investigators were blinded to clinical information during laboratory 
research analyses.   
16S rRNA Sequencing. 
DNA was isolated in a laminar flow hood to avoid contamination. Genomic DNA was 
extracted from 1 ml of urine using previously validated protocols7,165,166. Variable region 4 (V4) 
of the bacterial 16S rRNA gene was amplified via a two-step nested polymerase chain reaction 
(PCR) protocol, using modified universal primers 515F and 806R, as previously described7,165. 
Two quality controls assessed the contribution of extraneous DNA from laboratory reagents: a 
DNA extraction negative control with no urine added and a PCR negative control with no 
template DNA added. The final PCR product was purified from unincorporated nucleotides and 
primers using Qiaquick PCR purification kit (Qiagen, Valencia, CA) and Agencourt AMPure XP-
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PCR magnetic beads (Beckman coulter). Samples were normalized to equal DNA concentration, 
as determined by Nanodrop spectroscopy (Thermo Scientific, Waltham, MA). The sample 
library and the PhiX sequencing control library (Illumina) were denatured and added to the 
2x250 bp sequencing reagent cartridge, according to manufacturer’s instructions (Illumina). 
DNA Sequencing Analysis. 
Illumina MiSeq post-sequencing software preprocessed sequences, removing primers 
and sample indices. The open-source program mothur (v1.31.2) combined paired end reads and 
removed contigs (overlapping sequence data) of incorrect length (<285 bp, >300 bp) and/or 
contigs containing ambiguous bases167. The remaining modified sequences were aligned to the 
SILVA reference database168. Chimeric sequences were removed using UCHIME. The remaining 
sequences were taxonomically classified using a naïve Bayesian classifier and the RDP training 
set v9, and clustered into operational taxonomic units (OTUs)169. METAGENassist was used to 
link OTU nomenclature to taxonomic assignments170. 
The ABC trial was conducted with full IRB approval at all participating sites.  All samples 
were processed in duplicate and characterized as sequence-positive, sequence-negative or 
inconclusive. A sequence-negative sample was one in which DNA was not amplified in either 
technical replica. To avoid accidentally sequencing rare contaminants, we conservatively 
considered samples to be negative if DNA amplification was not visible on an agarose gel. A 
sequence-positive sample was one in which DNA was amplified from both replicas, the replicas 
had a Euclidian distance score less than 0.3, and the dominant genus (>45% sequences per 
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sample), if present, was the same in both replicas. Samples not meeting these criteria were 
deemed inconclusive and disregarded from further analysis (n= 12). For each sequence-positive 
sample, percent reads were calculated and replicates were then averaged for downstream 
analysis.   
To display the average sequence abundances, a histogram was produced, color-coded 
by bacterial taxa. Euclidean distance was calculated between samples and the complete 
method was used for hierarchical clustering in the statistical package R v2.15.1. The resulting 
dendrogram was divided into 8 urotypes165. The rare urotypes were grouped into an “other” 
category, condensing the original 8 urotypes to a total of 5 urotypes for use in the analysis 
(Lactobacillus, Gardnerella, Gardnerella/Prevotella, Diverse, and Other) plus the negative 
category. These urotypes, along with the sequence-negative group, were then compared to 
participant demographics, symptoms at baseline and clinical outcomes.  
Statistical Analysis. 
 Differences were examined descriptively at baseline, as were changes in clinical 
outcome measures for individuals defined as sequence-positive and sequence-negative, as well 
as for individuals classified by urotype, further described below. The differences in binary 
baseline and outcome measures across these two categorical measures of sequence were 
examined via contingency tables, with p values generated from Chi-squared tests and 
differences in mean values for continuous measures evaluated using general linear models. 
Because all analyses were considered descriptive, no adjustments were made for multiple 
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comparisons and p values should be interpreted accordingly. To compare the mean abundance 
of the top 10 most abundant taxa, the Wilcoxon rank sum test was performed. Statistical 
analyses were conducted using SAS version 9.3. 
Results 
 Approximately half (51.1%, 93/182) the urine samples were sequence-positive. Table 
B.1 displays demographics and baseline characteristics of participants relative to sequence 
status; the mean age was 58.5 years and most participants were white (77%). Sequence-
positive subjects were younger (55.8 +/- 12.2 vs. 61.3 +/-9.0 years, p=0.0007), had a higher 
body mass index (33.7 +/- 7.3 vs. 30.1 +/- 6.6 kg/m2, p=0.0009) and had a higher mean number 
of baseline UUIE (5.7 +/- 2.5 vs. 4.2 +/- 2.1 per day, p<0.0001). Race, ethnicity, prior 
anticholinergic use, or study treatment assignment did not differ between sequence-positive 
and sequence-negative cohorts.  
Sequence-positive subjects responded better to treatment with a larger decrease in baseline 
UUIE (-4.4 +/- 2.7 vs. -3.3 +/- 1.9, p=0.0013) with no evidence of interaction with treatment 
group (p=0.92). In both groups, sequence-positive subjects were less likely to develop UTI after 
initiation of study anti- incontinence treatment (9% vs. 27% post treatment UTI’s, p=0.0011) 
(Table B.2). In sequence-positive urines, hierarchical clustering revealed eight major urotypes, 
as shown by the horizontal line (Figure B.1, top). In seven of these urotypes, a single bacterial 
genus or family dominated (i.e., represented >45% total sequences in a sample) (Figure B.1, 
bottom). 
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Table B.1. Baseline Characteristics and Sequence Status 
Characteristic Overall Sequence 
Positive 
Sequence 
Negative 
p-value 
Age, N 182 93 89 0.0007 
   Mean (SD)  55.8 (12.2) 61.3 (9.0)  
   Median (Min-Max)  55.8 (31.1-85.4) 61.2 (43.1–83.1)  
Ethnicity, N (%)    0.054 
   Hispanic  23 (25%) 12 (13%)  
   Non-Hispanic  70 (75%) 77 (87%)  
Race, N (%)    0.15 
   White  68 (73%) 73(82%)  
   Non-White  25 (27%) 16 (18%)  
BMI, N  93 89 0.0009 
   Mean (SD)  33.7 (7.3) 30.1 (6.6)  
   Median (Min-Max)  32.8(20.5-52.4) 28.8 (18.7-48.5)  
Menopausal Status, N (%)    0.059 
   Pre-menopausal  17 (20%) 8 (9%)  
   Post-menopausal  70 (80%) 77 (91%)  
Prior anticholinergic use, N 
(%) 
   0.97 
   Yes  52 (56%) 50 (26%)  
   No  41 (44%) 39 (44%)  
Baseline Urgency Urinary 
Incontinence Episodes (UUIE) 
Stratum, N (%) 
   0.0036 
   5 to 8  11 (12%) 26 (29%)  
   9+  82 (88%) 63 (71%)  
Baseline UUIE, N  93 89 <0.0001 
   Mean (SD)  5.66 (2.5) 4.20 (2.1)  
   Median (Min-Max)  5.00 (1.7-12.0) 3.67 (1.7-9.7)  
OABq** Symptom Severity, N  93 89 0.78 
   Mean (SD)  45.6 (20.7) 46.3 (24.0)  
   Median (Min-Max)  47.7 (0-90.8) 46.2 (6.2-98.5)  
Treatment, N (%)    0.47 
   Active onabotulinumtoxin A  42 (45%) 45 (51%)  
   Active anticholinergic 
medication 
 51 (55%) 44 (49%)  
*p-value, testing sequence positive versus negative, ** OABq: Overactive Bladder quantitative 
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Figure B.1. The Urinary Microbiota Profile of Sequence Positive Participants. 
The urinary microbiota profiles of sequence positive participants cluster together, as 
demonstrated in the dendrogram (top), and by the dominant bacterial taxa present, as 
depicted in the histogram (bottom). The dendrogram was based on clustering of the 
Euclidean distance between urine samples and each line represents a separate individual. 
Urine samples that possessed the same dominant bacterial taxa grouped together in the 
dendrogram and were classified into the following urotypes, as shown by the dashed 
horizontal line: Lactobacillus, Gardnerella, Gardnerella/Prevotella, Enterobacteriaceae, 
Staphylococcus, Aerococcus and Diverse. The placement of the urotype grouping line 
provided clear distinction of urine samples by the dominant genera, while maintaining 
clusters that contain at least 2 urine samples. The histogram displays the bacterial taxa 
detected by sequencing as the percentage of sequences per urine by sequence positive 
participants (N=93). Each bar on the x-axis represents the urinary microbiota sequence based 
composition of a single participant. The y-axis represents the percentage of sequences per 
participant with each color corresponding to a particular bacterial taxon. Bacteria were 
classified to the genus level with the exception of Enterobacteriaceae and Lachnospiraceae, 
which could only be classified to the family level. The 15 most sequence abundant bacterial 
taxa were displayed and the remainder of the taxa, including unclassified sequences, were 
grouped into the category “Other”. 
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For example, in the first urotype, Enterobacteriaceae accounted for >90% of the total 
sequences in all of the eight samples. Nearly half of the sequence positive urines were 
dominated by the genus Lactobacillus (45%), followed by Gardnerella (17%), 
Gardnerella/Prevotella (9%), Enterobacteriaceae (9%), Staphylococcus (3%), Aerococcus (2%) 
and Bifidobacterium (2%). The remaining cluster was labeled “Diverse” to signify those (13%) 
without a dominant genus. While these more diverse samples were often composed of 
different genera, they grouped together (Figure B.1, bottom). Each urotype was observed in 
samples from ≥2 performance sites and several urotypes were observed at multiple clinical 
sites (Table B.3). 
 Most sequence-positive samples had a dominant genus (Figure B.1). To assess the 
prevalence of these genera in samples where they did not dominate, we calculated the 
proportion of sequences belonging to the dominant taxon of each urotype across all sequence- 
positive samples. Figure B.2 demonstrates that nearly all the sequence-positive samples 
contained Lactobacillus (with a median 20% Lactobacillus sequences per urine sample). With 
the exception of Gardnerella, the other urotype-defining taxa were less commonly detected in 
samples outside those they dominated. Cluster analysis (Figure B.1) revealed eight major 
urotypes: Lactobacillus, Gardnerella, Gardnerella/Prevotella, Enterobacteriaceae, 
Staphylococcus, Aerococcus, Bifidobacterium, and Diverse. Although some major clusters 
(especially Lactobacillus, Gardnerella and Diverse) branched into sub-clusters, for further 
analyses, we treated these sub-clusters as one urotype.  
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We also combined the less common urotypes (Gardnerella/Prevotella, 
Enterobacteriaceae, Staphylococcus, Aerococcus and Bifidobacterium) together (Other). We 
compared these five urotypes and the sequence-negative group to baseline demographic and 
clinical variables. 
Table B.2. Clinical Outcomes by Sequence Status 
Characteristics Sequence 
Positive 
Sequence Negative p-value 
Urinary tract infection, N (%)   0.001 
   Yes 8 (9%) 24 (27%)  
   No 85 (91%) 65 (73%)  
Change in UUIE, N 90 89 0.0013 
   Mean (SD) -4.36 (2.7) -3.32 (1.9)  
   Median (Min-Max) -4.03 (-11.7 – 0.7) -3.17 (-9.3-2.5)  
OABq Symptom Severity Change, N 90 89 0.37 
   Mean (SD) -46.8 (23.8) -43.7 (22.7)  
   Median (Min-Max) -48.1 (-86.7 – 
11.1) 
-44.4 (-93.3 – 9.2)  
OABq HRLQ* Change, N 90 89 0.60 
   Mean (SD) 39.2 (21.9) 37.2 (25.2)  
   Median (Min-Max) 37.5 (-9.0-96.7) 36.9 (-28.8-93.8)  
*Health Related Quality of Life Measurement 
Table B.3. Urotype Distribution Among Collection Locations.  
For each urotype, we verified that the samples came from at least two study sites, to rule out 
bias due to the collection location.  
Urotype N Site ID 
Aerococcus 2 08, 22 
Bifidobacterium 2 02, 16 
Diverse 12 02, 07, 15, 17, 18, 21 
Enterobacteriaceae 8 02, 06, 07, 17, 18 
Gardnerella 16 02, 06, 07, 15, 16, 17, 18, 22 
Gardnerella/Prevotella 8 02, 07, 08, 18, 22 
Lactobacillus 42 02, 06, 07, 14, 15, 16, 17, 18, 21, 22 
Staphylococcus 3 02, 17 
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Figure B.2. Distribution of Dominant Taxa in Urine of All Sequence Positive Participants 
The sequence proportion of dominant taxa (taxa that accounted for greater than 45% of 
the sequences in at least one sample) were graphed for the sequence positive samples 
(N=93). The boxplots represent the 25th, 50th and 75th percentile of the sequence 
proportion, while points represent outliers. Lactobacillus was detected in the majority of 
urine samples and the sequence abundance ranged from 0 to 100% of the total 
sequences per sample. The median amount of Lactobacillus sequences detected per 
urine was 20%. Gardnerella was the second most frequently detected genus, with 43% 
of samples containing >1% Gardnerella sequences Whereas Staphylocccus, Aerococcus, 
Enterobacteriaceae and Bifidobacterium were detected in high abundance in a few 
samples, they were present at very low levels or not at all in the remainder of samples. 
For example, Staphylococcus and Aerococcus were detected at >45% of total sequences 
in only 3 and 2 samples, respectively. Lacto, Lactobacillus; Gard, Gardnerella; Prev, 
Prevotella; Staph, Staphylococcus; Aero, Aerococcus, Entero, Enterobacteriaceae, and 
Bifido, Bifidobacterium. 
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Figure B.3. Demographic Variable Distribution by Urotype, Including the Sequence-
Negative Group. 
Boxplots are shown comparing each urotype and the sequence negative group to A) 
age, B) weight, BMI and C) the number of UUI episodes at baseline for each 
participant. Aero=Aerococcus, Bif=Bifidobacterium, Ent=Enterobacteriaceae, 
Gard=Gardnerella, Lac=Lactobacillus, Div = diverse, G/P =Gardnerella/Prevotella, 
Staph=Staphylococcus and Neg = sequence-negative group. N stands for the number 
of samples within each group. 
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Whereas race, ethnicity and menopausal status were similar across urotypes, age 
(p=0.005) and body mass index (p=0.014) differed (Table B.4). Additional analysis detected an 
upward trend for age with the Enterobacteriaceae-dominant and Staphylococcus-dominant 
urotypes and a downward trend with the Gardnerella/Prevotella-dominant urotype (Figure 
B.3A). Body mass index tended to be lower in the Enterobacteriaceae-dominant, 
Staphylococcus-dominant and sequence negative groups (Figure B.3B), whereas symptom 
severity was similar across urotypes. 
While Staphylococcus-dominant and sequence-negative groups showed a trend towards 
lower baseline UUIE (Figure B.3C), the number of urine samples representing these urotypes 
was small and the analysis lacked statistical power. Treatment response (change in UUIE, 
p=0.0017) and development of post-treatment UTI (p=0.0058) differed among the 5 urotypes 
(Table B.5). Baseline UUIE differed by incontinence severity (p=0.046) and frequency 
(p<0.0001) (Table B.4). We compared the mean sequence abundance of sequence-positive 
participants by clinical variables. The two treatment cohorts (anticholinergic and 
onabotulinumtoxin A) displayed very similar mean sequence profiles at baseline, as predicted 
given randomized treatment assignment (Figure B.4).  However, the mean sequence profile of 
the sequence-positive women who developed a post-treatment UTI differed from those who 
did not develop a UTI. On average, sequence-positive women who developed a post-treatment 
UTI had fewer Lactobacillus sequences (14 vs. 46%, p=0.009) (Figures B.4 and B.5). 
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Table B.4. Baseline Characteristics as a Function of Urotype. 
Characteristic Lactobacillus Gardnerella Diverse Other Negative p-value 
Age, N 42 16 12 23 89 0.0005 
   Mean (SD) 53.2 (11.5) 53.7 (10.0) 61.0(11.2) 59.5 (14.0) 61.3 (9.0)  
   Median  53.5 54.2 60.3 58.4 61.2  
Ethnicity, N (%)      0.24 
   Hispanic 10 (24%) 5 (31%) 4 (33%) 4 (17%) 12 (13%)  
   Non-Hispanic 32 (76%) 11 (69%) 8 (67%) 19 (83%) 77 (87%)  
Race, N (%)      0.20 
   Caucasian 28 (67%) 11 (69%) 11 (92%) 18 (78%) 73 (82%)  
   Non-Caucasian 14 (33%) 5 (31%) 1 (8%) 5 (22%) 16 (18%)  
BMI, N 42 16 12 23 89 0.014 
   Mean (SD) 33.8 (7.6) 32.6 (5.2) 35.2 (8.7) 33.3 (7.3) 30.1 (6.6)  
   Medain 32.5 32.4 36.0 32.8 28.8  
Menopausal 
Status,  
N (%)  
     0.22 
   Pre-menopausal 10 (26%) 4 (22%) 2 (17%) 1 (6%) 8 (9%)  
   Post-
menopausal 
29 (74%) 14 (78%) 10 (83%) 17 (94%) 77 (91%)  
Prior 
anticholinergic 
use, N (%) 
     0.71 
   Yes 23 (55%) 8 (50%) 9 (75%) 12 (52%) 50 (56%)  
   No 19 (45%) 8 (50%) 3 (25%) 11 (48%) 39 (44%)  
Baseline UUIE 
Stratum,  
N (%) 
     0.046 
   5 to 8 6 (14%) 2 (12%) 0 (0%) 3 (13%) 26 (29%)  
   9+ 36 (86%) 14 (88%) 12 (100%) 20 (87%) 63 (71%)  
Baseline UUIE, N 42 16 12 23 89 <0.0001 
   Mean (SD) 5.0 (2.1) 6.0 (2.8) 6.2 (1.9) 6.3 (2.9) 4.2 (2.1)  
   Median 4.50 5.17 6.50 6.00 3.67  
OABq Symptoms 
Severity, N 
42 16 12 23 89 0.49 
   Mean (SD) 65.2 (17.4) 66.6 (19.1)  69.2 
(17.5) 
73.8 (21.4) 68.8 
(18.5) 
 
   Median  60.0 71.67 70.0 76.7 70.0  
OABq HRQL, N 42 16 12 23 89 0.32 
   Mean (SD) 49.0 (17.7) 49.5 (21.2) 42.9 
(24.1) 
37.5 (22.5) 46.3 
(24.0) 
 
   Median  50.8 53.7 40.0 43.1 46.2  
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Table B.5. Clinical Outcomes as a Function of Urotype 
Characteristics Lactobacillus Gardnerella Diverse Other Negative p-value 
UTI, N (%)      0.0058 
   Yes 1 (2%) 1 (6%) 1 (9%) 5 (22%) 24 (27%)  
   No 41 (98%) 15 (94%) 11 (91%) 18 (78%) 65 (73%)  
Change in 
UUIE, N 
42 16 12 23 89 0.0017 
   Mean (SD) -3.8 (2.3) -4.9 (3.0) -5.2 (1.9) -5.0 (3.1) -3.3 (1.9)  
   Median -3.61 -4.08 -5.53 -4.90 -3.17  
OABq 
Symptom 
Severity 
Change, N 
42 16 12 23 89 0.38 
   Mean (SD) -42.7 (24.7) -48.0 (25.2) -51.8 (18.5) -51.1 (24.2) -43.7 
(22.7) 
 
   Median -45.0 -46.7 -48.2 -54.4 -44.4  
OABq HRQL 
Change, N 
42 16 12 23 89 0.38 
   Mean (SD) 35.2 (19.7) 36.4 (28.6) 48.5 (17.4) 43.8 (21.3) 37.3 
(25.2) 
 
  Median 33.5 35.3 48.5 46.4 36.9  
 
Discussion 
In adult women with UUI, the composition of the urinary microbiota is identifiable, 
variable and related to certain clinical variables of potential importance. As the female urinary 
microbiota has only recently been detected4,7,14,60,93,163,165, an expanded perspective is 
warranted. The current study demonstrates that the status of the female urinary microbiota 
(sequence-positive or sequence-negative) can be used to sub-classify women with UUI and that 
sequence-positive women can be further sorted by composition into urotypes, based on the 
dominant bacterial genus or family or the lack thereof. The clinical utility of such sorting is yet 
to be established. However, the likelihood that UUI is a heterogeneous urinary disorder could 
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make this new approach useful for patient phenotyping.  
 
Although the ABC study was designed prior to knowledge of the female urinary 
microbiota and our analysis was not based on an a priori hypothesis, the current findings add to 
the growing evidence that document the existence and define the characteristics of the female 
urinary microbiota4,7,14,60,93,163,165. Further study of the differences in biomass (sequence 
positive vs. sequence negative) and the microbial diversity by specific and dominant organisms 
is likely to advance our knowledge of UUI. The composition of the urinary microbiota and its 
clinical relationships also requires further study in other clinically relevant groups, including 
Figure B.4. Urinary Microbiota Profiles by UTI Outcome 
The 15 most abundant bacteria detected by sequencing were displayed as the percentage of 
sequences per sample on the y-axis. The vertical bars along the x-axis represent the microbiota 
profile of individual participants separated by UTI outcome. The urinary microbiota profiles of 
the eight UTI positive participants consist of the following urotypes: 1 Lactobacillus, 1 
Gardnerella, 2 Enterobacteriaceae, 1 Staphylococcus, 1 Aerococcus, 1 Bifidobacterium and 1 
diverse. The proportion of Lactobacillus-dominant urines and diverse urines is less in the UTI 
positive group compared to the UTI negative group. 
- 140 - 
 
 
 
women undergoing surgery for prolapse and/or stress urinary incontinence, and those without 
lower urinary tract symptoms. 
To understand potential clinical relationships with the female urinary microbiota, 
studies of comparison populations are clearly needed, including asymptomatic women and 
those affected by non-UUI urinary symptoms. In an unrelated, smaller study, we compared the 
female urinary microbiota of adult women with and without UUI165. The results of this previous 
study closely align with those of the current one. Approximately half the samples were 
sequence-positive and most of those were dominated by one genus, with the Lactobacillus and 
Gardnerella urotypes most common. However, several species were strongly associated with 
UUI. These include emerging uropathogens (e.g., Aerococcus urinae, Gardnerella vaginalis, and 
Lactobacillus gasseri). In contrast, Lactobacillus crispatus was associated with women without 
lower urinary tract symptoms.   
The bladder is an environment with low bacterial abundance, unlike the gut or the 
vagina. Although bacterial DNA was not sequenced from approximately half of our participants’ 
urine samples, it is possible that these sequence-negative bladders are not sterile, but rather 
contain bacteria at low difficult-to-sequence levels. The existence of this sequence-negative 
status is clinically important, as this group was at significantly greater risk for post-treatment 
UTI. This finding will require further study; it is possible that certain organisms, such as 
Lactobacillus, play an important regulatory or protective role to challenge the growth of 
common uropathogens, such as E. coli.  
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Combined with the extreme sensitivity of PCR, caution is needed in low abundance 
environments to appropriately distinguish true members of the urinary microbiota from rare 
contaminants. Thus, we conservatively considered samples that amplified weakly to be 
Figure B.5. Comparison of Average Bacterial Sequence Abundance in Urine by 
Treatment Group and UTI Outcome. 
The average amount of bacterial sequences detected in the sequence positive urine of 
each randomized treatment cohort (anticholinergic versus botox) and UTI outcome cohort 
(positive versus negative) was calculated. The average bacterial sequence abundance 
profiles were similar between treatment cohorts, whereas the profiles differed between 
UTI outcome cohorts. 
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sequence-negative to avoid over-interpretation of microbiota components. Even so, it is 
notable that the improved methods used in the current study reproducibly detected bacterial 
DNA in the urine of 56% of women in this population, compared to 39% in our previous 
analysis163. 
DNA-based techniques are increasingly popular for microbiota study because they can 
detect bacteria without culture. Indeed, several groups have used 16S rRNA gene sequence 
analysis to detect a microbiota in the lower urinary tract of adult women and men4,7,60,93,165,171-
173. Clinical reliance on standard urine cultures has limited our consideration of bacteria as 
etiological contributors to idiopathic lower urinary tract disorders, including UUI. This is 
because standard urine culture techniques underestimate the composition and diversity of 
bacteria, especially those that inhabit the lower urinary tract. Expanded urine culture 
techniques have been recently developed and shown to significantly outperform the standard 
techniques7,14, but these new methods were developed after the samples in this study were 
obtained. Importantly, recent studies using our newly developed expanded quantitative urine 
culture (EQUC) method have documented that bacteria detected by 16S rRNA sequencing are 
alive and thus the sequencing is not simply detecting DNA of dead organisms7,165.  
Some investigators may consider our analysis limited because our operational definition 
of “clinically free of UTI” used a negative dipstick, rather than require that they have a negative 
standard urine culture at baseline. Given the significant limitations of standard urine 
culture7,14,165, however, we do not consider this a major limitation for the ABC study or this 
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analysis. Furthermore, few samples included uropathogens, typically detected by standard 
urine culture (e.g., E. coli) that could be indicative of a UTI. Given the nature of the index study, 
which was aimed at clinical treatment of affected patients, there is no age-matched control 
population without UUI symptoms in this randomized trial. As one of the first studies of the 
female urinary microbiota, it is underpowered to definitively assess differences in the 
distribution of the urinary microbiota by race or certain other variables.  
Women with UUI are a heterogeneous population on the basis of their baseline urine 
bacterial sequence status and/or urotype. Nearly half of female trial participants with UUI, 
without evidence of clinical infection, had a urotype that was typically dominated by a single 
genus, most often Lactobacillus or Gardnerella. These bacterial communities appear to have 
clinical relationships with baseline UUI symptoms, response to treatment and risk for post-
treatment UTI. As research in this area expands and incorporates samples from other clinically 
relevant populations, we fully anticipate further refinements in our understanding of the role of 
the female urinary microbiota in health and disease. Our findings suggest that previously 
undetected bacteria in the bladder of women may have a role in UUI, providing expanded 
opportunities for prevention and improved treatment approaches for UUI, such as modification 
of the microbiota to improve response to UUI treatments. Our findings also suggest that some 
bacteria may play a protective role in the bladder as they do in other human biological niches. 
The potential for such a protective role warrants further study.
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APPENDIX C 
THE FEMALE URINARY MICROBIOME: A COMPARISON OF WOMEN WITH AND WITHOUT 
URINARY URGENCY INCONTINENCE 
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Overview of Appendix C 
 This paper was the first comparison between women with UUI and continent controls. 
Women with urgency urinary incontinence and continent controls were recruited at the Loyola 
urogynecgology department. At the initial visit, all UUI women underwent a clinical assesment, 
provided a catheterized urine speciment, and were prescribed 5mg of an anticholinergic. This is 
the description of the two cohorts at baseline. All sampels underwent 16S sequencing and 
EQUC. Another publication, Thomas-White & Hilt et al. 2016 (Appendix D)6, describes the 
conclusion of the study.  
We found that the microbiomes of UUI women are more diverse than controls, by total 
species isolated and number of OTUs. We also identified a single bacterial species, Lactobacillus 
crispatus, that is associated with controls and 10 species associated with UUI, including 
Actinobaculum schaalii, Actinomyces neuii, Aerococcus urinae, Arthrobacter cumminsii, 
Corynebacterium coyleae, Corynebacterium riegelii, Gardnerella vaginalis, Lactobacillus gasseri, 
Oligella urethralis, and Streptococcus anginosus.  Finally, this paper included an analysis of the 
comparison of 16S sequencing to EQUC and found that the two results are comparable, but 
both have strengths and weaknesses.  
Abstract 
Bacterial DNA and live bacteria have been detected in human urine in the absence of 
clinical infection, challenging the prevailing dogma that urine is normally sterile. Urgency 
urinary incontinence (UUI) is a poorly understood urinary condition characterized by symptoms 
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that overlap urinary infection, including urinary urgency and increased frequency with urinary 
incontinence. The recent discovery of the urinary microbiome warrants investigation into 
whether bacteria contribute to UUI. In this study, we used 16S rRNA gene sequencing to classify 
bacterial DNA and expanded quantitative urine culture (EQUC) techniques to isolate live 
bacteria in urine collected by using a transurethral catheter from women with UUI and, in 
comparison, a cohort without UUI. For these cohorts, we demonstrated that the UUI and non-
UUI urinary microbiomes differ by group based on both sequence and culture evidences. 
Compared to the non-UUI microbiome, sequencing experiments revealed that the UUI 
microbiome was composed of increased Gardnerella and decreased Lactobacillus. Nine genera 
(Actinobaculum,  Actinomyces, Aerococcus, Arthrobacter, Corynebacterium, Gardnerella, 
Oligella, Staphylococcus, and Streptococcus) were more frequently cultured from the UUI 
cohort. Although Lactobacillus was isolated from both cohorts, distinctions existed at the 
species level, with Lactobacillus gasseri detected more frequently in the UUI cohort and 
Lactobacillus crispatus most frequently detected in controls. Combined, these data suggest that 
potentially important differences exist in the urinary microbiomes of women with and without 
UUI, which have strong implications in prevention, diagnosis, or treatment of UUI.  
New evidence indicates that the human urinary tract contains microbial communities; 
however, the role of these communities in urinary health remains to be elucidated. Urgency 
urinary incontinence (UUI) is a highly prevalent yet poorly understood urinary condition 
characterized by urgency, frequency, and urinary incontinence. Given the significant overlap of 
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UUI symptoms with those of urinary tract infections, it is possible that UUI may have a 
microbial component. We compared the urinary microbiomes of women affected by UUI to 
those of a comparison group without UUI, using both high-throughput sequencing and 
extended culture techniques. We identified statistically significant differences in the frequency 
and abundance of bacteria present. These differences suggest a potential role for the urinary 
microbiome in female urinary health.  
Introduction 
The female urinary tract is a previously overlooked microbial niche. Recent detection of 
bacterial DNA4,60,174, and live bacteria7,14 in urine from women with and without lower urinary 
tract symptoms has provided compelling evidence that the female urinary tract possesses its 
own unique microbiota. Research into the roles of these bacterial communities in urinary 
health and disease requires sensitive and specific detection and classification. Although the 
comparatively low bacterial load in urine challenges such effort, expanded culture conditions 
have allowed researchers to detect bacteria at lower levels than previously used techniques. 
For example, we recently reported that bacteria overlooked by standard culture conditions are 
cultivable by adjusting the growth conditions to include increased urine volume, diverse growth 
media and atmospheric conditions, and lengthened incubation time7. Using expanded 
quantitative urine culture (EQUC), we isolated bacteria from 80% of examined urine samples 
collected by transurethral catheter, most (92%) of which had been reported as “no growth,” 
using a standard clinical microbiology urine culture protocol and a 103-CFU/ml threshold7. 
- 148 - 
 
 
 
Despite this significant advance, many urinary bacteria cannot be cultured under these 
conditions. Thus, culture-independent methods for bacterial detection, such as high-
throughput sequencing of the 16S rRNA gene, have emerged as the predominant research 
technique, especially as they become increasingly accessible due to declining sequencing cost 
and improved bioinformatics tools175. 
 There is a clinical need for these improved research techniques. For example, urgency 
urinary incontinence (UUI) is poorly understood chronic urinary condition that is often 
attributed to abnormal neuromuscular signaling and/or functioning. However, alternative or 
complementary mechanisms beyond neuromuscular abnormalities must be considered, since 
UUI pharmacological treatments aimed at the overactive bladder are ineffective in 
approximately half of the pharmacologically treated UUI population176,177. 
 UUI is common, affecting 1.5 to 22% of the U.S. population, most frequently women and 
the elderly177. Affected patients experience a sudden, intense need to urinate with involuntary 
urine loss that detracts from the patient’s quality of life178. A proportion of UUI cases resolve 
over time; however, it is a chronic condition for most women177. There is a large socioeconomic 
burden, with the costs of UUI in the United States projected to reach $76.2 billion by 2015110. 
 The clinical diagnosis of UUI requires exclusion of urinary tract infections (UTI); thus, 
infectious etiology is not considered for UUI. Given the clinical similarly of UUI and UTI 
symptoms, however, we and others have recently used expanded culture techniques7,14 and 
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quantitative PCR174 to show the presence of bacteria in standard culture-“negative” urine 
samples collected from UUI patients. 
 In this analysis, we utilized both 16S rRNA gene sequencing and EQUC to characterize 
the microbiome in urine obtained by transurethral catheter from women seeking treatment for 
UUI and a comparison group of women without UUI. Utilizing both techniques, we identified 
statistically significant differences in the frequency and abundance of bacteria present, 
suggesting a potential role for the urinary microbiome in female urinary health. 
Results 
Cohort Description. 
Table C.1 displays the UUI symptoms by cohort. Consistent with the intended 
composition of the cohorts, the UUI cohort reported more distress on both the urinary and 
prolapse subscales of the Pelvic Floor Distress Inventory (PFDI) (urinary distress inventory [UDI], 
102 [±47] versus 11 [±11] [P < 0.05]; Pelvic Organ Prolapse Distress Inventory [POPDI], 70 [±52] 
versus 28 [±32] [P < 0.05]). The UUI cohort also reported more-severe overactive bladder (OAB) 
symptoms (66 [±23] versus 4 [±7]; P < 0.05) and decreased quality of life as measured by health-
related quality of life (HRQL) (56 [±25] versus 99 [±3]; P < 0.05) compared to the non-UUI 
cohort. Table C.1 also displays the participant demographics by cohort. Marital status, diabetes, 
smoking, and prior pelvic surgeries did not differ by group. However, the UUI cohort was 
heavier (body mass index [BMI], 32 [±8] versus 28 [±6]; P = 0.01), less likely to be using estrogen 
(27% versus 61%; P < 0.05), and older (63 [±12] versus 49 [±14]; P < 0.05). 
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Table C.1. Participant demographics and symptoms 
 Value for group (na)b or statistic 
Characteristic UUI (60) Non-UI Controls 
(58) 
p-value 
Demographics    
   Age (yrs) 63 (±12) 49 (±14) <0.05 
   Race [no. (%)]   0.42 
      Caucasian 50 (83) 41(77)  
      African American 10 (17) 11 (21)  
      Asian 0 (0) 1 (2)  
   Estrogen Status [no. (%)]   <0.05 
      Estrogen Positive 16 (27) 31 (61)  
      Estrogen Negative 43 (73) 20 (39)  
   BMI (kg/m2) 32 (±8) 28 (±6) 0.01 
   Hypertension [no. (%)] 21 (35) 9 (17) 0.03 
   Coronary artery disease [no. (%)] 9 (15) 1 (2) 0.02 
Symptoms    
   Symptom scored 66 (±23) 4 (±7) <0.05 
   Health related quality of life (HRQL)d 56 (±35) 99 (±3) <0.05 
   Urinary Distress Inventory (UDI)e 102 (±47) 11 (±11) <0.05 
Pelvic Organ Prolapse Distress Inventory 
(POPDI)e  
70 (±52) 28 (±32) <0.05 
Colorectal-Anal Distress Inventory 
(CRADI)e 
71 (±61) 43 (±62) 0.02 
an, no. of subjects. bMean ± SD or no. (%). 
cPearson’s chi-square and Fisher’s exact tests were used with categorical variables. Student’s t test was used with 
continuous variables. 
dBased on OAB questionnaire. 
eBased on Pelvic Floor Disease Inventory. 
 
Sequence-Based Characterization of Female Urinary Microbiome. 
 Bacterial DNA was detected in similar proportions of urine samples (UUI, 63.9% [23/36]; 
non-UUI, 65.8% [25/38]). The lack of bacterial detection in the remaining samples may be due 
to low bacterial load, insufficient bacterial lysis, and/or primer bias rather than being conclusive 
evidence of no bacteria in these urine samples. 
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 Further analyses were performed on the samples with detectable bacterial DNA (for 
UUI, n = 23; for non-UUI, n = 25). The sequences from these samples were classified into 22 
phyla, 34 classes, 69 orders, 150 families, and 386 genera. The most abundant phyla detected 
were Firmicutes, with a median abundance of 60%, followed by Actinobacteria (16%), 
Proteobacteria (1.5%), and Bacteroidetes (0.6%). From each sample, the majority of sequences 
could be classified to the genus level. The two exceptions (C031 and C033) were 
predominantly Enterobacteriaceae (Figure C.1). In the remainder of the samples, the 
percentage of sequences per sample that could not be classified to the genus level ranged from 
Figure C.1. Urinary microbiome profile by cohort based on 16S rRNA gene V4 sequencing. 
Stacked bar plots depict the sequence abundances of the 15 most abundant genus- or 
family-level taxa in the UUI and non-UUI cohorts. Taxa were ranked according to mean 
abundance across all samples. The y-axis represents the percentage of sequences for a 
particular bacterial taxon; the x-axis represents the study participants separated by cohort. 
The family Enterobacteriaceae could not be classified to the genus level. The remainder of 
sequences was combined in the category labeled Other. 
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0.02 to 24.1%. At the genus level, the majority of urine samples were dominated by one or two 
bacterial families or genera, most frequently Lactobacillus and Gardnerella (Figure C.1).  
Table C.2. Urotype frequency by cohort 
 No. (%) of participants for group (na) p-valuec 
Urotype UUI (23)b Non-UI Controls 
(25)b 
p-value 
Gardnerella 6 (26) 3 (12) 0.23 
Sneathia 2 (9) 0 (0) 0.22 
Diverse 4 (17) 5 (20) 0.99 
Staphylococcus 1 (4) 0 (0) 0.48 
Enterobacteriaceae 0 (0) 2 (8) 0.49 
Lactobacillus 10 (43) 15 (60) 0.39 
an, no. of subjects.   cFisher’s exact test.    bAnalysis performed on the subset of samples with detectable bacterial 
DNA. 
 
Urine samples with the same dominant taxa clustered together in a dendrogram 
generated via hierarchical clustering of the Euclidean distance between urine samples (Figure 
C.2). We observed six groups, now termed urotypes, which were named based on either the 
dominant family or genus (Gardnerella, Sneathia, Staphylococcus, Enterobacteriaceae, and 
Lactobacillus) or the lack of a dominant family or genus (“diverse”). The most frequent urotype 
in both cohorts was Lactobacillus (43% UUI and 60% non-UUI controls), followed 
by Gardnerella (26% UUI and 12% non-UUI controls) (Table C.2). Three urotypes were present 
in both cohorts (Gardnerella, Lactobacillus, and diverse). The Staphylococcus and Sneathia 
urotypes were present only in the UUI cohort, whereas the Enterobactericeae urotype was 
present only in the Non-UI cohort; however, these differences were not statistically significant 
at our current sample size. 
- 153 - 
 
 
 
  
Figure C.2. Clustering of the urinary microbiome into urotypes. The dendrogram was based 
on hierarchical clustering of the Euclidean distance between samples in the combined UUI 
and non-UUI cohorts. The dashed line depicts where the clades were divided into 6 
urotypes: Gardnerella, Sneathia, Diverse, Staphylococcus, Enterobacteriaceae, and 
Lactobacillus. The Stacked bar plot below the dendrogram depicts the sequence 
abundances of the overall most abundant taxa. 
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We calculated the frequency that each genus was observed in each cohort (Figure C.3A). 
While Lactobacillus was detected in every sample in both cohorts, some genera were observed 
more frequently in one cohort than in the other. For example, Gardnerella (99% UUI, 60% non-
UUI; P = 0.003) and Aerococcus (74% UUI, 28% non-UUI; P = 0.002) were detected more 
frequently in the UUI cohort than in the non-UUI one. Conversely, Staphylococcus (61% UUI, 
92% non-UUI; P = 0.01) was observed less frequently in the UUI cohort than among non-UUI 
women. Actinobaculum (61% UUI, 44% non-UUI; P = 0.24) and Sneathia (22% UUI, 4% non-UUI; 
P = 0.09) exhibited a trend toward increased detection in the UUI cohort; however, this 
difference was not statistically significant at our current sample size. 
By calculating frequency, all samples are weighted similarly regardless of sequence 
abundance. For example, urine samples collected from control participants C013 and C036 both 
contained Lactobacillus sequences; however, the sequence abundances differed. For 
C013, Lactobacillus represented more than 99% of the sequences; for 
C036, Lactobacillus represented less than 5% of the total sequences (Figure C.1). To further 
investigate these differences, the median sequence abundance was calculated and compared 
between the cohorts (Figure C.3). The UUI cohort exhibited decreased Lactobacillus (14% UUI, 
67% non-UUI; P = 0.01) and increased Gardnerella (4% UUI, 0% non-UUI; P = 0.003) sequence 
abundances compared to those for the control cohort.  Figure C.S2 in the supplemental 
material displays the distribution of the 15 most abundant taxa detected by sequencing. 
 
- 155 - 
 
 
 
Figure C.3. Comparison of sequence-based urinary microbiome by cohort. The frequency (A) 
and median sequence abundance (B) of the overall most abundant taxa detected by 
sequencing were calculated. The families Enterobacteriaceae, Lachnospiraceae, and 
Ruminococcaceae could not be classified to the genus level. In panel A, a combination of 
Pearson chi-square and Fisher’s exact tests was used to compare the frequency of genera 
detected by sequencing between the cohorts. “*” represents a P value of <0.05. In panel B, a 
Wilcoxon rank sum test was used to compare the median sequence abundances between the 
cohorts. IQR, interquartile range. “*” represents P values of <0.05. 
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To measure the richness of the UUI and non-UUI urinary microbiomes, the number of 
observed operational taxonomic units (OTUs) and the Chao1 estimator were calculated. To 
measure diversity, the Shannon index and inverse Simpson index were calculated. Overall, the 
urinary microbiome exhibited an average of 97 OTUs per urine, a Chao1 index of 7,210, an 
inverse Simpson’s index of 1.72, and a Shannon index of 3.93 (Table C.3) There were no 
statistically significant differences between the UUI and non-UUI control cohorts based on 
these estimators of richness and diversity. 
Table C.3. Richness and diversity measures of the urinary microbiome 
Metric Total 
[mean 
(SD)] 
UUI (n=23)a Non-UUI controls 
(n=25)a 
p-valueb 
  Mean 
(SD) 
Min-Max Mean 
(SD) 
Min-Max  
No. of observed 
OTUs (richness) 
97.02 
(40.6) 
86.35 
(36.89) 
25-155 106.84 
(42.17) 
39-201 0.08 
Chao1 estimator 
(richness) 
7,210 
(5331) 
5, 977 
(4647) 
2,688-
20,021 
8,344 
(5,750) 
1,697-
22,997 
0.12 
Shannon index 
(diversity) 
1.72 (0.96) 1.70 
(0.91) 
0.17-3.68 1.74 
(1.02) 
0.30-3.83 0.88 
Inverse Simpson 
(diversity) 
3.93 (4.28) 3.69 
(3.39) 
1.03-
16.08 
4.15 
(5.07) 
1.07-
20.40 
0.71 
a Analysis performed on the subset of samples with detectable bacterial DNA. Min, minimum; Max, maximum. 
b Student’s t test. 
 
Culture-Based Characterization of the Female Urinary Microbiota 
Of the urine specimens assayed via EQUC, 71/90 (78.9%) grew bacterial species, while 
64 of the 71 (90.1%) that grew bacterial species were deemed culture negative (no growth) by 
standard culture. For the UUI and control cohorts, standard culture had false-negative rates of 
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90.3% and 90.0%, respectively. This highlights the limitations of the standard clinical 
microbiology protocol.  
Rarefaction curves comparing the number of bacteria species to the number of urine 
samples assayed reveal that the UUI cohort curve began to plateau at a higher number of 
isolates than the non-UUI cohort curve (Figure C.4), indicating that these two cohorts possess 
different urinary microbiota. In support of this supposition, there was a statistically significant 
difference between the median numbers of bacterial isolates cultured from the UUI women 
and those for the non-UUI women (4 [interquartile ratio (IQR) = 1 to 7] versus 1 [IQR = 1 to 
7]; P < 0.001). 
 
Figure C.4. Rarefaction curves of the cultured bacterial species by cohort. The plot depicts 
the number of species cultured via EQUC by the number of urine samples assayed. 
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The frequencies at which we culture each genus were compared between cohorts. Nine 
genera (Actinobaculum, Actinomyces, Aerococcus, Arthrobacter, Corynebacterium, Gardnerella, 
Oligella, Staphylococcus and Streptococcus) were more frequently isolated from the UUI cohort 
than from controls (Figure C.5). Four of these genera were isolated solely from the UUI cohort 
(Actinobaculum, Aerococcus, Arthrobacter, and Oligella); the concentrations ranged from 
10 CFU/ml to 100,000 CFU/ml. Using matrix-assisted laser desorption ionization–time of flight 
mass spectrometry (MALDI-TOF MS), the majority of the cultured isolates were classified to the 
species level, one taxonomic level further than was achievable with V4 sequencing. This finer 
level of resolution revealed additional differences between the cohorts. For example, the 
genus Lactobacillus was frequently detected in both cohorts; however, when examination at 
Figure C.5. Genus-level comparison of cultured urinary microbiota by cohort. The Pearson 
chi-square and Fisher’s exact tests were used to compare the frequencies of the genera 
isolated from urine via EQUC. *, P <0.05; **, P < 0.001. 
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the species level was done, distinct differences were detected between cohorts. Lactobacillus 
gasseri was more frequently isolated from the UUI cohort (27% UUI, 9% non-UUI; P = 0.02), 
whereas Lactobacillus crispatus was more frequently isolated from the control cohort (4% UUI, 
18% non-UUI; P = 0.037) (Figure C.6). Also, Actinobaculum schaalii, Actinomyces neuii, 
Aerococcus urinae, Arthrobacter cumminsii, Corynebacterium coyleae, Gardnerella vaginalis, 
Oligella urethralis, and Streptococcus anginosus were more frequently isolated from UUI 
women (see Table S2 in the supplemental material).  
 
 
Figure C.6: Species-level comparison of cultured urinary microbiota by cohort. The Pearson 
chi-square and Fisher’s exact tests were used to compare the frequencies of the species 
isolated from urine via EQUC. *, P < 0.05; **, P  < 0.01. 
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Figure C.7. Comparison of taxa detected by 16S rRNA gene sequencing and EQUC. (A) 
Comparison of sequence status and EQUC status for the 52 urine samples that were assayed by both 
methods. (B) Comparison of the taxa detected by sequencing and culture of the sequence-positive, 
EQUC-positive urine samples (n = 30). Each square was color coded based on whether the taxa were 
detected by sequence only (green), EQUC only (red), sequence and EQUC (yellow), or neither 
sequence nor EQUC (gray). 
A 
B 
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Comparison of Culture Versus Sequencing for Defining the Urinary Microbiome. 
More than half (58%; 30/52) of specimens examined by both EQUC and 16S rRNA gene 
sequencing tested positive for bacteria by both techniques. Bacteria were cultured from 14 
(27%) sequence-negative urine samples, while bacterial DNA was sequenced from 3 (6%) EQUC-
negative urine samples. Altogether, bacteria were detected in 90% (47/52) of urine samples by 
EQUC or sequencing or both. Only 10% (5/52) of the urine samples tested negative for bacteria 
by both approaches (Figure C.7A). 
 Of the 30 urine samples that were positive by both sequencing and EQUC, there was 
considerable overlap in terms of the bacterial taxa detected (Figure C.7B). A total of 18 
different genera were cultured, the majority of which were detected by sequencing, thus 
providing additional evidence of their presence in the urinary microbiome and indicating that 
many of the sequenced genera represent live bacteria. In some urine samples, EQUC detected 
genera that were not detected by sequencing; however, these nine genera were detected by 
sequencing in other urine samples, demonstrating that these genera could be amplified by the 
universal primers. Trueperella was the only cultured genus that was not detected at the 
sequencing level in any of the urine samples. In contrast, some genera, such as Atopobium, 
were detected via sequencing but not by culture, suggesting that even the expanded culture 
technique was limited. 
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Discussion 
 This analysis directly compared the urinary microbiome of women with UUI to that of 
women without UUI symptoms. We used two independent yet complementary techniques, 16S 
rRNA gene sequencing and extended culture, to characterize the female urinary microbiome. 
Both techniques identified statistically significant differences in the frequency and abundance 
of bacteria. These differences suggest a potential role for the urinary microbiome in female 
urinary health and warrant further study. 
 Each technique detected similar but not identical microbiome profiles. High-throughput 
sequencing provided the broader view of the bacteria present in the bladder, regardless of 
ability to cultivate the organisms. On the other hand, the cultured isolates could be identified to 
the species level, thus providing a finer level of resolution for the female urinary microbiome. 
Furthermore, these cultured isolates can be utilized in future studies to further investigate their 
potential for symbiosis or pathogenesis. Combined, these complementary techniques yielded 
overlapping results and provided the most complete description of the female urinary 
microbiome to date. 
 In both cohorts, one or two genera dominated the majority of the sequence profiles. 
The two most frequently detected genera, by both sequencing and culture, were Lactobacillus 
and Gardnerella. The former are lactic acid-producing, facultative anaerobic bacteria known to 
play protective roles in the vaginal tract by decreasing pH and producing various 
bacteriostatic/cidal compounds179,180. The latter are also facultative anaerobic bacteria 
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frequently isolated in the vaginal tract, often in association with bacterial vaginosis. In this 
study, Lactobacillus was detected at similar frequencies in both cohorts but displayed lower 
median sequence abundance for women with UUI than for those without UUI. Furthermore, at 
the species level, the Lactobacillus species differed between cohorts. Whereas L. gasseri was 
more frequently cultured in samples from the UUI cohort, L. crispatus was more frequently 
cultured in samples from controls. Why the distribution of these two Lactobacillus species 
differs between women with and without UUI remains unknown, but it is possible that these 
two members of the normal vagina flora perform distinct functions in the bladder. A similar 
scenario seems to be developing for Gardnerella, which was detected more frequently and in 
increased sequence abundance for the UUI cohort than for the non-UUI cohort. 
Since Gardnerella was detected in the urine of women without UUI, it is unlikely that the simple 
presence of Gardnerella indicates a dysbiotic environment. G. vaginalis can be cultured from 
the vaginal tracts of women with and without bacterial vaginosis181,182. G. vaginalis strains 
isolated from these two groups of women vary in their ability to adhere and induce cytotoxicity, 
suggesting the possibility of pathogenic and symbiotic strains of G. vaginalis182. Whether the 
isolates identified by MALDI-TOF MS as Gardnerella species fall into the latter category remains 
to be determined. 
Several bacterial genera were more frequently sequenced and cultured from the urine 
of women with UUI, including Actinobaculum, Actinomyces, Aerococcus, Arthrobacter, and 
Oligella. Interestingly, many of these genera contain emerging uropathogens, including 
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Actinobaculum schaalii, Aerococcus urinae, Oligella urealytica, and Arthrobacter cumminsii183-
187. Whether these bacteria contribute to UUI is unknown at this time. 
In addition to Lactobacillus and Gardnerella, many of the genera detected in the urinary 
microbiome are often found in the vaginal tract, including Bifidobacterium, Enterococcus, 
Actinomyces, Prevotella, and Atopobium15,181. Since the urine samples in this study were 
collected via transurethral catheter, as opposed to a voided approach, these genera are likely 
true inhabitants of the urinary tract and not vaginal contamination. This contention is 
supported by our previous demonstration that the microbiome sequence profile of 
catheterized urine is distinct from that of voided urine and instead closely resembles that of 
urine collected via suprapubic aspiration, which bypasses the vagina and urethra4. Genera 
found in both the urinary and vaginal tracts could suggest a shared urogenital microbiome. 
Alternatively, there could be differences at the species or strain levels, such that the vaginal and 
urinary community members differ. It is easy to imagine that the specific conditions of these 
quite different environmental niches could select for different traits. 
Two genera, Corynebacterium and Streptococcus, were cultured more frequently from 
UUI women yet were detected at similar frequencies by sequencing. A third 
genus, Staphylococcus, was more frequently cultured from UUI women but more frequently 
detected by sequencing in the control cohort. The simplest explanation for these discrepancies 
would be that certain species of these genera do not grow under the current EQUC conditions. 
Efforts to further extend this new protocol are planned. 
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Although the urinary microbiome shares a number of genera in common with other 
microbial sites within the human body, two key differences set the urinary microbiome apart. 
Compared to the colon, which contains 1011 to 1012 CFU/g188,  on average, the urinary tract 
microbiome consists of <104 CFU/ml total bacteria. In our study, the median amount of bacteria 
per urine was 85 CFU/ml. The urinary microbiome, with a median inverse Simpson index of 2.3 
and Shannon index of 1.5, is also less diverse than other microbial sites in the human body, 
such as the skin, mouth, and gastrointestinal tract2,189. Taken together, these findings suggest 
that the bladder is a relatively unique microbial site within the human body and may be more 
akin to other low-abundance sites, such as the eye171. 
Changes in microbial diversity within a niche have been linked to disease. Examples 
include decreased fecal microbiome diversity associated with Clostridium difficile infection190 
and increased vaginal microbiome diversity associated with bacterial vaginosis191. In this study, 
we did not detect large differences in sequence-based diversity between the two cohorts. It is 
possible that we were unable to detect a difference due to the lack of power with our small 
sample size. Alternatively, the amount of diversity within the urinary microbiome of UUI 
women may not differ from that for non-UUI women. Instead, the key distinction might be the 
bacterial types that are present. Although we did not detect differences in richness or diversity 
by sequence, we detected differences in the species richness between the cohorts by culture. A 
greater number of bacterial species were cultured from the UUI cohort than from the non-UUI 
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control cohort. This finding further demonstrates the power of utilizing multiple approaches to 
define a microbial community. 
The urine of UUI women was more likely to contain Actinomyces, Aerococcus, 
and Gardnerella and less likely to contain Lactobacillus than urine collected from women 
without UUI. The mechanism behind this observation is unknown. One possibility is that the 
UUI bladder selects for some bacteria over others, and as such, the presence of these 
organisms in the bladder could serve as a marker for dysbiosis. Another possibility is that these 
bacteria contribute to UUI symptoms, a supposition supported by the observation that each of 
the genera associated with the UUI cohort contains at least one reported pathogenic species. 
Taken together, this study, along with others, will eventually allow us to define a core or 
common urinary microbiome that can be used to detect alterations to that community.  
A limitation of this analysis is that our UUI and non-UUI cohorts differed in several 
characteristics that may have clinical relevance for the female urinary microbiome. Thus, we 
are unable to say whether age, BMI, or hormonal status affects our findings, and it is possible 
that our findings are related to these differences rather than to urinary symptomatology. 
Studies that describe the female urinary microbiome in large, well-characterized populations 
have not been published. Future studies, with larger sample sizes, will be required to evaluate 
these potentially important differences. Studies describing the longitudinal stability of the 
female urinary microbiome (including populations undergoing treatment for urinary disorders) 
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are also lacking. Such studies should be prioritized given the emerging evidence that the female 
urinary microbiome may yield important clinical information. 
Materials and Methods 
Study Design and Population. 
Following Loyola institutional review board (IRB) approval, participants gave verbal and 
written consent for chart abstraction and urine collection with analysis for research purposes. 
Participants were recruited from the clinical practice of the Female Pelvic Medicine and 
Reconstructive Surgery Center of Loyola University Medical Center between August 2012 and 
February 2014. These included women undergoing UUI treatment (UUI cohort) and a 
comparison group of women not bothered by urinary symptoms (non-UUI control cohort). All 
women were screened for potential study participation using the validated symptom 
questionnaire, the Pelvic Floor Distress Inventory (PFDI)192,193. Exclusion criteria for both 
cohorts included current UTI (based on urine dipstick) or history of recurrent UTI, antibiotic 
exposure in the past 4 weeks for any reason, immunologic deficiency, neurological disease 
known to affect the lower urinary tract, pelvic malignancy or radiation, untreated symptomatic 
pelvic organ prolapse (POP) greater than POP-Q stage II (vaginal protrusion more than 1 cm 
outside of the vaginal hymen), or pregnancy. Clinical and demographic information were 
abstracted from the electronic medical record. Enrolled participants completed the long form 
of the PFDI and the Overactive Bladder Questionnaire (OAB-q)110. Premenopausal woman and 
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postmenopausal women taking any form of estrogen replacement were considered estrogen 
positive. 
Sample Collection. 
Urine was collected aseptically via transurethral catheter. A portion of the urine sample 
was placed in a BD Vacutainer Plus C&S preservative tube for culturing. A separate portion for 
sequencing was placed at 4° C for <4 h following collection; 10% AssayAssure (Thermo 
Scientific; Waltham, MA) was added before storage at −80° C. 
 The first urine samples collected (14 UUI samples and 8 non-UUI control samples) were 
screened exclusively by 16S rRNA gene sequencing; this was before we implemented EQUC. 
Subsequent urine samples (22 UUI and 30 non-UUI control samples) were screened by both 16S 
rRNA gene sequencing and EQUC. The final urine samples (23 UUI and 15 non-UUI control 
samples) were screened only by EQUC without high-throughput sequencing. Thus, we used 
EQUC for 45 UUI and 45 non-UUI samples and 16S rRNA gene sequencing for 36 UUI and 38 
non-UUI samples. 
Urine Culture. 
For standard urine culture, we struck 0.001 ml of urine onto 5% sheep blood (BAP) and 
MacConkey agars (BD BBL prepared plated media), which were incubated aerobically at 35°C 
for 24 h. Each separate morphological colony type was counted and identified in any amount. 
The detection level was 1,000 CFU/ml, represented by 1 colony of growth on either plate. If no 
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growth was observed, the culture was reported as “no growth,” indicating no growth of 
bacteria at the lowest dilution, i.e., 1:1,000. 
For EQUC, we struck 0.1 ml of urine onto BAP, chocolate and colistin, naladixic acid 
(CNA) agars (BD BBL prepared plated media), which were incubated in 5% CO2 at 35°C for 48 h 
(see Figure S1). A second set of BAPs was inoculated with 0.1 ml of urine and incubated in room 
atmosphere at 35°C and 30°C for 48 h. We also inoculated 0.1 ml of urine onto each of two CDC 
anaerobe 5% sheep blood agar plates (BD BBL prepared plated media) and incubated either in a 
Campy gas mixture (5% O2, 10% CO2, and 85% N) or under anaerobic conditions at 35°C for 
48 h. The detection level was 10 CFU/ml, represented by 1 colony of growth on any of the 
plates. Finally, to detect any bacterial species that may be present at quantities lower than 
10 CFU/ml, 1.0 ml of urine was placed in thioglycolate medium (BD BBL prepared tubed media) 
and incubated aerobically at 35°C for 5 days. If growth was visually detected in the thioglycolate 
medium, the medium was mixed, and a few drops were plated on BAP and CDC Anaerobe 5% 
sheep blood agars for isolation and incubated aerobically and anaerobically at 35°C for 48 h. 
Each morphologically distinct colony type was isolated on a different plate of the same medium 
to prepare a pure culture that was used for identification. Matrix-assisted laser desorption 
ionization–time of flight mass spectrophotometry (MALDI-TOF MS) with the MALDI Biotyper 3.0 
software program (Bruker Daltonics, Billerica, MA) was used to identify the bacterial isolates, as 
described elsewhere7. To determine the false-negative rate, the following equation was used: 
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the number of false negatives (EQUC positive, standard negative) divided by the sum of the 
number of true positives (EQUC positive) and false negatives (EQUC positive, routine negative). 
DNA isolation from urine 
We used a previously validated DNA extraction protocol developed for the Human 
Microbiome Project. The protocol includes the addition of the peptidoglycan-degrading 
enzymes mutanolysin and lysozyme, which ensure robust lysis of Gram-positive and Gram-
negative species, to isolate genomic DNA from urine samples166. Briefly, 1 ml of urine was 
centrifuged at 13,500 rpm for 10 min, and the resulting pellet was resuspended in 200 µl of 
filter-sterilized buffer consisting of 20 mM Tris-Cl (pH 8), 2 mM EDTA, 1.2% Triton X-100, and 
20 µg/ml lysozyme and supplemented with 30 µl of filter-sterilized mutanolysin (5,000 U/ml; 
Sigma-Aldrich, St. Louis, MO). The mixture was incubated for 1 h at 37°C, and the lysates were 
processed through the DNeasy blood and tissue kit (Qiagen, Valencia, CA) according to the 
manufacturer’s protocol. DNA was eluted into 50 µl of buffer AE, pH 8.0, and stored at −20°C.  
16S rRNA Gene Library Generation and MiSeq Sequencing. 
Sequencing was performed using a MiSeq desktop sequencer (Illumina, San Diego, CA). 
First, a 16S rRNA gene amplicon library was generated via two consecutive PCR amplifications. 
In the first reaction, the variable 4 region (V4) of the 16S rRNA gene was amplified using the 
universal primers 515F and 806R, which were modified to encode the Illumina MiSeq 
sequencing primer sequence at the 5′ end (see Table C.S1 in the supplemental material). 
Reaction mixtures were incubated at 94°C for 2 min to denature the DNA template and 
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amplified for 30 cycles at 94°C for 30 s, 55°C for 30 s, and 72°C for 90 s. To ensure complete 
amplification, samples were incubated at 72°C for an additional 10 min. Ten-microliter aliquots 
of each reaction mixture were run on a 1% agarose gel. Samples containing a band of 
approximately 360 bp were considered PCR positive and subjected to further library 
preparation. Samples with no visible amplified product were considered PCR negative and not 
processed further. The PCR-positive reaction mixtures were diluted 1:50 and amplified for an 
additional 10 cycles, utilizing primers encoding the required adapter sequences for Illumina 
MiSeq sequencing and an 8-nucleotide (nt) sample index (see Table S1), using the PCR 
conditions described above. Unincorporated nucleotides and remaining primers were removed 
via use of the QIAquick PCR purification kit (Qiagen, Valencia, CA), and the DNA concentration 
of the eluted product was determined by Nanodrop spectroscopy (Thermo Scientific; Waltham, 
MA). One hundred nanograms of each sample amplicon was pooled and run through a 1% 
agarose gel. The final product, which includes the V4 region and the adapter sequences (390 to 
450 bp in length depending upon the length of the V4 region), was gel extracted via the 
QIAquick gel extraction kit and further purified via Agencourt AMPure XP-PCR magnetic beads 
(Beckman Coulter, Pasadena, CA). The final concentration of the pooled DNA was determined 
via Nanodrop spectroscopy and diluted in EBT (Elution Buffer with Tris; Illumina, San Diego, CA) 
to 2 nM. An equal volume of 0.2 N NaOH was added, incubated at room temperature for 5 min, 
and quenched with hybridization buffer (Illumina, San Diego, CA) to a final concentration of 
8 pM. The Human Microbiome Project mock community HM-782D (BEI Resources, ATCC, 
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Manassas, VA), a standard used to optimize our approach, was mixed 1:1 with randomly 
generated PhiX libraries, which are added to help focus the cameras on the sequencing clusters. 
This mixture was added to the sample library at equal volumes and placed in the 2 × 250 bp 
sequencing reagent cartridge according to the manufacturer’s instructions (Illumina, San Diego, 
CA). 
Care was taken to avoid bacterial DNA contamination by utilizing DNA-free reagents 
when applicable, filter sterilizing all solutions through a 0.2 µM filter, and working in a PCR-
clean hood. To control for the introduction of contaminating DNA, negative controls for 
extraction (no urine) and PCR (no template) were included in each experiment. The extraction 
negative control for each experiment was sequenced to identify spurious genera likely 
introduced from contaminated reagents and materials. 
Sequence Analysis. 
The Illumina MiSeq post-sequencing software preprocessed sequences by removing 
primers and sequence adaptors. Using the open-source software program mothur (v 1.31.2), 
the paired-end reads were assembled and contigs of incorrect length (<285 bp or >300 bp) 
and/or contigs containing ambiguous bases were removed167,194. These modified sequences 
were aligned to the SILVA reference database, and any potential chimeric sequences were 
detected and removed using the program UCHIME169. The remaining sequences were 
taxonomically classified, using a naive Bayesian classifier195 and the mothur-formatted RDP 
training set v9, and clustered into operational taxonomic units (OTUs), an operational definition 
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of a species-level cluster based on sequence similarity, using a 97% cutoff. The software 
program METAGENassist was used to link OTU nomenclature to taxonomic assignments170.  
 All samples were processed in duplicate, and the percent reads of the replicates were 
averaged for downstream analysis. Stacked bar plots based on sequence abundance were 
produced for each sample. Euclidean distance was calculated between samples, and the 
complete method was used for hierarchical clustering via R software, version 2.15.1196. 
Richness and diversity metrics, including the number of observed OTUs, Chao1 estimator, 
Shannon index, and inverse Simpson’s index, were calculated using mothur and were based on 
subsampling to the number of sequences in the sample with the least coverage. Urine is a low-
biomass environment, and thus the sequencing results are more likely to be influenced by 
extraneous DNA arising from reagents and resources; therefore, only reads representing 
>0.01% of the sample total were included in the stacked bar plots, dendrogram, and frequency 
and abundance analyses. 
Statistical Analysis. 
Statistical analyses, comparing participant demographics and symptoms, were 
performed using the SPSS software program, version 19. For continuous variables, 
Student’s t tests were applied. For categorical variables, Pearson chi-square and Fisher’s exact 
tests were performed. Results were considered significant when the P value was less than 0.05. 
 Statistical analyses of the microbiome data were performed using the SAS software 
program, version 9.3. The Wilcoxon rank sum tests were used to compare the median 
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abundances for the 15 most abundant sequenced taxa and all cultured genera between groups. 
The frequencies of detected genera were compared between groups, using either the Pearson 
chi-square or Fisher’s exact test, depending on assumption validity. No adjustments for multiple 
comparisons were made, since these analyses were considered descriptive. 
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Supplemental Material  
 
 
 
Figure C.S1. Outline of EQUC procedure.  
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Figure C.S2. Distribution of taxa detected by sequencing. The distribution of the top 15 most 
abundant taxa detected by sequencing is displayed as box plots. 
- 177 - 
 
 
 
Table C.S1. 16S ribosomal DNA (rDNA) V4 Amplicon Library Primers 
Primer  Primer sequence (5’ to 3’)  
Primary PCR primers  
Modified 515F  TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGGTGCCAGCMGCCGCGGTAA 
Modified 806R  GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGGGACTACHVGGGTWTCTAAT 
Secondary PCR primers  
501  AATGATACGGCGACCACCGAGATCTACACTAGATCGCTCGTCGGCAGCGTC  
502  AATGATACGGCGACCACCGAGATCTACACCTCTCTATTCGTCGGCAGCGTC 
503  AATGATACGGCGACCACCGAGATCTACACTATCCTCTTCGTCGGCAGCGTC  
504  AATGATACGGCGACCACCGAGATCTACACAGAGTAGATCGTCGGCAGCGTC 
505  AATGATACGGCGACCACCGAGATCTACACGTAAGGAGTCGTCGGCAGCGTC 
506  AATGATACGGCGACCACCGAGATCTACACACTGCATATCGTCGGCAGCGTC 
507  AATGATACGGCGACCACCGAGATCTACACAAGGAGTATCGTCGGCAGCGTC 
508  AATGATACGGCGACCACCGAGATCTACACCTAAGCCTTCGTCGGCAGCGTC 
701  CAAGCAGAAGACGGCATACGAGATTCGCCTTAGTCTCGTGGGCTCGG 
702  CAAGCAGAAGACGGCATACGAGATCTAGTACGGTCTCGTGGGCTCGG  
703  CAAGCAGAAGACGGCATACGAGATTTCTGCCTGTCTCGTGGGCTCGG  
704  CAAGCAGAAGACGGCATACGAGATGCTCAGGAGTCTCGTGGGCTCGG  
705  CAAGCAGAAGACGGCATACGAGATAGGAGTCCGTCTCGTGGGCTCGG  
706  CAAGCAGAAGACGGCATACGAGATCATGCCTAGTCTCGTGGGCTCGG  
707  CAAGCAGAAGACGGCATACGAGATGTAGAGAGGTCTCGTGGGCTCGG  
708  CAAGCAGAAGACGGCATACGAGATCCTCTCTGGTCTCGTGGGCTCGG 
709  CAAGCAGAAGACGGCATACGAGATAGCGTAGCGTCTCGTGGGCTCGG 
710  CAAGCAGAAGACGGCATACGAGATCAGCCTCGGTCTCGTGGGCTCGG  
711  CAAGCAGAAGACGGCATACGAGATTGCCTCTTGTCTCGTGGGCTCGG  
712   CAAGCAGAAGACGGCATACGAGATTCCTCTACGTCTCGTGGGCTCGG  
The adapter sequences are underlined in the 501 and 701 secondary primer sequences. The same 
sequences are found in each of the 500 and 700 primer series. The 8-nucleotide sample indices are 
bolded. 
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Overview of Appendix D 
 These data represent our first evidence that the bladder microbiome correlates with a 
health outcome, the response to medication. Because the symptoms of UUI and UTIs can 
overlap, a diagnosis of UUI is contingent upon a negative standard urine culture. Therefore, a 
bacterial etiology has not been considered for this disease. Instead, it is thought to be caused 
by aberrant signaling to the detrusor muscle, causing contractions and resulting in the urge to 
urinate. All medications aim to block this pathway in one way or another; however, all 
medications on the market have about a 50% efficacy rate. Therefore, we asked if there could 
be a bacterial component that would relate to response or lack of response to medication.  
This paper is the conclusion of the study reported on previously (Pearce et al 2014, 
Appendix C)3. In total, 74 UUI women and 60 controls were recruited. All patients had a clinical 
assessment and provided a catheterized urine sample for 16S rRNA sequencing and EQUC. The 
UUI patients were prescribed 5mg of the anticholinergic medication solifenacin. If they had not 
reported improvement from the medication by 4 weeks, they were given the option to increase 
to a 10mg dosage. By 12 weeks, we had 4 groups: controls, UUI patients that responded at 
5mg, UUI patients that responded to 10mg, and UUI patients that did not respond, even with 
an increased dose. We discovered that 5mg responders had a much less diverse (less rich) 
microbiota than 10mg and non-responders. Four bacterial species were more frequently 
isolated from 10mg and non-responders than from 5mg responders (Actinomyces neuii, 
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Staphylococcus simulans, Streptococcus anginosus, and Streptococcus pneumoniae 
/mitis/oralis). 
These data suggest that a more diverse bladder microbiota either prevents response to 
this medication or is the result of an environment that will not respond to medication. It also 
suggests that it is possible to predict who will respond to medication by measuring the total 
number of organisms in their bladder prior to treatment.  
Abstract 
Introduction. Many adult women have resident urinary bacteria (urinary 
microbiome/microbiota). In adult women affected by urinary urgency incontinence (UUI), the 
etiologic and/or therapeutic role of the urinary microbiome/microbiota remains unknown. 
Hypothesis. Microbiome/microbiota characteristics will relate to clinically relevant 
treatment response to oral UUI medication. 
Methods. Adult women initiating oral medication treatment for UUI and a comparator 
group of unaffected women were recruited in a tertiary care health care system. All participants 
provided baseline clinical data and urine. Women with UUI were given 5mg solifenacin with 
potential dose escalation to 10mg for inadequate UUI symptoms control at 4 weeks. Additional 
data and urine samples were collected from women with UUI at 4 and 12 weeks. The samples 
were assessed by 16S rRNA gene sequencing and enhanced quantitative urine culturing. The 
primary outcome was treatment response as measured by the validated Patient Global 
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Symptom Control (PGSC) questionnaire. Clinically relevant UUI symptom control was defined as 
a 4 or 5 score on the PGSC.  
Results. The diversity and composition of the urinary microbiome/microbiota of women 
with and without UUI differed at baseline. Women with UUI had more bacteria and a more 
diverse microbiome/microbiota. The clinical response to solifenacin in UUI participants was 
related to baseline microbiome/microbiota, with responders more likely to have fewer bacteria 
and a less diverse community at baseline. Non-responders had a more diverse community that 
often included bacteria not typically found in responders.   
Conclusions. Knowledge of an individual’s urinary microbiome/microbiota may help 
refine UUI treatment. Complementary tools, DNA sequencing and expanded urine culture, 
provide information about bacteria that appear related to UUI incontinence status and UUI 
treatment response in this population of adult women.  
Introduction 
Many adult women undergo treatment for urinary urgency incontinence (UUI), often 
with oral anticholinergic medication, such as solifenacin177. This medication class targets M3 
muscarinic receptors to decrease smooth muscle contraction, relieving UUI symptoms of 
urgency, frequency and urgency incontinence177. Although solifenacin decreases urgency 
episodes in approximately 60% of treated patients, symptoms may persist197-199 with 
approximately 40% of treated patients reporting bothersome symptoms 200. Clinicians recognize 
this lack of response, although the cause remains unclear and studies into the biologic basis for 
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persistent symptoms are lacking. Many UUI-affected patients are considered to have idiopathic 
etiology; however, this view pre-dates emerging evidence of resident urinary bacterial 
communities (urinary microbiota), recently reviewed 59,201,202. DNA sequencing and expanded 
urine culture techniques have demonstrated that adult urine is not sterile 4,5,7,13,14,59,60,203,204 and 
UUI-affected women have different resident bacterial compositions than non-UUI control 
populations203. 
 In this prospective cohort of adult women with UUI, we compared baseline urinary 
microbiota of women with UUI to those of non-affected controls. For UUI-affected women 
subsequently undergoing clinically indicated UUI treatment with solifenacin, we also 
determined urinary microbiota profiles throughout 12 weeks of treatment, using additional 
longitudinal samples collected at 4 and 12 weeks. We hypothesized that the 
microbiome/microbiota (e.g. diversity, overall community structure, and/or specific organisms) 
would differ between women with and without UUI and between those that responded to 
solifenacin and those that did not. Two complementary bacterial assessments, sequencing and 
expanded quantitative urine cultures (EQUC)7, were used to overcome the insensitivity of 
standard urine cultures. EQUC was not initially available; however, once this technique was 
available, it was applied to all remaining samples. 
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Methods 
Study Design and Population. 
This 12-week open label study began following Institutional Review Board approval. 
Participants gave verbal and written research consent for chart abstraction and urine collection 
with analysis for research purposes. Between August 2012 and July 2014, two cohorts of adult 
women were recruited at a tertiary health care setting, Loyola University Medical Center. 
Potential participants were screened for eligibility using the long version of the validated 
symptom questionnaire, the Pelvic Floor Distress Inventory (PFDI)193,205. Women seeking UUI 
treatment were recruited from a specialty Female Pelvic Medicine and Reconstructive Surgery 
center. Comparison controls screened negative for UUI using the PFDI and were recruited from 
women’s health practices within Loyola’s system. These controls were derived from a 
population of gynecologic patients; those who underwent surgical procedures had a variety of 
benign gynecologic conditions, most commonly abnormal uterine bleeding confirmed to be of a 
benign nature. Enrolled participants also completed the overactive bladder questionnaire (OAB-
Q)110. Exclusion criteria for both cohorts included current urinary tract infection (UTI) (based on 
urine dipstick), history of recurrent UTI, antibiotic exposure in the past four weeks for any 
reason, immunologic deficiency, neurological disease known to affect the lower urinary tract, 
pelvic malignancy or radiation, untreated symptomatic pelvic organ prolapse (POP) greater than 
POP-Q Stage II (vaginal protrusion more than one centimeter outside of the vaginal hymen) or 
pregnancy.  
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Control participants, without overactive bladder symptoms, provided a single 
catheterized urine sample for research purposes as well as clinical and questionnaire data. As 
part of normal clinical care, UUI-affected participants provided a catheterized urine sample 
prior to UUI treatment with solifenacin, which was provided at no cost for 12 weeks. 
Participants with UUI also agreed to provide 2 additional catheterized urine samples at 4 and 12 
weeks during UUI treatment for longitudinal analysis. The primary outcome was treatment 
response at 12 weeks. Treatment response was assessed (at 4 and 12 weeks) using the 
validated Patient Global Symptom Control (PGSC) questionnaire, which consists of a single 
question that addresses improvement following treatment. Scores of 4 or 5 were defined as 
“response”. PGSC scores <3 were considered “non-response”; these participants were offered a 
dosage increase to 10mg at 4 weeks. Women whose PGSC score >4 continued the solifenacin 
Figure D.1. Flow of study participants 
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5mg dose for 8 more weeks until primary outcome assessment at 12 weeks. Thus, definitions 
for 3 response groups were determined a priori: non-responders, 5mg responders and 10mg 
responders. Participants who were intolerant of the medication could withdraw at any point 
during the study. The research team assessed adverse events at normally scheduled visits, and 
at other intervals during participant-initiated contact. Figure D.1 shows the flow of UUI-
affected study participants. The primary outcome was symptomatic response, based on PGSC 
score, at 12 weeks. 
Sample Collection and Analysis. 
Urine was collected aseptically via transurethral catheter and a portion placed in a BD 
Vacutainer Plus C&S preservative tube for culture. Urine culture was performed as described7 
(E-Methods 1). A separate aliquot for sequencing was placed at 4°C for <4 h following 
collection; 10% AssayAssure (Sierra Molecular; Incline Village, NV) was added before storage at 
-80°C. Our protocols for DNA extraction, library construction, 16S rRNA sequencing and 
bioinformatics analysis have been described203. All genomic samples were processed in 
duplicate and analysis was performed using mothur software167. Relative abundance was 
calculated by generating the percent of total classified reads for each individual. All samples 
were processed in duplicate and the percent reads of replicates were averaged for downstream 
analysis, which included urotype identification and statistical analysis. Urotypes were 
determined as described203. Briefly, a culture urotype is determined by the dominant (>50%) 
identified organisms within a given sample. A sequencing urotype is determined by first 
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clustering sequences using a dendrogram and grouping based on similarity; this usually 
correlates with dominance (>50%) of one organism. Those communities without a dominant 
organism were classified as “Diverse” urotype. Dendrograms were calculated using Bray Curtis 
dissimilarity between samples, and the complete method was used for hierarchical clustering 
via R software, version 2.15.1196. To measure the diversity (richness and evenness of species 
within a sample), the alpha diversity (inverse Simpson’s index) was calculated using mothur 
software167.  
Protocol for the Eexpanded Quantitative Urine Culture (EQUC). 
Full protocol in supplement (Methods D.S1). For standard urine culture, 0.001 mL of 
urine was spread quantitatively onto 5% sheep blood (BAP) and MacConkey agars (BD BBL™ 
Prepared Plated Media), then incubated aerobically (35°C for 24 hours). Any amount of each 
separate morphologic colony type was identified and counted using a detection level of 1,000 
colony forming units (CFU)/mL (represented by 1 colony of growth on either plate). “No 
growth” was reported when no growth was observed, indicating no growth of bacteria at 
lowest dilution, i.e., 1:1000. 
The expanded quantitative urine culture (EQUC) technique uses 0.1 mL of urine spread 
quantitatively onto BAP, Chocolate and Colistin, Naladixic Acid (CNA) agars (BD BBL™ Prepared 
Plated Media), then incubated in 5% CO2 (35°C for 48 hours). A second set of BAPs were 
inoculated with 0.1 mL of urine and incubated in room atmosphere at 35°C and 30°C for 48 
hours, respectively. In addition, 0.1 mL of urine was inoculated onto each of two CDC Anaerobe 
- 187 - 
 
 
 
5% sheep blood agar (ABAP) plates (BD BBL™ Prepared Plated Media), and incubated in either a 
Campy gas mixture (5% O2, 10% CO2, 85% N) or in anaerobic conditions at 35°C for 48 hours. 
The detection level was 10 CFU/mL, represented by 1 colony of growth on any of the plates. 
Finally, to detect any bacterial species that may be present at quantities lower than 10 CFU/mL, 
1.0 mL of urine was placed in Thioglycollate Medium (BD BBL™ Prepared Tubed Media) and 
incubated aerobically at 35°C for 5 days. If growth was visually detected, the Thioglycollate 
Medium was mixed and a few drops were plated on BAP and ABAP agars for isolation, and 
incubated aerobically and anaerobically (35°C for 48 hours). Each morphologically distinct 
colony type was isolated on a different plate of the same media to prepare a pure culture that 
was used for organism identification. Matrix-Assisted Laser Desorption Ionization Time of Flight 
Mass Spectrometry (MALDI-TOF MS) with the MALDI Biotyper 3.0 software (Bruker Daltonics, 
Billerica, MA) was used to identify the bacterial isolates7. To determine the false-negative rate, 
the following equation was used: the number of EQUC positive but standard negative samples 
divided by the total number of EQUC positive samples. To determine the culture diversity 
within a population, a species accumulation curve was generated. Species accumulation curves 
illustrate the number of unique species cultured and identified (using EQUC) with each new 
patient sampled. When the curve plateaus, it indicates that the community is fully sampled and 
few, if any, new species will be identified. Therefore, it also measures the overall diversity of 
the population by total number of unique species isolated. 
Statistical Analysis. 
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Standard statistical methods were used to compare participant demographics and 
symptom data between UUI patients and controls. Continuous variables are reported as means 
and standard deviations (SD) or medians and interquartile ranges (IQR) and categorical 
variables are reported as frequencies and percentages. Collection of the primary outcomes at 
12 weeks was necessary for assignment to UUI response groups; therefore, participants who 
did not provide data through 12 weeks were not included in analyses involving response to 
solifenacin. Fisher’s exact and Kruskal-Wallis tests were used to compare demographic and 
culture (e.g., abundance and diversity) information among UUI response groups. For cultured 
organisms, abundance was measured using total CFU/ml; for sequencing, abundance was 
measured using percent classified reads or classified organisms. Post-hoc pairwise comparisons 
were made using Wilcoxon Rank sum tests for continuous variables with significant overall p-
values. A kappa statistic was estimated to determine agreement between urotype classification 
from samples with both EQUC and sequencing.  All statistical analyses were conducted using 
SPSS software version 19 or SAS software v9.4 (SAS Institute, Cary, NC). Significance was 
assessed at an alpha level of 0.05. Results were not adjusted for multiple-comparisons since the 
analyses are considered descriptive.      
Results 
Population Description Over the Course of the Study. 
Figure D.1 displays the flow of UUI subjects through the 12-week follow-up period. The 
study investigators withdrew participants who had received antibiotics for unrelated clinical 
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indications (2) and subjects who underwent a cystoscopy for clinical indications (2). An 
additional 17 participants withdrew by the 4-week visit: 7 due to side effects and 6 lost to 
follow up. Of the participants who provided UUI symptom response data at 4 weeks, 56% 
(32/57) reported adequate symptom control; all of the remaining 25 accepted dose escalation 
(10mg daily). 
Comparison of Baseline UUI to Controls. 
At baseline, participants included 74 UUI-affected women and 60 controls. The cohorts 
were similar with respect to race/ethnicity, diabetes, and smoking (Table D.1). Participants with 
UUI were more likely to suffer from hypertension [35% versus 18%, p=0.02] and coronary artery 
disease [12% versus 2%, p=0.02]. The UUI population also was older [61.5 years (SD:11.5) 
versus 49 (SD:14.7), p<0.001], heavier [BMI 32.7 (SD:8.4) versus 28 (SD:5.5), p<0.001], and more 
likely to be estrogen-negative (post-menopausal and not on hormone replacement therapy) 
[88% versus 43%, p-value<0.001]. As expected, UUI symptoms were significantly worse in UUI- 
than non-UUI participants. 
We detected the presence of bacterial DNA in a similar proportion of urine samples for 
each cohort (Controls: 43%, N=26/60, UUI: 50%, N=37/74, p=0.44 Table D.2A). Table D.2A and 
Table D.S2 display the assigned sequence urotypes. In both groups, the majority of samples 
were dominated by Lactobacillus [controls (61.5%, N=16/26), UUI (40.5%, N=15/37), p=0.13]. 
Alpha diversity (measured by the inverse Simpson index) of classified sequences between UUI 
and control was similar (p=0.76). 
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Table D.1. Participant demographics and symptoms scores 
Comparison of baseline demographics between cohorts and response groups. Independent t-tests and 
Chi-square tests used unless otherwise indicated. Fisher's Exact Test due to small, expected cell counts 
unless otherwise indicated. 
 Baseline  Baseline: 3 Response Groups  
 UUI  
(N=74) 
Non-UUI 
Control (N=60) 
p-value 5mg  
(N=25) 
10mg 
(N=15) 
Non 
(N=10) 
p-value 
Demographics         
Age (years) [Mean 
(SD)]  
61.5 
(SD:11.5) 
49  
(SD:14.7) 
<0.001a 60 
(SD:12.4) 
63 
(SD:13.5) 
67  
(SD:9) 
0.36b 
Body Mass Index 
(kg/m2)  [Mean (SD)] 
32.7  
(SD:8.4) 
28  
(SD:5.5) 
<0.001a 31  
(SD:7.6) 
30  
(SD:7) 
34  
(SD:9) 
0.41b 
Race/Ethnicity*   0.70    0.70 
Non Hispanic 
Caucasian 
56  
(77%) 
43  
(72%) 
17  
(68%) 
12  
(80%) 
9 (90%) 
Hispanic 
Caucasian 
5  
(7%) 
4 (7%) 3 (12%) 2 (13%) 0 (0%) 
African-American 13  
(18%) 
12  
(20%) 
5  
(20%) 
1  
(7%) 
1 (10%) 
Asian 0 (0%) 1 (2%) 0 (0%) 0 (0%) 0 (0%) 
Marital Status   0.01    0.71 
Married 38  
(51%) 
37  
(62%) 
15  
(60%) 
8  
(53%) 
5 (50%) 
Separated 3 (4%) 1 (2%) 1 (4%) 0 (0%) 0 (0%) 
Divorced 9  
(12%) 
6  
(10%) 
1  
(4%) 
3  
(20%) 
3 (30%) 
Widowed 14  
(19%) 
1  
(2%) 
4  
(16%) 
2  
(13%) 
1 (10%) 
Single 10  
(14%) 
15  
(25%) 
4  
(16%) 
2  
(13%) 
1 (10%) 
Estrogen Status**   <0.001    0.68 
Estrogen Positive 7 (9%) 32 (53%) 4 (16%) 2 (13%) 0 (0%) 
Estrogen Negative 65  
(88%) 
26  
(43%) 
20  
(80%) 
13  
(87%) 
10 
(100%) 
Unsure 2  
(3%) 
2  
(2%) 
1  
(4%) 
0  
(0%) 
0 (0%) 
Smoking 6 (8%) 4 (7%) 0.51 1 (4%) 1 (7%) 0 (0%) 0.99 
Diabetes 7  
(9%) 
2  
(3%) 
0.14 2  
(8%) 
1  
(7%) 
1 (10%) 0.99 
Hypertension 26  
(35%) 
11  
(18%) 
0.02 9  
(36%) 
5  
(33%) 
7 (70%) 0.13 
Coronary Artery 
Disease 
9  
(12%) 
1  
(2%) 
0.02 2  
(8%) 
2  
(13%) 
1 (10%) 0.84 
Prior Treatment for 
OAB 
37  
(50%) 
0  
(0%) 
<0.001 13  
(52%) 
11  
(73%) 
6 (60%) 0.45 
Vaginal Parity 
[Median, (IQR)] 
2  
(0-2.5) 
2  
(1-3) 
0.02c 2  
(2-3) 
2  
(0-3) 
2  
(0-5) 
0.88c 
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Table D.1. Continued 
Symptom comparison at baseline and 12 weeks 
 Baseline Baseline: 3 Response Groups  
 UUI 
(N=74) 
Non-UUI 
Control 
(N=60) 
p-value 5mg 
(N=25) 
10mg 
(N=15) 
Non 
(N=10) 
p-value 
Baseline Symptoms  
[Median (IQR)] 
       
Symptom Score d 70 
(55-85) 
0 
(0-5) 
<0.001c 62 
(42-88) 
75 
(65-85) 
69 
(55-78) 
0.61c 
HRQL d 52 
(33-75) 
100 
(98-100) 
<0.001c 68 
(50-76) 
59 
(36-87) 
50 
(31-70) 
0.43c 
UDI e 110 
(61-143) 
8 
(3-17) 
<0.001c 93 
(55-131) 
95 
(52-120) 
98 
(80-149) 
0.63c 
POPDI e 70 
(30-105) 
14 
(0-42) 
<0.001c 68 
(42-129) 
40 
(8-70) 
70 
(8-101) 
0.11c 
CRADI e 66 
(34-112) 
17 
(2-56) 
<0.001c 68 
(44-120) 
43 
(11-81) 
75 
(20-89) 
0.43c 
        
12 Week Symptoms 
[Median (IQR)] 
       
Symptom S,core d    18 
(8-33) 
18 
(5-28) 
54 
(18-63) 
0.01c 
HRQL d    93 
(86-99) 
94 
(88-99) 
70 
(61-86) 
0.008c 
UDI e    22 
(14-59) 
46 
(8-64) 
95 
(58-113) 
0.01c 
POPDI e    32 
(17-68) 
13 
(4-19) 
54 
(32-93) 
0.002c 
CRADI e    24 
(7-89) 
18 
(8-39) 
53 
(32-68) 
0.08c 
a Student’s T-Test  
b One-Way ANOVA 
c Wilcoxon rank sum test  
d Symptom Score and Health Related Quality of Life Score (HRQL), Based on OAB questionnaire 
e Urinary Distress Inventory (UDI), Pelvic Organ Prolapse Distress Inventory (POPDI), Colorectal-Anal Distress 
Inventory (CRADI), based on Pelvic Floor Disease Inventory  
* Self reported by participant 
** Estrogen status is defined as negative if the patient is post-menopausal and not on hormone replacement 
therapy. Estrogen positive is anyone pre-menopausal and/or on hormone replacement therapy. 
 
A large subset of baseline samples was processed by EQUC (UUI N=59/74, control 
N=52/60).  A greater proportion of UUI-affected women had cultivatable bacteria in their urine 
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compared to control women (84.7% versus 63.5%, p=0.01). The groups differed in proportion of 
cultured samples characterized by dominant organisms (culture urotypes) (Table D.2A): 
Lactobacillus [controls (45.5%, N=15/33) versus UUI (22%, N=11/50) p=0.03], and diverse 
[controls (6%, N=2/33) versus UUI (32%, 16/50) p=0.006 Table D.2A]. Relative to controls, UUI-
affected women had significantly more diversity in unique cultivatable organisms, as assessed 
by the number of unique cultivatable organisms per cohort (UUI= 80, Controls= 36, Figure D.2), 
significantly more cultured bacterial isolates per participant, as measured by the median [UUI 
(3) versus Controls (1), p<0.001, Figure D.2 inset] and significantly more cultivatable bacteria, as 
measured by median number of CFU per mL per urine specimen [UUI: 340 CFU (IQR: 50-1710) 
versus Controls: 20 CFU (IQR: 0-305), p=0.002].  
Characteristics in the Baseline Samples Correlated with Primary Outcome. 
Primary outcome data were available for 50 participants at 12 weeks, with 25 “5mg 
responders”, 15 “10mg responders” and 10 “non-responders”, for an overall response rate of 
80%. At baseline, compared to the withdrawn population, participants with primary outcome 
data weighed less [BMI 31.2 (SD:7.7) versus 35.8 (SD:9.2), p=0.03] and were more likely to have 
had previous pharmacologic treatment for OAB (60% versus 29%, p=0.01). They also had 
greater HRQL scores [61 versus 37, p=0.001] larger urinary distress inventory scores [95 versus 
131, p=0.02] (Table D.S1). We did not detect other significant group differences in baseline 
variables for participants who competed the study. (Table D.S1). 
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Table D.2. Urotype proportions 
*Undetermined urotype means the bacterial load in the 
sample was below the detectable threshold by either 
sampling method. 
**50 patients returned for the 12-week visit, however, 
only 48 were sequenced due to unclear specimen 
labeling. These two samples were processed by EQUC. 
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Figure D.2. Diversity of cultivatable bacteria is distinct between cohorts and response 
groups at baseline. Species accumulation analysis illustrates the number of unique species 
cultured and identified using expanded quantitative urine cultures (EQUC) with each new patient 
sampled. When the curve plateaus, it indicates that the community is fully sampled and few, if any, 
new species will be identified. Therefore, it also measures the overall diversity of the population by 
total number of unique species isolated. The urgency urinary incontinence (UUI) curve represents 
samples at baseline from individuals who may or may not respond. When we divide this curve into 
each group stratified by response, we see that baseline diversity of each groups is distinct, 
suggesting that baseline diversity could be predictive of treatment response. The 5-mg responders 
(grey triangles) had low diversity, with a total of 32 unique species isolated. The 10-mg responders 
(dark x) had high diversity, with a total of 54 unique isolates. Nonresponders (light x) had high 
diversity, with a total of 42 unique isolates. The median number of unique species was not 
significantly different between 10-mg responders and nonresponders: 5 [interquartile range (IQR) 
3–6] versus 8 (IQR 3–15), p value = 0.25 but was significantly different between 5-mg and 10-mg 
responders and between 5-mg and nonresponders: 1 (IQR 0–5) versus 5 (IQR 3–6), p value = 0.03; 
and 1 (IQR 0–5) versus 8 (IQR 3–15); p value = 0.02 
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 At baseline, the 3 response groups had similar demographics and symptom severity 
(Table S.1). At 12 weeks, the HRQL scores differed among all response groups (p=0.008). The 
median score for non-responders (70, IQR: 61-86) differed significantly from both responder 
groups: 5mg group (93, IQR: 86-99) and 10mg group (94, IQR: 88-99) (p=0.004 and p=0.008, 
respectively) (Table D.1). 
The urine samples from all 50 participants with primary outcome data were tested for 
detectable bacteria.  At baseline, a similar proportion of each response group had detectable 
bacterial DNA [5mg: 56% N=14/25, 10mg: 46.7% N=7/15, non-responders: 40% N=4/10, p=0.66, 
(Table D.2B], suggesting that there is no difference in the frequency of samples with detectable 
bacteria present in each response group. In contrast, when we compared bacterial community 
composition by distribution of urotypes (i.e., the number of individuals with microbiomes 
dominated by one organism), the baseline samples from each response group tended to be 
different; however, no statistical testing was conducted due to limited sample sizes. Compared 
to 10mg responders (12.5%, N=1/8), 5mg responders had a larger proportion of individuals with 
Lactobacillus-dominant urine (50%, N=7/14) (Table D.2B). The response groups had similar 
alpha diversities [5mg: 1.6 (IQR: 1.2-3.7), 10mg: 1.9 (IQR: 1.1-6.3), non-responders: 2.8 (IQR: 
1.7-4.1), p=0.55].  
The subset (N=39/50) of baseline urine samples from participants with primary outcome 
data that were cultured with EQUC included 19 “5mg responders”, 13 “10mg responders”, and 
7 “non-responders”.  Cultivatable organisms (EQUC) were detected in most participants: 5mg 
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responders: 73.7% (N=14/19), 10mg responders: 100% (N=13/13) and non-responders: 85.7% 
(N=6/7) (p=0.13, Table D.2B). The dominant urotype by response group was: 5mg response - 
Lactobacillus-dominant urotype 35.7% (N=5/14); 10mg - diverse urotype 38.5% (N=5/13) and 
30.8% (N=4/13) Streptococcus-dominant urotype; and non-responders – diverse urotype 50% 
(N=3/6). Each response group had a distinct species accumulation curve, with different total 
number of unique cultured bacterial isolates: 5mg (32), 10mg (54) and non-responders (42) 
(Figure D.2). Overall, there was a difference in the number of unique species isolated by 
response group (p=0.02). The median number of unique species isolated from each individual 
within each cohort was similar in the 10mg and non-responder groups [5 versus 8, p= 0.25 
Figure D.2 inset]. However, there was a statistically significant difference between the 5mg and 
the other responder groups: [5mg: 1 versus 10mg responders: 5 p= 0.03, or non-responders: 8, 
p= 0.02 Figure D.2 inset].  
Each response group contained several genera that differed from other response groups 
(Figure D.3A), with Actinomyces cultivated more commonly from 10mg responders and non-
responders than from 5mg responders (p=0.01 and 0.04, respectively). Streptococcus was 
cultivated more commonly from non-responders (p=0.002). In addition, several bacterial 
species differed between response groups (Figure D.3B).  
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Primary Outcome Comparison – 12 weeks. 
At 12 weeks, 48 of the 50 participants with primary outcome data were sequenced. Two 
samples were not sequenced due to inconclusive labeling. Of the remaining 48, 23 samples 
were positive for bacterial DNA (Table D.2B). Similar to baseline, the response groups had 
Figure D.3. Detection frequency of genera and significant species between response 
groups. Comparison of frequency of culture-based detection at genus (a) and species (b) 
levels for baseline urine by response group. Fisher’s exact test was used to 
calculate p values. * p = 0.05; ** p = 0.00 
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similar proportions of 12-week samples with detectable bacterial DNA [5mg: 43.5% N=10/23, 
10mg: 46.7% N=7/15, and non-responders: 60% N=6/10, p=0.70]. Statistical testing was not 
performed because of limited sample size; however, the 3 response groups trended toward 
different sequence urotype distributions, with larger proportions of Lactobacillus urotypes in 
5mg responders (70%, N=7/10), compared to 10mg responders (28.6%, N=2/7) and non-
responders (33.3%, N=2/6) (Table D.2B). The response groups had similar alpha diversity 
(p=0.18). 
 At 12 weeks, most (86%, N=38/44) EQUC-characterized urines demonstrated 
cultivatable organisms (Table D.2B). At 12 weeks, each response group tended toward different 
culture urotypes distributions: 5mg response - Lactobacillus-dominant urotype 38.9% N=7/18; 
10mg - diverse urotype 23.1% N=3/13 and 23.1% N=3/13 Streptococcus-dominant urotype; and 
non-responders – Lactobacillus 42.8% N=3/7 (Table D.2B). The species accumulation analysis of 
the baseline and 12-week samples show that the 10mg and non-responders decreased in 
diversity by 12 weeks, from 55 unique isolates to 23 for the 10mg group and from 40 to 29 for 
the non-responders. In contrast, the 5mg group increased in diversity, from 32 unique isolates 
to 41 (Figure D.S1). We did not detect a specific single genus that significantly declined in 
responders (5mg or 10mg) (Figure D.S2). At the conclusion of the specimen collection, we 
compared the two methods of bacterial assessment. Approximately half (49.8%, N=119/239) of 
all urine specimens sequenced had detectable bacterial DNA, whereas most specimens (80%, 
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N=140/177) cultured with EQUC grew organisms. Among the sequence-positive, culture-
positive individuals, the urotype classifications were moderately comparable (Kappa = 0.45)206. 
 When comparing EQUC to standard culture, we found EQUC detected more organisms 
overall.  Of all the urine samples in the study, 81.3% (N=165/203) grew bacteria by EQUC. Of 
those, 149 had been deemed culture negative (“No Growth”) by the standard culture, resulting 
in 90.3% false negative rate for standard culture. 
Discussion 
The female urinary microbiota in women affected by UUI appears to differ from a 
comparison group of unaffected women. Using two complementary techniques, we report 
differences in composition (urotype), diversity (number of unique bacterial species) and 
identity of certain bacteria at the genus and species levels. These differences, which were 
detectable prior to UUI treatment, appear related to treatment response. Moreover, following 
UUI treatment, certain microbiota characteristics appear associated with a clinically significant 
response to treatment. Overall, less diversity appears associated with fewer UUI symptoms and 
with treatment response at 5mg. We also found that bacterial diversity in women who required 
a higher dose to achieve adequate symptom control is more similar to the diversity found in 
non-responders, indicating that the diversity of cultivatable organisms might be used to predict 
treatment response. 
 The mechanistic relationship between bacterial diversity and UUI symptoms is 
unknown.  However, given our findings, important clinical questions regarding UUI etiology or 
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consequences will need careful study. In this research work, we selected 2 complementary 
study techniques to assess the bacterial milieu, one of which was developed after we started 
enrollment. Sequencing, which was available at the onset of our study, provided a broad 
picture of bladder bacteria, allowing a more complete analysis of bacterial diversity. In addition, 
sequencing could detect bacteria that even EQUC could not cultivate. However, urine samples 
contain low biomass relative to other anatomical sites (e.g., gut or vagina). Thus, a proportion 
of the study population did not contribute sequencing data. This lack of information was often 
resolved by the use of EQUC. This expanded culture technique for urine became available after 
our study started. EQUC not only confirms that bladder organisms are alive, but it also allows 
phenotyping of low biomass individuals not measurable by sequencing.  
The very low CFUs associated with UUI may prompt consideration of a lower CFU cut-off 
(perhaps >102) for a standard urine culture. Others have suggested lowering the culture 
threshold for UTI 14,46,207-209 and even for UUI 210; however, these studies focused on growing 
known uropathogens. Here, we showed that the bladder can contain a variety of organisms. 
Some are likely non-pathogenic normal flora. Others might have an impact on UUI and other 
lower urinary tract symptoms. Some of these might be protective, whereas others may 
contribute to symptoms. Indeed, we recently reported that detection of urinary microbiota by 
quantitative PCR is associated with a reduced risk of post-instrumentation UTI 5 and an 
association between Lactobacillus crispatus and the lack of lower urinary tract symptoms 203. 
Furthermore, several bacterial species appear to be associated with UUI 203. Thus, we 
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recommend the use of expanded culture conditions until our understanding of unrecognized 
uropathogens improves. EQUC is more likely than sequencing to be readily available in the 
clinical setting, and may prove useful for rapid phenotyping of individual patients, prior to 
treatment selection. This is especially important as no single clinical demographic variable 
adequately predicted treatment outcome.   
We have considered the implications of the minority of samples that were “negative” 
for both techniques. We currently consider this group to be “sub-threshold” rather than 
“sterile” and fully anticipate that the very low biomass individuals will be more fully described 
as technologies evolve. 
 The dominance of certain genera, such as Lactobacillus and Gardnerella, may prompt 
thoughts of vaginal contamination. Our use of aseptically collected specimens via transurethral 
catheter by experienced individuals, and our prior publications demonstrating the presence of 
Lactobacillus and Gardnerella in female bladder urine collected through suprapubic aspirates 4, 
supports the evidence that both genera are capable of residing in the bladder. The role of these 
organisms as members of the urinary microbiome and their relationships to vaginal microbiota 
requires further study. Because the bladder and vagina can contain the same species, the use of 
catheterized samples is recommended whenever possible and careful interpretation is required 
when using samples obtained by void.  
It is possible that baseline group differences contributed to our findings. However, since 
UUI incidence increases with age and is therefore linked to menopause status, our sample size 
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is not sufficient to further describe the separate effects of estrogen status, age, and UUI 
symptoms in relation with microbiota diversity. We acknowledge this possibility; yet, we wish 
to highlight the importance of the findings between treatment response groups (Figure C.2). 
Women with 1-4 bacterial isolates on EQUC were most likely to respond to the initial 5mg dose 
of solifenacin, whereas women with more diversity (≥5 bacterial isolates) were less likely to 
respond or needed an increased dose. These simple cut-offs, detectable prior to treatment, will 
require validation in larger patient populations. Therefore, in future studies, the use of both 
EQUC and sequencing for all collected urine specimens is recommended. The results are highly 
complementary, with sequencing measuring a broad picture of the population and the EQUC 
protocol measuring the cultivatable organisms within that population. 
 Clinicians can benefit from expanded knowledge about the bacterial communities that 
are present in patients with UUI. Although specific changes in clinical management cannot yet 
be recommended, this promising area of research is generating many new hypotheses.  In 
addition, our findings should inform the design of larger clinical studies that have potential to 
personalize UUI treatment, provide insight into UUI etiology, and offer promise for novel UUI 
prevention strategies. We believe that related urinary tract disorders may also benefit from this 
new knowledge. 
Conclusions. 
The response to oral UUI medication (solifenacin) may relate to individual urinary 
microbiota characteristics that are detectable prior to treatment. Our findings, especially the 
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importance of organism diversity, offer promising possibilities for new ideas for prevention and 
treatment of UUI in women. 
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Supplemental Material 
Methods D.S1. Protocol for the Expanded Quantitative Urine Culture (EQUC): For standard 
urine culture, 0.001 mL of urine was spread quantitatively onto 5% sheep blood (BAP) and 
MacConkey agars (BD BBL™ Prepared Plated Media), then incubated aerobically (35°C for 24 
hours). Any amount of each separate morphologic colony type was identified and counted 
using a detection level of 1,000 colony forming units (CFU)/mL (represented by 1 colony of 
growth on either plate). “No growth” was reported when no growth was observed, indicating 
no growth of bacteria at lowest dilution, i.e., 1:1000. 
The expanded quantitative urine culture (EQUC) technique uses 0.1 mL of urine spread 
quantitatively onto BAP, Chocolate and Colistin, Naladixic Acid (CNA) agars (BD BBL™ Prepared 
Plated Media), then incubated in 5% CO2 (35°C for 48 hours). A second set of BAPs were 
inoculated with 0.1 mL of urine and incubated in room atmosphere at 35°C and 30°C for 48 
hours, respectively. In addition, 0.1 mL of urine was inoculated onto each of two CDC Anaerobe 
5% sheep blood agar (ABAP) plates (BD BBL™ Prepared Plated Media), and incubated in either a 
Campy gas mixture (5% O2, 10% CO2, 85% N) or in anaerobic conditions at 35°C for 48 hours. 
The detection level was 10 CFU/mL, represented by 1 colony of growth on any of the plates. 
Finally, to detect any bacterial species that may be present at quantities lower than 10 CFU/mL, 
1.0 mL of urine was placed in Thioglycollate Medium (BD BBL™ Prepared Tubed Media) and 
incubated aerobically at 35°C for 5 days. If growth was visually detected, the Thioglycollate 
Medium was mixed and a few drops were plated on BAP and ABAP agars for isolation, and 
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incubated aerobically and anaerobically (35°C for 48 hours). Each morphologically distinct 
colony type was isolated on a different plate of the same media to prepare a pure culture that 
was used for organism identification. Matrix-Assisted Laser Desorption Ionization Time of Flight 
Mass Spectrometry (MALDI-TOF MS) with the MALDI Biotyper 3.0 software (Bruker Daltonics, 
Billerica, MA) was used to identify the bacterial isolates7. To determine the false-negative rate, 
the following equation was used: the number of EQUC positive but standard negative samples 
divided by the sum of the EQUC positive and standard positive samples and the EQUC positive 
but standard negative samples. 
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Table D.S1. Comparison of demographics and symptoms of completed and withdrawal 
populations at baseline 
 Completed Study  
(N=50) 
Withdrawal 
(N=24) 
p-value 
Demographics    
Age (years)  
  [Mean (Standard Deviation)] 
62.5 (SD:12.2) 59.5 (SD:10) 0.30a 
Body Mass Index (kg/m2)  
  [Mean (Standard Deviation)] 
31.2  
(SD:7.7) 
35.8  
(SD:9.2) 
0.03a 
Race/Ethnicity*   
0.40 
Non Hispanic Caucasian 38 (76%) 17 (71%) 
Hispanic Caucasian 5 (10%) 1 (4%) 
African-American 7 (14%) 6 (25%) 
Asian 0 (%) 0 (%) 
Marital Status   
0.31 
Married 28 (56%) 10 (42%) 
Separated 1 (2%) 2 (8%) 
Divorced 7 (14%) 2 (8%) 
Widowed 7 (14%) 7 (29%) 
Single 7 (14%) 3 (13%) 
Estrogen Status**   
0.47 
Estrogen Positive 6 (12%) 1 (4%) 
Estrogen Negative 43 (86%) 22 (92%) 
Unsure 1 (2%) 1 (4%) 
Smoking 2 (4%) 4 (17%) 0.08 
Diabetes 4 (8%) 3 (13%) 0.68 
Hypertension 21 (42%) 11 (46%) 0.75 
Coronary Artery Disease 5 (10%) 4 (17%) 0.46 
Prior Treatment for OAB 30 (60%) 7 (29%) 0.01 
Vaginal Parity [Median (IQR)] 2 (1-3) 2 (0.5-3) 0.56b 
    
Symptoms [Median (IQR)]    
Symptom Score c 70 (53-85) 80 (56-86) 0.31b 
Health Related Quality of Life (HRQL) c 61 (42-82) 37 (15-52) 0.001b 
Urinary Distress Inventory (UDI) d 95 (56-131) 131 (108-161) 0.02b 
Pelvic Organ Prolapse Distress Inventory (POPDI) 
d 
59 (15-95) 83 (42-132) 0.13b 
Colorectal-Anal Distress Inventory (CRADI) d 60 (20-112) 71 (43-127) 0.38b 
Fisher's Exact Test due to small, expected cell counts unless otherwise indicated. a Student’s T-Test,  
 b Wilcoxon rank sum test c Based on OAB questionnaire d Based on Pelvic Floor Disease Inventory * Self-reported 
by participant. ** Estrogen status is defined as negative if the patient is post-menopausal and not on hormone 
replacement therapy. Estrogen positive is anyone pre-menopausal and/or on hormone replacement therapy. 
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Table D.S2. A list of each patient’s urotype. It was included to fulfill the primary aim of the 
clinical trial: to phenotype each individual’s microbiome. Due to its size, it was excluded from 
this document. See PMID: 26423260 Supplementary Table 2. 
 
 
 
 
Figure D.S1. Species accumulation curves comparing baseline and 12-week diversity by 
response group 
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Figure D.S2. Frequency of detection of bacterial genera at baseline and 12 weeks of all 
responders (5mg and 10mg). Comparison of the frequency of detection for baseline and 12 
week urines in responders (including both 5mg and 10mg responders). There is no one genus 
that decreases significantly over that timeframe in individuals that respond to solifenicin.  
 
 
  
- 209 - 
 
 
 
Addendum 
For the Astellas projects (Appendix B-C), we completed many comparisons that were 
not published. Specifically, we were interested in any specific differences between the 5mg 
responders and either the non-responders or 10mg responders, analysis on the longitudinal 
data, and further comparison between sequencing and culture. Overall, the following data was 
inconclusive and therefore most was excluded from the publication.  
We did find a few organisms at baseline that were statistically different between the 
5mg responds and 10mg responders, as well as the 5mg responders and non-responders 
(Figure D.4). But in a 3-way comparison between all groups, only 4 species were found to be 
significant, and those were published (Figure D.3). We are not sure if the correlations we find in 
Figure D.4 are biologically significant.  
 The longitudinal data requires further investigation. We did not detect a change in the 
overall biomass of each niche over time (Figure D.5), suggesting that neither the treatment, nor 
the response to treatment, influenced bacterial load. We also did not detect a change in the 
overall frequency of species detection (Figure D.6). Therefore, there was no single organism 
that “disappeared” by 12 weeks and would account for symptom improvement. But, we did see 
that diversity in the 10mg and non-responders began to decrease by 12 weeks (Figure D.S1), 
suggesting that diversity is still the main contributing factor. 
The longitudinal data was tricky. Since we did not have any comparable longitudinal 
data from controls, we could not know if any changes we saw were due to medication, 
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symptom improvement, or basic every-day fluctuations. These data, and longitudinal data from 
the Mirabegron study, should be re-analyzed once we have a better understanding of 
longitudinal fluctuations from controls.  
Finally, I performed a comparison of 16S sequencing and EQUC (Figure D.7), which can 
be compared to the published heatmap in Figure D.7. While Figure D.7 compared species 
detection between EQUC and 16S sequencing, Figure D.7 compares the overall niche profiles in 
each group. First, I will focus on the left-most part of the graph, which describes samples that 
were characterized by both methods (no black bars). If you focus on the abundant genera, it 
becomes clear that certain organisms (e.g., Lactobacillus, Enterobacteriaceae, Gardnerella, and 
Bifidobacterium) appear in similar abundances in sequencing and EQUC. However, other genera 
(e.g. Micrococcus, Staphylococcus, Enterococcus, Alloscardovia, and Streptococcus) dominate 
the culture profiles, but are only a small percentage of the sequencing profiles. It could be that 
these organisms are more readily cultivatable or that they have difficulty being detected by 
sequencing. Throughout all our studies, we have had difficulty sequencing Streptococcus, 
particularly when it is dominant by EQUC. Additionally, the sequencing profiles of these 
samples indicate a predominance of low-abundance organisms (the “other” grouping). It could 
be that much of the sequencing is representing populations of as yet uncultivated bacteria 
(such as strict anaerobes), or simply an abundance of contamination. 
Next, we will focus on the right side of the graph that contains all the samples that were 
either culture- or sequence-negative, or both (with black bars). We know that EQUC has a lower 
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level of detection (>10 CFU/ml compared to >1000 CFU/ml); therefore, it makes sense that 
many samples would be EQUC-positive and sequence-negative. It is possible that those samples 
simply have a biomass in the range of 10-1000 CFU/ml. It is more confusing to consider the 
samples that are culture-negative but sequencing-positive, as this would not be a biomass 
issue. It is possible that these sequencing profiles might represent dead bacteria, or (since we 
know that bacteria can grow in improperly refrigerated samples) an overgrowth of bacteria 
following sample collection. Alternatively, it could be that these sequence results are from a 
contaminated sample-cup or some other contamination that was introduced early in the 
sample collection.  
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A. 
Figure D.4. Major genera (A) and species (B) isolated from controls and 3 response groups. 
These figures expand on Figure C.3. It includes controls as well as the response groups. (A) The 
frequency of isolation of common genera followed by the species within that genera. (B) 
Genera and species present at significantly different frequencies in the 5-mg solifenacin 
responder cohort (red) relative to either the 10-mg responder cohort (green) or the non-
responder cohort (purple). p < 0.05. Many of these organisms were significantly different from 
5mg responders in a two-way comparison (shown here) but only 4 organisms were 
significantly different in a 3-way comparison (Figure C.3B). 
B. 
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Figure D.5. Solifenacin does not exert a consistent effect upon urinary bacterial abundance. 
Total CFU/ml of baseline, 4-week and 12-week urine samples was plotted for each member of 
the 5-mg responder (top) and non-responder (bottom) groups. A similar lack of consistent 
effect was observed for 10-mg responders (data not shown). Notice that some data are missing, 
either because the sample was not subjected to EQUC or because the EQUC assay was negative. 
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Figure D.6. Solifenacin does not exert a major effect on the frequency of the most common 
FUM genera. For UUI patients, we plotted the frequency of each common genus detected in 
baseline, 4-week & 12-week urine samples. For comparison, we plotted the frequency of the 
same genera in the baseline urine samples of non-UUI controls. 
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Figure D.7. 16S rRNA sequence and EQUC analyses are complementary. Analyses of the 
baseline urines from the 10-mg responder group are compared. Each bar represents a patient-
participant; each color or family of colors represents an organism or a group of related 
organisms. For example, blues, reds and greens represent the genera Lactobacillus, 
Gardnerella, and Streptococcus, respectively. Light gray bars represent samples that were not 
assayed by EQUC; black bars represent samples that were PCR-negative and thus were not 
sequenced. 
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Overview of Appendix E 
 This study is our first published work on voided urine. The data confirms that increased 
diversity is associated with symptoms of UUI and demonstrated that voided urine can be used 
under some circumstances to detect a bladder microbiome urine signal. 
This study was in collaboration with the Urinary Incontinence Treatment Network 
(UITN). This network was put together to determine if doctors required patients to undergo 
urodynamic testing for a diagnosis of stress urinary incontinence. The value of urodynamic 
evaluation (ValUE) study211 had been previously published, but the network had biobanked 
urines from this study population. The majority of these urines were voided samples. All 
samples were sequenced in duplicate and diversity measurements were compared to 
demographics and symptom scores.  
 All the patients for this study were diagnosed with stress urinary incontinence (SUI), 
which is a sphynteric disorder that results in the loss of urine following coughing, sneezing, or 
lifting. SUI can be treated effectively with surgery, and often following surgery these patients 
will discover underlying UUI symptoms. Therefore, all patients took the Medical, Epidemiologic, 
and Social Aspects of Aging (MESA) questionnaire112,113 to measure symptoms of both SUI and 
UUI. Using a generalized estimating equation (GEE) model, we found correlations between 
diversity and BMI, hormone status, and symptoms of UUI. Specifically, decreased evenness is 
associated with symptoms of UUI but not SUI. This paper was reviewed in Nature Reviews 
Urology 2016212.  
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Abstract 
Background. Female urinary microbiota (FUM) are associated with urgency urinary 
incontinence (UUI) and treatment response to UUI medication. FUM of women with stress 
urinary incontinence (SUI) has not been described.  
Objective. Study the cross-sectional relationships between FUM features and 
demographic and clinical characteristics of women undergoing SUI surgery. 
Design, Setting, and Participants. Pre-operative urine specimens were available from 
197 women (174 voided, 23 catheterized) enrolled in a multi-center prospective randomized 
trial, the Value of Urodynamic Evaluation (ValUE) study. VaLUE excluded samples from women 
with urine dipstick suggestive of urinary tract infection. Collected demographic and clinical 
variables included SUI and UUI symptom measures, menopausal status, and hormone use.  
Outcome Measurements and Statistical Analysis. The bacterial composition of the 
urine was measured by sequencing the bacterial 16S rRNA gene. Phylogenetic relatedness and 
microbial diversity were compared to demographics and symptoms using generalized 
estimating equation (GEE) models. 
Results. The majority of 197 urine samples (86%) had detectable bacterial DNA. 
Bacterial diversity was significantly associated with higher BMI (p=0.02), increased Medical, 
Epidemiologic, and Social Aspects of Aging (MESA) urge index score (p=0.04), and hormonal 
status (p<0.001). No associations were detected with SUI symptoms. This increased diversity 
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was also associated with a concomitant lower frequency of Lactobacillus in hormone-negative 
women.  
Conclusions.  Women undergoing SUI surgery have detectable urinary microbiota.  The 
diversity of the microbiota was associated cross-sectionally with hormonal status, UUI 
symptoms and BMI. Further studies should elucidate the FUM effect on SUI treatment 
outcomes, especially with respect to persistent or de novo UUI symptoms. 
Introduction 
The influence of the human microbiota on health and disease is increasingly appreciated 
in a variety of medical fields. The female urinary microbiota (FUM), composed of resident 
bladder bacteria, was recently recognized when bacterial DNA and low levels of live bacteria 
were detected in catheterized urine specimens considered “sterile” by standard urine 
culture4,5,7.  
The FUM may have clinical relevance for a variety of urinary disorders. Microbial 
communities, such as the FUM, are often described by the predominant organism, the diversity 
of organisms and the amount of those organisms. We recently showed FUM diversity and/or 
composition to be associated with the presence and response to treatment of urgency urinary 
incontinence (UUI) in adult women3,6. We also showed an association between the FUM and 
risk of urinary tract infection (UTI) following urinary tract surgery63 or instrumentation5,65. 
However, the FUM of adult women with stress urinary incontinence (SUI) has not been 
investigated.  
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A biorepository of urine samples collected from a large, multi-center, National Institutes 
of Health sponsored clinical trial of women with uncomplicated SUI planning surgery had been 
previously established 211. This study describes the analysis of these samples by 16S rRNA gene 
sequencing to characterize the cross-sectional relationships between FUM parameters and 
demographic and clinical characteristics of adult women with SUI. 
Materials and Methods 
Subject Recruitment and Urine Collection.  
The Value of Urodynamic Evaluation (ValUE) study was an Institutional Review Board 
(IRB) approved, multi-center prospective randomized trial comparing surgical outcomes using 2 
strategies for pre-surgical testing: multichannel urodynamic testing versus standardized basic 
office evaluation113,211. Participants in the main study also provided written research consent to 
contribute a single baseline urine specimen to the biorepository.  The Loyola University Chicago 
IRB approved this analysis.   
Eligibility for the ValUE trial included adult women who reported symptoms of SUI >3 
months, had a post-void residual <150 mL, a negative urinalysis/standard urine culture, clinical 
assessment of urethral mobility, desire for SUI surgery, a positive provocative stress urinary test 
and a qualifying Medical, Epidemiologic, and Social Aspects of Aging (MESA) questionnaire112,113 
subscale score (stress > urge). Demographic and clinical characteristics were obtained by self-
report including hormonal status, which was categorized by the study team into the hormone 
group that most appropriately described the patient’s hormone use: pre-menopausal, post-
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menopausal (with or without self-reported, current exogenous hormone use) or uncertain 
about status.  
Urine specimens were collected prior to surgery by a standard protocol and tested by 
dipstick to exclude UTI at study entry.   Specimens were centrifuged at 500-1500g for 10 
minutes and the supernatant dispensed into ten 2cc Eppendorf tubes, which were frozen at -
80°C until shipped on dry ice to the National Institute of Diabetes and Digestive and Kidney 
diseases (NIDDK) biorepository. For this analysis, we retrieved available baseline urine 
specimens, which were shipped to Loyola University Chicago on dry ice, and stored at -80°C 
until processed for sequence analysis. The available samples came from 197 of the 630 (31%) 
ValUE participants; 174 samples were obtained by clean catch and 23 by catheterization. 
16S rRNA Gene Sequencing. 
Microbial composition was determined by sequencing the variable 4 (V4) region of the 
bacterial 16S rRNA gene, as described3,6,7,65. The V4 region is ~250 bp, ideal for MiSeq sequence 
technology (Illumina), and sufficient to classify most bacteria to the family or genus level194,213-
215. DNA isolation was performed in a laminar flow hood to avoid contamination. Genomic DNA 
was extracted from 1 ml of urine, using validated protocols3,7,166. The V4 region was amplified 
by a two-step polymerase chain reaction (PCR), using modified universal primers 515F and 
806R, as described3,7. Extraction negative controls (no urine) and PCR negative controls (no 
template) were included to assess contribution of extraneous DNA from reagents. Final PCR 
products were purified from unincorporated nucleotides and primers using Qiaquick PCR 
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purification kit (Qiagen, Valencia, CA) and Agencourt AMPure XP-PCR magnetic beads (Beckman 
coulter). Purified samples were normalized to equal DNA concentration, as determined by 
Nanodrop spectroscopy (Thermo Scientific, Waltham, MA). The sample library and PhiX 
sequencing control library (Illumina) were denatured and added to the 2x250 bp sequencing 
reagent cartridge, according to manufacturer’s instructions (Illumina). 
Sequence Processing. 
Each specimen was sequenced in duplicate and classified by phylogenetic diversity as 
measured by Bray-Curtis dissimilarity. A phylogenetic tree was generated and compared to 
percent total classified reads (relative abundance) at each taxonomic level (phyla, class, order, 
family, genus). For a genus level example, see Figure E.1.  
Each major branch or clade (termed urotype) in the phylogenetic tree was named for 
the predominant classified taxon (e.g., Lactobacillus). When there was no predominant taxon, 
we used the term “non-predominant” to describe the urotype3,6,201. MiSeq sequence reads 
were processed following mothur’s MiSeq SOP at http://www.mothur.org/wiki/MiSeq_SOP194, 
with minor modifications. Mothur software (version 1.34.4) 167 was used to process raw reads 
and, using default mothur parameters, to remove low quality and chimeric sequences. 
Taxonomic classification from phylum to genus level of sequence reads was performed by the 
RDP Classifier (version 2.5)195 using the default 0.8 confidence threshold. The sampling depth 
for this analytic set was set at 2000; the Kolmogorov–Smirnov test confirmed that when 
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subsampling depth exceeded 2000, the distribution of subsampled and original reads 
distribution had >95.9% similarity amongst all samples.  
Most (171/197) samples had detectable DNA with 338,000 and 340,000 reads 
subsampled for replicates 1 and 2, respectively. The 26 samples without detectable DNA were 
classified as “below the detection threshold.” Due to read depths less than 2000, two samples 
from replica 1 and one sample from replica 2 were also classified as “below the detection 
threshold”, for a total of 28 in replica 1 and 27 in replica 2. Using mothur’s built-in average-
linkage clustering algorithm, the cleaned high-quality sequences were clustered into species 
level operational taxonomic units (OTUs) based on the commonly used 97% similarity cutoff, 
resulted in 2579 and 3082 OTUs for replicas 1 and 2, respectively. We used the resultant OTU 
count table and the R package vegan196,216 to determine the Chao1 richness estimate, Pielou 
evenness index, and Shannon diversity index, which accounts for both richness and evenness, 
two measures of microbial diversity. Richness is a measure of the total number of unique taxa 
within a given individual, but does not take into account the distribution of those taxa. In 
contrast, evenness is a measure of distribution, or equality of representation, of taxa within an 
environment. Samples “below the detection threshold” lack diversity measurements; these 
were excluded from subsequent diversity comparisons. 
Statistical Analysis. 
Generalized Estimating Equations (GEE), extensions of Generalized Linear Models that 
account for correlation between replicas, were used to describe associations between 
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demographic and clinical factors with diversity measurements after adjusting for genus 
urotype. A gamma distribution with a log link was assumed for Shannon, Chao, and Peilou 
diversity measurements, due to their skewed nature. To be inclusive, we did not make 
adjustments for Type I error in the GEE analyses when determining potential clinical and 
demographic associations with microbiota characteristics. Only results from the lowest 
detected resolution level (i.e., genus) are reported. There was insufficient sample size and 
power to compare urotypes between catheterized and voided samples. All statistical analyses 
were conducted using SAS v9.4 (SAS Software Cary, NC) and statistical significance was assessed 
at α=0.05 level. 
Results 
The demographic and clinical characteristics of the 197 participants we studied (Table 
E.1) were similar to those of the overall trial population211. Most of these participants were 
non-Hispanic Caucasian (79%) and currently married (74%). The mean age of the subset was 51 
(SD:9.7) years. Forty-two percent of women were pre-menopausal, 31% post-menopausal 
without current exogenous hormone use, and 18% were using exogenous hormones; the 
remaining 10% were “unsure” of their status. Consistent with the entrance requirements for 
the trial211, women reported stress predominant UI with a median MESA stress index score of 
78 (IQR:59-89) and 76% reporting urinary leakage every day and/or night. Concomitant urinary 
symptoms were common at time of trial enrollment; the median MESA UUI score was 33  
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Table E.1. Baseline clinical demographic characteristics of ValUE participants assessed for 
urinary microbiota 
Demographics  N=197 
Age [Mean (SD)] 51 (9.7) 
Body Mass Index (kg/m2) [Mean (SD)] 29 (5) 
Race/Ethnicity*  
Hispanic 23 (12%) 
Non-Hispanic Caucasian  156 (79%) 
African-American 9(5%) 
Other  9(5%) 
Education  
Less High School 6 (3%) 
High School/GED 39 (20%) 
Some College 58 (29%) 
Completed 4 Years of College 53 (27%) 
Graduate/Professional Degrees 41(21%) 
Self Reported Hormonal Status*  
Pre-Menopausal  82 (42%) 
Post-Menopausal lacking exogenous hormones 61 (31%) 
Post-Menopausal or Uncertain about status on 
Exogenous hormones 
35 (18%) 
Uncertain about status lacking exogenous 
hormones 
19 (10%) 
Ever Pregnant 190 (96%) 
Number of Pregnancies, Mdn(Range) 3 (0-10) 
Vaginal Parity, Mdn (Range) 2 (0-7) 
History of Smoking 66 (33%) 
Currently Smoking 20 (10%) 
Currently Married 145 (74%) 
Prior Pelvic Surgeries 151 (77%) 
Prior Non-surgical Treatment 122 (62%) 
Symptom Severity  
MESA score a  
   Stress Index, Mdn(IQR) 78 (59-89) 
   Urge Index, Mdn(IQR) 33 (17-50) 
Frequency of Urine Leakage  
   Less than once a month 0 
   A few times a month 11 (6%) 
   A few times a week 36 (18%) 
   Every day and/or night 150 (76%) 
   Voiding Phase Dysfunction 7 (4%) 
   Suspected Intrinsic Sphincter Deficiency 39 (20%) 
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Table E.1. Continued 
Urine Measures N=167 
Specific Gravity, Mdn(IQR) 1 (1:01-1.02) 
Urine pH, Mdn(IQR) 6 (5-7) 
Blood  
   Negative  110 (70%) 
   Trace (Non-hemolyzed) 11 (7%) 
   Moderate (Non-hemolyzed) 5 (3%) 
   Trace 11 (7%) 
   Small (+) 6 (4%) 
   Moderate (++) 6 (4%) 
   Large (+++) 9 (6%) 
   Protein 25 (16%) 
DIVERSITY OUTCOME MEASURES [Mean (SD)]b  
Shannon 1.86 (0.97) 
Chao 124.08 (59.35) 
Pielou 0.43 (0.19) 
Glucose positive n (%) 6 (4%) 
Total number of SUI participants is 197. Mean (SD) or N(%) reported unless otherwise specified. 
Mdn=Median; SD=Standard deviation; IQR = Interquartile Range;  
aStress Index and Urge Indices were calculated using the MESA questionnaire. 
*Race/Ethnicity and Hormonal status per subject report 
bLeast Squares Means- adjusted for correlation between both replicas 
(IQR:17-50). As only 21 participants had an urgency index score of zero, dichotomous group 
comparisons by urgency index were not performed. 
Fourteen percent of the tested urine samples had bacterial DNA below the level of 
detection, were classified “below the detection threshold” [replica 1: 14% (27/197), replica 2: 
14% (28/197)] and not further analyzed. Figure E.1 displays a representative phylogenetic tree 
and histogram for replica 1 of the remaining samples classified at the genus level. Together, the 
phylogenetic tree and histogram show how samples cluster into urotypes. Supplementary 
Figure E.S1 displays similar representations for each replica at other taxonomic levels.  
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Figure E.1. Using phylogenetic similarity to determine similar profiles (aka urotypes) 
For each taxonomic level (Phylum, Class, Order, Family, Genus), all samples were compared 
to each other using Bray-Curtis similarity, which produces a phylogenetic tree, or 
dendrogram, in which shorter branches link similar samples, and longer branches link more 
dissimilar samples. Therefore, each tree can be divided into groups or clades. When aligned 
to relative sequencing abundance, the clades of each tree separate by the identity of the 
predominant organism. Below is one example, the genus classification from the first replica. 
The urotype indicates the clades that fall into the same urotype. Each urotype is named for 
the predominant genus. If no one genus is predominant, then the urotype is considered 
non-predominant. All corresponding graphs for each replica and each taxonomic level can 
be found in supplementary Figure S1. Genus Identification from the first sequencing replica 
set. 
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Replica 2: Frequency of Sequencing Urotype 
Table E.2. Urotype frequency across all taxonomic levels and between replicas 
Using Bray-Curtis dissimilarity, each dataset was divided into clades (row). A urotype is defined as a clade that is 
predominated by a single organism, or labeled as “non-predominant” when no single organism predominates. 
Here, the frequency of urotype identification is shown for each taxonomic classification for both replicas.  
Urine is a low biomass niche and some samples had so little DNA that the signal could not be distinguished from 
background, these samples are labeled as “below detection level”. 
Replica 1: Frequency of Sequencing Urotype 
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Replicas 1 and 2 yielded similar results (Table E.2). The only major difference involved 
samples of the Lactobacillus urotype, the most common urotype in both replicas (replica 1: 
46%, 90/197; replica 2: 37%, 72/197). The difference in Lactobacillus urotype frequency 
between replicas was mirrored by an inverse difference in the frequency of the “non-
predominant” urotype (replica 1: 5%, 10/197; replica 2: 12%, 23/197). This inverse classification 
of the most diverse samples in the Lactobacillus urotype as members of the “non-predominant” 
urotype (replica 1: 5%, 10/197; replica 2: 12% 23/197). This inverse relationship was primarily 
caused by phylogenetic reorganization and therefore reclassification of the most diverse 
samples in the Lactobacillus urotype as members of the non-predominant urotype. 
The results of the GEE analyses before and after adjustment for urotype were similar, 
thus only adjusted results are presented (Table E.3). We used two types of microbial diversity 
measurements: richness (total number of unique taxa) and evenness (equality of 
representation of taxa within an environment). Richness, as estimated by Chao1, was 
significantly associated only with urine pH (p=0.03). In contrast, richness and evenness, as 
measured together by the Shannon index, were significantly associated with BMI (p=0.02), 
MESA urge index score (p=0.04), and hormonal status (p<0.001) (Table E.3). Specifically, on 
average, a 10-unit increase in BMI was associated with a 0.1-unit increase in Shannon diversity 
(p=0.02). For a 10% increase in MESA urge index score, the Shannon index increased by 0.03 
units (p=0.04). Post-menopausal women not on exogenous hormones had a Shannon index 
0.23 units higher than did pre-menopausal women (p=0.004). 
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Table E.3. Association between microbiota characteristics and demographic factors or 
symptom severity adjusted for genus urotype 
 Community Diversity 
Gamma GEE Models Adjusted for Genus Urotype 
 Shannon Chao1 Peilou 
Demographics Beta SE p-value Beta SE p-value Beta SE p-value 
BMI 0.01 0.006 0.02 0.006 0.005 0.18 0.01 0.005 0.02 
Race/Ethnicity*   0.53   0.25   0.52 
   Hispanic 0.07 0.11 0.55 0.05 0.08 0.58 0.04 0.09 0.66 
   Non-Hispanic 
Caucasian  
Ref         
   African-American -0.15 0.22 0.51 0.08 0.09 0.36 -0.17 0.20 0.40 
   Other  -0.30 0.30 0.27 -0.28 0.15 0.05 -0.25 0.23 0.28 
Education   0.51   0.31   0.59 
Less High School 0.039 0.19 0.84 0.18 0.08 0.02 -0.01 0.16 0.96 
High School/GED -0.03 0.11 0.77 0.11 0.09 0.23 -0.03 0.09 0.70 
Some College Ref         
Completed 4 Years of 
College 
-0.12 0.09 0.18 0.003 0.07 0.97 -0.10 0.08 0.21 
Graduate/Professiona
l Degrees 
-0.16 0.11 0.15 0.07 0.08 0.34 -0.14 0.10 0.17 
Hormonal Status*   <0.001   0.32   <0.001 
Pre-Menopausal  Ref         
Post-Menopausal 
lacking exogenous 
hormones 
0.23 0.08 0.004 0.08 0.07 0.25 0.21 0.07 0.02 
Post-menopausal or 
Uncertain about 
exogenous 
hormonal status 
-0.28 0.14 0.05 -0.07 0.08 0.39 -0.26 0.12 0.04 
Uncertain about 
exogenous hormonal 
status 
0.21 0.09 0.02 -0.03 0.10 0.73 0.22 0.07 0.003 
Ever Pregnant -0.21 0.15 0.16 -0.04 0.10 0.73 -0.18 0.12 0.22 
Smoking History -0.16 0.07 0.04 -0.07 0.06 0.21 -0.13 0.06 0.06 
Currently Married 0.10 0.08 0.21 -0.04 0.06 0.54 0.11 0.07 0.11 
Prior Pelvic Surgeries -0.14 0.07 0.08 -0.02 0.06 0.72 -0.13 0.07 0.07 
Prior Non-surgical 
Treatment 
0.03 0.08 0.66 -0.02 0.06 0.73 0.04 0.07 0.54 
Generalized Estimating Equations (GEE), assuming a gamma distribution and log link, were used to assess the 
association between each demographic or symptom measurement for three separate microbial diversity 
measurements after adjusting for urotype at the genus level. P-values are not adjusted for type I error.   Diversity 
measurements include Shannon diversity (richness and evenness), Chao diversity (richness only) and Peilou 
(evenness only).  
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Table E.3 continued 
 
Community Diversity 
Gamma GEE Models Adjusted for Genus Urotype 
Symptom Severity 
Shannon Chao1 Peilou 
Beta SE 
P-
value 
Beta SE 
P-
value 
Beta SE 
P-
value 
MESA scorea          
    Stress Index 0.002 0.002 0.28 0.0003 0.002 0.87 0.002 0.002 0.31 
    Urge Index 0.003 0.002 0.04 0.002 0.001 0.18 0.003 0.001 0.04 
Frequency of Leakage   0.08   0.61   0.04 
A few times a month -0.38 0.24 0.11 -0.05 0.09 0.53 -0.37 0.21 0.07 
A few times a week -0.15 0.10 0.12 0.05 0.07 0.30 -0.15 0.08 0.06 
Every day and/or 
night 
Ref         
Urine Characteristics          
Protein 0.18 0.10 0.09 0.08 0.08 0.38 0.14 0.08 0.09 
Specific Gravity -0.18 0.01 0.32 -0.10 0.01 0.31 -0.14 0.008 0.32 
Urine pH -0.06 0.04 0.11 -0.07 0.03 0.03 -0.05 0.04 0.13 
Glucose -0.07 0.19 0.70 -0.13 0.11 0.25 -0.03 0.15 0.82 
Blood   0.40   0.69   0.29 
Negative  Ref         
Trace (Non-
hemolyzed) 
-0.08 0.16 0.60 -0.06 0.14 0.66 -0.06 0.14 0.69 
Moderate 
(Non-hemolyzed) 
-0.001 0.25 0.10 0.0853 0.13 0.50 0.008 0.24 0.97 
Trace 0.18 0.11 0.09 0.16 0.10 0.10 0.18 0.10 0.08 
Small (+) 0.21 0.13 0.11 -0.10 0.12 0.43 0.23 0.09 0.01 
Moderate (++) 0.39 0.18 0.03 0.13 0.15 0.39 0.32 0.14 0.03 
a MESA Questionnaire  - SUI and UUI index scores each ranging from 0-100 with higher scores indicating greater 
symptom severity) 
*Race/Ethnicity and Hormonal status per subject report 
 
Because these parameters did not associate with richness (Chao1), we tested evenness 
alone, as measured by Peilou diversity (Table E.3). Evenness was significantly associated with 
BMI (p=0.02), MESA urge index score (p=0.04), and estrogen status (p<0.001). On average, a 10-
unit increase in BMI was associated with a 0.1-unit increase in Peilou diversity. For a 10% 
increase in the MESA urge index score, the Pielou diversity. Finally, post-menopausal women 
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had a 0.21-unit higher diversity measurement compared to pre-menopausal women (p=0.02). 
Since these results were similar to those observed with the Shannon index, we conclude that 
increased community evenness associates with BMI, UUI symptoms and especially hormonal 
status. 
 
Because community evenness associates strongly with hormonal status, we constructed 
a visual comparison of microbial diversity subdivided by hormonal use (Figure E.2). Compared 
to other groups, the hormone-positive women (pre-menopausal and post-menopausal on 
Figure E.2. Phylogenetic diversity and urotype distribution between estrogen status 
Relative abundance of the microbial community at the genus level for each of the 4 estrogen 
groups. Each bar is a separate individual with the percent of total classified reads to the genus 
level represented on the y-axis. Phylogenetic relatedness as measured by Bray-Curtis 
dissimilarity is depicted in the dendrograms above each group.  
The full cohort is separated by hormone status: pre-menopausal, post-menopausal (with or 
without self-reported, current exogenous hormones) or uncertain about hormonal status. 
Estrogen positive groups (pre-menopausal and those currently on exogenous estrogen) have a 
greater prevalence of Lactobacillus-predominant individuals (blue) than the estrogen negative 
group. The estrogen negative group has a greater number of non-predominant (multi-
colored) profiles compared to the estrogen positive populations. 
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exogenous hormones) had a higher frequency of Lactobacillus or Gardnerella urotypes (66%) 
and a lower frequency of ‘non-predominant’ urotypes, while the hormone-negative women 
(post-menopausal not on exogenous hormones) had a lower frequency of Lactobacillus or 
Gardnerella urotypes (38%) and greater frequency of ‘non-predominant’ urotypes (p<0.001). 
Discussion 
In this study of women undergoing surgery for uncomplicated SUI, the presence of UUI 
symptoms appears related to increased microbial evenness, indicating that the FUM of women 
with UUI symptoms was less likely to be predominated by a single microbe. A similar 
relationship was observed between microbial evenness and hormone status and BMI. The 
clinical impact of these findings is significant, given the common coexistence of UUI in women 
who undergo surgical SUI treatment. While considerable uncertainty persists about the effects 
of SUI surgery on preexisting UUI symptoms and each individual patient’s risk of developing de 
novo UUI symptoms following SUI surgery, the microbiota may provide useful information for 
clinical phenotyping of patients prior to surgery. Without comparison to an age- and hormone 
status -matched continent control group, we cannot conclude that women with “pure” SUI are 
like continent women. However, it does appear that the presence and characteristics (i.e. 
evenness) of the FUM relate to UUI in this clinically relevant cohort of women undergoing SUI 
surgery. Our findings will require further research to validate and clarify the physiological 
mechanisms. 
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We observed this associated between microbial evenness and UUI symptoms despite 
the possibility of vulvovaginal contamination in these voided urine samples. Interestingly, the 
FUM detected in the pre-surgical voided urine samples of this cohort was similar to those 
assessed in catheterized samples obtained from other cohorts of women; specifically, the FUM 
of most women was dominated by Lactobacillus, Gardnerella, Streptococcus, or 
Corynebacterium with a small percentage not dominated by a single genus6,65,203. The main 
difference between the results of this study and those of previous studies was the increased 
biomass potentially caused by vulvovaginal contamination. 
Even given the potential for vulvovaginal contamination, we detected an association 
with UUI in this cohort of women undergoing SUI surgery. This association illustrates that 
voided urine can be used to detect bladder phenotypes. But, to ensure appropriate data 
interpretation of voided sample data, one must possess prior information of FUM composition 
from women of a similar cohort using catheter collection methods that obtain urine directly 
from the bladder.  
Research Implications 
 Our finding of a relationship between microbial evenness to hormonal status may 
provide clues for further study. Menopausal women not on exogenous hormones had increase 
microbial evenness and their FUM was less likely to be predominated by a single microbe. 
These results suggest that predominance (most often by Lactobacillus species) is typical of 
hormone-positive women and that loss of that predominance might be associated with UUI 
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symptoms. Increased microbial diversity, in particular community evenness, positively 
correlates with UUI and BMI symptoms, but not with SUI symptoms. BMI is considered a 
contributing factor to urgency symptoms 217, and the FUM of UUI women have been reported 
to be associated with BMI 3. Obesity is also associated with an increase in circulating estrogens, 
emphasizing that complex nature of vaginal and urinary health 218,219.  
It is well known that estrogen receptors are found throughout the lower urinary tract, 
supporting the likelihood that estrogen has a role in optimizing bladder function 220-222. 
Intriguingly, the use of intravaginal estrogen has been reported to improve the lower urinary 
tract symptoms of urinary urgency, frequency, SUI, UUI, and UTI 223. Direct effects of estrogen 
on the bladder could include maintenance of bladder structural and functional integrity via 
bladder wall thickness, expression of vascular epithelial growth factor, and effects on β3-
adrenoreceptor activity, as described in rats 224,225. Given that use of intravaginal estrogen 
correlated with an increase in Lactobacillus species and a decrease in anaerobic bacteria 18, it 
might also influence the FUM. 
 Although we did not assess the vaginal microbiota of Value of Urodynamic Evaluation 
study subjects, we note the FUM’s similarity to published data regarding the vaginal microbiota. 
We acknowledge the possibility that the vulvovaginal flora contributes to bacterial diversity. 
However, it is biologically plausible that both these adjacent anatomical sites experience 
microbial alterations related to estrogen status. The bladder is a low biomass niche that 
contains many organisms similar to those of the vagina, including Lactobacillus, Gardnerella, 
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and a diverse set of anaerobes. The relationship between these 2 biological niches deserves 
further study.  
 Our study has a number of strengths, including rigorous participant characterization, 
multisite recruitment, cutting-edge sequencing techniques and state-of-the-art analytical 
approaches. The use of voided urine might be considered a limitation, but its use allowed us to 
determine that voided urine could be used to phenotype women given the critical caveat that 
appropriate studies with catheterized urine had already been performed. In contrast, the study 
has limitations associated with the cross-sectional study design. The study also would have 
benefitted from controls matched for age, BMI, and estrogen status; paired vaginal samples 
and/or longitudinal sampling; further details regarding hormone status; a higher proportion of 
participant samples; increased proportion of catheterized urine specimens; and concurrent 
enhanced urine cultures 7. Finally, the known relationship between estrogen status and aging 
may mask a biological relationship that is rightfully attributed to only 1 of these variables. A 
larger study that includes women with various forms of urinary incontinence and matched 
controls will be needed.  
Conclusion 
Women undergoing SUI surgery have detectable urinary microbiota that may be of 
value for phenotyping patients. This cross-sectional analysis revealed that diversity of the 
microbiota was associated with UUI symptoms, hormonal status, and BMI. 
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Addendum 
Only two analyses were done for this study that did not make it into the paper and both 
of them were attempts to visually represent statistical data. A common method for showing 
similarity between samples is principle component analysis (or PCA), where similar data points 
will cluster together. Each data point is color-coded to hopefully illustrate what drives the 
clustering. Our data in this study, and many other studies, cluster based on urotype rather than 
any other demographic (Figure E.3). Thus, we know that the difference between samples is 
most likely driven by the dominant organism.  
 This paper relies heavily on statistical methods and a therefore a trust in the p-values 
generated through the GEE modeling. I wanted to have a visual representation of the p-values 
we had calculate. A biostatistician, Stephanie Kliethermes PhD, helped me generate graphs with 
lines of best fit that showed the association between UUI and Shannon diversity, but did not 
show an association between SUI and diversity (Figure E.4). These types of graphs did not 
provide any further information and were therefore not included in the published manuscript.  
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Figure E.3. Principal Component Analysis (PCA) of sequencing data at the family and phyla levels 
(from replica 1) does not show clustering by any demographic or symptom, but does show 
clustering by urotype. A PCA matrix was calculated using an R-script (Appendix I.3) using an input of a 
sequencing count table from replica 1 classified to the family level. The output was then uploaded into 
an online graphical interface, (Plotly Technologies Inc). The three dimensional graph was generated 
and color-coded by all tested demographics and symptoms (Age, race, UUI score, etc). No 
demographic revealed clustering. Only one representative graph is shown (hormone replacement 
therapy – Figure D.3A). The only metadata to indicate clustering was urotype or dominant organisms 
(Figure D.3B). This protocol was repeated for sequencing read tables at the OTU, Genus, Order, Class, 
and Phyla levels.  
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Figure E.4. Graphical representations of the p-values generated by GEE. The p-values (A) 
followed by the line of best fit for Stress index (B) and Urge index (C). 
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Overview of Appendix F 
 This study was completed in collaboration with Andy Schwaderer at Nationwide 
Children’s Hospital. This was a published pilot study on the microbiome of kidney stones. It is 
the first documented case of bacterial DNA and live bacteria in oxalate kidney stones (a type of 
stone not normally associated with bacteria). Andy’s lab was able to take the E. coli isolates 
from our EQUC, add them back into mice, and induce stone formation. The mice infected with 
E. coli had an increased bacterial and stone burden compared to those not infected.  
Abstract 
Background. The role of calcium oxalate crystals and deposits in UTI pathogenesis has 
not been established. The objectives of this study were to identify bacteria present in pediatric 
urolithiasis and, using in vitro and in vivo models, to determine the relevance of calcium oxalate 
deposits during experimental pyelonephritis.   
Methods. Pediatric kidney stones and urine were collected and both cultured and 
sequenced for bacteria. Bacterial adhesion to calcium oxalate was compared. Murine kidney 
calcium oxalate deposits were induced by intraperitoneal glyoxalate injection and kidneys were 
transurethrally inoculated with uropathogenic Escherichia coli to induce pyelonephritis 
Results. E. coli of the family Enterobacteriaceae was identified in patients by calcium 
oxalate stone culture. Additionally Enterobacteriaceae DNA was sequenced from multiple 
calcium oxalate kidney stones. E. coli selectively aggregated on and around calcium oxalate 
monohydrate crystals. Mice inoculated with glyoxalate and uropathogenic E. coli had higher 
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bacterial burdens, increased kidney calcium oxalate deposits and an increased kidney innate 
immune response compared to mice with only calcium oxalate deposits or only pyelonephritis.   
Conclusions. In a murine model, the presence of calcium oxalate deposits increases 
pyelonephritis risk, likely due to preferential aggregation of bacteria on and around calcium 
oxalate crystals. When both calcium oxalate deposits and uropathogenic bacteria were present, 
calcium oxalate deposit number increased along with renal gene transcription of inner stone 
core matrix proteins increased. Therefore, renal calcium oxalate deposits may be a modifiable 
risk factor for infections of the kidney and urinary tract. Furthermore, bacteria may be present 
in calcium oxalate deposits and potentially contribute to calcium oxalate renal disease. 
Introduction 
Approximately 10% of people develop a kidney stone during their lifetime226. Calcium 
oxalate (CaOx) accounts for 74% of stones227. Considerable overlap in CaOx urine super-
saturation exists between individuals with and without kidney stones; therefore, urine 
chemistries cannot be the only factor in stone formation228. Magnesium-ammonium-phosphate 
(struvite) stones form as a result of a urinary tract infection (UTI) with a urease-producing 
bacterium and are a conglomeration of bacteria, struvite crystals and protein matrix229. 
Furthermore emerging evidence indicates an interaction between bacteria and CaOx kidney 
stones. First, patients with kidney stones are more likely to have UTIs than the general 
population230,231. Second, in previous studies, bacteria have been cultured from 19–32% of 
CaOx stones, with non-urease-producing E. coli most commonly present232,233. E. coli, a major 
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member of the Gram-negative bacterial family Enterobacteriaceae, is a contributor to a wide 
range of kidney pathologies ranging from pyelonephritis to kidney allograft rejection234,235. 
Despite its role in other pathologies, the association between E. coli and CaOx disease has not 
been extensively investigated. 
Traditionally, the urinary tract has been considered sterile; however, high throughput 
sequencing technology and enhanced quantitative urine culture (EQUC) protocols have 
identified a urinary microbiome in culture-negative urine samples 6,7,203. Whether kidney stones 
also have a microbiome has not yet been evaluated. The objectives of this study were to 
determine whether bacteria are present in human CaOx kidney stones and, using in vitro and in 
vivo models, evaluate potential associations between E. coli and renal CaOx deposits. 
Materials and Methods 
Human Studies. 
Patients and Sample Collection. Human studies were approved by the Nationwide 
Children’s Hospital (NCH, Columbus, OH) Institutional Review Board (IRB13-00709) and adhered 
to the Declaration of Helsinki. Inclusion criteria consisted of patients with a kidney stone 
removal procedure by the NCH Urology Division. Exclusion criteria consisted of a history of 
known struvite, cysteine or uric acid stones. Written consent was obtained from legal guardians 
if the research subject was a minor additionally assent was obtained if children were ≥ 9 years 
of age. Following kidney stone removal, the urologist bisected the stone. Half of the stone was 
placed in a sterile eppendorf tube and the other half was sent for routine clinical stone analysis 
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(Louis C. Herring and Company, Orlando FL) Upper tract and bladder urine was collected with 
the kidney stones during the stone removal procedure. Immediately following sample 
acquisition, study staff was notified to process the samples. Patient history, including urine 
chemistries, were recorded and urine oxalate, calcium and citrate to creatinine ratios were 
compared to reported normal ranges236,237. 
Sample Processing. Stone fragments were rinsed with sterile PBS, and then 
homogenized in a bullet blender (Next Advance, Averill Park, NY). Stone homogenate and urine 
were aliquoted between urine C&S preservative (Becton Dickenson, Franklin Lakes NJ, United 
States) and 10% AssayAssure universal urine collection media (Thermo Scientific, Waltham MA) 
for culture and sequencing analysis, respectively. Sterile PBS with and without bullet blender 
beads was used as control to evaluate for contamination during stone processing. 
Enhanced Quantitative Urine Culture (EQUC). 0.1 mL of urine or kidney stone 
homogenate was inoculated onto BAP, Chocolate, Colistin, Naladixic Acid (CNA) agars or CDC 
anaerobe 5% sheep blood agar plates (BD BBL™ Prepared Plated Media) and EQUC was 
performed as previously described7. The detection level was 10 CFU/mL. Matrix Assisted Laser 
Desorption Ionization Time of Flight Mass Spectrophotometry (MALDI-TOF MS) was used to 
identify the bacterial isolates. 
DNA Isolation and 16S Amplicon Sequence Analysis. DNA extraction along with 16S 
rRNA gene library generation and DNA sequencing with a MiSeq desktop sequencer (Illumina, 
San Diego, CA) were performed as described previously203. The DNA from the kidney stones was 
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extracted as described previously with the exception that we used lysis buffer ALT in the Qiagen 
DNeasy kit. All samples were processed in duplicate, replicas were comparable; therefore, only 
the first replica was used for downstream analysis. Since urine is a low biomass environment, 
genera were reported only if a group representing 10% of the total reads in at least one sample; 
the rest of the reads are reported as “other”7,203. 
In vitroSstudies. CaOx monohydrate and dihydrate crystals were generated as 
previously described238. For the in vitro binding assay 100μg of CaOx or control silicon dioxide 
crystals (Strem Chemicals, Newburyport, MA) were mixed with 1x105 colony forming units 
(CFU)/ml GFP-labeled uropathogenic E. coli (UPEC, a gift from Matthew Mulvey, University of 
Utah) and incubated in Luria Broth (LB) in a 37°C orbital shaker (Thermo Scientific, Waltham 
MA). Silicon dioxide crystals were chosen as a control because they are commercially available 
and similar in size (10–20 nm) to the generated CaOx crystals. Additionally, silicon has been 
reported to cause kidney stones in human and is a well-established kidney stone component in 
veterinary medicine239,240. 
To quantify the area of crystals, Keyence BZ-II analyzer software was used. The area of 
the crystals was outlined using the Freehand Line feature of the Area Measure function. Within 
the area of the crystal, GFP-expressing UPEC were then counted within the area of the stone 
using the Count function. The same technique was employed for the background, outlining an 
area of the background using the Freehand Line and then counting the E. coli within the 
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outlined area. A ratio of E. coli per μm2 area was then generated by dividing the number of E. 
coli by the corresponding outlined area 
Murine Studies. 
Mice. In vivo murine studies were approved by the Institutional Animal Care and Use 
Committee (IACUC) protocol AR12-00067 and adhered to NIH Guide for the Care and Use of 
Laboratory Animals or the equivalent. C57BL/6 mice (Jackson lab, Bar Harbor, Maine, Stock no. 
000664) aged 6–10 weeks of were used for induction of pyelonephritis and/or CaOx 
nephropathy. Mice were euthanized by CO2 inhalation at the end of the study for assessment of 
kidney bacterial burden, CaOx deposits and kidney innate immune gene transcript evaluation. 
Induction of Kidney CaOx Induced Nephropathy and Pyelonephritis. 
Kidney CaOx deposits were induced in mice by injecting sodium glyoxalate 
(80mg/kg/day of glyoxalate (Sigma Aldrich, St Louis, MO) intraperitoneally (i.p.); this causes 
CaOx deposits to appear by 3 days and to peak at day 6241. Equivalent normal saline was used as 
negative control. Experimental pyelonephritis was induced by inoculating 108colony forming 
units (CFU) of the uropathogenic E. Coli (UPEC strain; CFTO73) transurethrally with a second 
inoculum of the same size performed 4 hours later242. 
Experimental Groups; Innate Immune Response Induced by CaOx Deposits. 
1. CaOx deposits: Sodium glyoxalate injection i.p for 6 days 
2. Negative control: Normal saline (NaCl) injections i.p. for 6 days 
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Male C57BL/6 mice were used for this experiment and evaluated at peak kidney CaOx 
deposition. The goal was to identify candidate innate immune genes to study the interaction of 
CaOx deposition and UPEC at an early time point. 
Experimental Groups; Early Innate Immune Response with CaOx Deposits and UPEC, Alone or 
in Combination. 
1. Kidney CaOx deposits: Sodium glyoxalate injection i.p. for 3 days 
2. UPEC inoculation: NaCl injections i.p. for 3 days, UPEC inoculation on day 1 
3. Kidney CaOx deposits and UPEC inoculation: Sodium glyoxalate injection i.p. for 3 days 
and 108 CFU UPEC inoculation on day 1. A schematic of the experimental design for this 
group is presented in Figure F.1. 
4. Negative control: NaCl injection i.p. for 3 days 
Figure F.1. Induction of CaOx deposits and experimental pyelonephritis in mice 
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The 3-day CaOx treatment/2-day experimental pyelonephritis time period was chosen 
because C57BL/6 mice clear infections by 3rd day242. Female mice were used for this 
experiment because UPEC inoculation is not possible with the male murine anatomy. 
Outcome Studies. 
Kidneys were bisected longitudinally and bacterial burden was determined by plating 
serial dilutions of half-kidney homogenate on a LB plate. The other half kidney was used for 
CaOx deposit and/or pyelonephritis confirmation or snap frozen for RNA extraction. Kidney 
deposits were visualized and quantified with Pizzolato staining using BZII analyzer software 
(Figure F.S1). Kidneys were cultured for bacterial burden as previously described243. The local 
renal CaOx induced innate immune response was determined using the RT2 Profiler 
Antibacterial Response Array (Qiagen, Valencia, CA, Catalog no. PAM148Z) according to the 
manufacturer’s directions. Gene expression was normalized using a panel of five housekeeping 
genes (Actb, B2m, Gapdh, Gusb, and Hsp90ab1). Targeted PCR was performed using KicqStart 
SYBR green primers (Sigma-Aldrich, St Louis, MO) for candidate innate immune genes identified 
in RT2 profiler assay. Gapdh (Real Time Primers, LLC, Elkins Park, PA) was used as a 
housekeeping gene for targeted PCR. All PCR reactions were performed on a 7500 PCR system 
(Applied Biosystems, Carlsbad, CA). 
Statistics. 
Statistical analysis was performed and graphs were generated using Prism software 
(GraphPad Software Inc, La Jolla, CA). The D’Agostino-Pearson Omnibus Test was used to 
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determine if data was normally distributed. Differences between groups were compared with 
the Student’s T-test or One-Way Anova if data was normally distributed; otherwise, the Mann 
Whitney or Kruskal Wallis methods were used. Percentages were transformed to arcsine values 
for analysis. Arrays were analyzed with the RT2 Profiler Data Analysis Software. For targeted 
PCR, expression was quantified using the 2-ΔΔCt method and normalized values to the reference 
gene Gapdh. 
Results 
Patients. 
Five patients were enrolled (Table E.1) between August 2013 and February 2014. 
Patient 5 did not have documented CaOx stones, but had a history of hypercalciuria and a urine 
pH of 6, inconsistent with struvite. Only patients 1 and 2 had a history of UTIs. No patients were 
diagnosed with a UTI during or 30 days prior to the stone removal procedure. However, patient 
1 was treated for a UTI following stone removal. 
Bacteria and/or Bacterial DNA is Present in Pediatric Kidney Stones. 
To guide murine studies and determine which, if any, bacteria are present in pediatric 
kidneys stones, we screened a limited number (5) of patients by EQUC and 16S rRNA gene 
sequencing. Bacterial DNA and live bacteria were detected in the kidney stones, upper tract 
(UT) urine, and bladder urine (Figure E.2). From each of these 5 patients, we obtained kidney 
stones, bladder urine and/or upper tract urine for a total of 13 samples. Of these 13 samples, 
EQUC isolated viable bacteria from 5 samples: 2 out of 5 kidney stones, 1 out of 5 UT urine 
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samples, and 2 out of 5 bladder urine samples. In contrast, 16S rRNA gene sequencing 
produced data from 8 out of 13 samples, including all 5 kidney stones. From these 8 samples, 
we obtained a total of 329,298 sequences. Excluding all sequences that were <0.01% of the 
reads in any sample, we identified 240 genera, 123 families, 66 orders, 42 classes, and 22 phyla.  
Table F.1. Patient characteristics 
Subj Age 
(yrs) 
/sex 
Dx Procedure Stone analysis 24 urine stone risk 
profile (mg/mg) 
1 20/M History of 
tuberculosis 
Right percutaneous 
nephrosto-lithotomy 
for 22 mm stone 
-CaOx monohydrate, 
98%; Protein, 2% 
Cit/Cr, 0.23 Ox/Cr, 
0.02 Ca/Cr, 0.16 
Ca/Cr, 0.23↑ 
2 13/F  Right percutaneous 
nephro-lithotomy for 
16mm stone 
CaOx monohydrate, 
18%; CaOx dihydrate, 
80%; Protein, 2% 
No urine stone risk 
profile completed 
3 15/F  Left ureteroscopy and 
laser lithotripsy for 
5mm stone 
CaOx monohydrate, 
50%; CaOx dihydrate, 
40%; CaPhos (hydroxyl 
form), 8%; Protein, 2% 
Cit/Cr, 0.31 Ox/Cr, 
0.03 Ca/Cr, 0.17 
4 12/F Ovarian 
cyst 
Right ureteroscopy 
and laser lithotripsy 
for 4mm stone 
CaOx monohydrate, 
55%; CaOx dihydrate, 
15%; CaPhos (carbonate 
form), 8%; CaPhos 
(hydroxyl form), 20%; 
Protein, 2% 
No urine stone risk 
profile completed 
5 12/M Seizures, 
treated 
with 
topiramate 
Right ureteroscopy 
and laser lithotripsy 
for 11mm stone 
Not completed. Cit/Cr, 0.13↓ Ox/Cr, 
0.04 Ca/Cr, 
0.10 #Ca/Cr, 0.23↑ 
^ different stone from same patient than stone used for microbiome sequencing. 
# random urine sample. Citrate/creatinine (Cit/Cr) normal is > 0.18 mg/mg. Oxalate to 
creatinine normal is < 0.1 mg/mg. Calcium/creatinine (Ca/Cr) normal is < 0.21 mg/mg. 
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Figure F.2. Kidney stones contain bacteria and/or DNA 
(A) Bacteria key. (B) All stones contained multiple bacterial taxa on sequencing (left column) 
Bacteria identified included the family Enterobacteriaceae (which includes E. coli), and the 
genera Pseudomonas, Gardnerella, Lactobacillus, Brucella, Phyllobacterium and 
Bradyrhizobium. Bacteria were cultured (right column) from 2 stones and represented the 
most abundant bacteria identified by sequencing. (C) Bacteria were only sequenced and 
cultured from upper tract urine in 1 patient. (D) When detected in the bladder urine, the 
taxa were similar to those observed in the stones, although the ratios were often dissimilar. 
To allow low percentage organisms to be visualized, the data was graphed on a logarithmic 
Y-axis. 
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Figure F.3. UPEC selectively aggregate around CaOx monohydrate crystals  
Following incubation with GFP labeled UPEC, bacteria (green) could be seen aggregating 
around CaOx monohydrate (A, arrows) but not CaOx dihydrate (A, arrowheads) or silicon 
dioxide (B, arrows) crystals. 
At 12 hours, significantly more bacteria per crystal surface area were seen with CaOx 
monohydrate crystals than with CaOx dihydrate crystals, silicon dioxide crystals or 
background. There were no other significant differences between groups. Magnification 
40X right panels, 100X left panels Scale bars = 20 microns. Incubation time = 6 hours for left 
panels and 12 hours for right panels. 
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From 3 urine samples, we obtained a total of 188,099 sequences. Excluding all 
sequences that were <0.01% of the reads in any sample, we identified 108 genera, 70 families, 
39 orders, 26 classes, and 12 phyla. From the 5 stones, we obtained a total of 158,848 
sequences. Excluding all sequences that were <0.01% of the reads in any sample, we identified 
201 genera, 109 families, 59 orders, 39 classes, and 19 phyla. All stones contained multiple 
bacterial taxa; however, Pseudomonas (85%) and Enterobacteriaceae (85%) dominated the 
stones from patients 1 and 2, respectively. These taxa were matched by EQUC, which 
cultured Pseudomonas aeruginosa from patient 1 and Escherichia coli from patient 2. Due to 
the lack of enough diversity in the V4 region, sequencing could not classify Enterobacteriaceae 
beyond the family level; however, this assignment matches the EQUC results, which 
identified E. coli. When detected in the bladder urines, the taxa were similar to those observed 
in the stones, although the ratios were often dissimilar. For example, whereas 
Enterobacteriaceae/E. coli dominated the stone microbiome of patient 2, Gardnerella was 
predominant in bladder urine. We selected uropathogenic E. coli (UPEC) for further in 
vitro and in vivo murine studies because experimental models for UPEC kidney infections are 
well established and there was evidence for Enterobacteriaceae/E. coli in human stones 
screened for by complementary EQUC and sequencing approaches. 
In vitro UPEC and CaOx Culture. 
Uropathogenic E. coli (UPEC) aggregate on and around CaOx monohydrate crystals in 
significantly greater numbers compared to CaOx dihydrate and control silicon dioxide crystals  
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Figure F4. Bacteria increases the murine CaOx deposit burden. 
A. The mean right (A), left (B) and combined mean (C) kidney bacterial burdens were lower with UPEC 
inoculation alone compared to kidneys with CaOx deposits and UPEC inoculation at 56,157±1.68x105 versus 
2.14x106±3.34x106; 24,843±69,527 versus 4.5x106±7.83x106 and 40,500±1.12x105 versus 5.28x106±1.78x106 
respectively. To present on a log scale graph, but not during statistical analysis, 0 values were assigned a value 
of 0.01 (D). Following glyoxalate injection, CaOx deposits are seen around the corticomedullary junction 
(arrows) (E) Following UPEC inoculation and glyoxalate injection, an increased distribution and number of CaOx 
deposits (arrows) is noted, extending into the medulla (arrowheads). D-E, representative 4X magnification 
image stitches, background cropped for clarity, scale bar = 1000μm. (F) CaOx deposit number per mean 4X 
imaging stitch cross-section area was significantly higher in the CaOx deposits and UPEC inoculation group 
compared to kidney stones alone. There was a higher percentage of CaOx deposit/total kidney cross section 
area (H) with CaOx deposits and UPEC than CaOx deposits alone. The location on the scatterplot for the 
representative images (D) and (E) are indicated by an arrowhead and arrow respectively. 
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(Figure F.3). A time-lapse movie of UPEC aggregation on/around to CaOx is presented in Video 
S1 (online). 
Renal CaOx Deposits Increase the Murine Bacterial Burden Following UPEC Inoculation. 
The bacterial burden was quantified 3 days after CaOx deposits induction (2 days post-
UPEC inoculation). When both CaOx deposits and UPEC inoculation were present (n = 9), the 
bacterial burden was 181, 38 and 82-fold higher in the right kidney, left kidney and mean 
kidney, respectively compared to UPEC inoculation alone (n = 9); (Figure F.4A-C). Kidney 
cultures from saline control mice or mice inoculated with only CaOx demonstrated no bacterial 
growth at 24 hours.  
UPEC Inoculation Results in Increased CaOx Deposition. 
Mice with CaOx deposits and UPEC inoculation (n = 10) had a significantly higher 
number of CaOx deposits per mean 4X image stitch cross section than mice inoculated with 
CaOx alone (n = 10); (Figure F.4D-F). (Figure F.4G-H). Renal CaOx deposits were not seen in the 
saline controls or in mice with UPEC inoculation alone (data not shown). 
CaOx Deposits Induce a Murine Renal Innate Immune Response. 
To identify innate immune genes with increased expression in response to CaOx 
deposits, we performed the RT2 Antibacterial Response Array. CaOx deposits induced a robust 
innate immune response at peak (6th day) CaOx deposits formation. Twelve of 84 genes were 
upregulated (>4-fold, P < 0.01) in mice with kidney CaOx deposits (n = 6) compared to saline 
controls (n = 6) (Figure F.5A). The upregulated genes were involved with inflammation, toll-like 
- 256 - 
 
 
 
Figure F.5. PCR results 
(A) At peak murine CaOx deposit formation (6 days), the RT2 Bacterial Response Array 
revealed that 12/83 genes were significantly up-regulated > 4 fold. These genes included 
the inflammatory genes Chemokine (C-C motif) ligand 5 (Ccl5), Cluster of differentiation 
14 (Cd14), Interleukin 1β (Il1b), Interleukin 6 (Il6), Lysozyme 2 (Lyz2), Mediterranean 
fever (Mefv), and Tumor necrosis factor (Tnf); the toll-like signaling genes, Interleukin–1 
receptor-associated kinase 3 (Irak3) Toll-like receptor adaptor molecule 1 (Ticam1) and 
Toll-like receptor 2 (Tlr2) along with the inflammasome genes NLR family, apoptosis 
inhibitory protein 1 (Naip1) and NOD-like receptor family, pyrin domain containing 3 
(Nlrp3). (B) In female C57Bl/6 mice, targeted RT-PCR revealed that at day 3 the 
inflammatory genes CD14 and Il6 are not increased in UPEC alone inoculated mice or 
CaOx alone inoculated mice compared to saline control, but are when both CaOx 
deposits and UPEC inoculation are present. (C) Toll-like signaling genes: Tlr2 followed a 
similar pattern to the inflammatory genes while Irak3 was not increased at day 3. (D) The 
inflammasome genes were not up-regulated at 3 days in any of the groups (E) Stone 
matrix protein inner core components were markedly up-regulated, but only when both 
CaOx deposits and UPEC inoculation were present. 
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receptor signaling and inflammasome formation. A table outlining the 84 genes, heat map and 
complete results are presented in Table F.S1, Figure F.S1, and File S1 (online) respectively.  
UPEC and CaOx together protentiate the murine renal innate immunce response 
 To determine whether UPEC alters the CaOx induced innate immune response, we 
evaluated expression of innate immune genes in mice with UPEC inoculation alone (n = 5), 
kidney stones alone (n = 6), combined UPEC and CaOx inoculation (n = 6), and saline controls (n 
= 4). We also evaluated the expression of Osteopontin (Spp1) and Calgranulin B (S100A9), since 
Figure F.5. Continued 
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they encode proteins present in the inner core of CaOx stones (15). No significant differences in 
inflammatory response, toll-like receptor signaling, inflammasome genes or stone matrix 
protein inner core genes were found with UPEC inoculation only, CaOx inoculation only or 
saline control mice. However, when mice were inoculated with both CaOx and UPEC, 2/2 
inflammatory genes, ½ toll-like receptor gene and most notably 2/2 stone matrix protein genes 
were significantly elevated (Figure F.5B-D). 
Discussion 
We hypothesize that bacteria and renal CaOx deposits potentiate individually induced 
nephropathy (Figure F.6). Urine is not always sterile and contains a microbiome8,162. Thus, 
dysbiosis may create a urinary environment conducive to kidney stone formation; conversely, 
CaOx crystals or deposits may form a nidus for bacteria, increasing UTI risk. In support of our 
hypothesis, we have demonstrated that human kidney stones have a microbiome (Figure F.2), 
UPEC aggregate around CaOx monohydrate crystals (Figure F.3), renal CaOx deposits potentiate 
murine pyelonephritis (Figure F.4A-C). UPEC inoculation of the murine kidney increases calcium 
oxalate deposition (Figure F.4D-H) and induces local expression of innate immune proteins 
(Figure F.5) associated with the stone inner core. 
Children with idiopathic hypercalciuria have increased rates of urinary tract 
infections244,245. Furthermore, patients with non-struvite kidney stones often have positive 
urine cultures233. We were able to detect bacteria in human kidney stones but not in upper 
tract urine; this suggests that the CaOx stones represent an area of concentrated bacteria. Our 
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murine studies provide the first experimental evidence that renal CaOx deposits increase 
pyelonephritis susceptibility. Despite the frequency of kidney stones and UTIs, the biologic, 
diagnostic, and therapeutic relevance of their association remains largely unknown.  
 
Figure F.6. Speculated mechanisms for bacterial contribution to CaOx stones 
(A) Figure key. (B) Bacteria bind to CaOx crystals that may provide a nidus for 
pyelonephritis or remain persist in a subclinical state (1) and bacterial communities form a 
biofilm (2). The biofilm results in crystal aggregation (3). (C) The bacterial enzymes citrate 
lyase splits citrate resulting in increased CaOx supersaturation (1). CaOx crystals form 
providing a key element of lithogenesis. (D) Bacteria bind to the urothelium (1) that results 
in secretion of innate immune proteins from recruited inflammatory cells (2) and the 
urothelium (3) The innate immune proteins are incorporated as stone matrix proteins. 
- 260 - 
 
 
 
Determining whether treatment of hypercalciuria and kidney stones reduces UTI risk remains to 
be determined. Additionally, a more extensive evaluation of CaOx crystal and UPEC adhesion 
forces with atomic force microscopy warrants consideration. 
The identification of bacteria in CaOx kidney stones raises the possibility that bacteria or 
bacterial biofilms are components of CaOx stone formation (Figure F.6) as they are in struvite 
stones229. Four out of 5 (80%) of the kidney stones were positive for Enterobacteriaceae family 
by sequencing. EQUC identified E. coli, a major member of family Enterobacteriaceae in one of 
the three kidney stones. These complementary methods for bacterial identification indicate 
that Enterobacteriaceae may be associated with pediatric kidney stones. Since the positive 
cultures were from large kidney stones (Table F.1, Figure F.2) it is possible that EQUC may not 
be sensitive in smaller kidney stones with smaller bacterial loads. Additionally, sequencing was 
positive for Pseudomonas and Gardnerella in 5/5 and 4/5 stones, respectively; both species 
have been detected previously in adult CaOx stones. Sequencing identified bacteria in 100% of 
stones, well above the 19–32% positive CaOx culture rate previously reported232,233. Whenever 
EQUC identified a bacterium, sequencing also identified it. In contrast, sequencing identified 
many more bacteria than did EQUC. The increased sensitivity of sequencing relative to culture 
may be due to the inability of some bacteria to be readily cultured, the ability of sequencing to 
detect and identify bacteria that are not viable or culturable, and the ability of sequencing to 
detect smaller numbers of bacteria. This increased likelihood of finding bacteria with 
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sequencing compared to culture correlates with what has been described previously for the 
urinary microbiome4. 
We are not aware of prior reports of Bradyrizobium in urine or kidney stones, but it has 
been identified elsewhere in the human microbiome246. Phyllobacterium is an environmental 
organism247. Brucella does not appear to be a contaminating organism because it was not 
present in controls including sterile PBS and the bullet blender beads. It also was not found in 
the upper tract urine. Furthermore Brucella is not an environmental organism or found 
spontaneously in mice but may be found in livestock and unpasteurized milk, which the 
investigating facilities do not study248. Our high throughput sequencing uses the V4 
hypervariable region of the 16S rRNA gene and is therefore only able to classify to the genus 
level. Therefore, what the sequence analysis identified as Brucella could represent an organism 
that has a similar V4 region such as Ochrobactrum249. Ochrobactrum has been identified in 
human urine and we submit that our findings may demonstrate that it may also be found in 
kidney stones250. 
With the exception of patient 1, the upper tract urine was culture-negative and 
sequence-negative. Therefore it is unlikely that bacteria DNA from the surrounding upper tract 
urine contaminated the kidney stone. This discrepancy in bacterial loads between the upper 
tract urine and kidney stones could be explained by pre-operative prophylactic antibiotics that 
patients received, which might have had time to sterilize the upper tract urine but not reach 
the inner stone or the bladder urine. Alternatively, the upper tract with higher flow may not be 
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conducive to bacterial growth compared to the relative urine stasis in the bladder. Additionally, 
the CaOx surface characteristics may be more prone to bacterial growth or colonization than 
urine or urine epithelial cells. 
We demonstrated that E. coli aggregates around CaOx monohydrate crystals compared 
to CaOx dihydrate crystals and control silicon dioxide crystals. Bacterial adhesion to crystals is 
complex because biological properties very based on crystalline form251. Future studies will 
include direct evaluation of adhesive forces between a wide variety of crystals and bacteria 
with atomic force microscopy252. Our findings build upon the findings by Chutipongtanate and 
co-workers who demonstrated that bacteria including E. coli interact with CaOx crystals253. 
Specifically they demonstrated that intact viable, but not dead, bacteria enlarged CaOx 
aggregates253. 
Traditionally, supersaturation of CaOx has been considered the primary mechanism for 
stone formation. Bacteria in kidney stones or urine may alter urine supersaturation (Figure 
F.6C). Prior research demonstrated that culture positive urine samples have lower citrate levels 
than culture-negative samples and lower bacterial utilization of citrate via citrate lyase254,255. 
The correlation of urine chemistries with the urine and kidney stone microbiome was beyond 
the scope of this project, but remains an area for future research. 
Human kidney stones are increasingly recognized to have an inflammatory 
component256,257. The kidney stone matrix is predominated by inflammatory proteins. It has 
been shown that CaOx crystals induce an inflammatory response through dendritic cell 
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secretion of Il–1β, inflammasomes are involved in kidney stone pathogenesis and urine Il–6 
levels are increased in patients with kidney stones258-261. Furthermore, the innate immune 
proteins Osteopontin (Spp1) and Calgranulin B (S100A9) have consistently been identified in the 
inner core of CaOx deposits262. A potential mechanism for kidney stone formation consists of 
bacteria/CaOx induction of innate immune proteins that are incorporated into the kidney stone 
matrix inner core, leading to progression from crystalluria to stone formation (Figure F.6D). The 
finding that most inflammatory mediators were not significantly elevated in oxalate loaded 
mice versus saline controls or UPEC alone indicated that the immune response is not due to 
oxalate poisoning but represent synergy between CaOx and UPEC (Figure F.5). A similar 
mechanism occurs in extra-renal calcifications. Specifically, bacteria are present in vascular 
calcifications and innate immune recognition of bacteria accelerates atherosclerosis263,264. At an 
early time point in murine CaOx induced disease, an oxalate load or UPEC inoculation 
individually did not significantly increase the innate immune response, whereas the 
combination of CaOx deposit and UPEC inoculation increased both the innate immune 
response, most importantly the stone inner core matrix protein gene expression and the renal 
CaOx deposit burden. 
Conclusion 
Kidney stones have a microbiome that includes Enterobacteriaceae. E. coli aggregate 
around CaOx monohydrate crystals, and murine UPEC inoculation is associated with increased 
renal CaOx deposition along with the innate immune response, including increased expression 
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of stone matrix proteins, during experimental murine CaOx nephropathy. Further renal CaOx 
depositions increase the bacterial burden during murine pyelonephritis. Perhaps kidney stones 
and/or CaOx crystalluria represents a reversible risk factor that should be screened for in 
patients with recurrent pyelonephritis. Limitations of this study include lack of documentation 
of stone composition in the kidney stone of one patient and the previously mentioned 
limitations in bacterial DNA sequencing technology. Future studies will be needed to confirm 
whether low abundance organisms are passive environmental contaminants or directly 
involved in lithogenesis. Additionally, murine renal CaOx models have key differences from 
human kidney stone disease. We studied human urolithiasis, in vitro CaOx crystals and murine 
CaOx deposits under the broad umbrella of CaOx disease. CaOx deposition in mice occurs 
acutely and is located mostly in the interstitial space. In humans CaOx deposition is mostly 
tubular and occurs over a long period of time. Because of these key differences, our murine 
findings will need to be validated in human patients or an animal model, when one is available 
that closely approximates human urolithiasis, to determine whether bacteria have any 
relevance in human kidney stone disease. Whether bacteria are essential for CaOx kidney stone 
formation, a disease-modifying factor or largely an uninvolved association remains to be 
determined. However, this study provides proof-of-concept that bacteria can worsen the CaOx 
kidney deposit disease course and vice versa. Our screen of 5 kidney stones for bacteria was 
meant to guide our murine studies, clearly sequencing of a much larger cohort of patients is 
needed to characterize the kidney stone microbiome and determine if the bacteria we 
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identified are frequently present in other cohorts. Future studies will also be needed to 
determine mechanisms responsible for the association and/or interaction between bacteria 
and calcium oxalate disease. 
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Supplemental Material 
 
Figure F.S1. Quantifying kidney deposits 
(A) Pizzolato stain of a 4X cross-section image stitch (upper panel) in which the CaOx deposits 
are stained black. A zoom view (lower panel) demonstrates individual CaOx deposits (B) The 
“dynamic cell count” feature of the BZ900 microscope software identifies and outlines the 
CaOx deposits (yellow) in the 4X image stitch (upper panel) with the outlines of individual 
software-identified CaOx deposits visible in zoom view (lower panel). 
Subsequently the software records the number, major axis and area of the kidney CaOx 
deposits. 
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Appendix F – Video 1. 
Not included in this document. Online at: 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4598009/ 
Figure F.S2. Heatmap of the antibacterial response array 
A heatmap (upper panel) and table (lower panel) of the RT2 Profiler Antibacterial Response Array 
results. 
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Addendum 
We had never before detected Brucella in any sample, yet in this study, we sequenced 
Brucella in 3/5 samples (Figure F.8). At first, we were curious about this new organism and 
decided that we should try to culture it in the future. It did not take us long to realize that we 
were incredibly lucky that we did not cultivate this organism. According to the CDC, Brucella 
causes a severe zooinotic infection, Brucellosis, which can cause fever, swelling, and 
neurological conditions. In developing nations, it is usually transmitted to humans through milk 
or raw meat, but the main source of Brucellosis infection in the US is from laboratory use 265. 
Furthermore, Brucella is a BSL3 organism and considered to be a bioweapon; simply opening a 
plate growing Brucella is sufficient for infection by aerosolization 265,266. In hindsight, we were 
thankful that we had accidentally failed to grow it.  
However, we soon discovered that Brucella is very closely related to a non-pathogenic 
bacterium, Ochrabactrum (Figure F.7). Ochrabactrum is commonly misidentified as Brucella 
with 16S sequencing 267. We sent the V4 amplicons from this study to a Brucella expert, Jeffery 
Foster from Northern Arizona University, and he could not determine if it was truly Brucella or 
Ochrabactrum from the 250bp V4 segment. About a year later, we were able to isolate 
Ochrabactrum from kidney stone samples. Therefore, we think that these samples actually 
contain Ochrabatrum, not Brucella. Oddly, we have never cultured or sequenced Ochrabactrum 
in bladder urine; so far, it seems to be confined to kidney stones.  
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All other kidney stone-associated organisms are species that we commonly find in the 
bladder. This led us to question if Brucella or Ochrabactrum have ever been associated with 
calcium deposits before. We did find that Brucellosis infection can cause calcium deposits in the 
liver and spleen, but it was a more common occurrence in the pre-antibiotic era 268. There have 
also been reports of Brucella-filled calcium nodules in and on skeletons from archeological digs 
269,270. All of this may be coincidence, but it may be interesting to study Ochrabactrum and 
kidney stones or even the connection between bacteria and calcium deposits elsewhere in the 
body. 
We did find that Brucellosis infection can cause calcium deposits in the liver and spleen, 
but it was a more common occurrence in the pre-antibiotic era 268. There have also been 
reports of Brucella filled calcium nodules in and on skeletons from archeological digs 269,270. All 
of this is coincidence, but it may be interesting to study the connection between bacteria and 
calcium deposits elsewhere in the body.  
 Finally, the paper only briefly compares sequencing to culture. Therefore, I have 
included a relative abundance graph (Figure F.8) as well as a table comparing the two (Table 
F.2). Overall, (besides the Brucella/Ochrabactrum samples) both methods provide similar 
results.   
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Figure F.7. Phylogenetic tree of Brucella and Ochrabactrum 
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Figure F.8. Relative abundance of sequenced patient urine and stones 
Depicting the same data as in Figure E.2. Microbiome profile as determined by 16S amplicon 
sequencing. Stacked bar plots depict the sequence abundance of the most abundant genus- or 
family- level taxa. The y axis represents the percentage of sequences for a particular bacterial 
taxa; the x axis represents the kidney stone and urine samples separated by study participant. 
Family Enterobacteriaceae could not be classified to the genus level. Black bars indicate 
unamplifiable samples, meaning that the 16S DNA could not be distinguished above 
background levels. The remainder of sequences were combined in the category Other. 
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Table F.2. Comparison of EQUC results to sequencing  
Kidney Stones, Upper Urinary Tract (UUT), and bladder urine isolates were cultured via EQUC 
and identified using MALDI-TOF. The culture results are compared to the most abundant 
species sequenced in each sample. 
Site Cultured Organism 
Colony 
Forming 
Units/mL 
Most Abundant 
Sequence 
Organism 
KS-13 
UUT 
Pseudomonas 
aeruginosa       
10,000 
CFU/mL Pseudomonas     
Kidney 
Stones 
Pseudomonas 
aeruginosa       
10,000 
CFU/mL Pseudomonas     
KS-19 
Bladder Urine 
Escherichia coli                       
Gardnerella vaginalis 300 CFU/mL Gardnerella 
UUT None   Negative 
Kidney 
Stones Escherichia coli                     
10,000 
CFU/mL Enterobacteriacea 
KS-24 
Bladder Urine None None Lactobacillus 
UUT None None Negative 
Kidney 
Stones None None Brucella 
KS-23 
Bladder Urine None None Negative 
UUT None None Negative 
Kidney 
Stones None None Brucella 
KS-30 
Bladder Urine Actinomyces turicensis             10 CFU/mL Negative 
Kidney 
Stones None None Brucella 
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APPENDIX G 
GENOMES OF GARDNERELLA STRAINS UNCOVER AN ABUNDANCE OF PROPHAGES WITHIN THE 
BLADDER MICROBIOME 
 
Malki, R., Shapiro, J., Price, T.K., Hilt, E.E., Thomas-White, K., Sircar, T., Rosenfeld, A.B., Kuffel, 
G., Zilliox, M.J., Wolfe, A.J., Putonti, C. Genomes of Gardnerella Strains Uncover an Abundance 
of Prophages within the Bladder Microbiome. PloS one 2016;11:e0166757, PMID: 27861551 
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Overview of Appendix G 
 This work was performed in collaboration with the Putonti Lab at the Lakeshore Campus 
and the majority of the bioinformatics was done in their lab. However, their Gardnerella 
analysis supports the hypothesis that 2 unique species of Gardnerella exist. Furthermore, within 
each species, there is no specific clading correlating with collection site. This suggests that 
Gardnerella is not specific to a given niche.  
Abstract 
Bacterial surveys of the vaginal and bladder human microbiota have revealed an 
abundance of many similar bacterial taxa. As the bladder was once thought to be sterile, the 
complex interactions between microbes within the bladder have yet to be characterized. To 
initiate this process, we have begun sequencing isolates, including the clinically relevant 
genus Gardnerella. Herein, we present the genomic sequences of four Gardnerella strains 
isolated from the bladders of women with symptoms of urgency urinary incontinence; these 
are the first Gardnerella genomes produced from this niche. Congruent to genomic 
characterization of Gardnerella isolates from the reproductive tract, isolates from the bladder 
reveal a large pangenome, as well as evidence of high frequency horizontal gene transfer. 
Prophage gene sequences were found to be abundant amongst the strains isolated from the 
bladder, as well as amongst publicly available Gardnerella genomes from the vagina and 
endometrium, motivating an in depth examination of these sequences. Amongst the 
39 Gardnerella strains examined here, there were more than 400 annotated prophage gene 
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sequences that we could cluster into 95 homologous groups; 49 of these groups were unique to 
a single strain. While many of these prophages exhibited no sequence similarity to any lytic 
phage genome, estimation of the rate of phage acquisition suggests both vertical and horizontal 
acquisition. Furthermore, bioinformatic evidence indicates that prophage acquisition is ongoing 
within both vaginal and bladder Gardnerella populations. The abundance of prophage 
sequences within the strains examined here suggests that phages could play an important role 
in the species’ evolutionary history and in its interactions within the complex communities 
found in the female urinary and reproductive tracts. 
Background 
 Gardnerella, a member of the Bifidobacteriaceae family, is a genus of facultative 
anaerobes within the vaginal microbiota of both healthy women and those diagnosed with 
bacterial vaginosis (BV)181,271-273. Similarly, our group found Gardnerella in urine collected from 
adult female bladders by transurethral catheter4,6,7,65. This corresponds with microbiome 
studies of voided urine: Gardnerella was present regardless of sex or symptom 
status13,60,172,204,274. Furthermore, the bladders of healthy individuals include other bacterial 
taxa also detected within the vaginal microbiota4,6,7,13,14,60,65,204,274. To date, thirty-nine G. 
vaginalis isolates from the vagina or endometrium have been sequenced275-279, including four 
complete genomes; the remaining genomes are represented as scaffolds or contigs. Analysis of 
G. vaginalis genomes found evidence of a large pangenome that consists of a modestly sized 
core genome in addition to strain-specific genes275,280. 
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 Prior investigations of G. vaginalis genomes from the reproductive tract have uncovered 
indications of substantial horizontal gene transfer (HGT), including the acquisition of genes 
from other human-associated taxa275,280,281. In addition to natural competence, G. vaginalis may 
also include phage-mediated gene transfer, as coding regions of bacteriophage (phage) origin 
are ubiquitous within these genomes280. Similarly, genomic sequences from other bacterial taxa 
within the vaginal microbiota also contain parts of or entire temperate phage genomes282,283. 
Prior studies have posited that lysogenic lactobacilli phages could contribute to a shift in the 
vaginal microbiota leading to BV (for a review, see Turovskiy et al 2011273). Phages have been 
found to play a crucial role in the structuring of microbial communities, including those residing 
within the human body284, driving bacterial genetic diversity103 and adaptation to changes in 
the environment285. Although several phages induced from vaginal lactobacilli have been 
identified158,286, currently no phages have been characterized for Gardnerella. While evidence 
suggests that phages are likely contributors to HGT in commensal communities282,285,287, the 
extent of their effect on the human microbiome is just now being explored288-290. Within many 
other microbiota, including the bladder, the virome remains largely unexplored. 
 Herein, we present the genomic sequences of four Gardnerella strains isolated from the 
bladders of adult women with symptoms of urgency urinary incontinence (UUI). Comparative 
genomics between these strains and publicly available isolates revealed a highly conserved core 
genome across the bladder and vaginal isolates. Analogous to prior observations for this 
species, the Gardnerella strains isolated from the bladder also contain a large number of 
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prophage gene sequences. The pervasiveness of prophage sequences in Gardnerella genomes 
from both the female urinary and reproductive tracts motivated our thorough bioinformatic 
investigation. A comprehensive interrogation of the over 400 annotated prophage gene 
sequences identified here provides insight into the adaptive ability of Gardnerella, as well as 
the larger community of phages within the female urinary community. 
Materials and Methods 
Strain Isolation and DNA Extraction. 
 The Gardnerella and Gardnerella vaginalis isolates were isolated from transurethral 
catheterized urine specimens of adult women with UUI6 using the previously described 
Enhanced Quantitative Urine Culture (EQUC) protocol7. Microbial identification was determined 
using a Matrix-Assisted Laser Desorption/Ionization-Time-of-Flight Mass Spectrometer (MALDI-
TOF MS, Bruker Daltonics, Billerica, MA) as described7. Pure cultures were stored at -80°C in a 2 
ml CryoSaver Brucella Broth with 10% Glycerol, no beads, Cryovial, for preservation (Hardy 
Diagnostics). 
The preserved pure culture isolates were grown on CDC Anaerobic 5% sheep blood 
(Anaerobic BAP) agar (BD BBL™ Prepared Plated Media) under anaerobic conditions at 35°C for 
48 hours. MALDI-TOF MS was performed for species/genus verification. An isolated colony was 
transferred to 5mL tryptic soy broth (TSB) supplemented with 10% fetal bovine serum (FBS) and 
grown under anaerobic conditions at 35°C for 48 hours. 1 mL of culture was collected, and cells 
were resuspended in 1 mL of buffered saline peptone (PBS). 
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Genomic DNA extraction was performed using a phenol-chloroform extraction protocol. 
Briefly, cells were resuspended in 0.5 mL DNA Extraction Buffer (20 mM Tris-Cl, 2 mM EDTA, 
1.2% Triton X-100, pH 8) followed by addition of 50 μL Lysozyme (20mg/mL), 30 μL 
Mutanolysin, and 5 μL RNase (10 mg/mL). After a 1-hour incubation at 37°C, 80 μL 10% SDS, 
and 20 μL Proteinase K were added followed by a 2-hour incubation at 55°C. 210 μL of 6 M NaCl 
and 700 μL phenol-chloroform were then added. After a 30-minute incubation with rotation, 
the solutions were centrifuged at 13,500 RPM for 10 minutes, and the aqueous phase was 
extracted. An equivalent volume of Isopropanol was then added, and solution was centrifuged 
at 13,500 RPM for 10 minutes after a 10-minute incubation. The supernatant was decanted and 
the DNA pellet was precipitated using 600 μL 70% Ethanol. 
Genome Sequencing, Assembly, and Annotation. 
 DNA samples were diluted in water to a concentration of 0.2 ng/μl as measured by a 
fluorometric-based method (Life Technologies) and 5 μl was used to obtain a total of 1 ng of 
input DNA. Library preparation was performed using the Nextera XT DNA Library Preparation 
Kit (Illumina) according to manufacturer’s instructions. The isolates were barcoded, pooled and 
each isolate was sequenced twice, on two separate runs, using the Illumina MiSeq platform and 
the MiSeq Reagent Kit v2 (300-cycles) to produce 150 bp paired-end reads. Sequencing reads 
were parsed into individual folders according to the respective barcodes. 
 The following protocol produced an assembly with the least number of scaffolds and the 
highest overall coverage (Table G.1). Reads were paired using Geneious (Biomatters Ltd., 
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Auckland, New Zealand) for each isolate for each sequencing run. De novo assembly was 
performed, combining the two runs per isolate, using the Geneious plug-in for Velvet120 (k = 
99). Sequence contigs were then extended and scaffolds were constructed using the tool 
SSPACE121. Resulting contigs were again assembled using the Geneious de novo assembler at 
the Medium-Low sensitivity setting. Annotations were performed for each of the contigs using 
the RAST annotation pipeline291, as well as the BASys bacterial annotation system292. RISPR 
arrays were predicted using CRISPRdb293. A local nucleotide database was created for each 
strain using the protein coding regions predicted by RAST. Each predicted coding region was 
then reciprocally BLASTed (blastn). Genes were determined to be homologs if the query 
coverage and the sequence identity were both greater than 70%. 
 Raw sequencing reads as well as assembled contigs are available through NCBI: Gv18-4 
(SRA: SRX1688291, WGS: LWSP00000000), Gv23-12 (SRA: SRX1688198, WGS: LWSQ00000000), 
G26-12 (SRA: SRX1688301, WGS: LWSR00000000), and G30-4 (SRA: SRX1688300, 
WGS: LXJL00000000). S1 Table lists the annotated protein functionalities within the four strains; 
annotations are available and can be queried through NCBI. 
Phylogenetic Analysis. 
Single Gene Trees: 16S rRNA gene sequence analysis was performed by excising the full 
length 16S sequence from the assembled genomes and querying each against the NCBI nr/nt 
database via blastn. Sequences producing full-length hits were collected and aligned using 
MUSCLE169. The phylogenetic tree was constructed using RAxML130 and visualized using 
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PhyloWidget294. Phylogenetic analysis of the VLY gene sequences was aligned using ClustalW295. 
As before, RAxML and PhyloWidget were used to derive and visualize the tree, respectively.  
Core Genome Tree. While 43 strains are presently publicly available through NCBI 
for G. vaginalis, this study considered only those that were (1) isolated from the vagina or 
endometrium and (2) are documented within the literature182,275-279. Supplementary Table 3 
lists the 35 publicly available strains meeting these criteria. The species tree was derived by first 
identifying the core set of genes within the 39 Gardnerella strain sequences (genome, scaffold, 
or contig collections). Incomplete genomes (scaffold or contig status) were retrieved from NCBI. 
Their sequences were individually submitted to the RAST server and annotated291. For the three 
complete genomes, G. vaginalis 409–05 (NC_013721), 14019 (NC_014644), and HMP9231 
(NC_017456), the ffn format files were retrieved from NCBI’s FTP site. The core gene set was 
determined by first creating a local nucleotide BLAST database with the coding regions 
annotated for the G. vaginalis 14019 strain. Annotated coding regions in other sequences were 
BLASTed locally (using BLASTn, e-value<10−5), returning the top hit only. Genes producing hits in 
all other 38 genomes were identified as members of the core genome. The core gene set 
contains 183 genes (S4 Table), a significantly smaller group than previously used when 
considering smaller numbers of strains275,280. Each core gene and its orthologs were aligned 
using ClustalW295. Alignments were concatenated producing a concatenated gene alignment 
(super-gene alignment) using an in-house script in R (available upon request). The Maximum-
likelihood tree was derived using RAxML130. Trees were visualized using PhyloWidget294. 
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Assessing Presence/Absence of Coding Regions of Interest. 
The absence of coding regions identified with key carbohydrate metabolism 
functionalities within the G26-12 and G30-4 genome analyses was experimentally verified via 
PCR. Coding regions within the Gv18-4 genomic sequence with the following functional 
annotations were retrieved: (1) chitin and N-acetylglucosamine utilization, (2) deoxyribose and 
deoxynucleoside catabolism, (3) D-gluconate and ketogluconates metabolism, (4) formaldehyde 
assimilation, (5) lactose and galactose uptake and utilization, (6) trehalose biosynthesis, uptake 
and utilization, and (7) xylose utilization. In total, 22 genes were identified. Each was BLASTed 
against the nr/nt database, specifying the genus Gardnerella, to retrieve orthologs from other 
strains. All annotations within the GenBank files retrieved were manually inspected verifying 
similar confirmed/predicted protein functions. Primers were designed for each gene, targeting 
conserved regions amongst all orthologs, and obtained from Eurofins MWG Operon (Huntsville, 
AL). In total, 66 PCR reactions were conducted, testing each of the primer pairs against: Gv18-4 
(serving as a positive control), G30-4, and nuclease-free water (serving as a negative control). 
All Gv18-4 reactions produced amplicons of the expected sizes. G30-4 and the negative controls 
did not produce amplicons. Primer sequences are listed in S6 Table. 
Prophage Identification. 
 Genes annotated as phage or viral in origin were extracted from each of the genome 
sequence annotations. Local BLAST databases were used for both identifying the orthologous 
clusters of prophage sequences, as well as the putative origin of prophage clusters. First, a local 
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nucleotide database was created, including all of the sequences predicted as phage from all 
39 Gardnerella strains. Each individual putative phage coding region sequence was then 
BLASTed (blastn) against this local database (maximum 100 results), detecting identity to itself, 
as well as similarity to other sequences. Each hit was further qualified; hits with a sequence 
identity and query coverage greater than or equal to 80% were considered homologous. Once 
clusters were identified, the sequences within the cluster were aligned using ClustalW and 
manually inspected to guarantee correct clustering (File S1 [not included here due to size]). 
Identification for the origin of each cluster was performed similar to above; the local database 
used for conducting blastn searches was the complete collection of viral RefSeq coding regions. 
The all.fna.tar.gz file was retrieved from ftp://ftp.ncbi.nlm.nih.gov/genomes/Viruses/. 
Homologs were called when query coverage was ≥80%. The sequence identity threshold was 
considerably lower ≥35%. A cluster was considered to show no homology to any RefSeq coding 
region if it did not meet both of these conditions. 
Estimating Rates of Phage Acquisition. 
 Rates of phage acquisition were estimated using the R package corHMM296, which 
implements a Hidden Markov Model to estimate the rate of evolution of traits occurring across 
a phylogeny. Each phage was encoded as a binary trait according to its presence/absence as 
visualized in Figure G.3. Using this method to estimate the “rate of evolution,” therefore, 
provides a meaningful proxy for the rate of phage acquisition across the tree. For any given 
phage, the rate of acquisition is expected to scale with its total number of occurrences in the 
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tree, and horizontally transmitted phages are expected to have faster relative rates than 
vertically transmitted phages (as seen in Figure G.4). 
Results and Discussion 
Genome Features. 
Four Gardnerella strains were previously isolated from the bladders of four different 
female patients with symptoms of urgency urinary incontinence3,6. While MALDI-TOF identified 
two of these strains as G. vaginalis (henceforth denoted as Gv18-4 and Gv23-12), it did not 
resolve the other two strains to the species level (G26-12 and G30-4). 16S rRNA gene 
sequencing for each isolate confirmed the strains belong to the genus Gardnerella (Figure 
G.S1). All four isolates were sequenced, assembled, and annotated and are publicly available 
via NCBI. The genomic sequences varied slightly in size from 1.48 to 1.62 Mbp (Table G.1). 
Table G.1. Genomic characteristics of four Gardnerella strains isolated from female bladders 
Genome G26-12 G30-4 G18-4 G23-12 
Length 1,484,647 1,590,395 1,624,172 1,595,255 
GC% 42.5 41.9 40.9 41.2 
# Protein coding regions 1172 1242 1240 1243 
# RNAs 48 48 45 46 
# CRISPR arrays 5 8 2 4 
# Scaffolds 175 183 324 301 
Max Scaffold Length 57,529 42,968 11,232 11,376 
N50 Length 16,568 20,497 11,232 11,376 
Average Coverage 526 714 197 631 
INSDC ID LWSR00000000 LXJL00000000 LWSP00000000 LWSQ00000000 
 
Homologs, as well as strain-specific coding regions, were identified within the genomes 
of these bladder Gardnerella strains (Figure G.1A). Although Gv18-4 and Gv23-12 were 
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indistinguishable on the basis of their 16S rRNA sequences (Figure G.S1), instances of both 
strain-specific gene acquisition and loss within their genomes were detected (Table S1 [Not 
included here due to size]). Annotation also revealed the type I CRISPR/Cas system in all four 
genomes, with multiple CRISPR loci per genome (Table G.1). 
Comparison between the two strains identified by MALDI-TOF analysis to the species 
level (Gv18-4 and Gv23-12) and those identified to the genus level (G26-12 and G30-4) revealed 
disparity in the number of genes with the annotated functionalities of carbohydrate 
metabolism, membrane transport, and cell wall and capsule synthesis (Figure F.1B); however, 
the genetic variation observed between the Gv and G strains is statistically significant only for 
loci that regulate carbohydrate metabolism. Consistent with previous studies that illustrated 
the ability of different Gardnerella strains to ferment and use different carbohydrates182, 
annotation of the genome for G26-12 and G30-4 suggest that they lack coding regions with the 
following functionalities: chitin and N-acetylglucosamine utilization, trehalose biosynthesis, 
trehalose uptake and utilization, lactose and galactose uptake and utilization, lactose 
utilization, formaldehyde assimilation, xylose utilization, deoxyribose and deoxynucleoside 
catabolism, D-gluconate and ketogluconates metabolism. The absence of these coding regions 
within the G26-12 and G30-4 genome sequences was confirmed experimentally via PCR.  
 The genomes of these bladder strains were further examined with respect to the 
presence/absence of coding regions associated with virulence, as previously defined by 
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Yeoman et al.280 (Table F.S2). Genes associated with biofilm formation (glycosylases and 
glycosyltransferases) and epithelial adhesion (fimbria/pili) were identified in all four genomes;  
 
Figure G.1. Characterization of predicted coding regions  
(A) Homology and (B) annotated frequency within the four bladder Gardnerella strains. (**p 
value <0.05 between the two predicted Gardnerella strains and the two predicted G. 
vaginalis strains; *p value <0.1). Strains are represented using the same colors in both 
panels.  
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however, type-1 fimbrial precursors were found only within the genomes of G26-12 and G30-4. 
Genes associated with antibiotic/antimicrobial resistance, including those that encode the ABC-
type multidrug transport system and the DedA protein (which has been shown to be required 
for drug resistance in E. coli297) were present within all four genomes. However, tetracycline 
resistance proteins were encoded within the Gv18-4, Gv23-12, and G26-12 strains, but not in 
the G30-4 strain. Genes associated with protection or evasion from the immune response (alkyl 
hydroperoxide reductase and Rib-family surface protein) were found within all four of the 
bladder strains. Furthermore, the coding region for the vaginolysin (VLY) gene, which is 
selective for human cells280,298, was highly conserved within all four strains, in spite of the two 
amino acid substitutions that separate the Gv18-4 strain from the type strain for the genus 
ATCC 14019 (Figure G.S2). Finally, the Gardnerella strains G26-12 and G30-4 contained an 
annotated rRNA methyltransferase associated with Gardnerella cytotoxicity280 and with 
haemolytic activity in other bacterial species299. Interestingly, only the Gv18-4 and Gv23-12 
strains contained genes that encode sialidase, which has been experimentally proven to 
contribute to mucin degradation in BV276, although presence of the gene is not predictive of 
actual sialidase activity 300 and thus warrants further investigation. 
Phylogenetic Analysis and the Gardnerella Pangenome. 
 In an effort to assess the similarity/difference between Gardnerella strains isolated from 
the female bladder and those isolated from the female reproductive system, all publicly 
available sequenced strains isolated from the vagina or endometrium were retrieved from NCBI 
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(Table G.S3). This set includes 35 complete, scaffold, or contig genome sequences. Extending 
beyond the 16S rRNA gene marker, the evolutionary history of this genus was considered by 
investigating sequence homologies within the “core” Gardnerella genome (Methods; Table 
G.S4. In total, 183 genes were identified as belonging to this core gene set, less than identified 
in prior studies of far fewer genomes275,280. As shown in Figure G.2, the strains isolated from the 
bladder are not monophyletic, establishing that the Gardnerella core genome does not 
correlate with a single isolation location. Examination of all coding sequences for all 39 
investigated genomes revealed no gene(s) exclusive to the bladder strains. While the vast 
majority of the genes within the core set demonstrated an evolutionary history identical to that 
of the species tree (Figure G.2), genes indicative of intragenic recombination, such as VLY (S2 
Figure), were also identified. Nevertheless, the species tree (Figure G.2) we derived largely 
concurs with the tree produced by Ahmed et al275. In comparison to the phylogeny of Ahmed et 
al., which included 17 genomes and a core genome of 473 genes, their Group 3 and 4 are both 
contained within Clade A in Figure G.2. Our Clade B corresponds to their Group 2 and our Clade 
C is within their Group 1; only two of the genomes within Clade C were included in the prior 
analysis of Ahmed et al. As expected, each clade had significantly more homologous genes (404, 
799, 762 and 635 for Clades A through D, respectively) (Figure G.2A), a likely residual of 
undersampling, biased sampling, and/or clade-specific functional conservation. 
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The bladder strains G26-12 and G30-4 were determined to belong to Clade A, which also 
includes three strains isolated from BV+ patients (Figure G.2B). While the phylogeny based 
upon the core gene set does not correspond with isolation location, some clades appear to 
have a higher incidence of strains isolated from patients diagnosed as BV+. Because genes 
Figure G.2. Phylogenetic analysis of Gardnerella strains 
Maximum Likelihood species tree of Gardnerella strains based upon sequence homology 
within the core gene set. (A) Phylogenetic tree listing branch supports and distinction of the 
four clades within the tree. Numbers within black circles indicate the number of homologous 
genes within each clade and the core Gardnerella genome.  
(B) Maximum Likelihood tree including branch lengths and isolation information with respect 
to location and diagnosed symptom. Strains isolated from the bladder and sequenced in this 
study are labeled in red; strains listed in green were isolated from the vagina/endometrium of 
BV+ patients; strains in light blue were isolated the vagina/endometrium of STD+ patients. All 
remaining strains (indicated in black font) were isolated from the vagina or endometrium. 
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associated with virulence are not exclusively present within genomes isolated from 
symptomatic patients275,280, it is not surprising that several are included within the core gene 
set identified here. The lack of correspondence between phylogenetic history and symptoms is 
supported by prior studies, which hypothesized that gene expression variation 
within G. vaginalis strains may trigger BV development301 and single point mutations may result 
in greater potential for cytotoxicity182. Thus, there appears to be no single gene that correlates 
with BV symptoms. This is, however, not surprising given that G. vaginalis strains are present 
within both the BV- and BV+ vagina302, and it is but one of the taxa that coincides with BV 
symptoms272. 
Mobile Elements. 
The four bladder Gardnerella genomes varied in their number of ORFs predicted to be 
viral (bacteriophage) in origin.  The number of prophage gene sequences per genome had no 
correspondence to evolutionary history (Figure G.2). This is true for the four Gardnerella strains 
isolated from the bladder, as well as for the 35 strains isolated from the reproductive system. 
For example, the G. vaginalis strain JCP8522, a vaginal BV+ strain276, has only one ORF 
annotated as a phage gene. In contrast, the Gv18-4 strain sequenced as part of this study 
contains the most, 33, phage-like gene sequences within a Gardnerella genome to date. Table 
G.S5 (not included due to size) lists the 442 annotated prophage genes within the 39 genomes 
examined. Due to the incomplete (scaffold/contig) status of the majority of the genomes 
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included in the analysis here, we evaluated predicted prophage genes (median length 939 bp) 
individually. 
 To identify homologs, the nucleotide sequences for all annotated prophage genes across 
all Gardnerella genomes were examined. Based upon the combination of sequence identity and 
query coverage, 104 clusters of orthologous prophage genes were identified (File S1 – not 
included due to size). Within larger clusters, prophage homolog sequences were highly 
conserved between genomes. Forty-nine clusters, however, included only a single prophage 
gene sequence, indicative of frequent independent acquisition of viral sequences. This is 
further supported by the variation in prophage genes identified within strains isolated from the 
same patient. While the genomes of JCP8481A and JCP8481B (both isolated from a single 
patient as denoted by A and B276) contain the same set of prophage gene sequences, the 
genomes of JCP8151A/B and JCP8017A/B do not (Figure G.3, Table G.S5); this captures the 
likely prevalence of lysogenic phage excision, as well as gene loss, events. Likewise, the 
genomes of 00703Bmash, 00703C2mash, and 00703Dmash, which are from sequential isolates 
from the same patient275, vary in their prophage gene content (Figure G.3, Table G.S5). This 
diversity, even within a single patient, suggests intra-host prophage gene gain/loss. 
Examination of the 37 largest prophage gene clusters suggested that prophage 
introduction within the Gardnerella genus has occurred by both vertical and lateral inheritance. 
These larger clusters include orthologous prophage gene sequences present within five or 
more Gardnerella genomes; the most pervasive prophage gene sequences were present within 
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Figure G.3. Presence/absence of prophage gene sequences from larger clusters 
Clusters of orthologous prophage genes found within five or more of the 
39 Gardnerella genomes are shown using a distinct color. Open circles indicate that the 
prophage sequences belonging to the particular cluster show no/poor sequence homology 
to characterized lytic phages. Closed circles indicate moderate (query coverage ≥80%, 
nucleotide sequence identity ≥35%) to high homology to a phage genome sequence record 
in NCBI. Nucleotide sequence identity for the prophage genes in each cluster is indicated by 
the bar chart at the top of the figure. 
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21 of the 39 Gardnerella genomes examined here. As shown in Figure G.3, several of the larger 
prophage gene clusters have representatives across the entire phylogenetic tree and some sets 
of clusters appeared to have been lost within particular lineages. Half of the 104 prophage gene 
clusters identified exhibit little to no resemblance to any sequence within the current GenBank 
nr/nt nucleotide database of characterized phage sequences; this includes several of the 
prophage genes within the larger clusters (represented as open circles in Figure G.3). For those 
prophage gene sequences that exhibit homology to characterized phage genes, hits were 
frequently identified to the genomes of Bacillus-, Mycobacterium-, and Staphylococcus-
infecting phages.  Previous targeted gene surveys of the bladder have routinely found 
Staphylococcus within the community7,65,203. 
 Although Gardnerella-infecting phages have yet to be isolated, the abundance of 
prophage gene sequences in the genomes (Table G.S5) and the presence of the CRISPR/Cas-
system (Table G.1) suggests that phages capable of infecting Gardnerella spp. exist. This 
assumption is corroborated by prior analyses of spacer sequences within 
21 G. vaginalis genomes, in which 70.7% of the spacers showed no homology to sequences 
within the GenBank database281. While many of the clusters exhibiting homology to sequences 
in GenBank identified lytic phages annotated as infecting an array of different bacterial genera, 
analysis of eleven of the 104 clusters resulted in the description of phages thought to infect a 
single taxon. These included several of the larger clusters shown in Figure G.3: clusters 12, 15, 
and 30 were found to have homology to Bacillus-infecting phages; clusters 22 and 35 were 
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determined to be similar to phages infecting Mycobacterium species; while cluster 29 exhibited 
a likeness to Staphylococcus-infecting phages (Table G.S5). Yet, all of these phages are of the 
family Siphoviridae. Homologies identified for these prophage sequences provide a foundation 
for future work in the isolation of Gardnerella-specific phages. More broadly, these prophage 
gene sequences provide insight into the phage community within the human microbiota. 
 Lateral gene acquisition is ubiquitous; however, there is a strong discordance between 
the evolutionary tree (Figure G.2; Figure G.S1) and trees derived from strain:prophage gene 
presence/absence profiles (results not shown). To distinguish clusters acquired via HGT from 
those linearly inherited from a common ancestor, the genomes of 39 Gardnerella strains were 
examined. Clusters were compared given the number of occurrences and the rate of evolution 
of viral infection (Figure G.4). From this analysis, two groups can be observed. The phage gene 
clusters in the top right quadrant appear to have evolved quickly relative to their prevalence 
across strains and have likely been integrated into the Gardnerella genomes via HGT. In 
contrast, the four clusters in the bottom right quadrant appear to have been acquired by 
vertical transmission. Thus, we hypothesize that prophage integration has been occurring over 
a long time scale.  
Given this evidence of phage-host interactions and the results of recent studies 
illuminating the vital contributions of viruses within other human microbioata104,289,290, one can 
surmise that phages are playing a significant role within both the bladder and reproductive 
system communities.  
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As the bladder microbiota have only recently been discovered and subsequently 
surveyed4,6,7,14,60,65,174,203, their microbiome remains largely uncharacterized. The presence of 
the CRISPR/Cas system within the four Gardnerella strains sequenced here suggest phages are 
present and prolific within the bladder. Given the existence of both Gardnerella and 
Lactobacillus within both the female bladder4,6,7,65,203 and the vaginal17,303,304 microbiota, some 
insight can be gleaned from the latter. It is likely that phages play an important role in bacterial 
genome evolution and potentially disease in both niches. Evidence of phages has previously 
been found within the vaginal microbiota158,305. The incidence of Lactobacilli phages may have 
medical significance, as vaginal lactobacilli may be culled or repressed by phages within the 
Figure G.4. Determining mechanisms of prophage gene acquisition  
Colors correspond with the cluster colors in Figure 3. Dashed lines are the mean value for 
each axis 
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microbiota leading to BV158,273. Increased prophage numbers within L. crispatus genomes from 
the human vagina relative to avian isolates suggests high frequency of phage within the human 
microbiota283. Phage-like sequences within both the bladder and vaginal bacterial 
microbiomes–prophage sequences as well as CRISPR spacer sequences–often show little to no 
homology to characterized sequenced phage species, insinuating that numerous genetically 
diverse phages have yet to be discovered. 
Conclusion 
Comparison of four new bladder-associated Gardnerella genomes to genomes from the 
reproductive system identifies strain-specific and lineage-specific genes, suggesting a 
large Gardnerella pangenome may exist. There is, however, no distinct difference between 
strains isolated from a particular niche. Of particular interest is the high incidence of prophages 
within the Gardnerella genomes and the variability in the number per strain, as well as their 
putative origin. While prior studies into the prophages of vaginal lactobacilli propose that phage 
may play a significant role in community dynamics within the vagina, this proposal has yet to be 
empirically tested. The Gardnerella genome analyses conducted here find evidence of ancient, 
as well as contemporary, phage infection; the fact that isolates from the same individual vary in 
their prophage gene sequences supports the latter. Bioinformatic inspections of prophage and 
CRISPR spacer sequences find little to no correspondence with characterized phage sequences, 
suggesting that Gardnerella-infecting phages exist, although they have yet to be isolated in the 
laboratory. Nonetheless, evidence presented here suggests that phages play a role within the 
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complex microbial communities of both the reproductive tract and the bladder, warranting 
future exploration of their viromes. The continued isolation and empirical characterization 
of Gardnerella species from the human microbiota is necessary to learn whether microbiome-
virome interactions help to establish and maintain ones’ bladder health and, if so, how 
perturbations of this equilibrium result in bladder pathologies. 
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Supplemental Data 
 
 
Figure G.S1. Phylogenetic tree based on the 16S rRNA gene 
Notice that the 16S gene is not sufficient to discriminate between the different clades seen in 
Figure G.2., suggesting horizontal transfer of the 16S gene.  
 
Table G.S1. Presence/absence of gene functionality within the four bladder isolates. This table 
was excluded from this document due to its large size.  
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Figure G.S2. Phylogenetic analysis of VLY gene 
(A) Amino acid sequence alignment of four bladder Gardnerella isolates and representatives 
from other clades; clades are indicated to the left of each strain/isolate name. Mismatches 
within the alignment are highlighted (red/blue text). (B) Maximum likelihood phylogenetic tree 
for the VLY gene. Bran supports are indicated.  
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Table G.S2. Presence/absence of virulence genes within the four bladder isolates  
Glycosyltransferases (biofilm formation 
Gv 
18-4 
Gv  
23-12 
G  
26-12 
G  
30-4 
Function 
  X X A/G-specific adenine glycosylase (EC 3.2.2.-) 
X X X X glycosyl transferase, group 1 family protein 
  X  Glycosyl transferase, group 2 family protein 
X X X X Glycosyltransferase 
X X   Glycosyltransferase (EC 2.4.1.-) 
X X X X Multimodular transpeptidase-transglycosylase (EC 2.4.1.129) (EC 
3.4.-.-) 
X X X X probable glycosyltransferase 
X X X X putative glycosyl transferase domain protein 
Fimbria/Pili 
Gv 
18-4 
Gv  
23-12 
G  
26-12 
G 30-
4 
Function 
  X X Fimbrial subunit type 1 precursor 
  X X 
Type-1 fimbrial major subunit precursor (FIG00672113: hypothetical 
protein) 
X X X X TadE pilus assembly (FIG00672510: hypothetical protein) 
X X X X 
Type IV prepillin peptidase (Permeases of the major facilitator 
superfamily) 
X X X  
Type-II fimbrial major subunit precursor (COG4932: Predicted outer 
membrane protein) 
Antibiotic/Antimicrobial resistance 
Gv 
18-4 
Gv  
23-12 
G  
26-12 
G 30-
4 
Function 
  X  
Multidrug resistance ABC transporter ATP-binding and permease 
protein 
X X X  Similar to tetracycline resistance protein 
X X X X ABC-type multidrug transport system, ATPase component 
X X X X DedA protein 
Protection function or evasion of immune response 
Gv 
18-4 
Gv  
23-12 
G  
26-12 
G 30-
4 
Function 
 X X X Alkyl hydroperoxide reductase protein C (EC 1.6.4.-) 
X X X X Alkyl hydroperoxide reductase protein F (EC 1.6.4.-) 
X X X X Rib-family surface protein (FIG00672534: hypothetical protein) 
Cytotoxicity 
Gv 
18-4 
Gv  
23-12 
G  
26-12 
G 30-
4 
Function 
X X X X Vaginolysin (vly) (Thiol-activated cytolysin) 
  X X RNA binding methyltransferase FtsJ like 
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Table G.S3. List of 35 genomes retrieved from NCBI for genome comparisons 
Strain (All G. 
vag) Isolation Site Disease State Size (Mb) GC% Accession 
Genome 
Status Ref 
00703Bmash Vagina 
BV+; STD (Herpes 
simplex virus 2) 1.56605 42.3 ADET01 Contig 
275 
00703C2mash Vagina 
BV+; STD (Herpes 
simplex virus 2) 1.54668 42.3 ADEU01 Contig 
275 
00703Dmash Vagina 
BV-; STD (Herpes 
simplex virus 2) 1.4908 43.4 ADEV01 Contig 
275 
0288E Endometrium BV+ 1.70877 41.2 ADEN01 Contig 275 
1400E Endometrium BV+ 1.71633 41.2 ADER01 Contig 275 
14019 Vagina BV- 1.66735 41.4 
NC_01464
4 
Complete 
Genome 
280 
14019 MetR 
Laboratory 
culture of 
ATCC strain 
14019 BV- 1.6611 41.3 LIYA01 Contig 
279 
1500E Endometrium BV+ 1.54824 43 ADES01 Contig 275 
284V Endometrium 
BV+; 
STD(Chlamydia 
trachomatis) 1.65084 41.2 ADEL01 Contig 
275 
315-A Vagina Unknown 1.65328 41.4 AFDI01 Contig  
3549624 Vagina Unknown 1.73225 41.4 LFWD01 Contig 278 
409-05 Vagina BV+ 1.61755 42 
NC_01372
1 
Complete 
Genome 
280 
41V Vagina BV- 1.65937 41.3 AEJE01 Contig  
1-May Vagina BV- 1.67284 42 ADAN01 Contig 182 
55152 Endometrium BV+ 1.64319 41.3 ADEQ01 Contig 275 
6119V5 Vagina BV- 1.4996 43.3 ADEW01 Contig 275 
75712 Vagina BV- 1.67297 41.3 ADEM01 Contig 275 
AMD Vagina BV+ 1.60676 42.1 ADAM01 Contig 182 
HMP9231 Vagina BV- 1.72652 41.2 
NC_01745
6 
Complete 
Genome 
280 
JCM 11026 
(ATCC 14018) Vagina BV- 1.66741 41.4 
NZ_AP012
332 
Complete 
Genome 
277 
JCP7275 Vagina BV+ 1.56223 41 ATJS01 Scaffold 276 
JCP7276 Vagina BV Intermediate 1.65959 41 ATJR01 Scaffold 276 
JCP7659 Vagina BV+ 1.53594 41.9 ATJQ01 Scaffold 276 
JCP7672 Vagina BV- 1.60353 41.2 ATJP01 Scaffold 276 
JCP7719 Vagina BV+ 1.56315 42 ATJO01 Scaffold 276 
JCP8017A Vagina BV+ 1.60792 42.1 ATJN01 Scaffold 276 
JCP8017B Vagina BV+ 1.60225 42 ATJM01 Scaffold 276 
JCP8066 Vagina BV- 1.52073 42.2 ATJL01 Scaffold 276 
JCP8070 Vagina BV+ 1.47925 42.2 ATJK01 Scaffold 276 
JCP8108 Vagina BV+ 1.66559 41.1 ATJJ01 Scaffold 276 
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Table G.S3. continued       
Strain (All G. 
vag) Isolation Site Disease State Size (Mb) GC% Accession 
Genome 
Status Ref 
JCP8151A Vagina BV+ 1.56045 42 ATJI01 Scaffold 276 
JCP8151B Vagina BV+ 1.55414 42.2 ATJH01 Scaffold 276 
JCP8481A Vagina BV+ 1.57288 42.9 ATJG01 Scaffold 276 
JCP8481B Vagina BV+ 1.57388 42.9 ATJF01 Scaffold 276 
 
Tables G.S4-G.S6 and File S1. were not included due to size. These can be found online at: 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5115800/ 
 
Table G.S4. Core genes Identified for the 39 Gardnerella genomes examined.  
 
Table G.S5. Prophage sequences, clusters and putative orgins within the 39 Gardnerella 
genomes.  
 
Table G.S6. PCR primers for amplification of Gv-specific carbohydrate metabolism coding 
regions.  
 
File G.S1. Fasta sequence for the individual prophage gene clusters.  
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APPENDIX H 
THE CLINICAL URINE CULTURE: ENHANCED TECHNIQUES IMPROVE DETECTION OF CLINICALLY 
RELEVENT MICROORGANISMS 
 
 
Price TK, Dune T, Hilt EE, Thomas-White KJ, Kliethermes S, Brincat C, Brubaker L,  
Wolfe AJ, Mueller ER, Schreckenberger P. The Clinical Urine Culture: Enhanced Techniques 
Improve Detection of Clinically Relevant Microorganisms. J Clin Microbiol. 2016 
May;54(5):1216-22. doi: 10.1128/JCM.00044-16. PMID: 26962083 
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Overview of Appendix H 
 This paper was our team’s first attempt to match EQUC to standard urine culture  (SUC) 
results and patient symptoms of UTIs. We discovered that the operational definition of a UTI 
was vague and insufficient. EQUC detected uropathogens in 84% of women who thought they 
had a UTI, while SUC only detected uropathogens in 33% of those women This study provided 
the groundwork for an upcoming EQUC versus SUC clinical trial that I have been highly involved 
in planning. This trial will randomize each patient into either an EQUC or SUC culture protocol 
to determine if EQUC provides improved patient outcomes, including increased resolution of 
symptoms and decreased recurrence.  
Abstract 
Enhanced quantitative urine culture (EQUC) detects live microorganisms in the vast 
majority of urine specimens reported as “no growth” by the standard urine culture protocol. 
Here, we evaluated an expanded set of EQUC conditions (expanded-spectrum EQUC) to identify 
an optimal version that provides a more complete description of uropathogens in women 
experiencing urinary tract infection (UTI)-like symptoms. One hundred fifty adult urogynecology 
patient-participants were characterized using a self-completed validated UTI symptom 
assessment (UTISA) questionnaire and asked “Do you feel you have a UTI?” Women responding 
negatively were recruited into the no-UTI cohort, while women responding affirmatively were 
recruited into the UTI cohort; the latter cohort was reassessed with the UTISA questionnaire 3 
to 7 days later. Baseline catheterized urine samples were plated using both standard urine 
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culture and expanded-spectrum EQUC protocols: standard urine culture inoculated at 1μl onto 
2 agars incubated aerobically; expanded-spectrum EQUC inoculated at three different volumes 
of urine onto 7 combinations of agars and environments. Compared to expanded-spectrum 
EQUC, standard urine culture missed 67% of uropathogens overall and 50% in participants with 
severe urinary symptoms. Thirty-six percent of participants with missed uropathogens reported 
no symptom resolution after treatment by standard urine culture results. Optimal detection of 
uropathogens could be achieved using the following: 100 μl of urine plated onto blood (blood 
agar plate [BAP]), colistin-nalidixic acid (CNA), and MacConkey agars in 5% CO2 for 48 h. This 
streamlined EQUC protocol achieved 84% uropathogen detection relative to 33% detection by 
standard urine culture. The streamlined EQUC protocol improves detection of uropathogens 
that are likely relevant for symptomatic women, giving clinicians the opportunity to receive 
additional information not currently reported using standard urine culture techniques. 
Introduction 
The diagnostic gold standard for clinically relevant urinary tract infection (UTI) continues 
to be questioned for both clinical and research purposes. Since the 1950s, clinical practice has 
relied on detecting ≥105CFU/ml of a known uropathogen using the standard clinical urine 
culture protocol306. The standard urine culture was initially described for detection of patients 
at risk for pyelonephritis36; interpretation has been generalized to diagnose lower urinary tract 
infection despite studies reporting limitations of the ≥105-CFU/ml threshold37,39,207,209. While 
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the clinical focus has centered on various cutoff thresholds, the basic uropathogen detection 
method remains unchanged. 
Given emerging evidence that documents the presence of urinary microbiota in many 
adult women 4,6,7,14,60,65,93,174,203, it is clear that the mere presence of an organism should not 
prompt antibiotic treatment. However, clinicians are likely to benefit from a more complete 
report of organisms present within a symptomatic patient's urine. Recent evidence reports 
bacteria in ∼90% of “no-growth” standard urine cultures7,203. We hypothesized that, in women 
experiencing UTI-like symptoms, an improved culture protocol would provide a more complete 
description of potentially treatable, clinically relevant uropathogens. This study evaluated 
various combinations of urine volumes, media, atmospheric environments, and incubation 
durations to determine conditions that optimally balance uropathogen detection with 
feasibility. 
Materials and Methods 
Study Design and Patient Population. 
Following institutional review board (IRB) approval, we enrolled 75 women who 
reported UTI symptoms and 75 who did not based on their yes/no response to the question 
“Do you feel you have a UTI?” Participants were seeking clinical care at Loyola University 
Medical Center's Female Pelvic Medicine and Reconstructive Surgery center between June 2014 
and August 2015. 
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Participants gave verbal and written research consent and provided permission for 
abstraction of their demographic and clinical information from the electronic medical record. At 
baseline, urinary symptoms were characterized using a self-completed, validated UTI symptom 
assessment (UTISA) questionnaire, completed by both cohorts307. Participants were 
dichotomized based on their yes/no response to the question “Do you feel you have a UTI?” 
Those who responded affirmatively (UTI cohort) completed the UTISA questionnaire again by 
phone 3 to 7 days post enrollment and were queried about the magnitude of symptom 
resolution, if any. All clinical treatment was individually based on physician assessment of 
patient symptoms and standard urine culture results. Exclusion criteria included age of <18 
years, pregnancy, catheterization (indwelling or intermittent), or insufficient English skills to 
complete study measures. 
Sample Collection and Analysis 
Consistent with patient care clinical protocol, urine was collected via transurethral 
catheter and then placed into two BD Vacutainer Plus C&S preservative tubes: one sent to the 
clinical microbiology laboratory for diagnostic purposes and one sent to the researchers for 
testing. 
Table H.1 displays all culture protocols used by the clinical microbiology laboratory staff 
and the researchers. The standard urine culture protocol used 1 μl of urine, spread 
quantitatively (i.e., pinwheel streak) onto 5% sheep blood (blood agar plate [BAP]) and 
MacConkey agars (BD BBL Prepared Plated Media; Cockeysville, MD) and incubated aerobically 
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at 35°C for 24 h. The modified standard urine culture used the same agars and temperature but 
changed the incubation condition to 5% CO2; if pinpoint growth was seen at 24 h, the agars 
were held for another 24 h under the same conditions. Unrelated to this study, the clinical 
microbiology laboratory adopted the modified standard urine culture for diagnosis during 
patient recruitment for this study. Thus, diagnostic testing for patients 1 to 107 was the 
standard urine culture, while the modified standard urine culture was used for patients 108 to 
150. However, this change did not impact data presented in this study, as standard urine 
culture data for patients 108 to 150 were obtained by analyzing the corresponding subset of 
expanded enhanced quantitative urine culture (EQUC) conditions (i.e., 1 μl BAP and MacConkey 
agars; aerobic, 35°C; 24 h). 
The conditions of the original enhanced quantitative urine culture (EQUC) protocol were 
described previously7. In this study, we expanded those conditions (i.e., expanded-spectrum 
EQUC protocol), using three urine volumes (1 μl, 10 μl, and 100 μl) and additional plating 
conditions (Table H.1). Each urine sample was spread quantitatively onto BAP, chocolate, and 
colistin-nalidixic acid (CNA) agars (BD BBL Prepared Plated Media) and incubated in 5% CO2 at at 
35°C for 48 h; BAP and MacConkey agars were incubated aerobically at 35°C for 48 h; two CDC 
anaerobic 5% sheep blood (anaerobic BAP) agars (BD BBL Prepared Plated Media) were 
incubated either in microaerophilic Campy gas mixture (5% O2, 10% CO2, 85% N) or 
anaerobically at 35°C for 48 h.  
Three sets of these conditions were used for each urine sample, each using one of the 
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Table H.1. Summary of urine cultivation protocols for catheterized urine specimens 
Protocol Vol (µl) 
of 
urine 
Medium or 
media 
Conditions Incubation(s) 
(h) for 
microbial 
identification 
Patient 
sample 
identifier a 
Standard 
urine 
culture 
1 BAP, 
MacConkey 
agar 
Aerobic, 35°C 24 1-107 
Modified 
urine 
culture 
1 BAP, 
MacConkey 
agar 
5% CO2, 35°C 24, 48 108-150 
Expanded-
spectrum 
EQUC 
1,10, 
and 
100 
BAP, 
MacConkey 
agar 
Aerobic, 35°C 24, 48 1-150 
  BAP, 
chocolate 
agar, CNA 
agar 
5% CO2, 35°C 24, 48  
  CDC 
anaerobic 
BAP 
Anaerobic, 35°C 48  
  CDC 
anaerobic 
BAPb 
Miroaerophilic gas 
mixture (5% O2, 10% 
CO2, 85% N), 35°C 
48  
Streamlined 
EQUC 
100 BAP, 
MacConkey 
agarc, CNA 
agar 
5% CO2, 35°C 48 1-150d 
a Refers to the patient samples on which the corresponding protocol assessed the urinary microbiota. For 
diagnosis, the standard urine culture protocol was used on patient samples 1 to 107; the modified standard urine 
culture was used on patient samples 108 to 150. For research, all patient samples were assessed by expanded-
spectrum EQUC. 
bThe CDC anaerobic BAP microaerophilic gas mixture condition was used only for samples 10 to 150. 
cThe MacConkey 5% CO2 condition was not part of the expanded-spectrum EQUC protocol. 
dThe streamlined EQUC protocol was performed using a subgroup of agars/conditions from the expanded-
spectrum EQUC protocol; therefore, it was used on all patient samples. 
 
urine volumes, for a total of 21 agars per sample. All agars were documented for growth (i.e., 
for morphologies and CFU per milliliter) at 24 and 48 h, except the two anaerobic BAP 
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conditions. Each distinct colony morphology was subcultured at 48 h to obtain pure culture for 
microbial identification. 
Microbial identification was determined using a matrix-assisted laser desorption 
ionization–time of flight mass spectrometer (MALDI-TOF MS; Bruker Daltonics, Billerica, MA) as 
described previously7. Only clinically relevant microbes (i.e., known and emerging 
uropathogens) were used to calculate uropathogen detection. These uropathogens were 
selected based on previously published case reports of UTI. 
UTISA Questionnaire. 
This questionnaire asks the participant to rate the degree of severity and bother for 
seven common UTI symptoms: frequency of urination, urgency of urination, incomplete bladder 
emptying (urinary retention), pain or burning during urination (dysuria), lower abdominal 
discomfort or pelvic pain/pressure, lower back pain, and blood in the urine (hematuria). Scores 
for each symptom range from 0 to 3; a 0 corresponds to no symptom present, whereas a 3 
indicates highest severity or bother. The seven symptoms can be clustered into four symptom 
domains: urination regularity (frequency and urgency), problems with urination (incomplete 
bladder emptying and pain or burning), pain associated with the UTI (abdominal or pelvic pain 
and lower back pain), and blood in the urine307. 
Statistical Analyses 
Continuous variables were reported as means and standard deviations (SDs) or medians 
and interquartile ranges (IQRs); categorical variables were reported as frequencies and 
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percentages. Pearson chi-square tests (or Fisher's exact tests, when necessary) and 2-
sample t tests (or Wilcoxon rank sum tests, when appropriate) were used to compare 
demographics and culture results (e.g., abundance and diversity) between cohorts. Measures of 
alpha diversity (diversity within a population) were represented as Shannon diversity indices 
and/or graphically by species accumulation curves (which plot accumulation of unique species 
per group for each additional sample included). All statistical analyses were conducted using 
SAS software v9.4 (SAS Institute, Cary, NC) or Systat software version 13.1 (Systat Software Inc., 
Chicago, IL). 
Results 
Participant Demographic and Symptoms. 
Table H.2 describes demographics of the two cohorts (75 no-UTI and 75 UTI patients). 
Most participants were white (81%) and overweight (mean body mass index [BMI] = 29.3 
kg/m2). Most participants (92%, 138/150) reported at least one urinary symptom; as expected, 
women in the UTI cohort had higher UTISA questionnaire scores. 
Expanded-spectrum EQUC: urinary microbiota characteristics 
Nearly all (93% [139/150]) catheterized urine samples grew bacterial colonies with at 
least one combination of the expanded-spectrum EQUC protocol's conditions (Table H.1). The 
no-UTI and UTI cohorts had similar proportions of cultivatable urine samples (89% [67/75] 
versus 96% [72/75]; P = 0.12), similar numbers of total unique species detected per cohort (75 
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versus 66), and similar median numbers of species detected per urine sample (3 [IQR = 1 to 5] 
versus 2 [IQR = 1 to 4]; P = 0.12) (see Table S1 in the supplemental material). 
However, the cohorts differed in organism diversity, genus-level composition, and species-level 
composition. The no-UTI cohort had more diversity with greater species richness as depicted by 
species accumulation curves (see Figure H.S1 in the supplemental material) and greater alpha 
diversity as measured by the Shannon diversity index (no-UTI = 3.89 versus UTI = 3.49). The 
genera Streptococcus (P = 0.003) and Gardnerella (P = 0.04) were more prevalent in the no-UTI 
cohort, while the genus Escherichia (P < 0.001) was detected more often in the UTI cohort (see 
Figure H.S2). Five species, namely, Gardnerella vaginalis (P = 0.4), Streptococcus 
mitis/oralis/pneumoniae (P = 0.01), Streptococcus parasanguinis (P = 0.02), Streptococcus 
salivarius (P = 0.05), and Streptococcus sanguinis (P = 0.01), were detected more often in the 
no-UTI cohort; in contrast, the species Escherichia coli (P < 0.001) was more prevalent in the UTI 
cohort (see Figure H.S3). 
The genera Streptococcus (P = 0.003) and Gardnerella (P = 0.04) were more prevalent in 
the no-UTI cohort, while the genus Escherichia (P < 0.001) was detected more often in the UTI 
cohort (see Figure H.S2). Five species, namely, Gardnerella vaginalis (P = 0.4), Streptococcus 
mitis/oralis/pneumoniae (P = 0.01), Streptococcus parasanguinis (P = 0.02), Streptococcus 
salivarius (P = 0.05), and Streptococcus sanguinis (P = 0.01), were detected more often in the 
no-UTI cohort; in contrast, the species Escherichia coli (P < 0.001) was more prevalent in the UTI 
cohort (see Figure H.S3). 
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Table H.2. Demographic characteristics and symptoms 
Clinical variable Entire cohort 
(n=150) 
No-UTI cohort 
(n=75) 
UTI cohort 
(n=75) 
p-valued 
Age (yr), mean (SD) 62.3 (14.9) 60.6 (12.3) 64.0 (17.1) 0.16a 
BMI (kg/m2), mean (SD) 29.3 (6.3) 28.8 (5.9) 29.9 (6.6) 0.27 a 
Race/ethnicity, no. (%)     
     White 121 (81) 59 (79) 62 (83) 
0.90c 
     Hispanic 15 (10) 9 (12) 6 (8) 
     Black 9 (6) 5 (7) 4 (5) 
     Asian 4 (3) 2 (3) 2 (3) 
     Other 1 (1) 0 (0) 0 (0) 
No. of vaginal deliveries,  
median (IQR) 
2 (0-11) 2 (0-6) 2 (0-11) 0.80b 
Sexually active, no. (%) 58 (39) 37 (49) 21 (28) 0.01 
Previous antibiotic treatment, no. (%) 45 (30) 20 (27) 25 (33) 0.37 
Current anticholinergic treatment, no. (%) 26 (17) 9 (12) 17 (23) 0.08 
Type of anticholinergic used, no. (%)    
0.75c 
     Oxybutynin 9 (6) 3 (4) 6 (8) 
     Solifenacin 8 (5) 3 (4) 5 (7) 
     Fesoterodine 4 (3) 2 (3) 2 (3) 
     Tolterodine 2 (1) 1 (1) 1 (1) 
     Oxybutynin patch 1 (1) 0 (0) 1 (1) 
     Trospium chloride 1 (1) 0 (0) 1 (1) 
     Mirabegron (Myrbetriq) 1 (1) 0 (0) 1 (1) 
Previous vaginal estrogen use, no. (%) 32 (21) 11 (15) 21 (28) 0.05 
Current vaginal estrogen use, no. (%) 29 (19) 10 (13) 19 (25) 0.06 
Prior urogynecologic surgery, no. (%) 40 (27) 13 (17) 27 (36) 0.01 
Symptoms of incontinence,  
no. (%) 
    
     Stress urinary incontinence 17 (11) 10 (13) 7 (9) 0.44 
     Urgency urinary incontinence 26 (17) 11 (15) 15 (20) 0.39 
     Mixed urinary incontinence 42 (28) 27 (36) 15 (20) 0.03 
Urgency-frequency syndrome, 
no. (%) 
18 (12) 9 (12) 9 (12) 0.99 
Myofascial pain, no. (%) 55 (37) 20 (27) 35 (47) 0.01 
Painful bladder syndrome, pelvic pain, and 
dyspareunia, no. (%) 
4 (3) 0 (0) 4 (5) 0.06c 
UTISA score, mean (SD)e     
     Urination regularity 6.6 (4.3) 5.4 (4.3) 7.9 (3.9) <0.001a 
     Problems with urination 3.4 (3.6) 2.0 (2.5) 5.4 (3.7) <0.001a 
     Pain associated with UTI 3.2 (3.6) 2.1 (3.1) 4.3 (3.8) <0.001a 
     Blood in the urine 0.2 (0.8) 0.1 (0.4) 0.4 (1.1) 0.08a 
aIndependent t test.  bWilcoxon rank sum test.  cFisher's exact test. 
dChi-square test used unless otherwise indicated. Boldface indicates P values that are significant at ≤0.05. 
eUTISA scores for urinary regularity, problems with urination, and pain associated with UTI range from 0 to 12. 
UTISA scores for blood in the urine range from 0 to 6. 
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Uropathogen Detection. 
We next modeled our evaluation to uropathogen detection by the expanded-spectrum 
EQUC protocol with regard to the following parameters: detection compared to standard urine 
culture, detection with different urine volumes, and detection using different plating 
conditions. With these findings, we then identified an optimal subset of expanded-spectrum 
EQUC conditions for improved detection of uropathogens, which we call the streamlined EQUC 
protocol. 
Expanded-Spectrum EQUC Versus Standard Urine Culture. 
The expanded-spectrum EQUC protocol detected a total of 182 uropathogens in all the 
catheterized urine samples, 110 uropathogens in the UTI cohort urine samples, and 72 
uropathogens in in the non-UTI cohort urine samples. Whereas the expanded-spectrum EQUC 
did not miss any uropathogen detected by standard urine culture, the standard urine culture 
protocol detected 33% (60/182) of all detected uropathogens, 50% (55/110) of those detected 
in the UTI cohort, and only 7% (5/72) of those detected in the non-UTI cohort. 
The expanded-spectrum EQUC protocol detected all uropathogens at a higher average 
CFU per milliliter in the UTI cohort than in the no-UTI cohort (Figure H.1). This protocol 
detected E. coli in a total of 50 samples obtained from both cohorts; of these, standard urine 
culture detected E. coli in 88% (44/50). From the UTI cohort alone, expanded-spectrum EQUC 
detected E. coli in 43 samples; of these, standard urine culture detected E. coli in 91% (39/43). 
In contrast, standard urine culture detected a strikingly low fraction (12% [16/132]) of the non- 
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Figure H.1. Average CFU per milliliter of uropathogens between the UTI and no-UTI cohorts  
Depicted are the average CFU per milliliter with which the various uropathogens were 
cultured for both cohorts: UTI (blue bars) and no-UTI (red bars). Average CFU of Klebsiella 
pneumoniae (P = 0.04) and Streptococcus agalactiae (P = 0.02) are significantly higher in the 
UTI cohort (*). Several uropathogens had substantially lower average CFU-per-milliliter 
values in the no-UTI cohort than in the UTI cohort: Aerococcus urinae (P = 0.12), Enterococcus 
faecalis (P = 0.09), Escherichia coli (P = 0.08), Staphylococcus aureus (P = 0.06), and 
Streptococcus anginosus (P = 0.08). Independent t test (*, P < 0.05). Black bars depict 
common UTI thresholds (≥105 CFU/ml and ≥103 CFU/ml). 
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 E. coli uropathogens detected in the two cohorts by the expanded-spectrum EQUC protocol. 
This percentage was only slightly better in the UTI cohort alone, where standard urine culture 
detected 24% (16/67) of the non-E. coli uropathogens detected by the expanded-spectrum 
EQUC protocol. Therefore, standard urine culture's capacity to detect E. coli dramatically 
skewed its overall uropathogen detection value. 
 
 
 
Table H.3. Optimal detection of specific uropathogens by the expanded-spectrum EQUC 
protocol a. 
aListed are the uropathogens and the number of times that each was cultured under each expanded-spectrum 
EQUC plating condition. The condition(s) that best detected each uropathogen is shaded. 
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Expanded-Spectrum EQUC: Urine Volumes. 
Uropathogen detection differed greatly based on expanded-spectrum EQUC urine 
volumes: for 100 μl, 96% detection (174/182); for 10 μl, 65% detection (118/182); and for 1 μl, 
52% detection (95/182) versus standard urine culture (33% [60/182]). Some uropathogens 
were detected equally by all volumes (e.g., E. coli and Pseudomonas aeruginosa); others most 
often required 100 μl for detection (e.g., Aerococcus urinae, Alloscardovia 
omnicolens, Enterococcus faecalis, and Streptococcus anginosus) (see Figure H.S4).  
Expanded-Spectrum EQUC: Plating Conditions. 
Table H.3 displays uropathogens and the number of times that each was cultured under 
the various expanded-spectrum EQUC plating conditions. After 48 h incubation, CDC anaerobic 
BAP incubated anaerobically detected the most uropathogens (63% [115/182]), followed by 
BAP in 5% CO2 (62% [112/182]), CDC anaerobic BAP incubated microaerophilically (54% 
[98/182]), chocolate agar in 5% CO2 (53% [96/182]), BAP incubated aerobically (52% [94/182]), 
CNA agar in 5% CO2 (43% [79/182]), and MacConkey agar incubated aerobically (34% [62/182]). 
Although the CNA agar condition detected fewer uropathogens, it ideally detected Gram-
positive uropathogens when Gram-negative bacteria overwhelmed other agars. For example, of 
the 47 samples where a Gram-negative uropathogen was present at ≥50,000 CFU/ml, the CNA 
agar condition detected 27 underlying Gram-positive uropathogens, all of which were missed 
by standard urine culture (see Table S2A in the supplemental material). Conversely, of the 
- 317 - 
 
 
 
seven samples where a Gram-positive uropathogen was present at ≥50,000 CFU/ml, the 
MacConkey condition detected two underlying Gram-negative uropathogens (see Table H.S2B). 
Table H.4. Detection of uropathogens in UTI cohort without symptom improvement 
Post-
enrollment 
questionnaire 
response 
(sample  ID) 
Antibiotic 
prescribed 
Uropathogen(s) detected by protocol(s): 
Standard urine 
culture and 
expanded 
spectrum EQUC 
Expanded-spectrum EQUC only d 
Same (145) SMZ-TMPb E. coli Strep. anginosus 
Same (048) Nitrofurantoin E. coli Strep. anginosus 
Same (134) SMZ-TMPb E. coli  A. urinae, C. riegelii 
Same (033) Ciprofloxacin Kleb. pneumoniae  
Same (060) Nitrofurantoin E. coli  
Same (109) Nitrofurantoin E. coli  
Same (122) Ciprofloxacin E. coli  
Same (135) Nitrofurantoin E. coli  
Same (136) Nitrofurantoin E. coli  
Worse (082) Nitrofurantoin E. coli  
Same (140)  Staph. lugdunensis  
Same (116)  E. coli  
Worse (128)  E. coli  
Same (126)  
Lactobacillus 
speciesc 
Staph. lugdunensis, Strep. anginosus 
Same (121)   P. mirabilis 
Same (029)   A. urinae, Kleb. Pneumoniae 
Same (139)   Allo. omnicolens, O. urethralis, M. morganii 
Same (052)   Strep. anginosus 
Same (067)   Strep. anginosus 
Worse (025)   Candida albicans 
Worse (112)   Strep. agalactiae, Strep. anginosus 
Worse (142)   E. coli 
Same (084)    
Same (108)    
aUropathogens detected and missed by the standard urine culture in urine samples obtained by catheter from the 
UTI cohort patients who reported feeling the same or worse for the postenrollment questionnaire. Antibiotics 
were prescribed based on the reporting of the standard urine culture results. 
bSMZ-TMP, sulfamethoxazole-trimethoprim.  
cLactobacillus species is not considered a uropathogen, but it was detected at >100,000 CFU/ml by standard urine 
culture.  
dAll of the uropathogens detected by the expanded-spectrum EQUC protocol would have been detected using the 
streamlined EQUC protocol. 
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Streamlined EQUC Protocol. 
One hundred microliters of urine plated on a combination of BAP and CNA agars in 5% 
CO2 and MacConkey agar under aerobic conditions would have detected 84% (152/182) of all 
uropathogens detected by the expanded-spectrum EQUC protocol. This is vastly superior to the 
33% (60/182) uropathogen detection by standard urine culture. In the UTI cohort alone, the 
streamlined EQUC protocol (Table H.1) would have detected 91% (100/110) of uropathogens, 
compared to only 52% (57/110) by standard urine culture. 
Symptom Resolution. 
Seventy-nine percent (59/75) of the participants in the UTI cohort completed the follow-
up UTISA questionnaire. Following clinically selected treatment based on standard urine culture 
(or modified standard urine culture), 59% (35/59) of participants reported symptom 
improvement, while 41% (24/59) reported no improvement (same or worse) (Table H.4). Half 
(12/24) of the 24 participants who did not improve had at least one uropathogen detected only 
by the expanded-spectrum EQUC protocol, and 13 (54%) had microorganisms of unknown 
pathogenicity, which were detected only by the expanded-spectrum EQUC protocol (see Table 
S3 in the supplemental material). Importantly, all of these missed uropathogens would have 
also been detected using the streamlined EQUC protocol. Ten of the 24 patients who did not 
improve had been clinically treated with antibiotics based on the finding of a standard urine 
culture-detected uropathogen. However, in 3 (30%) of these 10 patients, the expanded-
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spectrum EQUC (as well as streamlined EQUC) detected an additional Gram-positive 
uropathogen (Aerococcus urinae, Corynebacterium riegelii, or Streptococcus anginosus). 
Discussion 
Accurate diagnosis for women with UTI symptoms is critical, both to target appropriate 
therapy and to limit inappropriate antibiotic use. Our study demonstrates deficiencies in the 
standard urine culture protocol that limit potentially important information that should be 
provided to clinicians. Our findings suggest that improved detection of clinically relevant urinary 
microbes can be achieved in all diagnostic clinical laboratories using the following conditions: a 
100-μl urine sample obtained by transurethral catheter plated onto BAP, CNA, and MacConkey 
agars, with incubation of all agars in 5% CO2 for 48 h. While incubation of MacConkey agar in 
5% CO2 may not improve Gram-negative bacillus recovery, we recommend that all agars be 
incubated in 5% CO2 for the convenience of using a single incubator. All detected uropathogens 
will grow under the conditions described in the streamlined EQUC protocol. 
Our findings support the use of the streamlined EQUC protocol to more fully describe 
uropathogens. We also recommend that 1μl of the catheterized urine be plated onto BAP and 
MacConkey agars and incubated in 5% CO2 for 24 h with an option to incubate for 48 h 
(modified standard urine culture). The streamlined EQUC protocol provides the most thorough 
detection of uropathogens, while the modified standard urine culture ensures accurate colony 
count assessment and is beneficial for species detection of underlying uropathogens when 
bacterial colony counts of a predominant uropathogen exceed 105 CFU/ml. The need for 
- 320 - 
 
 
 
modified standard urine culture inclusion is apparent from the observation that the expanded-
spectrum EQUC (and the streamlined EQUC) protocols were not 100% sensitive. In the 
expanded-spectrum EQUC protocol, the use of 100 μl urine detected the most microbes and 
the most uropathogens. However, a small number of uropathogens were detected only with 
the use of a smaller urine volume (10 μl). This apparent paradox likely results from microbial 
overcrowding in samples containing high numbers of CFU; in these circumstances, 100 μl was 
not ideal for distinguishing morphologies. While addition of selective media (i.e., CNA and 
MacConkey agars) helped detect underlying uropathogens, some samples contained both 
Gram-positive and Gram-negative bacteria at high CFU numbers, likely making the 100-μl 
expanded-spectrum EQUC volume less efficient. 
Streamlined EQUC would provide more information to clinicians who are considering 
the clinical need for uropathogen(s) treatment; many of these are currently missed by the 
standard urine culture protocol. Until better information is available concerning the 
relationship between clinically important UTI and CFU per milliliter, we recommend that these 
testing conditions (i.e., streamlined EQUC) be used for patients with recurrent UTIs or patients 
with clear UTI-like symptoms despite a negative standard urine culture result. Nonetheless, it is 
clear that treatment based on standard urine culture results limits diagnostic information that 
may be useful for symptom resolution. This study did not assess symptom relief in patients 
whose uropathogens were detected only with the streamlined EQUC protocol. Such studies are 
clearly needed. 
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Compared to the expanded-spectrum EQUC, the standard urine culture missed 67% 
(122/182) of all detected uropathogens and 88% (116/132) of non-E. coli uropathogens. 
Detection of uropathogens by the standard urine culture was slightly better for the UTI cohort 
alone (50% total missed [55/110]; 76% non-E. coli missed [51/67]). This improvement may 
result from the higher average uropathogen CFU per milliliter in the UTI cohort (Figure H.1), 
making detection by standard urine culture more likely. The data in Table H.1 also reveal that 
the use of one threshold for UTI diagnosis is likely incorrect. Use of the ≥105-CFU/ml threshold 
would result in untreated uropathogens in the UTI cohort (Figure H.1). Lowering the threshold 
to ≥103 CFU/ml, however, creates other concerns. While use of the ≥103-CFU/ml threshold 
would leave fewer uropathogens in the UTI cohort untreated, it would detect some 
uropathogens in the no-UTI cohort. Since individuals in the no-UTI cohort presumably do not 
have an infection (i.e., no/low severity of urinary symptoms), it is unlikely that they would 
benefit from antibiotic use. This creates a problem in diagnosis and treatment of UTIs and is 
likely the reason for the current ambiguity surrounding urine cultures. From these data, we 
suggest the possibility that, for UTI diagnosis, each uropathogen may have its own unique 
threshold (e.g., ≥102 CFU/ml for Aerococcus urinae, ≥103 CFU/ml for Streptococcus agalactiae, 
and ≥104 CFU/ml for Klebsiella pneumoniae). 
Our findings in a selected, health care-seeking population of women should be 
generalized with caution to community-dwelling women who may or may not have similar 
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microbial profiles in health or during UTI. Microbial characterization of women longitudinally 
may provide additional context for interpretation of standard and streamlined culture results. 
It appears that simple changes to the commonly performed standard urine culture 
protocol have the capacity to provide potentially useful clinical information. Importantly, the 
urine must be collected by catheter, as we have previously shown that vulvovaginal 
contamination renders clean-catch voided specimens obsolete4. At this time, we suggest that 
the recommended culture conditions (i.e., streamlined EQUC) be considered both as a 
supplemental test when individuals with UTI-like symptoms have “no growth” via standard 
urine culture and for use with individuals with persistent UTI-like symptoms (i.e., recurrent UTI). 
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Supplementary Data 
 
 
Figure H.S1. Species accumulation curves of UTI and No-UTI Cohorts  
Species accumulation data depicts the number of unique species cultured (using the Expanded 
Spectrum EQUC) with each new patient sampled. When the curve plateaus, it indicates that the 
community is fully sampled and few, if any, new species will be identified. Therefore, it also 
measures the overall diversity of the population in terms of species richness. The UTI cohort 
(blue line) is comprised of 66 species. The No-UTI cohort (red line) is comprised of 75 species. 
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Figure H.S2. Frequency of detection of genera in the UTI and No-UTI cohorts 
Depicts the frequency (i.e., percentage) of detection (using the Expanded Spectrum EQUC) of 
the urine samples containing each genus between the UTI (blue bars) and No-UTI (red bars) 
cohorts. Streptococcus (p=0.003), Gardnerella (p=0.04), and Escherichia (p<0.001). 
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Figure H.S3. Species significantly different between the UTI and No-UTI cohorts 
Depicts the frequency (i.e., percentage) of detection (using the Expanded Spectrum EQUC) of 
the species that are statistically associated with either the UTI (blue bars) and No-UTI (red bars) 
cohorts. Gardnerella vaginalis (p=0.04), Streptococcus mitis/oralis/pneumoniae (p=0.01), 
Streptococcus parasanguinis (p=0.02), Streptococcus salivarius (p=0.05) and Streptococcus 
sanguinis (p=0.01) are associated with the No-UTI cohort. Escherichia coli (p<0.001) is 
associated with the UTI cohort. Pearson chi-square and Fisher’s exact test (* p<0,05; **p<0.01, 
*** p<0.001). The species S. mitis, S. oralis, and S. pneumoniae were grouped together because 
they cannot accurately be distinguished using MALDI-TOF MS. 
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Figure H.S4. Detection of Uropathogens by each expanded spectrum EQUC urine volume 
Depicts the total number of times each uropathogen was identified by each of the urine 
volumes (1 µL, 10 µL, 100 µL) in the Expanded Spectrum EQUC protocol as well as the Standard 
Urine Culture protocol: Standard Urine Culture (blue bars), 1µL Expanded Spectrum EQUC 
(purple bars), 10 µL Expanded Spectrum EQUC (green bars), and 100 µL Expanded Spectrum 
EQUC (red bars). 
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 Table H.S1. Urinary microbiota characteristics 
 UTI 
(n=75) 
No-UTI 
(n=75) 
p-value 
Cultivatable Urine Samples 72 (96%) 6 (89%) 0.12* 
Total number of unique species 66 75  
Median number of unique specie per isolate, mdn (IQR) 2 (1-4) 3 (1-5) 0.12 ** 
Shannon Diversity index 3.49 3.89  
IQR = Interquartile Range. Mdn = median 
* Chi-Square Test 
**Wilcoxon Rank Sum Test 
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Overview of Appendix I 
 This paper was the first characterization of the bladder microbiome during pregnancy, 
or the maternal urinary microbiome (MUM). The patient population in all our work thus far has 
been in older women (peri- or post-menopausal). Characterizing women during pregnancy was 
our first opportunity to look at the bladder in younger and primarily healthy women. Because of 
the small sample size, we were not able to find any significant associations between the 
microbiome and pre-term birth (for those data see the Addendum). However, we did show that 
standard culture was insufficient to detect uropathogens in these women.  
This study was also the impetus for our methods paper. These samples were collected in 
the Labor and Delivery Department at Loyola, not the Urogynecology Department. The 
differences in the facilities and staff led to some unforeseen issues; in particular, we realized 
that samples were sometimes collected in the middle of the night and thus sat at room 
temperature until the morning, resulting in bacterial growth. Due to this growth, the 
sequencing data and culture data do not match as well as in other studies. We decided to 
follow up on this discrepancy by testing all our standard procedures. The data from these tests 
will be put together into a methods paper.  
Abstract 
Objective. To characterize the bladder microbiota in pregnancy 
Methods. A prospective observational study of 51 pregnant women, admitted to a 
tertiary care hospital, who underwent straight catheterization urine collection or transurethral 
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foley catheter placement. 16S rRNA gene sequencing and enhanced quantitative urine culture 
(EQUC) assessed the maternal bladder microbiota with comparisons made to standard urine 
culture results. 
Results. EQUC and 16S rRNA gene sequencing detected bacteria in the majority of 
participants. Lactobacillus and Gardnerella were the most commonly detected microbes. In 
contrast, standard urine culture had a 100% false negative rate and failed to detect several 
known or emerging urinary pathogens.  
Conclusions. There are live bacteria in the bladders of most pregnant women. This 
challenges the definition of asymptomatic bacteriuria.  
Introduction 
Asymptomatic bacteriuria (ASB) is defined as the presence of a uropathogen in the 
absence of physical symptoms 308. ASB strains have long been thought to be non-pathogenic 
variants of pathogenic species, especially Escherichia coli or Streptococcus agalactiae (also 
known as Group B Strep). However, in certain populations, such as the general obstetric 
population, untreated ASB is associated with subsequent urinary tract infection (UTI). This 
includes pyelonephritis 309, which is associated with adverse pregnancy outcomes, maternal 
sepsis and preterm labor 309,310. Thus, routine screening and treatment of ASB is recommended 
during pregnancy 311,312.  
However the current approach to ASB screening is limited by the assumption that the 
female bladder naturally exists in a sterile state 313,314; thus, the presence of bacteria in urine is 
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currently considered abnormal. However, several recent studies have revealed the existence of 
bacterial communities in the bladders of non-pregnant peri-menopausal women8,9,162,202,315. 
One of the earliest studies compared multiple urine collection methods4, including suprapubic 
aspiration (SPA), which bypasses vulvo-vaginal contamination. This study noted that the 
bacterial DNA (microbiome) detected in urine obtained by transurethral catheter closely 
resembled those obtained by SPA, and diverged substantially from the microbiomes in vaginal 
swabs and mid-stream voided urine. Thus, transurethral catheterized urine specimens 
accurately sample the bladder and is thus the appropriate urine collection method for 
investigation of the bacteria present in the urinary bladders of women (the female bladder 
microbiota) 4.   
To determine whether bacterial DNA detected by 16S rRNA gene sequencing originated 
from live bacteria within the bladder, our group developed an enhanced quantitative urine 
culture (EQUC) protocol that detects bacteria in the vast majority of catheterized urine samples 
deemed “no growth” by standard clinical microbiology urine culture methods 3,7. Thus, 
standard urine culture does not detect the presence of a large number of bacterial species, 
including most uropathogens 43.  
Given compelling enhanced culture and DNA sequence evidence that the female urinary 
bladder of peri-menopausal women is not sterile, we questioned the sterility of urine obtained 
from the bladders of younger pregnant women. Specifically, we used the complementary 
approaches of EQUC and 16S rRNA gene sequencing to determine if urine obtained by 
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transurethral catheterization contains microbiota and then compared those results to a 
standard clinical microbiology urine culture protocol. We found that the standard culture 
protocol typically used to diagnose ASB misses many diverse microbes, including known and 
emerging uropathogens. We conclude that bladder urine of most pregnant women is not 
sterile. 
Materials and Methods 
Participant Recruitment. 
Following Loyola Institutional Review Board approval, we prospectively invited pregnant 
patients presenting to labor and delivery to participate in the study if they were ≥18 years of 
age, proficient in English and undergoing straight catheterization urine collection or placement 
of a transurethral foley catheter as part of their clinical care. We excluded patients who had 
used antibiotics within the last 4 weeks for any reason. Participants gave written informed 
research consent. At enrollment, participants provided demographic information, UTI history, 
medication (including antibiotic) use, obstetric history, tobacco use and other comorbidities. As 
part of standard obstetric care, this cohort had undergone screening for ASB. For all patients, 
we recorded gestational age at time of sample collection  
Sample Collection and Urine Culture. 
Urine was collected aseptically via the transurethral catheter into a sterile collection 
cup. As per clinical protocol, a portion of the urine sample was placed into a BD Vacutainer Plus 
C&S preservative tube and sent to the research lab for standard urine culture and EQUC 
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assessment. Due to the lack of appropriate refrigeration facilities in the clinic, the remainder of 
the urine was stored at room temperature for 1-8 hours before being processed and stored 
down at -80°C with 10% AssayAssure (Sierra Molecular; Incline Village, NV) for subsequent 
sequencing.  
 Within 24 hours of urine collection, both standard and enhanced (EQUC) urine cultures 
were set up. Both protocols are provided in Table H.S1 and have been described previously 7. 
The detection limit for the standard protocol was 1000 colony forming units per milliliter 
(CFU/ml); for EQUC, it was 10 CFU/ml. If EQUC was unable to detect bacteria, the sample was 
considered to be below the detection threshold. For samples with bacteria detected, alpha 
diversities were measured, the Bray-Curtis distance calculated 196, and the complete method 
was used for hierarchical clustering using RStudio 115. The resulting dendrogram was divided 
into fourteen clusters (termed urotypes) that were named on the basis of the predominant 
organism. When a cluster had no predominant organism, it was called a “diverse” urotype.  
16S rRNA Gene Sequencing. 
DNA isolation protocols and 16S rRNA gene sequence analysis have been described 
previously 3. Briefly, total DNA was extracted from 1ml of catheterized urine under a laminar 
flow hood, using the Qiagen DNeasy Blood and Tissue Kit (Qiagen, Valencia, CA). The 4th 
variable region was amplified using Illumina adapted universal primers (515F and 806R).  
Extraction negative controls (no urine) and PCR negative controls (no template) were included 
to assess contribution of extraneous DNA from reagents. Final PCR products were purified from 
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unincorporated nucleotides and primers using Agencourt AMPure XP-PCR magnetic beads 
(Beckman Coulter). Purified samples were normalized to equal DNA concentration, as 
determined by the Bioanalyzer (Aligent, Santa Clara, CA). The sample library and PhiX 
sequencing control library (Illumina) were denatured and added to the MiSeq 2x250 bp 
sequencing reagent cartridge, according to manufacturer’s instructions (Illumina). 
Sequence Processing. 
Each specimen was sequenced in duplicate. MiSeq sequence reads were processed 
following mothur’s MiSeq SOP at http://www.mothur.org/wiki/MiSeq_SOP 194, with minor 
modifications. Mothur software (version 1.34.4) 167 was used to process raw reads and, using 
default mothur parameters, to remove low quality and chimeric sequences. Taxonomic 
classification from phylum to genus level of sequence reads was performed by the RDP 
Classifier (version 2.5) 195], using the default 0.8 confidence threshold. To determine if each 
sample is accurate and reliable, all samples must have greater than 2000 reads, be distinct from 
the corresponding extraction control, and be comparable to its replicate. 
Using genus-level classification, from a single replica, alpha diversities were measured, 
the Bray-Curtis distance calculated 196, and the complete method was used for hierarchical 
clustering using RStudio 115. The resulting dendrogram was divided into six clusters, termed 
urotypes, named on the basis of the predominant organism. When a cluster had no 
predominant organism, it was termed the “diverse” urotype. 
Statistical Analysis. 
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For cultured organisms, abundance was measured using total colony forming units per 
millileter (CFU/ml). Continuous variables are reported as means and standard deviations (SD) or 
medians and interquartile ranges (IQR). Post-hoc pairwise comparisons were made using 
Wilcoxon Rank sum tests for continuous variables with significant overall p-values using 
statistical software, SAS software v9.4 (SAS Institute, Cary, NC). 
Results 
All 51 recruited participants were included in the study analysis. Table I.1 displays the 
cohort’s demographic characteristics. The average age was 30 years, and most (68%) 
participants were obese. The average gestational age at sample collection was 36 weeks, the 
majority (74%) were enrolled within 2 days of delivery, and seventeen (33%) subjects delivered 
prior to 37 weeks. 
Sequencing Results. 
A bladder microbiome was detected in 68.6% (35/51) of participants by 16S rRNA 
sequencing, which resulted in a total of 3,605,762 reads from 7 phyla, 14 classes, 18 orders, 28 
families, and 31 genera. Figure I.1 displays the maternal bladder microbiome profile for each 
participant grouped by predominant organism. The majority of sequenced individuals were of 
the Lactobacillus-predominant urotype (60%, 21/35), followed by Gardnerella (25.7%, 9/35) 
(Table I.2). A small number of individuals were dominated by the genus Staphylococcus (N=1), 
the order Bacilliales (which includes the genus Enterococcus, N=2), or the family 
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Enterobacteriaceae (which contains the species Escherichia coli, N=1). Only one patient had no 
predominant organism, thereby that individual’s urotype was considered to be “diverse.”  
Table I.1. Patient Demographics for the Maternal Urinary Microbiome Project 
 N=51 
Mean Maternal age (years) 30 (19-41) 
Nulliparity (%) 49.0% 
Race/Ethnicity 
    Caucasian 
    African-American  
    Hispanic 
    Asian 
N (%) 
16 (31.3%) 
17 (33.3%) 
14 (27.5%) 
4 (7.8%) 
BMI (kg/m2) 
   Normal (18.5 – 24.9) 
   Overweight (25 – 29.9) 
   Obese (30 – 34.5) 
   Morbidly Obese (>35) 
 Mean BMI (range) 
 
5 (9.8%) 
11 (21.6%) 
19 (37.3%) 
16 (31.3%) 
34.3 (22.0-58.4) 
Education 
   High School 
   Some College 
   College 
   Graduate 
 
11 (21.6%) 
19 (37.3%) 
11 (21.6%) 
10 (19.6%) 
Gestational age at delivery (weeks) 37 (19w2d - 41w2d) 
Gestational age at collection (weeks) 36 (19w0d – 41w1d) 
GU Infection/Colonization 
   GBS positive 
   UTI during this pregnancy 
   History of any UTI 
 
6 (11.8%) 
4 (7.8%) 
12 (23.5%) 
Medical Comorbidities 
   Gestational Diabetes Mellitus 
   Diabetes Mellitus 
   Gestational Hypertension 
   Chronic Hypertension 
   Renal Disease 
 
3 (5.9%) 
2 (3.9%) 
2 (3.9%) 
6 (11.8%) 
2 (3.9%) 
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Table I.2. Frequency of profiles using either sequence or EQUC data  
Frequency of Sequencing Profiles  Frequency of Culture Profiles 
BDT a 16/51 (31.4%)  BDT a 17/51 (33.3%) 
Sequenced 35/51 (68.6%)  Cultured 34/51 (66.7%) 
Lactobacillus 21/35 (60%)  G. vaginalis 7/34 (22.6%) 
Gardnerella 9/35 (25.7%)  L. iners 5/34 (14.3%) 
Bacilli/Enterococcus 2/35 (5.7%)  L. crispatus 5/34 (14.3%) 
Enterobacteriaceae 1/35 (2.9%)  E. faecalis 3/34 (8.8%) 
Staphylococcus 1/35 (2.9%)  L. gasseri 3/34 (8.8%) 
   L. jensenii 3/34 (2.9%) 
Diverse b 1/35 (2.9%)  S. epidermidis 2/34 (5.9%) 
   A. schaalii 1/34 (2.9%) 
   C. coyleae 1/34 (2.9%) 
   C. glabrata 1/34 (2.9%) 
   Diverse 1/34 (2.9%) 
   L. johnsonii 1/34 (2.9%) 
   S. anginosus 1/34 (2.9%) 
aBDT, below detection threshold 
bA diverse profile indicates a diverse community lacking a single predominant organism 
The microbiome of participants with a Lactobacillus urotype was significantly less 
diverse than Gardnerella urotype subjects as determined by the Shannon Diversity Index and 
Inverse Simpson Index, which measure both richness and evenness (Table I.3). The 
microbiomes of participants with a Gardnerella urotype were more even, as measured by the 
Peilou Index. This is visible in the Gardnerella urotype profiles, which show a greater presence 
of other genera, including Lactobacillus, Ureaplasma, Aerococcus, Atopobium and/or 
Lachnospiraceae (Figure I.1A).  
Enhanced Culture Results. 
EQUC detected live microbes in the majority of participants (66.7%, 34/51), similar to 
that proportion of samples that were positive by sequencing (Table H.2, Figure H.1B).  At the 
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Figure I.1. Sequencing and Culture profiles of the Maternal Urinary Microbiome. 
The sequencing profiles (A) and culture profiles (B) are shown. Each bar represents a urine 
sample from one patient. On the y-axis is the relative abundance, or percent of classified 
sequencing reads (A) or colony forming units per ml (B) per individual. Each bar or taxon is 
color coded by family or genus (A) or species (B). All samples were phylogenetically 
compared to each other using Bray-Curtis similarity, resulting in a phylogenetic tree or 
dendrograms. The length of each branch of the dendrograms represents the similarity 
between samples. We divided the samples into clades by identifying a profile threshold. The 
clades group together by dominant organism; these groups are termed “sequence profiles” 
(A) or “culture profiles” (B), which are listed underneath. The sequencing dataset (A) divided 
into 6 profiles, Lactobacillus, Enterobacteriaceae, Bacilli, Gardnerella, Staphylococcus, and a 
mixed profile termed ‘Diverse’. The culture profile (B) divided into 13 profiles, S. 
epidermidis, L. gasseri, S. anginosus, L. jensenii, C. glabrata, E. faecalis, L. iners, L. johnsonii, 
C. coyleae, A. schaalii, G. vaginalis, and a mixed profile termed ‘Diverse’. 
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genus level, the most common culture profile was predominated by Lactobacillus (50%, 17/34), 
similar to that observed by sequencing. This genus level Lactobacillus profile was composed of 
the following species: L. gasseri, L. jensenii, L. iners, L. johnsonii and L. crispatus. Thus, with 
respect to the major dominant profiles, sequencing and EQUC obtained similar results. 
The combination of 16S sequencing and EQUC detected bacteria in 80% (41/51) of 
participants and reached the same conclusion regarding urotype in 64% (33/51) of all the 
participants. Considering only participants with positive results for both methods, these two 
methods reached the same conclusion in 82% (23/28) of participants (Figure I.1).  
Figure I.1. Continued 
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Table I.3. Differences in alpha diversity measurements between the Lactobacillus and 
Gardnerella sequencing Four different alpha diversity measurements were calculated from the 
sequencing data: Shannon diversity (a measurement of richness and evenness), Inverse 
Simpson (richness and evenness), total number of species (richness only) and Pielou (evenness 
only). P-values were generated using a Wilcoxon rank sum test.  
 
Gardnerella 
urotype (N=9) 
Lactobacillus 
urotype (N=21) 
P-value 
Shannon Diversity Index,  
Mdn (IQR) 
1.28 
(1.13-1.53) 
0.54 
(0.35-0.91) 
0.0003 
Inverse Simpson Index,  
Mdn (IQR) 
2.5 
(2.02-3.10) 
1.8 
(1.10-1.53) 
0.0005 
Total number of Species,  
Mdn (IQR) 
83 
(63-94) 
77 
(74-87) 
0.8562 
Pielou Index,  
Mdn (IQR) 
0.3 
(0.28-0.34) 
0.13 
(0.08-0.20) 
0.0003 
 
Standard Urine Culture Results Versus EQUC. 
Standard urine culture results were available for all participants. The standard urine 
culture was negative for all samples. In contrast, EQUC detected bacteria in 34/51 subjects. 
Thus, the standard urine culture had a 100% false negative rate. In 15 participants, the standard 
protocol also did not detect several known or emerging urinary pathogens, including 
Actinobaculum schaalii (N=1), Alloscardovia omnicolens (N=1), Candida albicans (N=1), Candida 
parapsiosis (N=1), Corynebacterium urealyticum (N=1), Enterococcus faecalis (N=7), Escherichia 
coli (N=1), Staphylococcus aureus (N=1), Streptococcus agalactiae (also known as GBS, N=1), 
and Streptococcus anginosus (N=5) (Table I.4). Five patients grew two or more of these 
uropathogens. Some of these organisms (A. schaalii, A. onmicolens, and C. urealyticum) would 
not normally grow under standard urine culture conditions. Many of these patients contained 
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organisms at thresholds below the detectable level of standard urine culture (10-100 CFU/ml). 
However, four individuals contained one of these organisms at greater than 1000 CFU/ml; thus, 
in theory, these bacteria could have been detected by standard culture, but they were not.   
Table I.4: Colony Forming Units/ml of EQUC Detected Uropathogens. Fifteen patients 
contained detectable uropathogens using EQUC. Here we show the colony forming units per ml 
of urine of all detectable uropathogens in those individuals. 
 
 Actinobaculum 
schaalii 
Alloscardovia. 
omnicolens 
Candida 
albicans 
Corynebcaterium 
urealyticum 
Staphylococcus 
aureus 
MUM_07 0 0 0 0 10 
MUM_03 10 0 0 0 0 
MUM_22 0 0 310 0 0 
MUM_55 0 0 0 100 0 
MUM_56 0 100 0 0 0 
 
 Candida 
parapsiosis 
Enterococcus 
facalis 
Escherichia 
coli 
Streptococcus 
agalactiae 
Streptococcus 
anginosus 
MUM_11 10 0 0 0 10 
MUM_15 0 70 0 0 20 
MUM_19 0 10 0 0 10 
MUM_25 0 700 0 0 0 
MUM_35 0 10000 1000 0 0 
MUM_41 0 0 0 0 1100 
MUM_42 0 10 0 30 60 
MUM_47 0 10 0 0 0 
MUM_58 0 5000 0 0 0 
 
History of UTIs During the Current Pregnancy. 
Uropathogens have been known to recur and it is possible that some of these patients 
had a prior infection. To determine if the patients with detectable uropathogens had previously 
been treated for UTIs we looked at the medical records for prior UTI treatment during the 
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current pregnancy. Four patients reported UTI-like symptoms during their current pregnancy. 
One PTL/pPROM patient had an Enterococcus UTI in the 1st trimester and was treated with 
cephalexin. An indicated pre-term patient was treated in the second trimester with cephalexin 
for a UTI caused by an unknown organism. Two full term patients documented a single UTI 
during this pregnancy: one was treated early in their pregnancy but their records are 
unavailable; the second patient was treated with ceftriaxone for Gonorrhea in the first 
trimester and nitrofurantoin in the second trimester for symptoms with a negative urine 
culture. At time of sample collection, none of these four patients had detectable uropathogens 
by either EQUC or standard culture. 
Discussion 
In this prospective observational pilot study of pregnant women admitted to labor and 
delivery and undergoing a clinically indicated bladder catheterization, a large majority of 
pregnant women had evidence of bladder microbes by 16S RNA sequencing or EQUC or both. 
Most importantly, EQUC demonstrates the existence of live microbes in catheterized urine 
samples obtained from women late in gestation. This high rate of microbe detection stands in 
stark contrast to the low rate of detection by the standard urine culture method, which had a 
100% false negative rate for identification of bladder microbes compared to EQUC. Critically, 
standard urine culture did not identify several known or emerging uropathogens.  
The evidence of live microbes in the bladders of most pregnant women questions the 
notion that the urine of pregnant women is sterile. Additionally, these findings challenge the 
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utility of the term ASB; if the bladders of most pregnant women contain bacteria, then what 
does the term asymptomatic bacteriuria mean?  We believe these data support the findings of 
studies from non-pregnant women, namely that the majority of women have an identifiable 
urinary microbiome. As with microbiota of other human microbial niches, the maternal bladder 
microbiota likely vary in response to nearby microbial niches and/or system influences, such as 
antibiotic use, systemic disease or perturbations in the immune system. As current standard of 
care suggests screening and treating ASB during pregnancy, an expanded understanding of the 
maternal urinary microbiome is needed using new approaches that refine our working 
definition of what are problematic urinary microbes during pregnancy. Further research is 
needed to understand how the microbiota might also play preventative or protective roles and 
to determine the dysbiotic effects of antibiotics.   
The strengths of this investigation are the prospective design, the use of catheterized 
urine specimens and the use of the robust combination of EQUC and 16S rRNA sequencing 
techniques 3,6,7. Together, these techniques illustrate the limited view provided by the standard 
urine culture, which was specifically designed to detect fast growing bacteria with limited 
nutrient requirements and no aversion to oxygen (especially Escherichia coli, the most common 
cause of UTI). In contrast, EQUC utilizes larger urine volumes, varied media and incubation 
states, and longer incubation times to also detect anaerobes, slow growing bacteria and those 
that require special nutrients 7 (Table I.S1). Because EQUC can classify bacteria to the species 
level, the total number of culture profiles was much greater than the number of profiles 
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detected by sequencing, which typically classifies only to the genus level. However, 16S rRNA 
gene sequencing complements EQUC by detecting bacteria independent of culture 51,316. 
We acknowledge that our study has limitations. First, the small sample size reduces our 
ability to statistically compare important subgroups, such as preterm versus term deliveries. In 
addition, we were unable to account for potential confounding factors, such as demographics 
or medical comorbidities. Further studies also are needed to characterize the bladder 
microbiome throughout each trimester of pregnancy. 
A theoretical concern exists that the detected bacteria may represent urethral or vaginal 
contamination. However, as described previously, a prior investigation comparing the bacterial 
profiles of vaginal swabs and urine obtained by transurethral catheter, suprapubic aspirate, and 
the mid-stream voided method concluded that bacteria detected in urine obtained by 
suprapubic aspirate or transurethral catheter represent true residents of the bladder. As the 
samples in the current study were obtained by transurethral catheterization, we conclude that 
our findings are not the result of contamination and instead document the presence of live 
bladder microbiota in pregnant women. 
We also recognize that EQUC and 16S sequencing did not universally agree regarding 
specimen profile, potentially due to differences in sample storage prior to processing. The 
culture tubes contain a preservative that prevents bacterial growth at room temperature, but 
the sequencing tubes did not. Therefore, bacterial growth in the sequencing tubes could 
account for the majority of the discrepancies between the data (Figure I.1). This is an issue that 
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should be considered in the design of future studies. Even given these discrepancies with 
sequencing data, however, the culture data clearly shows the presence of greater than 103 
CFUs of many different organisms, including known and emerging uropathogens.  
Because this study also documents the poor performance of the standard urine culture, 
these findings offer us the opportunity to improve our understanding of the maternal bladder 
microbiota, especially as it relates to clinically relevant definitions of ASB. Of particular concern 
was the finding of bacteria by our EQUC technique that had gone undetected by the standard 
urine culture method. Of the bacteria identified by EQUC, several are known or emerging 
urinary pathogens, including Enterococcus faecalis, Streptococcus anginosus, and 
Actinobaculum schaalii (recently renamed Actinotignum schaalii 317). These results require 
confirmation in a larger study.  
Currently, we do not recommend a change in clinical practice because we do not yet 
know the impact of the previously undetected microbes. Some of the newly detected microbes 
are likely beneficial and antibiotic treatment could preclude their ability to protect. Future 
study into the roles of the detected microbes is indicated.  
While the majority of the pregnant women in this study possessed detectable and 
identifiable bladder microbiota, the microbiota of several women was below the detection 
threshold, similar to previous reports of peri-menopausal women 308-310,318,319. We use the term 
below the detection threshold instead of “negative” or “sterile” to emphasize that these urines 
likely have a low biomass that cannot be detected using the current methods. Since we are 
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unable to prove sterility, we believe this is a more accurate scientific approach. Indeed, a recent 
study showed that the use of larger volumes of urine could result in detection of bacteria by 
DNA sequencing in all samples 320. 
In conclusion, we believe this study documents the presence of live microbiota in the 
bladders of pregnant women, an observation that warrants further study.  Future investigations 
should clarify the normal bladder microbiota in pregnancy and identify changes over the course 
of pregnancy. This would allow for a deeper understanding of the normal maternal bladder 
microbiota and how they can become altered in ways that lead to pathologic conditions. For 
example, this new knowledge would clarify the definition and risk factors associated with ASB 
during pregnancy. Other factors should be investigated, especially the relationship between the 
maternal bladder microbiota and those of other pelvic floor niches, especially the vagina. 
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Supplementary Material 
Table I.S1.  Culture protocols 
Protocol Volume Media Atmospheric 
Conditions 
Time 
Standard Urine 
Culturea,c 
1 uL  
 
Blood Agar  
MacConkey Agar  
Aerobic 24 hrs 
35° 
Enhanced 
Quantitative Urine 
Culture (EQUC)b,c 
100 uL 
  
Blood Agar 
Chocolate Agar  
CNA Agar  
Anaerobic Blood Agar  
Aerobic 
CO2 
Anaerobic 
48 hrs 
35° 
aFor standard urine culture, we struck 0.001 ml of urine onto 5% sheep blood (BAP) and 
MacConkey agars (BD BBL prepared plated media), which were incubated aerobically at 35°C 
for 24 hours. Each separate morphological colony type was counted and identified in any 
amount. The detection level was 1,000 colony-forming units per milliliter (CFU/ml), represented 
by 1 colony of growth on either plate. If no growth was observed, the culture was reported as 
“no growth,” indicating no growth of bacteria at the lowest dilution, i.e., 1:1,000.  
bFor EQUC, we struck 0.1 ml of urine onto BAP, chocolate and colistin, naladixic acid (CNA) 
agars (BD BBL prepared plated media), which were incubated in 5% CO2 at 35°C for 48 hours. A 
second BAP plate and CDC anaerobe 5% sheep blood agar plate (BD BBL prepared plated 
media) were also inoculated with 0.1 ml of urine and incubated under anaerobic conditions at 
35°C for 48 hours. The detection level was 10 CFU/ml, represented by 1 colony of growth on 
any of the plates. Each morphologically distinct colony type was isolated on a different plate of 
the same medium to prepare a pure culture for identification.  
cTo identify bacterial isolates, matrix-assisted laser desorption ionization–time of flight mass 
spectrophotometry (MALDI-TOF MS) with the MALDI Biotyper 3.0 software program (Bruker 
Daltonics, Billerica, MA) was used. 
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Figure I.S1. Comparison of culture and sequencing for all 51 individuals. 
To compare each individual’s sequencing results and culture results we lined up the relative 
abundance graphs for each. The relative abundance (or total classified CFU/ml per individual) 
culture profiles (A) are compared to the relative abundance (or total classified reads per 
individual) of the sequencing profiles (B). The culture classification is given at the genus level 
to better compare to sequencing results. Each genus is represented as a color-coded bar for 
each individual, where each color represents a family or genus. 
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Addendum 
One of the initial analyses we attempted was the comparison between pre-term births 
and full term births. We tried grouping our women in two ways: (1) by gestational age at time 
of urine collection (Table I.5 and Figure I.2) and (2) by the type of pre-term birth (Figure I.3). 
We ran into a few problems.  
First, our sample size was too small, so even if we saw a trend, it would not be 
statistically significant. Second, we have not measured the microbiome over the course of 
pregnancy; therefore, we do nott know if it normally changes. This was problematic for 
interpretation. Were any changes we were seeing due to the normal fluctuation of the 
microbiome or an indication of a pre-term birth?  
Finally, we found out later that our groupings in Figure I.3 were arbitrary designations. 
The idea was that indicated pre-term birth would not be associated with a change in the 
microbiome because there was nothing medically wrong with these women. Women with Pre-
term Labor with Pre-Mature Rupture of Membranes (PTL-PPROM) had a sudden severe 
reaction that caused their pre-term birth and that could have a microbiological component 
(such as an infection with GBS). However, when we went back to confirm these designations, 
we were informed that they were arbitrary. Therefore, these data were removed from the final 
version of the manuscript.  
Finally, because we wanted to compare these women to a fairly healthy cohort, we 
compared these data to our control women from Appendix B-C. However, those control 
- 350 - 
 
 
 
samples had been previously published and that published patient population was significantly 
older, so the analysis was only presented in a poster (Table I.6). 
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Table I.5. Comparison of the MUM dataset by gestational age at time of sample collection. 
The percentage of urotype profiles by EQUC and sequencing are compared between full term 
(<37 weeks) and pre-term (<20-36 weeks).  
EQUC  Sequencing 
 Gestational Age   Gestational Age 
Urotype >37 
weeks 
<20-36 
weeks 
 Urotype >37 
weeks 
<20-36 
weeks 
N 33 17  N 33 17 
Undetermined* 
27.3% 
(9/33) 
47% 
(8/17) 
 
Undetermined* 
21.2% 
(7/33) 
47.1% 
(8/17) 
Total Processed 
72.3% 
(24/33) 
52.9% 
(9/17) 
 
Total Processed 
78.8% 
(26/33) 
52.9% 
(9/17) 
       
Lactobacillus 
45.8% 
(11/24) 
22.2% 
(2/9) 
 
Lactobacillus 
50% 
(13/26) 
55.5% 
(5/9) 
Gardnerella 
29.2% 
(7/24) 
22.2% 
(2/9) 
 
Gardnerella 
23.1% 
(6/26) 
22.2% 
(2/9) 
Staphylococcus 
8.3% 
(2/24)  
 
Staphylococcus 
3.8% 
(1/26)   
Diverse 
 
33.3% 
(3/9) 
 
Diverse 
15.4% 
(4/26)   
Enterococcus 
4.2% 
(1/24)  
 
Enterococcus 
3.8% 
(1/26)   
Enterobacteriaceae 
4.2% 
(1/24)  
 
Enterobacteriaceae 
3.8% 
(1/26)   
Candida 
4.2% 
(1/24)  
 
Ureaplasma 
  
11.1% 
(1/9) 
Streptococcus 
4.2% 
(1/24)  
 
Bacillales 
  
11.1% 
(1/9) 
Corynebacterium 
 
11.1% 
(1/9) 
    
Actinobaculum 
 
11.1% 
(1/9) 
    
*Samples that were either culture or sequences negative were deemed “Undetermined” 
because we think they are below our level of detection, but are not “sterile”. 
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Figure I.2. Relative abundance of 16S rRNA profiles by Gestational Age. A graphical 
representation of the sequence part of Table H.5. 
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Figure I.3. Relative Abundance Profiles separated by Pre-Term versus Full Term Pregnancies. 
The patients were divided into three groups: Pre-term labor with premature rupture of 
membranes (PTL-PPROM), Indicated pre-term, and full term. The relative abundance for each 
individual at the genus level, for (A) sequence data and (B) culture data. To allow for 
comparison between sequencing and culture, the patient samples are in the same order for 
both A and B. To compare the biomass within each population, the distribution of colony 
forming units per milliliter (CFU/ml) is graphed as a boxplot (C). Underneath is the mean and 
interquartile range (IQR) for each group. Because the microbiota might change during the 
course of pregnancy, for the full term population, we considered only those samples that were 
collected within two days of delivery (N=45).  
- 354 - 
 
 
 
 
Table I.6. Comparison of the Urotype Frequencies found in the MUM data set to older 
controls. The older controls dataset was collected and published during the Astellas project 
(Appendix C-D).  
MUM dataset  Control Samples 
Urotype EQUC Seq  Urotype EQUC Seq 
N 51 51  N 33 17 
Undetermined* 
33.3% 
(17/51) 
31.4% 
(16/51) 
 
Undetermined* 
21.2% 
(7/33) 
47.1% 
(8/17) 
Total Processed 
66.7% 
(34/51) 
68.6% 
(35/51) 
 
Total Processed 
78.8% 
(26/33) 
52.9% 
(9/17) 
       
Lactobacillus 
38.2% 
(13/34) 
51.4% 
(18/35) 
 
Lactobacillus 
45.5% 
(15/33) 
61.5% 
(16/26) 
Gardnerella 
32.4% 
(11/34) 
22.9% 
(8/35) 
 
Gardnerella 
6.1% 
(2/33) 
15.4% 
(4/26) 
Diverse 
  
8.6% 
(3/35) 
 
Diverse 
6.1% 
(2/33) 
15.4% 
(4/26) 
Staphylococcus 
5.9% 
(2/34) 
2.9% 
(1/35) 
 
Staphylococcus  
6.1% 
(2/33)   
Streptococcus 
5.9% 
(2/34)   
 
Streptococcus 
6.1% 
(2/33)   
Enterobacteriaceae 
2.9% 
(1/34) 
2.9% 
(1/35) 
 
Enterobacteriaceae 
6.1% 
(2/33) 
3.9% 
(1/26) 
Candida 
5.9% 
(2/34) 
2.9% 
(1/35) 
 
Enterococcus 
6.1% 
(2/33)  
Corynebacterium 
2.9% 
(1/34)   
 
Candida 
3.0% 
(1/33)   
Actinobaculum 
2.9% 
(1/34)   
 
Alloscardovia 
3.0% 
(1/33)   
Aerococcus 
2.9% 
(1/34)   
 
Micrococcus 
3.0% 
(1/33)   
Bacilliales 
 
2.9% 
(1/35) 
 
Strep/Bifido 
6.1% 
(2/33)   
Ureaplasma 
  
2.9% 
(1/35) 
 
Unknown 
3.0% 
(1/33)   
       
Mean Age 30 yrs  Mean Age 52yrs 
Median Alapha Diversity 1.2  Median Alapha Diversity 2.1 
Median # of Isolates 1 [IQR:0-3]**  Median # of Isolates 1 [IQR:0-2]** 
*We use the term undetermined instead of “negative” to make the distinction that these urines are not sterile  
** p-value= 0.3827  
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APPENDIX J 
PRESENT BUT UNACCOUNTED FOR: 
THE UROPATHOGENS IN PRE-SURGICAL URINARY MICROBIOMES 
 
 
Thomas-White, K., Fok, C, Ghanayem, K., Mueller, E.R., Wolfe, A.J., and Brubaker, L. Pre-
Operative Urinary Microbiome Reveals Post-Operative Urinary Tract Infection Risk. Presented at 
ICS and AUGS annual meeting 2015. Received a Young Investigator Award from ICS and Best 
Clinical Paper Award from AUGS 2015 
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Overview of Appendix J 
 For the American Society for Urognycology (AUGS) and International Continence Society 
(ICS) meetings, if an abstract is accepted for an oral presentation the authors are required to 
submit the data in manuscript form. Therefore, I wrote this “placeholder paper” to accompany 
my abstract entitled, “Pre-Operative Urinary Microbiome Reveals Post-Operative Urinary Tract 
infection Risk”. The presentation for this abstract was awarded a Young Investigator Award at 
ICS and the placeholder paper was awarded Best Clinical Paper Award at AGUS.  
Patients for this study were recruited by Cynthia Fok prior to my joining LUEREC. Initial 
analysis of these patient samples were previously published in Fok et al. 2013 63. The initial 
study design recruited patients prior to surgery and collected catheterized urine, vaginal swabs, 
and perineal swabs on the day of surgery (DOS). The patients were then followed through 
surgery and assessed for adverse effects including, post-operative UTI. In this manuscript, I 
compared the results of 16S rDNA sequencing to standard culture results. All samples have 
currently been sequenced with help from Kathryn Ghanayem. Currently the data is going 
through an in-depth analysis by Qunfeng’s bioinformatics group. A complete manuscript is 
planned for late 2017.  
Abstract 
Objective. Women have a 1 in 5 risk of developing a post-operative urinary tract 
infection (UTI) following urogynecologic surgery, even with pre-operative screening and 
treatment. Patients with positive day of surgery (DOS) standard urine cultures (>1000 CFU/ml) 
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were about six times more likely to develop a post-operative UTI than patients with negative 
standard urine cultures. This study assessed whether a distinct pre-operative urinary 
microbiome is associated with post-operative UTI. 
Methods. This analysis used catheterized urine samples that were collected and 
cultured using the standard urine culture protocol in a prior study 63. For this analysis, we 
paired these urine samples with the vaginal and perineal swabs obtained from the same 
participant. Samples were sequenced using the V4 region of the 16S rRNA gene and classified 
using the mothur software package 167. The cohort was grouped first by standard DOS culture 
result, then by post-operative UTI development. Finally, for each patient, the urinary 
microbiome was compared to her vaginal and perineal microbiomes. 
Results. Of 303 patients, 25 had detectable bacteria in their DOS urine sample by 
standard culture. The standard culture results primarily detected uropathogenic taxa, e.g. 
Pseudomonas, Staphylococcus, and Enterobacteriaceae (which includes E. coli, Proteus, and 
Klebsiella); the sequencing data matched these DOS culture results. The urinary microbiomes of 
the 278 patients who were DOS culture-negative tended to be dominated by Lactobacillus, 
Gardnerella, or Corynebacterium or they were diverse. The UTI organism cultured post-
operatively was often detected in baseline DOS samples: in women with DOS culture-positive 
urines, it was generally detected in the urine; in women with DOS culture-negative urines, it 
was typically detected in the vaginal and perineal swabs.   
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Conclusion. Detectable differences in pathogenic taxa are present prior to surgery in 
most women who developed a post-operative UTI, suggesting that the causative organism may 
be present before the onset of surgery. Detection and treatment of this uropathogenic 
reservoir offers an opportunity to reduce the risk of post-operative UTI. 
Brief Summary. 16S rRNA sequence data of urinary, perineal and vaginal microbiomes 
suggest that a uropathogenic reservoir is associated with post-operative urinary tract 
infections. 
Introduction 
Hospital-acquired urinary tract infections (UTI) are an important clinical quality metric.  
Approximately 7-24% of urogynecology surgery patients develop a post-operative UTI 203 
despite prophylactic antibiotics and other preventive measures. The conceptual model for post-
operative UTIs is based on introduction of uropathogens into the bladder during surgical 
events, such as catheterization, cystoscopy and/or systemic antibiotics 321-324. This notion, 
however, is challenged by the recent discovery of bacteria in the female bladder 3-5,7,13,60 in the 
absence of vulvo-vaginal contamination 4. In addition, emerging evidence suggests that the 
bacterial cause of the UTI (i.e., the uropathogen) can be present in the bladder prior to surgery 
63. It is also possible that the uropathogen that that causes the post-operative infection is 
present prior to surgery in a separate niche (i.e., a niche-reservoir). 
Disruption of the urinary microbiome could occur in response to any number of events 
that happen during urogynecologic surgical intervention (e.g., physical disruption, antibiotic 
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use, or inflammation). Similar to microbial communities in other body sites, when a niche is 
disturbed, it could easily be re-colonized post-operatively with an infectious agent. A prime 
example is Clostridium difficile, which often flourishes in the gastrointestinal tract following 
antibiotic treatment 325.  
We previously reported that patients with positive day of surgery (DOS) urine cultures 
(>1,000 CFU/ml) were almost six times as likely to develop a post-operative UTI as patients with 
negative DOS standard urine cultures 63. Therefore, we hypothesized that patients who develop 
a post-operative UTI carry one or more uropathogens prior to surgery that increase that 
individual’s risk of a post-operative secondary infection. To test this hypothesis, we analyzed 
DOS samples by 16S rRNA gene sequencing, seeking to detect the subsequent UTI uropathogen 
in one or more of three potential reservoirs: the bladder, the vagina, and/or the perineum. 
Methods 
Study Design. 
Patient-participant recruitment and initial characterization was completed in a previous 
study 63, during which transurethral catheter urine, and standardized vaginal swabs and 
perineal swabs were collected from surgical patients immediately prior to initiation of POP/UI 
surgery. In this previous study 63, the urine samples taken on the DOS and those taken for 
diagnosis of post-operative UTI were analyzed by the standard culture protocol. In the current 
study, we sequenced all urine samples with at least 2 ml of urine remaining. Twenty-three of 
the original urine samples had insufficient volume and thus were not included in the current 
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analysis. In contrast, we were able to include 24 participants who had been excluded from the 
previous study due to incomplete symptom data, which are not required for this analysis. 
Based on standard urine culture results, we grouped the patients into two cohorts: DOS 
culture-positive or DOS culture-negative. Standard urine cultures were considered positive if 
they contained >1,000 CFU/ml of a known or emerging uropathogen. We subdivided the 
cohorts based on DOS culture results by post-operative UTI development, resulting in 4 groups: 
DOS culture-negative and UTI-negative (neg/neg), DOS culture-negative UTI-positive (neg/pos), 
DOS culture-positive UTI-positive (pos/pos), and DOS culture-positive UTI-negative (pos/neg). 
Following 16S rRNA gene sequencing of the urines and of both vaginal and perineal 
swabs, we compared the microbiomes of the three pelvic floor niches (i.e., bladder, vagina, and 
perineum) to the standard culture results obtained in the previous study. 
DNA Isolation from Urine. 
DNA isolation, PCR amplification, and 16S rRNA sequencing of urine cultures has been 
described previously 203. To avoid contamination, isolation of DNA was performed in a laminar 
flow hood. Genomic DNA was extracted from 1 ml of urine, or from 100ul of swab solution, 
using previously validated protocols developed for the Human Microbiome Project 7,166,203. To 
isolate genomic DNA from urine samples, this protocol includes the addition of the 
peptidoglycan degrading enzymes, mutanolysin and lysozyme, that ensure robust lysis of Gram-
positive and Gram-negative species 166. For consistency, all swabs were processed using the 
same protocol. Briefly, 1 ml of urine was centrifuged at 13,500 rpm for 10 min, and the 
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resulting pellet was resuspended in 200 µl of filter-sterilized buffer consisting of 20 mM Tris-Cl 
(pH 8), 2 mM EDTA, 1.2% Triton X-100, and 20 µg/ml lysozyme and supplemented with 30 µl of 
filter-sterilized mutanolysin (5,000 U/ml; Sigma-Aldrich, St. Louis, MO). The mixture was 
incubated for 1 h at 37°C, and the lysates were processed through the DNeasy blood and tissue 
kit (Qiagen, Valencia, CA), according to the manufacturer’s protocol. The DNA was eluted into 
50 µl of buffer AE, pH 8.0, and stored at -20° C. 
Variable region 4 (V4) of the bacterial 16S rRNA gene was amplified via a two-step 
polymerase chain reaction (PCR) protocol, as described previously 7,203. Briefly, in the first 
amplification, the V4 region was amplified using Illumina MiSeq modified universal primers 
515F and 806R. Extraction negative controls (no urine) and PCR negative controls (no template) 
were included to assess the contribution of extraneous DNA from reagents. Ten-microliter 
aliquots of each reaction mixture were run on a 1% agarose gel. Samples containing a band of 
approximately 360 bp were considered PCR-positive and subjected to further library 
preparation. Samples with no visible amplified product were considered PCR-negative and not 
processed further. The PCR positive reaction mixtures were diluted 1:50 and amplified for an 
additional 10 cycles, using primers encoding the required adapter sequences for Illumina MiSeq 
sequencing and an 8-nucleotide sample index. The PCR reaction was purified and size selected 
using Agencourt AMPure XP-PCR magnetic beads (Beckman Coulter, Pasadena, CA). Each 
sample was quantified using the Qubit flourometeric system (Thermo-Fisher). The samples 
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were pooled, quantified to a standard volume, and placed in the 2 X 250 bp sequencing reagent 
cartridge, according to the manufacturer’s instructions (Illumina, San Diego, CA).  
DNA Sequence Analysis   
The Illumina MiSeq post-sequencing software preprocessed sequences by removing 
primers and sample indices. The open-source program mothur (v1.31.2) combined the paired 
end reads and removed contigs (overlapping sequence data) of incorrect length (<285 bp, >300 
bp) and/or contigs containing ambiguous bases 167. We aligned the remaining modified 
sequences to the SILVA reference database, and discarded sequences if 50% or more of their 
nucleotides failed to align. Chimeric sequences were removed using UCHIME 169. The remaining 
sequences were taxonomically classified using a naïve Bayesian classifier and the RDP training 
set v9, and clustered into operational taxonomic units (OTUs) 195. METAGENassist was used to 
link OTU nomenclature to taxonomic assignments 170. 
Urine samples typically contain small amounts of bacteria (i.e., low biomass). Given our 
desire to confirm results with technical replicates, all urine samples were processed in duplicate 
and were classified as either sequence-positive or sequence-negative. A sequence-positive 
sample was one in which DNA was amplified from both replicas and, if present, the dominant 
taxon (representing >50% of sequences from the sample) was the same in both replicas. For 
each sequence-positive sample, a representative sequence profile was used for further analysis. 
A sequence-negative sample was one in which DNA was not amplified in either technical 
replica. To avoid accidentally sequencing rare contaminants, we conservatively considered 
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samples to be negative if DNA amplification was not visible on an agarose gel. Swab samples 
tend to be high biomass; therefore, very few were PCR-negative. As such, we only performed a 
replicate if the swab sample was PCR-negative to confirm the result.  
We considered samples with cultivatable bacteria at ≥1,000 CFU/ml as a high biomass 
population. Sequencing is sensitive but not quantitative; therefore, we considered urines to 
have a high abundance of an organism if the reads represented greater than 10% of the total 
sequences for a given sample. Sequences representing less than 10% were considered low 
abundance sequences within a sample. To display the sequence abundance for each sample, a 
histogram was produced and color-coded by bacterial taxa. Next, Bray-Curtis distance was 
calculated between samples and the complete method was used for hierarchical clustering 
using RStudio 196. The resulting dendrogram was divided into clusters, which were termed 
sequence urotypes, and named by the dominant taxa present or as ‘diverse’ if no single taxon 
was dominant. Sequence-negative samples were given the designation ‘undetermined’ urotype. 
Results 
Most (91.7%, 278/303) of the 303 patients with complete, qualifying sample sets had 
negative DOS urine cultures; only 3.7% (10/278) developed post-operative UTI. However, of the 
25 individuals with DOS culture positive urines, 32% (8/25) developed post-operative UTI. 
Therefore, the risk of post-operative UTI is significantly greater in the DOS culture-positive 
population (32% vs 3.7% p≤0.001). 
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Table J.1. Comparison between DOS culture-positive and -negative, UTI-positive and -
negative for sequence urotypes. The population was divided into those that had a positive 
standard culture at DOS and those that did not. Within each group, the risk of developing a 
post-operative UTI was calculated. Each sample was classified by the dominant organism (i.e., 
Urotype) or classified as diverse if no one organism dominated. 
 Day of Surgery 
Culture Negative 
Day of Surgery 
Culture Positive 
 
 UTI 
Negative 
UTI 
Positive 
UTI 
Negative 
UTI 
Positive 
P-value 
Frequency of UTIs  
3.7% 
(10/278) 
 
32% 
(8/25) 
<0.001 
Undetermineda 
60.8% 
(163/268) 
80% 
(8/10) 
5.8%  
(1/17) 
0% 
(0/8) 
<0.001 
Sequenced 
39.2% 
(105/268) 
20% 
(2/10) 
94.1% 
(16/17) 
100% 
(8/8) 
 
Enterobacteriaceae b 
2.9% 
(3/105) 
 
37.5% 
(6/16) 
12.5% 
(1/8) 
<0.001 
Pseudomonas   
31.3% 
(5/16) 
37.5% 
(3/8) 
<0.001 
Staphylococcus 
1% 
(1/105) 
 
12.5% 
(2/16) 
25% 
(2/8) 
<0.001 
Diverse 
19% 
(20/105) 
 
12.5% 
(3/16) 
12.5% 
(1/8) 
0.24 
Lactobacillus 
56.2% 
(59/105) 
100% 
(2/2) 
6.3% 
(1/16) 
12.5% 
(1/8) 
0.11 
Gardnerella 
12.4% 
(13/105) 
   1.0 
Corynebacterium 
6.7% 
(7/105) 
   1.0 
Actinobaculum 
1% 
(1/105) 
   1.0 
Aerococcus 
1% 
(1/105) 
   1.0 
Streptococcus 
1% 
(1/105) 
   1.0 
aWe use the term “undetermined” instead of “negative” to make it clear that these urines might not be sterile. 
“Undetermined” samples are below the level of detection by the current methods.  
b This family contains Escherichia, Klebsiella and Proteus. The V4 region of the 16S rRNA gene does not have 
enough information to classify the family Entrobacteriaceae into its respective genera. Averages are means and P-
values were calculated using Fischer’s exact test.  
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Table J.1 displays the results within the 4 subgroups: DOS culture-negative and UTI-
negative (Figure J.1A), DOS culture-negative UTI-positive (Figure J.1B), DOS culture-positive 
UTI-positive (Figure J.1C), and DOS culture-positive UTI-negative (Figure J.1D). The proportion 
of urines with an undetermined urotype (i.e., sequence-negative) differed significantly by group 
(p≤0.001). There were few undetermined urotypes in the DOS culture-positive groups; we 
reproducibly sequenced 94.1% (16/17) and 100% (8/8) of the baseline DOS culture-positive 
urine samples from the UTI-negative and UTI–positive groups, respectively. In contrast, many of 
the DOS culture-negative group had undetermined urotypes; we reproducibly sequenced only 
39.2% (105/268) and 20% (2/10) of the DOS culture-negative urines for the UTI-negative and 
UTI-positive groups, respectively. We infer that the culture-positive urine samples possess more 
bacterial biomass than do the culture-negative samples. 
Characterization of the Urinary Reservoir. 
The frequency, or distribution, of organisms differed between the 4 groups. The DOS 
culture-negative women who did not develop a post-operative UTI (Table J.1, Figure J.1A) were 
more likely to have urinary microbiomes dominated by the following urotypes: Lactobacillus 
(56.2%, 59/105, blue), Gardnerella (12.4%, 13/105, red), Corynebacterium (6.7%, 7/105, 
orange), or Diverse (no dominant organism) (19%, 20/105, multi-colored). DOS culture-negative 
women who developed a post-operative UTI (3.7%) tended to have bacterial DNA below the 
threshold for sequencing, i.e., undetermined urotype (80%, 8/10, Table J.1). The remainder of 
the culture-negative women (20%, 2/10) each had a Lactobacillus urotype. In contrast, DOS  
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culture-positive urines were significantly more dominated by uropathogenic species, e.g. 
Pseudomonas (green, p≤0.001), Staphylococcus (light blue, p≤0.001) and Enterobacteriaceae (in 
yellow, including E. coli, Proteus, and Klebsiella, p≤0.001) (Table J.1 and Figure J.1 C-D). 
Although the DOS culture-positive group that developed a UTI had a urotype profile similar to 
those that did not develop a UTI (Table J.1, Figure J.1D), the microbiome of the former group 
tended to be more diverse. Most urine samples in this group contained both a uropathogen 
and another organism (e.g Staphylococcus with Actinobaculum, Pseudomonas with 
Lactobacillus, Enterobacteriaceae with Bifidobacterium). 
Figure J.1. Urine sequencing profiles by day-of-surgery (DOS) culture and post-operative 
UTI results. The relative abundance (or total classified sequences per individual) is 
represented as a color-coded bar for each individual, where each color represents a family or 
genus classified by sequencing. The cohort is divided into 4 groups: DOS culture negative UTI 
negative (A), DOS culture negative UTI positive (B), DOS culture positive UTI negative (C), 
DOS culture positive UTI positive (D). 
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Characterization of the Vaginal and Perineal Microbiomes. 
For each participant, we compared the urinary microbiome to the vaginal and perineal 
microbiomes, using the percent of total sequences, where greater than 10% of sequences was 
considered high abundance, and between 10% and 0.01% was considered low abundance 
(Figure J.2A-C). Most DOS culture-positive samples (76.9% (20/26), Table J.3) contained a high 
abundance of sequences belonging to the family or genus identified by standard culture,  
Figure J.2. Day of Surgery urines, vaginal swabs and perineal swabs. The relative abundance 
(or total classified sequences per individual) is represented as a color-coded bar for each 
individual, where each color represents a family or genus classified by sequencing. Each 
group of sample represents one patient with their urine, vaginal and perineal microbiomes 
for each. Black bars indicated a low biomass sample that did not amplify beyond background 
levels (i.e., PCR negative or undetermined urotype). 
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indicating that sequencing tended to match the culture results. For the DOS culture-positive 
group that developed a post-operative UTI, the family or genus of the bacterium identified by 
standard culture was often detected by sequencing in the urine at high abundance (50.0%, 4/8). 
When the bacterium was not detected or present at low abundance in the urine, it was present 
in the vagina and perineum at high abundance (12.5%, 1/8) or at low abundance (37.5%, 3/8). 
Thus, the organism of interest was found in one of the three niches in all patients (Table J.2 and 
Table J.3). 
Table J.2. Percent of sequence detection of cultured organism in each of three pelvic floor 
microbiomes. The genus of the culture organism was compared to the percent of sequences detected 
for that genus or family in each of the three locations (urine, vagina, and perineum). Samples with large 
numbers of reads are in red, and samples with lower numbers of read are in green. The three groups 
with culture information are shown: (A) DOS culture-positive, UTI-positive, (B) DOS culture-positive, UTI-
negative, (C) DOS culture-negative, UTI-positive.  
Group DOS Culture 
Results 
DOS - 
Urine 
DOS - 
Vag 
DOS - 
Per 
UTI Culture 
results 
DOS - 
Urine 
DOS - 
Vag 
DOS - 
Per 
A. 
Pos/ 
Pos 
GUM_223: 
Clost 
0 0 
 
GUM_223: 
Enterobact 
0 0.07% 
 
GUM_225: 
Strept 
0 0 0.4 
GUM_225: 
Pseudo 
39.30% 0.03% 0 
GUM_263: 
Enterobact 
88.70
% 
13.90
% 
13.60
% 
GUM_263: 
Enterobact 
88.70% 13.90% 13.60% 
GUM_267: 
Staphy 
35% 0.60% 2.50% 
GUM_267: 
Enterobact 
0.08% 0.30% 0.30% 
GUM_271: 
Staphy 
91% 0.10% 0.10% 
GUM_271: 
Enterobact 
0 0.01% 0.15% 
GUM_273: 
Pseudo 
97% 0 0.01% 
GUM_273: 
Lacto 
1.60% 83.50% 75.90% 
GUM_309: 
Enterobact 
99.10
% 
0.17% 0.11% 
GUM_309: 
Enterobact 
99.10% 0.17% 0.11% 
GUM_314: 
Pseudo 
89.90
% 
0.06% 0.04% 
GUM_314: 
Pseudo 
89.90% 0.06% 0.04% 
a sequences were in high abundance if present at >10% of total sequences.   
b sequences were considered low abundance if present between 10% and 0.01% 
cN/A indicates samples that were undetermined, or had a biomass below our level of detection 
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Table J.2. Continued 
 DOS Culture Results DOS - Urine DOS - Vag DOS - Per 
B. Pos/ 
Neg 
GUM_062: 
Enterobacteriaceae 
N/A 0 N/A 
GUM_097: 
Staphylcoccus 
99.60% 
 
0.16% 
GUM_104: 
Enterobacteriaceae 
99.80% 0.30% 0.70% 
GUM_147: 
Enterobacteriaceae 
99.90% 
 
84.40% 
GUM_164: 
Staphylococcus 
98.70% 0.02% 0.02% 
GUM_179: 
Pseudomonas 
49.30% 0 N/A 
GUM_212: 
Pseudomonas 
82.60% 0 0 
GUM_213: 
Enterobacteriaceae 
98.20% 0.04% 0.39% 
GUM_237: 
Enterobacteriaceae 
99.70% 0.82% 1.80% 
GUM_255: 
Enterobacteriaceae 
90.90% 0.60% 0.16% 
GUM_261: 
Enterobacteriaceae  
0.07% 0.04% 
GUM_265: 
Pseudomonas 
96.40% 0.05% 0 
GUM_268: Bacilli 0 0 0 
GUM_284: 
Pseudomonas 
95.30% 0.02% 0.02% 
GUM_285: 
Pseudomonas 
94.60% 0.01% 0 
GUM_327: 
Enterococcus 
0 0 0 
GUM_330: 
Streptococcus 
16.30% 0.01% 0.30% 
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Table J.2. Continued 
 UTI Culture results DOS - Urine DOS - Vag DOS - Per 
C.Neg/ 
Pos 
GUM_027: 
Enterococcus 
N/A 0 0 
GUM_038: 
Enterococcus 
N/A 0 0.04% 
GUM_125: 
Enterococcus 
N/A 0 0.11% 
GUM_153: 
Enterobacteriaceae 
N/A 0 0.73% 
GUM_226: 
Corynebacterium 
12.40% 17.30% 40.90% 
GUM_235: 
Streptococcus 
4.90% 32.40% 2.30% 
GUM_274: 
Lactobacillus 
N/A 90% 3.70% 
GUM_298: 
Peptoniphilus 
N/A 0.11% 0.34% 
GUM_315: 
Enterobacteriaceae 
N/A 
 
0.44% 
GUM_320: 
Enterobactiaceae 
N/A 0.01% 0.94% 
a sequences were in high abundance if present at >10% of total sequences.   
b sequences were considered low abundance if present between 10% and 0.01% 
cN/A indicates samples that were undetermined, or had a biomass below our level of detection 
 
While a similar pattern was observed for the DOS culture-negative population, the 
organism of interest was detected in the perineum in 80% (8/10) of patients, albeit often in 
very low abundance (with one exception <4%, Table J.2C). Thus, the contribution from the 
perineum and vaginal microbiomes was much more striking due to the low bacterial biomass, 
and therefore lack of sequencing result, in the bladder (Table J.2C, green vs red and yellow).  
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Table J.3. Cumulative sequence detection results by pelvic floor niche.  The percent of high 
and low abundance sequence detection of the culture organisms is listed cumulatively for all 
three UTI groups show in Table J.2. 
 
Percent of Sees that 
match culture 
DOS - 
Urine 
DOS - 
Vag 
DOS - 
Per 
UTI Culture 
results 
DOS - 
Urine 
DOS - 
Vag 
DOS - 
Per 
At high abundance a 76.9% 
(20/26) 
3.8% 
(1/26) 
7.7% 
(2/26)  
33.3% 
(6/18) 
22.2% 
(5/18) 
22.2% 
(4/18) 
At low abundance b 0% 
(0/26) 
53.8% 
(14/26) 
57.7% 
(15/26)  
16.7% 
(3/18) 
38.9% 
(7/18) 
66.7% 
(12/18) 
 
 
Discussion 
Our data suggest that most post-operative UTIs are related to uropathogens that are 
either present in the bladder or in the adjacent pelvic niches of the vagina or perineum prior to 
surgery. Our prior analysis 63 demonstrated that a pre-surgical DOS standard urine culture 
effectively identifies a group of urogynecologic patients at increased short-term risk for UTI. 
The current analysis extends those findings to document the detectable pre-surgical presence 
of the likely post-operative UTI-associated uropathogen.  
Currently, urine cultures at the onset of urogynecologic surgery are not widely included 
as a standard of care practice. Moreover, the adjacent pelvic microbial niches in the vaginal or 
perineal swabs are not routinely assessed prior to surgery. While clinicians could increase pre-
operative (or DOS) urine culture assessment to screen for women at increased UTI risk, 
standard urine culture results typically do not become available to the clinician until 24-48 hour 
following initial plating. Development of rapid culture-independent diagnostics, involving 
sequencing or PCR of known or suspected uropathogens, could expedite identification of 
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individuals at increased risk for post-operative UTI, allowing targeted studies of risk-reducing 
interventions. 
Clinicians will incorporate the emerging evidence that demonstrates that bacterial DNA 
exists in the bladders of healthy women 4,7,13,60,93,203,204 and women with lower urinary tract 
symptoms (LUTS) 7,60,203,326,327, including patients undergoing urogynecologic surgery 4,93. 
Results from the current study require clinicians to consider modified clinical algorithms that 
complement urinary results with information about pelvic niches whose microbiomes may 
interact with those of the bladder.  
Similar to other human microbial niches, it is inappropriate to attempt suppression of all 
microorganisms with antibiotic use. Clinicians will need additional information in order to 
judiciously prescribe antibiotics to effectively prevent clinical infection and/or associated 
morbidity, especially in women with an increased risk of post-operative UTI. 
 This analysis demonstrates that valuable information can be made available through the 
use of culture-independent methods to describe pelvic floor specimens obtained on the DOS. 
Not surprisingly, in women with positive DOS urine cultures, sequencing almost always 
detected the genus or family of the previously cultured bacterial species in their DOS urine. In 
this urine sample, sequencing often detected the genus or family of the suspected post-
operative UTI-associated uropathogen, verifying that uropathogens could be present in the 
bladder on the DOS. When sequencing did not detect the suspected post-operative UTI-
associated uropathogen in DOS urine, it detected it in one or more of the two adjacent pelvic 
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floor niches albeit at lower abundance. In contrast, women whose DOS urine culture was 
negative and developed a post-operative UTI typically had an undetermined (low bacterial 
biomass) urinary microbiome. However, in these women, sequencing typically detected the 
suspected UTI-associated uropathogen in at least one adjacent microbiome, most often the 
perineum. The observation that potential uropathogenic organisms can be present in the 
bladder, vagina and/or perineum of urogynecological surgery patients prior to surgery suggests 
the involvement of a uropathogenic reservoir, a microbial niche that allows for a secondary 
post-operative infection.  
We were intrigued to detect potential uropathogens in a subgroup of women with DOS 
urine samples who did not develop a UTI. This may be related to a variety of biologic scenarios: 
(1) her immune system could resist infection, (2) the standard surgical prophylaxis effectively 
eradicated the organism and/or (3) the bacterium detected by standard culture was a non-
pathogenic strain of a known uropathogenic species.  
The larger group of DOS culture-negative women who did not develop a UTI tended to 
have detectable urinary microbiomes that resemble those of other cohorts of women without 
UTI 3,7. These microbiomes could contain ‘good’ bacteria that protect against post-operative 
UTIs. A similar concept has been proposed for protection against post-instrumentation UTIs 5.   
The concept of cross-inoculation and microbial sharing is not surprising in the pelvis, 
where activities include urinary tract instrumentation, routine hygienic events such as wiping, 
and/or sexual activities. This concept must be revisited to include the resident bacterial 
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community of the bladder in order to understand the interaction between the different pelvic 
floor microbiomes and their contribution to health and disease.  
A limitation of this study is the use of the standard urine culture protocol, which has a 
high false negative rate; enhanced culture protocols that more effectively identify urinary 
bacteria are now available 7,14. In addition, 16S rRNA sequencing has limitations (e.g., 
classification depth and detection threshold for low biomass samples); however, sequencing 
did generally detect the bacterium identified by standard culture, as well as numerous other 
bacteria that standard culture cannot detect.  
Future studies that test UTI risk-reduction strategies will require intervention beyond 
reliance on a standard peri-operative antibiotic administration. Patients and clinicians will 
mutually benefit from a reduction in potentially preventable post-operative UTIs in 
urogynecologic patients. 
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APPENDIX K 
A NEW SPECIES OF GARDNERELLA: G. URINALIS 
 
 
Thomas-White, K., Putonti, C., Nitin, K., Forster, S., Lawley, T., and Wolfe, A.J.,   
(In preparation) 
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Overview of Appendix K 
 Bacterial vaginosis (BV) is defined as a dysbiosis of the vaginal flora that leads to 
irritation of the vaginal tract and can lead to an increase risk of preterm birth, and sexually 
transmitted infections 271,328. The cause of BV is unknown, but many suspect Gardnerella 
vaginalis to either be the cause or at least a biomarker of this dysbiosis, however on G. 
vaginalis pathogenicity are inconclusive 302. Many women, particularly of African American or 
Hispanic descent, will have low levels vaginal Lactobacillus and a more mixed community 
dominated by Gardnrella 15.  
Until recently the 16S gene was considered the gold standard for speciation, but it is not 
perfect. Although uncommon, the 16S gene can be horizontally transferred (HRT) 329. If HRT is 
suspected, there are other means to speciate (e.g. comparing the 40 marker genes and Average 
Nucleotide Identity(ANI)), particularly if the full genome is sequenced 330.  
G. vaginalis is the only known species of this genus and it has been shown to have a high 
rate of horizontal gene transfer (HGT) 105. Additionally, the genomes that have been sequenced 
to date show a large variation in the number and type of genes (pan genome) between isolates 
with similar 16S regions (Appendix G)105,275,280. Culture urine isolates have identified two 
separate morphologies of Gardnerella, identified as G. vaginalis and “Gardnerella species” by 
MALDI-TOF mass spec. In studies of women with over active bladder (OAB), G. vaginalis is 
associated with symptoms of UUI and Gardnrella species is associated with controls 
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(unpublished data). We propose that two separate species of Gardnerella exist, G. vaginalis and 
the newly identified G. urinalis.  
Results 
Figure K.1 shows the preliminary comparison of 13 Gardnerella strains isolated from 
catheterized urine from women with OAB, continence controls (“C”), and two isolates from 
pregnant women (MUM). All strains were identified by MALDI-TOF mass spec as either G. 
vaginalis or G. species. From this point forward, I will refer to G. species as G. urinalis.  
As expected, the 16S gene shows high amount of similarity between all strains. There do 
seem to be two clades of Gardnerella but the difference is not sufficient to identify different 
species (Figure K.1A). The differences between clades becomes much more apparent when we 
analyze the 40 marker genes which clearly shows two distinct clades, one for each species 
(Figure K.1B). There is one exception, MUM02, which contained two strains of Gardnrella and 
both cladded in the G. urinalis side of the tree. ANI comparison shows that the G. vaginalis 
clade is 88% different from the G. urinalis clade (Figure K.1C). A difference of 90-95% is usually 
sufficient to differentiate between species, 88% might even indicate a new genera. Within the 
G. urinalis clade, there seems to be two subclades that are 93% similar to each other. This 
suggests the possibility of two separate species within the G. urinalis clade.  
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A. 16S gene 
Figure K.1. Genomic analysis of 13 Gardnerella strains. (A) A maximum likelihood tree of 
16S genes from Gardnerella strains and reference strains.(B) A maximum likelihood tree 
of 40 marker genes 
B. 40 marker genes 
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Discussion 
 The data presented here is preliminary. An additional 12 isolates have been sequenced 
and will be added to this dataset. It is possible that I will have those genomes analyzed and 
Figure K.1. Continued 
C.            
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figures ready by the time I submit my thesis. If not, I do think that these data are compelling 
enough to claim that there are at least two distinct species of Gardnerella.  
 If these results are verified, it would provide an explanation as to why Gardnerella has 
never been proven to be a causative factor for BV. We hypothesize that G. urinalis is a 
commensal, as it is normally associated with continent controls. While G. vaginalis may be 
pathogenic or an opportunistic pathogen. Delineation of these two species may help future 
research into etiology and treatment of BV.  Additionally, the genomes sequenced here will be 
publicly available and will provide important references for future research.  
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APPENDIX L 
MOTILITY OF URINARY ISOLATES 
 
Montelongo-Hernandez, C., Zemaitaitis, B, Christiensen, D, and Thomas-White, K. 
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Overview of Appendix L 
At least one strain from each species isolated from the bladder was tested for motility. 
Each isolate was grown on Tryptic Soy Agar, Brain Heart Infusion (BHI) Agar, or MRS agar, tested 
on a range of agar concentrations (1%, 0.85%, 0.55%, and 0.4%). The majority of isolates were 
non-motile (Table K.1). The only organisms that were motile were known uropathogens 
(Bacillus, Enterobacter, Escherichia, Klebsiella, and Proteus, Table K.1). This deomonstrates that 
the commensal bacteria do not seem to have motility when tested in vitro.  
  
- 383 - 
 
 
 
Table L.1. Results of Motility Tests 
Motility Genus # 
Species 
tested 
Motility Genus # 
Species 
tested 
All Non-
Motile 
Actinobaculum 1 
All 
Motile 
Bacillus 4 
Actinomyces 7 Enterobacter 4 
Aerococcus 2 Escherichia 1 
Alloscardovia 1 Klebsiella 1 
Arthrobacter 1 Proteus 1 
Bifidobacterium 2    
Brevibacterium 1 
No 
Growth 
Anaerococcus 2 
Campylobacter 1 Fingoldia 1 
Corynebacterium 14 Fusobacterium 1 
Enterococcus 1 Prevotella 2 
Facklamia 1 Propionibacterium 1 
Gamella 5 Slackia 1 
Gardnerella 1    
Globicatella 1    
Kocuria 1    
Lactobacillus 7    
Micrococcus 1    
Neisseria 3    
Oligella 1    
Pasteurella 1    
Peptinophilus 1    
Propionobacterium 2    
Pseudomonas 1    
Rothia 1    
Streptococcus 15    
Staphylococcus 8    
Trueperella 1    
Veilonella 1    
Weeksella 1    
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APPENDIX M 
SCRIPTS 
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Versions of these scripts can be found in the Wolfe lab share drive at: N:\Krystal\scripts 
1. Calculating percent of total for relative abundance graphs, and create Dendrograms 
#R script to run PCA from a count table 
#This example uses an input from the UITN dataset. Input is located in the Wolfe Share 
drive at: N:\LUREC\UITN\2015_Analysis\PCoA_Plots\Rep1_Phylum\ Rep1-
2000UITN_all_Phylum_Metadata.csv 
#load the packages required 
library(vegan) 
library(gplots) 
 
#Read in your count table 
Rep1_Family <- read.csv("Rep1-2000UITN_all.summary.family.csv") 
 
#Give the dimensions of the table for your reference 
dim(Rep1_Family) 
#Remove and save row names 
row.names(Rep1_Family) <- Rep1_Family$Sam_ID 
Rep1_Family <- Rep1_Family[, -1] 
#Convert to percentages 
Rep1Family.prop <- Rep1_Family/2000 #The sequences were sub-sampled to 2000 
#Print the percentages to a csv 
write.csv(Rep1Family.prop, file = "Rep1_Family_Percent", quote = FALSE) 
 
#Create Dendrogram 
Rep1Family.dist <- vegdist(Rep1Family.prop, method = "bray") 
# Chose average/complete/or single linkage hierarchical clustering.  
Rep1Family_row.clus <- hclust(Rep1Family.dist, "complete") 
 
#To change the size of the writing  
par(ps = 2)  #Size 2 font is small enough to see the sample names of each sample in a 300 
sample set.  
#Plot the dendrogram with the ends of the branches in alignment 
plot(Rep1Family_row.clus, hang = -1) 
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2. Calculate Diversity measurements from a count table216 
#R script to run PCA from a count table 
#This example uses an input from the UITN dataset. Input is located in the Wolfe Share 
drive at: N:\LUREC\EST_Effect of Estrogen_KTW_ST\Data\Previous Analysis\EQUC Diversity 
in R 
#load packages 
library(vegan) 
#set the file you want to work in: 
setwd("N:/LUREC/EST_Effect of Estrogen_KTW_ST/Data/Previous Analysis/EQUC Diversity 
in R") 
 
#Read your Count table in 
EST1_20_gen <- read.csv("EST_Genus_samples1-20_1-9.csv") 
#give the dimensions of the table for your reference 
dim(EST1_20_gen)  
 
# Remove and save row names  
row.names(EST1_20_gen) <- EST1_20_gen$Sam_ID 
EST1_20_gen <- EST1_20_gen[, -1] 
dim(EST1_20_gen)  
 
#Calculate diversity measurements: 
H <- diversity(EST1_20_gen) #Shannon Index (richness and evenness) 
simp <- diversity(EST1_20_gen, "simpson") #Simpson index 
invsimp <- diversity(EST1_20_gen, "inv") #Inverse simpson index (richness and evenness) 
alpha <- fisher.alpha(EST1_20_gen) 
pairs(cbind(H, simp, invsimp, alpha), pch="+", col="blue") 
 
## Species richness (S) and Pielou's evenness (J): 
S <- specnumber(EST1_20_gen) ## Sum of all the species in that sample (richness only) 
J <- H/log(S) ## Peilou (evenness only) 
 
#Print out all calculations as new columns on your dataframe 
EST_div <- cbind(H, simp, invsimp, S, J, alpha) 
 
write.csv(EST_div, file="EST_genus_1-20_DivOnly.csv", row.names=TRUE) 
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3. PCA – this script was modified from an online tutorial: Computing and visualizing PCA in 
R331. 
#R script to run PCA from a count table 
#This example uses an input from the UITN dataset. Input is located in the Wolfe Share 
drive at: N:\LUREC\UITN\2015_Analysis\PCoA_Plots\Rep1_Phylum\ Rep1-
2000UITN_all_Phylum_Metadata.csv 
 
#load packages 
library(stats) 
library(ggbiplot) 
library(rgl) 
# Read in your count table 
R1P <- read.csv("Rep1-2000UITN_all_Phylum_with_metadata.csv", header = T) 
head(R1P, 3) 
#Remove and save row names 
row.names(R1P) <- R1P$Sam_ID 
R1P <- R1P[, -1] 
dim(R1P) 
#Which columns contain PCA data (versus any with metadata) 
R1P <- R1P[, 1:23] 
R1P_pca <- prcomp(R1P, 
                 center = TRUE, 
                 scale = TRUE) 
summary(R1P_pca) 
#Save the PCA lines plot as pdf 
pdf("R1P_lines.pdf") 
plot(R1P_pca, type = "lines") 
dev.off() 
#Save the PCA output as a csv file 
 
R1P_pca <- R1P_pca$x[,1:23] 
write.csv(R1P_pca, file="R1P_pca.csv", quote=FALSE) 
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APPENDIX N 
LISTS OF ISOLATES USE IN THE NICHE COMPARISON STUDIES 
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Table N.1. A List of the Vaginal Isolates Used in Chapter III. These vaginal genomes are all 
publicly available, the majority of which were collected by the HMP 11. Vaginal genomes were 
only included if the metadata specifically stated that the isolate had been collected from the 
vagina (“urogenital” isolates were excluded) 
Species Strain Assembly Accession 
Actinomyces_neuii MJR8396A GCA_001546135.1 
Actinomyces_sp S4-C9 GCA_000758775.1 
Actinomyces_sp S6-Spd3 GCA_000758755.1 
Actinomyces_urogenitalis S6-C4 GCA_000758745.1 
Aerococcus_christensenii KA00635 GCA_001552755.1 
Aerococcus_viridans ATCC11563 GCA_000178435.1 
Alloscardovia_omnicolens CMW7705A GCA_001546145.1 
Anaerococcus_hydrogenalis MJR7738A GCA_001546155.1 
Anaerococcus_lactolyticus S7-1-13 GCA_000758765.1 
Anaerococcus_tetradius MJR8151 GCA_001546165.1 
Arcanobacterium_sp S3PF19 GCA_000758825.1 
Atopobium_deltae DNF00019 GCA_001552785.1 
Atopobium_parvulum DNF00906 GCA_000758945.1 
Atopobium_vaginae DSM15829 GCA_000159235.2 
Bacillus_coagulans GED7749B GCA_001546215.1 
Bacteroidales_bacterium KA00251 GCA_001552775.1 
Bacteroidales_bacterium KA00344 GCA_001552765.1 
Bifidobacterium_bifidum MJR8628B GCA_001546225.1 
Bifidobacterium_breve ACS-071-V-Sch8b GCA_000213865.1 
Bifidobacterium_breve GED8481 GCA_001546235.1 
Bifidobacterium_breve JCP7499 GCA_000466545.1 
Bifidobacterium_dentium ATCC27679 GCA_000146775.1 
Citrobacter_freundii GED7749C GCA_001546285.1 
Citrobacter_koseri GED7778C GCA_001546305.1 
Clostridiales_bacterium KA00274 GCA_001552885.1 
Clostridiales_bacterium S5-A14a GCA_000758905.1 
Clostridium_perfringens MJR7757A GCA_001546355.1 
Coriobacteriales_bacterium DNF00809 GCA_001552935.1 
Corynebacterium_freneyi DNF00450 GCA_000758965.1 
Corynebacterium_kroppenstedtii DNF00591 GCA_001552955.1 
Corynebacterium_sp DNF00584 GCA_001552965.1 
Corynebacterium_tuscaniense DNF00037 GCA_000759055.1 
Dialister_micraerophilus DSM19965 GCA_000194985.1 
Enterococcus_faecium MJR8396B GCF_001546375.1 
Finegoldia_magna ATCC53516 GCA_000159695.1 
Fusobacterium_equinum CMW8396 GCA_001546395.1 
Fusobacterium_nucleatum MJR7757B GCA_001546435.1 
Fusobacterium_nucleatum Subsp-nucleatum_ATCC23726 GCA_000178895.1 
Gardnerella_vaginalis 409-05 GCA_000025205.1 
Gardnerella_vaginalis ATCC14019 GCA_000159155.2 
Gardnerella_vaginalis GED7275B GCA_001546445.1 
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Gardnerella_vaginalis GED7760B GCA_001546455.1 
Gemella_asaccharolytica KA00071 GCA_001553005.1 
Gemella_haemolysans DNF01167 GCA_001553035.1 
Lachnoanaerobaculum_saburreum DNF00896 GCA_001552975.1 
Lactobacillus_gasseri SV-16A-US GCA_000177035.2 
Lactobacillus_iners DSM_13335 GCA_000160875.1 
Lactobacillus_crispatus 125-2-CHN GCA_000162255.1 
Lactobacillus_crispatus 214-1 GCA_000177575.1 
Lactobacillus_crispatus CTV-05 GCA_000165885.1 
Lactobacillus_crispatus FB049-03 GCA_000301115.1 
Lactobacillus_crispatus FB077-07 GCA_000301135.1 
Lactobacillus_crispatus JV-V01 GCA_000160515.1 
Lactobacillus_crispatus MV-1A-US GCA_000161915.2 
Lactobacillus_crispatus SJ-3C-US GCA_000176975.2 
Lactobacillus_crispatus vmc3 GCA_001541385.1 
Lactobacillus_crispatus vmc4 GCA_001541405.1 
Lactobacillus_crispatus vmc5 GCA_001541515.1 
Lactobacillus_crispatus vmc6 GCA_001541505.1 
Lactobacillus_crispatus vmc7 GCA_001541535.1 
Lactobacillus_crispatus vmc8 GCA_001541585.1 
Lactobacillus_gasseri 2016 GCA_000439915.1 
Lactobacillus_gasseri 202-4 GCA_000175055.1 
Lactobacillus_gasseri 224-1 GCA_000177415.1 
Lactobacillus_gasseri JV-V03 GCA_000143645.1 
Lactobacillus_gasseri MV-22 GCA_000155935.2 
Lactobacillus_gasseri SJ-9E-US GCA_000176995.2 
Lactobacillus_iners ATCC55195 GCA_000185405.1 
Lactobacillus_iners LEAF_2052A-d GCA_000179955.1 
Lactobacillus_iners LEAF_2032A-d GCA_000179935.1 
Lactobacillus_iners SPIN_2503V10-d GCA_000149145.2 
Lactobacillus_jensenii 115-3-CHN GCA_000162435.1 
Lactobacillus_jensenii JV-V16 GCA_000159335.1 
Lactobacillus_jensenii SJ-7A-US GCA_000162335.1 
Lactobacillus_oris PB013-T2-3 GCA_000180015.1 
Lactobacillus_rhamnosus 51B GCA_000699985.1 
Lactobacillus_salivarius ACS-116-V-Col5a GCA_000179475.1 
Lactobacillus_vaginalis ATCC49540 GCA_000159435.1 
Leptotrichia_wadei KA00185 GCA_001553045.1 
Mageeibacillus_indolicus 0009-5_S7-24-11 GCA_000733145.1 
Megasphaera_sp MJR8396C GCA_001546855.1 
Mobiluncus_curtisii ATCC43063 GCA_000196535.1 
Mobiluncus_curtisii ATCC51333 GCA_000185425.1 
Mobiluncus_curtisii Subsp_curtisii_ATCC35241 GCA_000146285.1 
Mobiluncus_curtisii Subsp_holmesii_ATCC35242 GCA_000185445.1 
Mobiluncus_mulieris ATCC35239 GCA_000146895.1 
Mycobacterium_parascrofulaceum BAA614 GCA_000164135.1 
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Oligella_urethralis DNF00040 GCA_000759065.1 
Olsenella_sp DNF00959 GCA_001553055.1 
Parvimonas_sp KA00067 GCA_001553085.1 
Peptoniphilus_coxii DNF00729 GCA_001553115.1 
Peptoniphilus_duerdenii BAA-1640 GCA_000146345.1 
Peptoniphilus_harei CMW7756A GCA_001546555.1 
Peptoniphilus_lacrimalis DNF00528 GCA_000759145.1 
Peptoniphilus_sp DNF00840 GCA_001553125.1 
Peptostreptococcus_anaerobius KA00810 GCA_001553145.1 
Peptostreptococcus_sp MV1 GCA_000758885.1 
Porphyromonadaceae_bacterium KA00676 GCA_001553165.1 
Prevotella_amnii DNF00058 GCA_000759315.1 
Prevotella_amnii DNF00307 GCA_001553225.1 
Prevotella_bivia DNF00188 GCA_000759045.1 
Prevotella_bivia DNF00320 GCA_000759245.1 
Prevotella_bivia DNF00650 GCA_000759165.1 
Prevotella_bivia GED7760C GCA_001546565.2 
Prevotella_buccalis DNF00853 GCA_000759185.1 
Prevotella_buccalis DNF00985 GCA_000759265.1 
Prevotella_corporis MJR7716 GCA_001546595.1 
Prevotella_denticola DNF00960 GCA_000759205.1 
Prevotella_disiens DNF00882 GCA_000759225.1 
Prevotella_histicola JCM15637_DNF00424 GCA_000759075.1 
Prevotella_melaninogenica DNF00666 GCA_000144405.1 
Prevotella_sp DNF00663 GCA_001553265.1 
Prevotella_sp S7-1-8 GCA_000758925.1 
Prevotella_timonensis S9-PR14 GCA_000762405.1 
Propionibacterium_avidum MJR7694 GCA_001546875.1 
Proteus_mirabilis GED7834  
Pseudoglutamicibacter_albus DNF00011 GCA_000758985.1 
Roseomonas_cervicalis ATCC49957 GCA_000164635.1 
Staphylococcus_haemolyticus DNF00585 GCA_000759125.1 
Staphylococcus_lugdunensis MJR7738 GCA_001546615.1 
Staphylococcus_simulans MJR7712 GCA_001546635.1 
Streptococcus_equinus ATCC700338 GCA_000146405.1 
Streptococcus_mitis CMW7705B GCA_001546795.1 
Streptococcus_salivarius GED7778A GCA_001546835.2 
Tissierella_bacterium KA00581 GCA_001552895.1 
Tissierella_bacterium S5-A11 GCA_000758865.1 
Tissierella_bacterium S7-1-4 GCA_000758845.1 
Varibaculum_cambriense DNF00696 GCA_001553285.1 
Veillonella_atypica CMW7756B GCA_001546845.1 
Veillonella_dispar DNF00926 GCA_001553315.1 
Veillonella_montpellierensis DNF00314 GCA_000759285.1 
Veillonella_parvula ACS-068-V-Sch12 GCA_000215025.2 
Veillonella_sp DNF00869 GCA_001553345.1 
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Veillonellaceae_bacterium DNF00626 GCA_001553355.1 
Veillonellaceae_bacterium DNF00751 GCA_001553395.1 
Veillonellaceae_bacterium KA00182 GCA_001553405.1 
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Table N.2. A List of the Gut Isolates Used in Chapter III. These isolates were collected by the 
Lawley lab and are publicly available 146. 
Species Strain 
Alistipes_finegoldii R_Hilary_H2_8 
Alistipes_finegoldii Hilary_H6_8 
Anaerostipes_hadrus Hilary_H4_24 
Anaerostipes_hadrus H5_19 
Anaerotruncus_colihominis DSMZ_H4_64_HMI_6 
Anaerotruncus_colihominis Hilary_H4_64 
Anaerotruncus_colihominis Hilary_H5_63 
Anaerotruncus_colihominis Nature_Treg_PRJDB532_st13 
Anaerovorax_odorimutans R_DSMZ_FMT23_9get5_HMI_23 
B_glucerasea R_DSMZ_FMT23_BA916F__HMI_29 
Bacteroides_caccae Hilary_H1_3 
Bacteroides_coprocola DSMZ_HMI_42 
Bacteroides_coprocola Hilary_H4_3 
Bacteroides_finegoldi Hilary_H1_5 
Bacteroides_finegoldii Hilary_H3_6 
Bacteroides_intestinalis Hilary_H5_4 
Bacteroides_ovatus Hilary_H6_4 
Bacteroides_plebius DSMZ_HMI_43 
Bacteroides_plebius Hilary_H4_5 
Bacteroides_salyersiae Hilary_H3_17 
Bacteroides_thetaiotaomicron R_Hilary_H4_6 
Bacteroides_thetaiotaomicron Hilary_H5_3 
Bacteroides_thetaiotaomicron Hilary_H6_6 
Bacteroides_uniformis Hilary_H4_4 
Bacteroides_vulgatus Hilary_H4_2 
Bacteroides_xylanisolvens Hilary_H1_4 
Bifidobacterium_adolescentis Hilary_H3_7 
Bifidobacterium_adolescentis Hilary_H4_11 
Bifidobacterium_bifidum Hilary_H3_38 
Bifidobacterium_pseudocatenulatum Hilary_H3_40 
Blautia_hydrogenotrophica R_Hilary_H2_20 
Blautia_hydrogenotrophica Hilary_H2_36 
Blautia_luti DSMZ_FMT23_12get12_HMI_26 
Blautia_luti DSMZ_HMI_35 
Blautia_luti DSMZ_HMI_41 
Blautia_luti Hilary_H1_41 
Blautia_luti Hilary_H3_45 
Blautia_luti Hilary_H4_26 
Blautia_luti Hilary_H5_23 
Blautia_producta DSMZ_FMT23_jet16HMI_28 
Blautia_producta DSMZ_HMI_46 
Blautia_producta Hilary_H5_31 
Blautia_producta Nature_Treg_st6 
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Blautia_wexlerae R_Hilary_H4_27 
Butyricicoccus_pullicaecorum DSMZ_HMI_48 
Butyricicoccus_pullicaecorum Hilary_H5_45 
Butyricicoccus_pullicaecorum Hilary_H5_46 
Butyricoccus_pullicaecorum DSMZ_FMT23_12get7 _HMI_31 
C_maritium R_DSMZ_FMT23_16get2_HMI_32 
Catenibacterium_mitsuokai R_Hilary_H1_10 
Clostridaceae_sp Nature_Treg_PRJDB527_st8 
Clostridium_asparagiforme Nature_Treg_PrJDB534_st15 
Clostridium_baratti Hilary_H5_17 
Clostridium_bartlettii Hilary_H1_15 
Clostridium_boltae Hilary_H5_27 
Clostridium_bolteae Bature_Treg_PRJDB526_st7 
Clostridium_bolteae Nature_Treg_PRJDB529_st10 
Clostridium_celerecrescens DSMZ_H5_39_ HMI_18 
Clostridium_celerecrescens Hilary_H5_39 
Clostridium_celerescens DSMZ_H4_37_HMI_19 
Clostridium_celerescens Hilary_H4_37 
Clostridium_clostridioforme R_DSMZ_FMT23_B060_HMI_27 
Clostridium_clostridioforme DSMZ_H5_37_ HMI_16 
Clostridium_clostridioforme R_Hilary_H2_21 
Clostridium_clostridioforme Hilary_H4_30 
Clostridium_clostridioforme Hilary_H5_37 
Clostridium_cocleatum Hilary_H3_28 
Clostridium_disporicum Hilary_H4_18 
Clostridium_disporicum Hilary_H4_19 
Clostridium_disporicum R_Hilary_H6_18 
Clostridium_ghonii R_Hilary_H6_15 
Clostridium_hathewayi DSMZ_H3_49_HMI_14 
Clostridium_hathewayi Hilary_H2_25 
Clostridium_hathewayi Hilary_H3_49 
Clostridium_hathewayi Hilary_H5_29 
Clostridium_hatyewayi Nature_Treg_st4 
Clostridium_indolis Nature_Treg_PRJDB528_st9 
Clostridium_innocuum Hilary_H4_16 
Clostridium_innocuum Hilary_H5_11 
Clostridium_lituseburense Hilary_H4_22 
Clostridium_methylpentosum R_DSMZ_HMI_36 
Clostridium_methylpentosum R_Hilary_H2_30 
Clostridium_nexile DSMZ_HMI_47 
Clostridium_nexile Hilary_H5_34 
Clostridium_orbiscindens DSMZ_H4_63_HMI_4 
Clostridium_orbiscindens DSMZ_HMI_50 
Clostridium_oroticum DSMZ_H2_18_HMI_10 
Clostridium_oroticum DSMZ_H5_35_HMI_8 
Clostridium_oroticum Hilary_H2_18 
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Clostridium_oroticum Hilary_H4_38 
Clostridium_oroticum Hilary_H5_35 
Clostridium_paraputrificum Hilary_H4_20 
Clostridium_perfringens Hilary_H3_1 
Clostridium_ramosum Nature_Treg_PRJDB536_st18 
Clostridium_saccharogumia R_DSMZ_FMT23_B054_HMI_24 
Clostridium_saccharogumia DSMZ_FMT23_H4_15_HMI_25 
Clostridium_saccharogumia Hilary_H4_15 
Clostridium_saccharogumia Nature_Treg_st1 
Clostridium_saccharolyticum DSMZ_HMI_34 
Clostridium_saccharolyticum Hilary_H1_39 
Clostridium_scindens Nature_Treg_PRJDB540_st26 
Clostridium_scindens Nature_Treg_st5 
Clostridium_sp Nature_Treg_PRJDB535_st16 
Clostridium_straminisolvens DSMZ_FMT23_15e_HMI_30 
Clostridium_thermocellum DSMZ_H5_59_HMI_1 
Clostridium_thermocellum DSMZ_H5_66_HMI_22 
Clostridium_thermocellum Hilary_H5_59 
Clostridium_thermocellum Hilary_H5_66 
Clostridium_xylanolyticum DSMZ_H4_41_HMI_7 
Clostridium_xylanolyticum R_DSMZ_HMI_37 
Clostridium_xylanolyticum R_Hilary_H2_19 
Clostridium_xylanolyticum Hilary_H4_41 
Collinsella_aerofaciens R_Hilary_H2_9 
Collinsella_aerofaciens Hilary_H4_10 
Collinsella_aerofaciens Hilary_H5_8 
Coprococcus_comes Hilary_H1_34 
Coprococcus_eutactus Hilary_H1_22 
Coprococcus_eutactus R_Hilary_H2_11 
Dorea_formicigenerans Hilary_H4_33 
Dorea_longicatena Hilary_H6_29 
Eubacterium_contortum DSMZ_H4_39_HMI_9 
Eubacterium_contortum Hilary_H4_39 
Eubacterium_contortum Hilary_H4_43 
Eubacterium_eligens Hilary_H4_42 
Eubacterium_fissicatena Nature_Treg_PRJDB537_st21 
Eubacterium_fissicatens DSMZ_HMI_33 
Eubacterium_fissicatens Hilary_H1_29 
Eubacterium_halii R_Hilary_H1_25 
Eubacterium_hallii Hilary_H6_32 
Eubacterium_infirmum DSMZ_H3_30_HMI_20 
Eubacterium_infirmum DSMZ_H5_15_HMI_21 
Eubacterium_infirmum Hilary_H3_30 
Eubacterium_infirmum Hilary_H5_15 
Eubacterium_ramulus Hilary_H3_53 
Eubacterium_rectale Hilary_H4_46 
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Eubacterium_siraeum Hilary_H5_47 
Faecalibacterium_prausnitzii Hilary_H1_17 
Faecalibacterium_prausnitzii Hilary_H5_50 
Faecalibacterium_prausnitzii Hilary_H6_39 
Flavonifractor_plautii DSMZ_H4_62_HMI_2 
Flavonifractor_plautii DSMZ_H5_64_HMI_3 
Flavonifractor_plautii R_Hilary_H2_32 
Flavonifractor_plautii Hilary_H4_58 
Flavonifractor_plautii Hilary_H4_62 
Flavonifractor_plautii Hilary_H4_63 
Flavonifractor_plautii Hilary_H5_16 
Flavonifractor_plautii Hilary_H5_54 
Flavonifractor_plautii Hilary_H5_55 
Flavonifractor_plautii R_Hilary_H5_56 
Flavonifractor_plautii Hilary_H5_60 
Flavonifractor_plautii Hilary_H5_64 
Flavonifractor_plautii Nature_Treg_st3 
Fusicatenibacter_saccharivorans DSMZ_H5_42_HMI_15 
Fusicatenibacter_saccharivorans Hilary_H5_38 
Fusicatenibacter_saccharivorans Hilary_H5_42 
Lachnosipraceae_sp Nature_Treg_PRJDB538_st23 
Lachnospira_pectinoschiza DSMZ_H1_27_ HMI_11 
Lachnospira_pectinoschiza Hilary_H1_27 
Lachnospira_pectinoschiza Hilary_H2_16 
Lachnospira_pectinoschiza Hilary_H4_49 
Lachnospiraceae_sp Nature_Treg_PRJDB531_st12 
Lachnospiraceae_sp Nature_Treg_PRJDB541_st27 
Lachnospiraceae_sp Nature_Treg_PRJDB543_st29 
Megasphaera_elsdenii DSMZ_HMI_40 
Megasphaera_elsdenii Hilary_H4_17 
Mitsuokella_jalaludinii Hilary_H1_16 
Oscillibacter_valericigenes DSMZ_HMI_38 
Oscillibacter_valericigenes Hilary_H2_39 
Oscillospiraceae_sp Nature_Treg_PRJDB539_st24 
Parabacteroides_distasonis Hilary_H3_21 
Parabacteroides_distasonis Hilary_H5_6 
Parabacteroides_distasonis Hilary_H6_9 
Parabacteroides_merdae Hilary_H4_9 
prausnitzii_ H5_51 
Prevotella_copri Hilary_H1_1 
Roseburia_faecis DSMZ_H3_52_HMI_12 
Roseburia_faecis Hilary_H3_52 
Roseburia_faecis Hilary_H3_8 
Roseburia_hominis Hilary_H1_36 
Roseburia_intestinalis Hilary_H6_28 
Roseburia_inulinivorans DSMZ_HMI_44 
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Roseburia_inulinivorans Hilary_H3_54 
Roseburia_inulinivorans Hilary_H4_51 
Ruminococcus_albus DSMZ_HMI_45 
Ruminococcus_albus DSMZ_HMI_52 
Ruminococcus_albus Hilary_H4_61 
Ruminococcus_albus Hilary_H6_42 
Ruminococcus_bromii DSMZ_HMI_51 
Ruminococcus_bromii Hilary_H3_4 
Ruminococcus_bromii Hilary_H5_48 
Ruminococcus_bromii Hilary_H6_38 
Ruminococcus_flavefaciens DSMZ_H5_62_HMI_62 
Ruminococcus_flavefaciens DSMZ_HMI_49 
Ruminococcus_flavefaciens Hilary_H5_58 
Ruminococcus_flavefaciens Hilary_H5_62 
Ruminococcus_gnavus R_Hilary_H2_28 
Ruminococcus_gnavus Hilary_H4_53 
Ruminococcus_obeum R_DSMZ_HMI_39 
Ruminococcus_obeum Hilary_H1_44 
Ruminococcus_obeum Hilary_H3_47 
Ruminococcus_obeum Hilary_H5_20 
Ruminococcus_obeum Hilary_H5_36 
Ruminococcus_sp Nature_Treg_PRJDB533_st14 
Ruminococcus_torques DSMZ_H4_55_ HMI_17 
Ruminococcus_torques R_Hilary_H2_10 
Ruminococcus_torques Hilary_H3_59 
Ruminococcus_torques R_Hilary_H5_33 
Sarcina_ventriculi Hilary_H4_21 
Turibacter_sanguinis Hilary_H1_12 
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Table N.3. A List of Urinary Isolates used in Chapter III. These isolates were sequenced by the 
Wellcome Trust for a niche comparison study. Most of the strains sequenced were collected as 
part of the Astellas study (Appendix C-D), the maternal urinary microbiome (Appendix I), with 2 
E. coli genomes from a UTI study (Appendix H). 
 
Sequence ID Species Isolate 
Collection ID 
Patient ID 
16933_8#1 Corynebacteriaceae UMB0147 OAB033 
16933_8#10 Micrococcaceae UMB0867 MUM_05 
16933_8#11 Streptococcaceae UMB0252 OAB040 
16933_8#12 Corynebacteriaceae UMB0338 OAB048 
16933_8#13 Lactobacillaceae UMB0099 OAB027 
16933_8#16 Micrococcaceae UMB0031 C022 
16933_8#17 Brevibacteriaceae UMB0426 OAB051 
16933_8#18 Lactobacillaceae UMB0045 C037 
16933_8#19 Enterobacteriaceae UMB0789 C033 
16933_8#2 Bifidobacteriaceae UMB0061 OAB018 
16933_8#20 Enterobacteriaceae UMB0140 OAB031 
16933_8#21 Streptococcaceae UMB0832 MUM_12 
16933_8#24 Enterobacteriaceae UMB0900 EQUC078 
16933_8#25 Micrococcaceae UMB0131 OAB030 
16933_8#26 Moraxellaceae UMB0416 OAB041 
16933_8#27 Streptococcaceae UMB0008 C012 
16933_8#29 Actinomycetaceae UMB0319 OAB040 
16933_8#30 Enterobacteriaceae UMB0901 EQUC075 
16933_8#31 Neisseriaceae UMB0321 OAB040 
16933_8#32 Enterococcaceae UMB0891 OAB061 
16933_8#33 Bifidobacteriaceae UMB0912 MUM_02 
16933_8#34 Streptococcaceae UMB0839 MUM_15 
16933_8#36 Neisseriaceae UMB0023 C019 
16933_8#37 Bifidobacteriaceae UMB0913 MUM_02 
16933_8#38 Actinomycetaceae UMB0086 OAB025 
16933_8#39 Aerococcaceae UMB0111 OAB029 
16933_8#4 Actinomycetaceae UMB0063 OAB019 
16933_8#40 Bifidobacteriaceae UMB0682 OAB030 
16933_8#41 Lactobacillaceae UMB0803 C031 
16933_8#44 Actinomycetaceae UMB0402 OAB041 
16933_8#46 Lactobacillaceae UMB0044 C037 
16933_8#47 Propionibacteriaceae UMB0211 OAB018 
16933_8#48 Actinomycetaceae UMB0116 OAB029 
16933_8#49 Lactobacillaceae UMB0007 C012 
16933_8#5 Bifidobacteriaceae UMB0233 OAB023 
16933_8#50 Bifidobacteriaceae UMB0032A C023 
16933_8#52 Bifidobacteriaceae UMB0386 OAB045 
16933_8#53 Lactobacillaceae UMB0085 OAB024 
16933_8#54 Pseudomonadaceae UMB0740 OAB055 
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16933_8#56 Enterobacteriaceae UMB0315 OAB039 
16933_8#57 Bifidobacteriaceae UMB0032B C023 
16933_8#58 Streptococcaceae UMB0820 OAB072 
16933_8#59 Bifidobacteriaceae UMB0915 MUM_05 
16933_8#6 Staphylococcaceae UMB0894 C042 
16933_8#60 Bifidobacteriaceae UMB0298 OAB045 
16933_8#61 Micrococcaceae UMB0083 OAB023 
16933_8#62 Micrococcaceae UMB0024 C019 
16933_8#7 Actinomycetaceae UMB0125 OAB023 
16933_8#8 Aerococcaceae UMB0844 MUM_19 
16933_8#9 Lactobacillaceae UMB0824 OAB047 
17957_1#1 Lactobacillaceae UMB0003 C008 
17957_1#11 Lactobacillaceae UMB0187 OAB035 
17957_1#12 Streptococcaceae UMB0329 OAB031 
17957_1#13 Bacillaceae UMB0728 C01 
17957_1#17 Actinomycetaceae UMB0018 C019 
17957_1#20 Veillonellaceae UMB0371 OAB043 
17957_1#26 Neisseriaceae UMB0112 OAB029 
17957_1#35 Enterobacteriaceae UMB0210 OAB018 
17957_1#39 Lactobacillaceae UMB1297 EQUC146 
17957_1#41 Clostridiales Family XI UMB0040 C030 
17957_1#42 Streptococcaceae UMB0119 OAB021 
17957_1#43 Corynebacteriaceae UMB0220 OAB031 
17957_1#45 Bacillaceae UMB0763 OAB047 
17957_1#46 Dermacoccaceae UMB0893 C030 
17957_1#47 Deleted UMB1298 EQUC146 
17957_1#49 Corynebacteriaceae UMB0042 C037 
17957_1#50 Aerococcaceae UMB0126 OAB023 
17957_1#52 Dermabacteraceae UMB0490 OAB045 
17957_1#54 Aerococcaceae UMB0898 OAB059 
17957_1#57 Streptococcaceae UMB0050 C038 
17957_1#58 Actinomycetaceae UMB0138 OAB031 
17957_1#59 Aerococcaceae UMB0232 OAB023 
17957_1#61 Streptococcaceae UMB0776 C027 
17957_1#65 Bifidobacteriaceae UMB0064 OAB019 
17957_1#66 Aerococcaceae UMB0139 OAB031 
17957_1#68 Aerococcaceae UMB0514 OAB059 
17957_1#69 Nocardiaceae UMB0777 C025 
17957_1#73 Aerococcaceae UMB0072 OAB015 
17957_1#74 Streptococcaceae UMB0142 OAB031 
17957_1#75 Actinomycetaceae UMB0250 OAB040 
17957_1#77 Actinomycetaceae UMB0796 OAB041 
17957_1#79 Enterobacteriaceae UMB0660 OAB062 
17957_1#81 Lactobacillaceae UMB0077 OAB021 
17957_1#82 Actinomycetaceae UMB0181 OAB035 
17957_1#88 Actinomycetaceae UMB0183 OAB035 
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17957_1#9 Lactobacillaceae UMB0004 C008 
21837_8#14 Staphylococcaceae UMB0202 OAB017 
21837_8#15 Lactobacillaceae UMB0505 OAB049 
21837_8#16 Streptococcaceae UMB0540 OAB060 
21837_8#17 Bifidobacteriaceae UMB0558 SUI08 
21837_8#19 Bifidobacteriaceae UMB0670 OAB052 
21837_8#20 Corynebacteriaceae UMB0736 K-19 
21837_8#21 Corynebacteriaceae UMB0770 OAB049 
21837_8#22 Lactobacillaceae UMB0775 SUI12 
21837_8#23 Streptococcaceae UMB0830 MUM_12 
21837_8#24 Streptococcaceae UMB0833 MUM_19 
21837_8#26 Bifidobacteriaceae UMB0277 OAB042 
21837_8#27 Bifidobacteriaceae UMB0358 OAB049 
21837_8#28 Streptococcaceae UMB0001 C008 
21837_8#29 Lactobacillaceae UMB0012 C015 
21837_8#31 Aerococcaceae UMB0028 C019 
21837_8#32 Actinomycetaceae UMB0045  
21837_8#34 Bifidobacteriaceae UMB0072  
21837_8#35 Corynebacteriaceae UMB0079 OAB022 
21837_8#36 Propionibacteriaceae UMB0092 OAB017 
21837_8#37 Staphylococcaceae UMB0100 OAB027 
21837_8#38 Staphylococcaceae UMB0113 OAB029 
21837_8#39 Enterococcaceae UMB0184 OAB035 
21837_8#42 Bifidobacteriaceae UMB0214 OAB018 
21837_8#43 Streptococcaceae UMB0216 OAB018 
21837_8#44 Staphylococcaceae UMB0226 OAB035 
21837_8#45 Enterobacteriaceae UMB0243 OAB039 
21837_8#46 Micrococcaceae UMB0272 OAB041 
21837_8#49 Bifidobacteriaceae UMB0406 OAB041 
21837_8#50 Lactobacillaceae UMB0444 OAB053 
21837_8#51 Streptococcaceae UMB0489 OAB045 
21837_8#52 Streptococcaceae UMB0507 OAB049 
21837_8#53 Lactobacillaceae UMB0646 OAB032 
21837_8#55 Enterobacteriaceae UMB0683 OAB017 
21837_8#56 Lactobacillaceae UMB0819 OAB062 
21837_8#59 Lactobacillaceae UMB0006 C009 
21837_8#61 Enterobacteriaceae UMB0011 C014 
21837_8#62 Corynebacteriaceae UMB0017 C018 
21837_8#63 Actinomycetaceae UMB0021 C019 
21837_8#64 Streptococcaceae UMB0025 C019 
21837_8#65 Bifidobacteriaceae UMB0026 C019 
21837_8#66 Bifidobacteriaceae UMB0038 C029 
21837_8#67 Streptococcaceae UMB0039 C029 
21837_8#68 Corynebacteriaceae UMB0043 C037 
21837_8#69 Staphylococcaceae UMB0048 C041 
21837_8#70 Enterococcaceae UMB0051 C038 
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21837_8#71 Streptococcaceae UMB0054 C046 
21837_8#73 Bifidobacteriaceae UMB0057 C053 
21837_8#74 Bifidobacteriaceae UMB0058 C054 
21837_8#75 Aerococcaceae UMB0611 C03 
21837_8#76 Staphylococcaceae UMB0722 C02 
21837_8#78 Streptococcaceae UMB0727 C02 
21837_8#79 Streptococcaceae UMB0731 C056 
21837_8#80 Lactobacillaceae UMB0733 C056 
21837_8#82 Bifidobacteriaceae UMB0767 C032 
21837_8#83 Streptococcaceae UMB0788 C027 
21837_8#85 Bifidobacteriaceae UMB0797 C032 
21837_8#86 Lactobacillaceae UMB0799 C033 
21837_8#87 Bifidobacteriaceae UMB0829 C033 
21837_8#90 Bifidobacteriaceae UMB0989 C016 
21837_8#92 Alcaligenaceae UMB1341 C28 
21837_8#94 Lactobacillaceae UMB1398 C33 
21837_8#95 Corynebacteriaceae UMB1400 C33 
21837_8#96 Bifidobacteriaceae UMB1428 C040 
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Table N.4. A List of Genomes used in Chapter V.  
A. A list of Urinary and Vaginal Isolates collected from participants in the Estrogen Study. Clinical 
isolates sequenced for this study. Patients that contained the same species in both the bladder and 
vagina at baseline and 12 weeks were chosen for this arm of the study. Each set of 4 is delineated by 
highlighting. The only exception is patient EST11’s G. vaginalis group which did not have a baseline 
bladder isolate.  Only one isolate from patient EST15’s S. anginosus set is currently sequenced. The other 
4 are still being processed. 
Sequence ID Patient ID Location 
Time 
Point Species 
Isolate 
Collection ID 
AW-002 EST08 vag Base Aerococcus urinae UMB2324 
AW-003 EST08 cath Base Aerococcus urinae UMB2325 
AW-015 EST08 cath 12w Aerococcus urinae UMB3669 
AW-017 EST08 vag 12w Aerococcus urinae UMB3673 
AW-006 EST11 vag Base Corynebacterium amycolatum UMB2514 
AW-010 EST11 vag 12w Corynebacterium amycolatum UMB3570  
AW-012 EST11 cath 12w Corynebacterium amycolatum UMB3560 
AW-024 EST11 cath Base Corynebacterium amycolatum UMB2505 
AW-005 EST11 cath Base Corynebacterium coyleae UMB2503 
AW-007 EST11 vag Base Corynebacterium coyleae UMB2517 
AW-011 EST11 cath 12w Corynebacterium coyleae UMB3558 
AW-013 EST11 vag 12w Corynebacterium coyleae UMB3562 
AW-020 EST05 cath base Corynebacterium coyleae UMB1939 
AW-021 EST05 vag base Corynebacterium coyleae UMB1951 
AW-028 EST05 cath 12w Corynebacterium coyleae UMB2890 
AW-029 EST05 vag 12w Corynebacterium coyleae UMB2897 
AW-001 EST08 vag Base Eschericia coli UMB2277 
AW-004 EST08 cath Base Eschericia coli UMB2328 
AW-014 EST08 cath 12w Eschericia coli UMB3668 
AW-016 EST08 vag 12w Eschericia coli UMB3670 
AW-025 EST11 vag base Gardnerella vaginalis UMB2512 
AW-030 EST11 cath 12w Gardnerella vaginalis UMB3559 
AW-031 EST11 vag 12w Gardnerella vaginalis UMB3565 
AW-022 EST10 cath base Lactobacillus crispatus UMB2389 
AW-023 EST10 vag base Lactobacillus crispatus UMB2407 
AW-032 EST10 cath 12w Lactobacillus crispatus UMB4313 
AW-033 EST10 vag 12w Lactobacillus crispatus UMB4315 
AW-008 EST16 cath Base Lactobacillus iners UMB3008 
AW-009 EST16 vag Base Lactobacillus iners UMB3029 
AW-018 EST16 cath 12w Lactobacillus iners UMB5013 
AW-019 EST16 vag 12w Lactobacillus iners UMB5018 
AW-026 EST14 cath base Streptococcus anginosus UMB2816 
AW-027 EST14 vag base Streptococcus anginosus UMB2825 
AW-034 EST14 cath 12w Streptococcus anginosus UMB4619 
AW-035 EST14 vag 12w Streptococcus anginosus UMB4628 
AW-036 EST15 cath base Streptococcus anginosus UMB2908 
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B. A list of the publicly available reference genomes used for comparison, downloaded from 
NCBI  
Species Strain Assembly Accession 
Abiotrophia defectiva ATCC49176 GCA_000160075.2 
Aerococcus urinae  ACS120_VCol10a GCA_000193205.1 
Aerococcus urinae  CCUG36881 GCA_001543175.1 
Aerococcus urinae  NBRC15544 GCA_001544335.1 
Aerococcus urinae  AU3 GCA_001649715.1 
Corynebacterium amycolatum SK46 GCA_000173655.1 
Corynebacterium amycolatum ICIS53 GCA_001722255.1 
Corynebacterium bovis DSM20582 GCA_000183325.2 
Corynebacterium coyleae DSM4418 GCA_900105505.1 
Escherichia coli BL21 GCA_000009565.2 
Escherichia coli K12_MG1655 GCA_000005845.2 
Escherichia coli O83:H1_NRG857C GCA_000183345.1 
Escherichia coli UPEC_CFT073 GCA_000007445.1 
Gardnerella vaginalis 409-05 GCA_000025205.1 
Gardnerella vaginalis ATCC14019 GCA_000159155.2 
Gardnerella vaginalis HMP9231 GCA_000213955.1 
Klebsiella pneumoniae HS11286 GCA_000240185.2 
Lactobacillus crispatus FB077 GCA_000301135.1 
Lactobacillus crispatus CTV-05 GCA_000165885.1 
Lactobacillus crispatus FB049-03 GCA_000301115.1 
Lactobacillus crispatus JV V01 GCA_000160515.1 
Lactobacillus crispatus 125-2-CHN GCA_000162255.1 
Lactobacillus crispatus 214-1 HMP GCA_000177575.1 
Lactobacillus crispatus ST1 GCA_000091765.1 
Lactobacillus iners DSM1335 GCA_000160875.1 
Lactobacillus iners ATCC55195 GCA_000185405.1 
Lactobacillus iners LactinV11V1-d GCA_000149065.2 
Lactobacillus iners AB1 GCA_000177755.1 
Lactococcus lactis II1403 GCA_000006865.1 
Pediococcus acidilactici DSM20284 GCA_000146325.1 
Streptococcus agalactiae 2603VR GCA_000007265.1 
Streptococcus anginosus C1051 GCA_000463465.1 
Streptococcus anginosus C238 GCA_000463505.1 
Streptococcus anginosus MAS624 GCA_000478925.1 
Streptococcus anginosus SA1_831165 GCA_000831165.1 
Streptococcus anginosus SK1138 GCA_000287595.1 
 
 
 
- 404 - 
 
 
REFERENCE LIST 
1. Sender R, Fuchs S, Milo R. Revised Estimates for the Number of Human and Bacteria Cells 
in the Body. PLoS Biol 2016;14:e1002533. 
2. Human Microbiome Project C. Structure, function and diversity of the healthy human 
microbiome. Nature 2012;486:207-14. 
3. Pearce MM, Hilt EE, Rosenfeld AB, et al. The Female Urinary Microbiome: a Comparison of 
Women with and without Urgency Urinary Incontinence. MBio 2014;5. 
4. Wolfe AJ, Toh E, Shibata N, et al. Evidence of uncultivated bacteria in the adult female 
bladder. J Clin Microbiol 2012;50:1376-83. 
5. Brubaker L, Nager CW, Richter HE, et al. Urinary bacteria in adult women with urgency 
urinary incontinence. International urogynecology journal 2014. 
6. Thomas-White KJ, Hilt EE, Fok C, et al. Incontinence medication response relates to the 
female urinary microbiota. International urogynecology journal 2015. 
7. Hilt EE, McKinley K, Pearce MM, et al. Urine is not sterile: use of enhanced urine culture 
techniques to detect resident bacterial flora in the adult female bladder. J Clin Microbiol 
2014;52:871-6. 
8. Whiteside SA, Razvi H, Dave S, Reid G, Burton JP. The microbiome of the urinary tract--a 
role beyond infection. Nat Rev Urol 2015;12:81-90. 
9. Thomas-White K, Brady M, Wolfe AJ, Mueller ER. The bladder is not sterile: History and 
current discoveries on the urinary microbiome. Curr Bladder Dysfunct Rep 2016;11:18-24. 
10. Cho I, Blaser MJ. The human microbiome: at the interface of health and disease. Nat Rev 
Genet 2012;13:260-70. 
- 405 - 
 
 
 
11. Group NHW, Peterson J, Garges S, et al. The NIH Human Microbiome Project. Genome 
research 2009;19:2317-23. 
12. Pearce MM, Zilliox MJ, Rosenfeld AB, et al. The female urinary microbiome in urgency 
urinary incontinence. Am J Obstet Gynecol 2015;213:347 e1- e11. 
13. Lewis DA, Brown R, Williams J, et al. The human urinary microbiome; bacterial DNA in 
voided urine of asymptomatic adults. Frontiers in cellular and infection microbiology 
2013;3:41. 
14. Khasriya R, Sathiananthamoorthy S, Ismail S, et al. Spectrum of bacterial colonization 
associated with urothelial cells from patients with chronic lower urinary tract symptoms. J 
Clin Microbiol 2013;51:2054-62. 
15. Ravel J, Gajer P, Abdo Z, et al. Vaginal microbiome of reproductive-age women. Proc Natl 
Acad Sci U S A 2011;108 Suppl 1:4680-7. 
16. Gajer P, Brotman RM, Bai G, et al. Temporal dynamics of the human vaginal microbiota. 
Sci Transl Med 2012;4:132ra52. 
17. Ravel J, Brotman RM, Gajer P, et al. Daily temporal dynamics of vaginal microbiota before, 
during and after episodes of bacterial vaginosis. Microbiome 2013;1:29. 
18. Brotman RM, Shardell MD, Gajer P, et al. Association between the vaginal microbiota, 
menopause status, and signs of vulvovaginal atrophy. Menopause 2014;21:450-8. 
19. Santoro N, Komi J. Prevalence and impact of vaginal symptoms among postmenopausal 
women. J Sex Med 2009;6:2133-42. 
20. Sturdee DW, Panay N, International Menopause Society Writing G. Recommendations for 
the management of postmenopausal vaginal atrophy. Climacteric 2010;13:509-22. 
- 406 - 
 
 
 
21. Nelken RS, Ozel BZ, Leegant AR, Felix JC, Mishell DR, Jr. Randomized trial of estradiol 
vaginal ring versus oral oxybutynin for the treatment of overactive bladder. Menopause 
2011;18:962-6. 
22. Tseng LH, Wang AC, Chang YL, Soong YK, Lloyd LK, Ko YJ. Randomized comparison of 
tolterodine with vaginal estrogen cream versus tolterodine alone for the treatment of 
postmenopausal women with overactive bladder syndrome. Neurourology and 
urodynamics 2009;28:47-51. 
23. Serati M, Salvatore S, Uccella S, Cardozo L, Bolis P. Is there a synergistic effect of topical 
oestrogens when administered with antimuscarinics in the treatment of symptomatic 
detrusor overactivity? European urology 2009;55:713-9. 
24. Raz R, Stamm WE. A controlled trial of intravaginal estriol in postmenopausal women with 
recurrent urinary tract infections. The New England journal of medicine 1993;329:753-6. 
25. Raz R, Colodner R, Rohana Y, et al. Effectiveness of estriol-containing vaginal pessaries and 
nitrofurantoin macrocrystal therapy in the prevention of recurrent urinary tract infection 
in postmenopausal women. Clin Infect Dis 2003;36:1362-8. 
26. Raz R. Urinary tract infection in postmenopausal women. Korean J Urol 2011;52:801-8. 
27. Shreiner AB, Kao JY, Young VB. The gut microbiome in health and in disease. Curr Opin 
Gastroenterol 2015;31:69-75. 
28. Dewhirst FE. The Oral Microbiome: Critical for Understanding Oral Health and Disease. J 
Calif Dent Assoc 2016;44:409-10. 
29. Grice EA. The skin microbiome: potential for novel diagnostic and therapeutic approaches 
to cutaneous disease. Semin Cutan Med Surg 2014;33:98-103. 
30. Cui L, Morris A, Huang L, et al. The microbiome and the lung. Ann Am Thorac Soc 2014;11 
Suppl 4:S227-32. 
- 407 - 
 
 
 
31. Lu LJ, Liu J. Human Microbiota and Ophthalmic Disease. Yale J Biol Med 2016;89:325-30. 
32. Duclaux E. Pasteur: The History of the Mind. Philidelphia and London: W.B. Saunders 
Company; 1920. 
33. Bloom DA, McGuire EJ, Lapides J. A brief history of urethral catheterization. The Journal of 
urology 1994;151:317-25. 
34. Roberts W. On the Occurrence of Micro-Organisms in Fresh Urine. Br Med J 1881;2:623-5. 
35. Kass EH. Pyelonephritis and bacteriuria. A major problem in preventive medicine. Ann 
Intern Med 1962;56:46-53. 
36. Kass EH. Asymptomatic infections of the urinary tract. Trans Assoc Am Physicians 
1956;69:56-64. 
37. Stamm W, Counts G, Running K, Fihn S, Turck M, Holmes K. Diagnosis of coliform infection 
in acutely dysuric women. The New England journal of medicine 1982;307:463-8. 
38. Stark RP, Maki DG. Bacteriuria in the Catheterized Patient. New England Journal of 
Medicine 1984;311:560-4. 
39. Lipsky BA, Ireton RC, Fihn SD, Hackett R, Berger RE. Diagnosis of bacteriuria in men: 
specimen collection and culture interpretation. J Infect Dis 1987;155:847-54. 
40. Thomas MH, Pacita LR, Marsha EC, Ann ES. Voided Midstream Urine Culture and Acute 
Cystitis in Premenopausal Women. New England Journal of Medicine 2013;369. 
41. Hooton TM, Roberts PL, Cox ME, Stapleton AE. Voided midstream urine culture and acute 
cystitis in premenopausal women. The New England journal of medicine 2013;369:1883-
91. 
- 408 - 
 
 
 
42. Price TK. The Contribution of the Femal Urinary Microbiota to Lower Urinary Tract 
Symptoms Loyola University Chicago; 2015. 
43. Price TK, Dune T, Hilt EE, et al. The Clinical Urine Culture: Enhanced Techniques Improve 
Detection of Clinically Relevant Microorganisms. J Clin Microbiol 2016;54:1216-22. 
44. Lapides J, Diokno AC, Silber SJ, Lowe BS. Clean, intermittent self-catheterization in the 
treatment of urinary tract disease. 1972. The Journal of urology 2002;167:1131-3; 
discussion 4. 
45. Maskell R, Pead L, Allen J. The puzzle of "urethral syndrome": a possible answer? Lancet 
1979;1:1058-9. 
46. Maskell RM. The natural history of urinary tract infection in women. Med Hypotheses 
2010;74:802-6. 
47. Drabu YJ, Sanderson PJ. Urine culture in urethral syndrome. Lancet 1980;1:37-8. 
48. Seal DV, Cuthbert EH. Doubtful significance of fastidious bacteriuria in the urethral 
syndrome. Lancet 1982;1:115. 
49. Eckburg PB, Bik EM, Bernstein CN, et al. Diversity of the human intestinal microbial flora. 
Science 2005;308:1635-8. 
50. Ley RE, Turnbaugh PJ, Klein S, Gordon JI. Microbial ecology: human gut microbes 
associated with obesity. Nature 2006;444:1022-3. 
51. Dubnau D, Smith I, Morell P, Marmur J. Gene conservation in Bacillus species. I. Conserved 
genetic and nucleic acid base sequence homologies. Proc Natl Acad Sci U S A 1965;54:491-
8. 
52. Woese CR, Fox GE. Phylogenetic structure of the prokaryotic domain: the primary 
kingdoms. Proceedings of the National Academy of Sciences of the United States of 
America 1977;74:5088-90. 
- 409 - 
 
 
 
53. Van de Peer Y, Chapelle S, De Wachter R. A quantitative map of nucleotide substitution 
rates in bacterial rRNA. Nucleic Acids Res 1996;24:3381-91. 
54. Arumugam M, Raes J, Pelletier E, et al. Enterotypes of the human gut microbiome. Nature 
2011;473:174-80. 
55. Wu GD, Chen J, Hoffmann C, et al. Linking long-term dietary patterns with gut microbial 
enterotypes. Science 2011;334:105-8. 
56. Quince C, Lundin EE, Andreasson AN, et al. The impact of Crohn's disease genes on 
healthy human gut microbiota: a pilot study. Gut 2013;62:952-4. 
57. Jolliffe IT, Cadima J. Principal component analysis: a review and recent developments. 
Philos Trans A Math Phys Eng Sci 2016;374:20150202. 
58. Jombart T, Devillard S, Balloux F. Discriminant analysis of principal components: a new 
method for the analysis of genetically structured populations. BMC Genet 2010;11:94. 
59. Whiteside SA, Razvi H, Dave S, Reid G, Burton JP. The microbiome of the urinary tract-a 
role beyond infection. Nat Rev Urol 2015;12:81-90. 
60. Fouts DE, Pieper R, Szpakowski S, et al. Integrated next-generation sequencing of 16S 
rDNA and metaproteomics differentiate the healthy urine microbiome from 
asymptomatic bacteriuria in neuropathic bladder associated with spinal cord injury. J 
Transl Med 2012;10:174. 
61. Coorevits L, Heytens S, Boelens J, Claeys G. The resident microflora of voided midstream 
urine of healthy controls: standard versus expanded urine culture protocols. Eur J Clin 
Microbiol Infect Dis 2017;36:635-9. 
62. Afgan E, Baker D, van den Beek M, et al. The Galaxy platform for accessible, reproducible 
and collaborative biomedical analyses: 2016 update. Nucleic acids research 2016. 
- 410 - 
 
 
 
63. Fok CS, McKinley K, Mueller ER, et al. Day of surgery urine cultures identify urogynecologic 
patients at increased risk for postoperative urinary tract infection. The Journal of urology 
2013;189:1721-4. 
64. Thomas-White K, Fok C, Mueller E, Wolfe A, Brubaker L. Pre-Operative Urinary 
Microbiome Reveals Post-Operative Urinary Tract Infection Risk. Neurourology and 
urodynamics 2015;34:S21-S2. 
65. Pearce MM, Zilliox MJ, Thomas-White KJ, et al. The female urinary microbiota in urgency 
urinary incontinence. Am J Obstet Gynecol 2015. 
66. Mehta M, Goldfarb DS, Nazzal L. The role of the microbiome in kidney stone formation. Int 
J Surg 2016;36:607-12. 
67. Thomas-White KJ, Kliethermes S, Rickey L, et al. Evaluation of the urinary microbiota of 
women with uncomplicated stress urinary incontinence. Am J Obstet Gynecol 2016. 
68. Diebel K. Lactobacillus crispatus produces a bactericidal molecule that kills uropathogenic 
E. coli: Loyola University Chicago; 2016. 
69. Pistone G. Determination, Identification, and Characterization of Inhibitory Molecules 
produced by Lactobacillus crispatus: Loyola University Chicago; 2017. 
70. Lane MC, Alteri CJ, Smith SN, Mobley HL. Expression of flagella is coincident with 
uropathogenic Escherichia coli ascension to the upper urinary tract. Proc Natl Acad Sci U S 
A 2007;104:16669-74. 
71. Schwan WR. Flagella allow uropathogenic Escherichia coli ascension into murine kidneys. 
Int J Med Microbiol 2008;298:441-7. 
72. Wang C, Symington JW, Ma E, Cao B, Mysorekar IU. Estrogenic modulation of 
uropathogenic Escherichia coli infection pathogenesis in a murine menopause model. 
Infect Immun 2013;81:733-9. 
- 411 - 
 
 
 
73. Devillard E, Burton JP, Hammond JA, Lam D, Reid G. Novel insight into the vaginal 
microflora in postmenopausal women under hormone replacement therapy as analyzed 
by PCR-denaturing gradient gel electrophoresis. European journal of obstetrics, 
gynecology, and reproductive biology 2004;117:76-81. 
74. Heinemann C, Reid G. Vaginal microbial diversity among postmenopausal women with 
and without hormone replacement therapy. Canadian journal of microbiology 
2005;51:777-81. 
75. Mirmonsef P, Hotton AL, Gilbert D, et al. Free glycogen in vaginal fluids is associated with 
Lactobacillus colonization and low vaginal pH. PloS one 2014;9:e102467. 
76. Mirmonsef P, Modur S, Burgad D, et al. Exploratory comparison of vaginal glycogen and 
Lactobacillus levels in premenopausal and postmenopausal women. Menopause 
2015;22:702-9. 
77. Baldassarre M, Giannone FA, Foschini MP, et al. Effects of long-term high dose 
testosterone administration on vaginal epithelium structure and estrogen receptor-alpha 
and -beta expression of young women. Int J Impot Res 2013;25:172-7. 
78. Aroutcheva A, Gariti D, Simon M, et al. Defense factors of vaginal lactobacilli. Am J Obstet 
Gynecol 2001;185:375-9. 
79. Reid G, Bruce AW. Probiotics to prevent urinary tract infections: the rationale and 
evidence. World journal of urology 2006;24:28-32. 
80. Benness C WG, Cutner A. Does low dose vaginal oestradiol improve frequency and 
urgency in postmenopausal women. International Urogynaecology Journal 1992:281. 
81. Eriksen PS, Rasmussen H. Low-dose 17 beta-estradiol vaginal tablets in the treatment of 
atrophic vaginitis: a double-blind placebo controlled study. European journal of obstetrics, 
gynecology, and reproductive biology 1992;44:137-44. 
- 412 - 
 
 
 
82. Cardozo LD, Wise BG, Benness CJ. Vaginal oestradiol for the treatment of lower urinary 
tract symptoms in postmenopausal women--a double-blind placebo-controlled study. J 
Obstet Gynaecol 2001;21:383-5. 
83. Luthje P, Brauner H, Ramos NL, et al. Estrogen supports urothelial defense mechanisms. 
Sci Transl Med 2013;5:190ra80. 
84. Sanchez Freire V, Burkhard FC, Schmitz A, Kessler TM, Monastyrskaya K. Structural 
differences between the bladder dome and trigone revealed by mRNA expression analysis 
of cold-cut biopsies. BJU international 2011;108:E126-35. 
85. Saez S, Martin PM. Evidence of estrogen receptors in the trigone area of human urinary 
bladder. J Steroid Biochem 1981;15:317-20. 
86. Koss LG, Hoda RS. Koss's cytology of the urinary tract with histopathologic correlations. 
New York: Springer; 2012. 
87. Mestas J, Hughes CC. Of mice and not men: differences between mouse and human 
immunology. J Immunol 2004;172:2731-8. 
88. Squier CA, Mantz MJ, Schlievert PM, Davis CC. Porcine vagina ex vivo as a model for 
studying permeability and pathogenesis in mucosa. J Pharm Sci 2008;97:9-21. 
89. Machado D, Castro J, Palmeira-de-Oliveira A, Martinez-de-Oliveira J, Cerca N. Bacterial 
Vaginosis Biofilms: Challenges to Current Therapies and Emerging Solutions. Front 
Microbiol 2015;6:1528. 
90. Anderson GG, Palermo JJ, Schilling JD, Roth R, Heuser J, Hultgren SJ. Intracellular bacterial 
biofilm-like pods in urinary tract infections. Science 2003;301:105-7. 
91. Mulvey MA, Schilling JD, Hultgren SJ. Establishment of a persistent Escherichia coli 
reservoir during the acute phase of a bladder infection. Infect Immun 2001;69:4572-9. 
- 413 - 
 
 
 
92. Hannan TJ, Totsika M, Mansfield KJ, Moore KH, Schembri MA, Hultgren SJ. Host-pathogen 
checkpoints and population bottlenecks in persistent and intracellular uropathogenic 
Escherichia coli bladder infection. FEMS Microbiol Rev 2012;36:616-48. 
93. Nienhouse V, Gao X, Dong Q, et al. Interplay between bladder microbiota and urinary 
antimicrobial peptides: mechanisms for human urinary tract infection risk and symptom 
severity. PloS one 2014;9:e114185. 
94. Le PT, Pearce MM, Zhang S, et al. IL22 regulates human urothelial cell sensory and innate 
functions through modulation of the acetylcholine response, immunoregulatory cytokines 
and antimicrobial peptides: assessment of an in vitro model. PloS one 2014;9:e111375. 
95. Brooks T, Keevil CW. A simple artificial urine for the growth of urinary pathogens. Lett 
Appl Microbiol 1997;24:203-6. 
96. Wu XR, Lin JH, Walz T, et al. Mammalian uroplakins. A group of highly conserved urothelial 
differentiation-related membrane proteins. J Biol Chem 1994;269:13716-24. 
97. Parsons CL, Boychuk D, Jones S, Hurst R, Callahan H. Bladder surface glycosaminoglycans: 
an epithelial permeability barrier. J Urol 1990;143:139-42. 
98. Hurst RE, Zebrowski R. Identification of proteoglycans present at high density on bovine 
and human bladder luminal surface. J Urol 1994;152:1641-5. 
99. Nickel JC, Cornish J. Ultrastructural study of an antibody-stabilized bladder surface: a new 
perspective on the elusive glycosaminoglycan layer. World journal of urology 1994;12:11-
4. 
100. Datsenko KA, Pougach K, Tikhonov A, Wanner BL, Severinov K, Semenova E. Molecular 
memory of prior infections activates the CRISPR/Cas adaptive bacterial immunity system. 
Nature communications 2012;3:945. 
101. Sternberg SH, Richter H, Charpentier E, Qimron U. Adaptation in CRISPR-Cas Systems. Mol 
Cell 2016;61:797-808. 
- 414 - 
 
 
 
102. Yoganand KN, Sivathanu R, Nimkar S, Anand B. Asymmetric positioning of Cas1-2 complex 
and Integration Host Factor induced DNA bending guide the unidirectional homing of 
protospacer in CRISPR-Cas type I-E system. Nucleic acids research 2017;45:367-81. 
103. Koskella B, Brockhurst MA. Bacteria-phage coevolution as a driver of ecological and 
evolutionary processes in microbial communities. FEMS Microbiol Rev 2014;38:916-31. 
104. Edlund A, Santiago-Rodriguez TM, Boehm TK, Pride DT. Bacteriophage and their potential 
roles in the human oral cavity. J Oral Microbiol 2015;7:27423. 
105. Malki K, Shapiro J, Price TK, et al. Genomes of Gardnerella strains uncover an abundance 
of prophages within the bladder microbiome. PloS one 2016. 
106. Malki K, Sible E, Cooper A, et al. Seven Bacteriophages Isolated from the Female Urinary 
Microbiota. Genome Announc 2016;4. 
107. Santiago-Rodriguez TM, Ly M, Bonilla N, Pride DT. The human urine virome in association 
with urinary tract infections. Front Microbiol 2015;6:14. 
108. Lopatina A, Medvedeva S, Shmakov S, Logacheva MD, Krylenkov V, Severinov K. 
Metagenomic Analysis of Bacterial Communities of Antarctic Surface Snow. Front 
Microbiol 2016;7:398. 
109. Sun CL, Thomas BC, Barrangou R, Banfield JF. Metagenomic reconstructions of bacterial 
CRISPR loci constrain population histories. The ISME journal 2016;10:858-70. 
110. Coyne K, Revicki D, Hunt T, et al. Psychometric validation of an overactive bladder 
symptom and health-related quality of life questionnaire: the OAB-q. Quality of life 
research : an international journal of quality of life aspects of treatment, care and 
rehabilitation 2002;11:563-74. 
111. Rahn DD, Ward RM, Sanses TV, et al. Vaginal estrogen use in postmenopausal women 
with pelvic floor disorders: systematic review and practice guidelines. International 
urogynecology journal 2014. 
- 415 - 
 
 
 
112. Herzog AR, Fultz NH. Prevalence and incidence of urinary incontinence in community-
dwelling populations. J Am Geriatr Soc 1990;38:273-81. 
113. Nager CW, Brubaker L, Litman HJ, et al. A randomized trial of urodynamic testing before 
stress-incontinence surgery. The New England journal of medicine 2012;366:1987-97. 
114. Salter SJ, Cox MJ, Turek EM, et al. Reagent and laboratory contamination can critically 
impact sequence-based microbiome analyses. BMC Biol 2014;12:87. 
115. Team R. RStudio: Integrated Development for R. Boston, MA URL 
http://www.rstudio.com/: RStudio Inc.; 2015. 
116. Green MR, Sambrook J, Sambrook J. Molecular cloning : a laboratory manual. 4th ed. Cold 
Spring Harbor, N.Y.: Cold Spring Harbor Laboratory Press; 2012. 
117. Lamble S, Batty E, Attar M, et al. Improved workflows for high throughput library 
preparation using the transposome-based Nextera system. BMC biotechnology 
2013;13:104. 
118. Page AJ, De Silva N, Hunt M, et al. Robust high throughput prokaryote de novo assembly 
and improvement pipeline for Illumina data. BioRxiv Beta, Cold Spring Harbor Press 2016. 
119. Gladman S, Seemann T, Consortium VB. Velvet Optimiser: For automatically optimising 
the primary parameter options for the Velvet de novo sequence assembler. 2008. 
120. Zerbino DR, Birney E. Velvet: algorithms for de novo short read assembly using de Bruijn 
graphs. Genome research 2008;18:821-9. 
121. Boetzer M, Henkel CV, Jansen HJ, Butler D, Pirovano W. Scaffolding pre-assembled contigs 
using SSPACE. Bioinformatics 2011;27:578-9. 
122. Boetzer M, Pirovano W. Toward almost closed genomes with GapFiller. Genome biology 
2012;13:R56. 
- 416 - 
 
 
 
123. Seemann T. Prokka: rapid prokaryotic genome annotation. Bioinformatics 2014;30:2068-
9. 
124. Pruitt KD, Tatusova T, Brown GR, Maglott DR. NCBI Reference Sequences (RefSeq): current 
status, new features and genome annotation policy. Nucleic acids research 2012;40:D130-
5. 
125. Joshi NA FJ. Sickle: A sliding-window, adaptive, quality-based trimming tool for FastQ files 
Version 1.33 ed2011. 
126. Bankevich A, Nurk S, Antipov D, et al. SPAdes: a new genome assembly algorithm and its 
applications to single-cell sequencing. J Comput Biol 2012;19:455-77. 
127. Rutherford K, Parkhill J, Crook J, et al. Artemis: sequence visualization and annotation. 
Bioinformatics 2000;16:944-5. 
128. Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ. Basic local alignment search tool. 
Journal of molecular biology 1990;215:403-10. 
129. Katoh K, Standley DM. MAFFT multiple sequence alignment software version 7: 
improvements in performance and usability. Mol Biol Evol 2013;30:772-80. 
130. Stamatakis A. RAxML version 8: a tool for phylogenetic analysis and post-analysis of large 
phylogenies. Bioinformatics 2014;30:1312-3. 
131. Letunic I, Bork P. Interactive Tree Of Life v2: online annotation and display of phylogenetic 
trees made easy. Nucleic acids research 2011;39:W475-8. 
132. Ash C, Farrow JA, Dorsch M, Stackebrandt E, Collins MD. Comparative analysis of Bacillus 
anthracis, Bacillus cereus, and related species on the basis of reverse transcriptase 
sequencing of 16S rRNA. Int J Syst Bacteriol 1991;41:343-6. 
133. Rossello-Mora R, Amann R. The species concept for prokaryotes. FEMS Microbiol Rev 
2001;25:39-67. 
- 417 - 
 
 
 
134. Sorek R, Zhu Y, Creevey CJ, Francino MP, Bork P, Rubin EM. Genome-wide experimental 
determination of barriers to horizontal gene transfer. Science 2007;318:1449-52. 
135. Ciccarelli FD, Doerks T, von Mering C, Creevey CJ, Snel B, Bork P. Toward automatic 
reconstruction of a highly resolved tree of life. Science 2006;311:1283-7. 
136. Kim M, Oh HS, Park SC, Chun J. Towards a taxonomic coherence between average 
nucleotide identity and 16S rRNA gene sequence similarity for species demarcation of 
prokaryotes. Int J Syst Evol Microbiol 2014;64:346-51. 
137. Goris J, Konstantinidis KT, Klappenbach JA, Coenye T, Vandamme P, Tiedje JM. DNA-DNA 
hybridization values and their relationship to whole-genome sequence similarities. Int J 
Syst Evol Microbiol 2007;57:81-91. 
138. Konstantinidis KT, Tiedje JM. Genomic insights that advance the species definition for 
prokaryotes. Proc Natl Acad Sci U S A 2005;102:2567-72. 
139. Mende DR, Sunagawa S, Zeller G, Bork P. Accurate and universal delineation of 
prokaryotic species. Nature methods 2013;10:881-4. 
140. Wayne LG. International Committee on Systematic Bacteriology: announcement of the 
report of the ad hoc Committee on Reconciliation of Approaches to Bacterial Systematics. 
Zentralbl Bakteriol Mikrobiol Hyg A 1988;268:433-4. 
141. Carver TJ, Rutherford KM, Berriman M, Rajandream MA, Barrell BG, Parkhill J. ACT: the 
Artemis Comparison Tool. Bioinformatics 2005;21:3422-3. 
142. Assefa S, Keane TM, Otto TD, Newbold C, Berriman M. ABACAS: algorithm-based 
automatic contiguation of assembled sequences. Bioinformatics 2009;25:1968-9. 
143. Kurtz S, Phillippy A, Delcher AL, et al. Versatile and open software for comparing large 
genomes. Genome biology 2004;5:R12. 
- 418 - 
 
 
 
144. Marchler-Bauer A, Derbyshire MK, Gonzales NR, et al. CDD: NCBI's conserved domain 
database. Nucleic acids research 2015;43:D222-6. 
145. Grissa I, Vergnaud G, Pourcel C. CRISPRFinder: a web tool to identify clustered regularly 
interspaced short palindromic repeats. Nucleic acids research 2007;35:W52-7. 
146. Browne HP, Forster SC, Anonye BO, et al. Culturing of 'unculturable' human microbiota 
reveals novel taxa and extensive sporulation. Nature 2016;533:543-6. 
147. Hummelen R, Macklaim JM, Bisanz JE, et al. Vaginal microbiome and epithelial gene array 
in post-menopausal women with moderate to severe dryness. PloS one 2011;6:e26602. 
148. Earle KA, Billings G, Sigal M, et al. Quantitative Imaging of Gut Microbiota Spatial 
Organization. Cell host & microbe 2015;18:478-88. 
149. Faust K, Sathirapongsasuti JF, Izard J, et al. Microbial co-occurrence relationships in the 
human microbiome. PLoS computational biology 2012;8:e1002606. 
150. Truschel ST, Wang E, Ruiz WG, et al. Stretch-regulated exocytosis/endocytosis in bladder 
umbrella cells. Mol Biol Cell 2002;13:830-46. 
151. Thomas-White KJK, S.; Rickey, L.; Lukacz, E.; Richter, H.E.; Moalli, P.; Zimmern, P.; Norton, 
P.; Kusek, J.W.; Wolfe, A.J.; and Brubaker, L. Evaluation of the Urinary Microbiota of 
Women With Uncomplicated Stress Urinary Incontinence. American Journal of Obstetrics 
and Gynecology (Submitted) 2016. 
152. Barr-Beare E, Saxena V, Hilt EE, et al. The Interaction between Enterobacteriaceae and 
Calcium Oxalate Deposits. PloS one 2015;10:e0139575. 
153. Pastore MN, Kalia YN, Horstmann M, Roberts MS. Transdermal patches: history, 
development and pharmacology. Br J Pharmacol 2015;172:2179-209. 
154. Sokol A, Shveiky D. Clinical Anatomy of the Vulva, Vagina, Lower Pelvis, and Perineum. 
Glob libr women's med 2008. 
- 419 - 
 
 
 
155. Foxman B. Epidemiology of urinary tract infections: incidence, morbidity, and economic 
costs. Dis Mon 2003;49:53-70. 
156. Schreiber HLt, Conover MS, Chou WC, et al. Bacterial virulence phenotypes of Escherichia 
coli and host susceptibility determine risk for urinary tract infections. Sci Transl Med 
2017;9. 
157. Roos V, Ulett GC, Schembri MA, Klemm P. The asymptomatic bacteriuria Escherichia coli 
strain 83972 outcompetes uropathogenic E. coli strains in human urine. Infect Immun 
2006;74:615-24. 
158. Kilic AO, Pavlova SI, Alpay S, Kilic SS, Tao L. Comparative study of vaginal Lactobacillus 
phages isolated from women in the United States and Turkey: prevalence, morphology, 
host range, and DNA homology. Clin Diagn Lab Immunol 2001;8:31-9. 
159. Manrique P, Bolduc B, Walk ST, van der Oost J, de Vos WM, Young MJ. Healthy human gut 
phageome. Proc Natl Acad Sci U S A 2016;113:10400-5. 
160. Manrique P, Dills M, Young MJ. The Human Gut Phage Community and Its Implications for 
Health and Disease. Viruses 2017;9. 
161. Visco AG, Brubaker L, Richter HE, et al. Anticholinergic therapy vs. onabotulinumtoxina for 
urgency urinary incontinence. The New England journal of medicine 2012;367:1803-13. 
162. Brubaker L, Wolfe AJ. The new world of the urinary microbiota in women. Am J Obstet 
Gynecol 2015;213:644-9. 
163. Brubaker L, Nager CW, Richter HE, et al. Urinary bacteria in adult women with urgency 
urinary incontinence. Int Urogynecol J 2014;25:1179-84. 
164. Visco AG, Brubaker L, Richter HE, et al. Anticholinergic versus botulinum toxin A 
comparison trial for the treatment of bothersome urge urinary incontinence: ABC trial. 
Contemp Clin Trials 2012;33:184-96. 
- 420 - 
 
 
 
165. Pearce MM, Hilt EE, Rosenfeld AB, et al. The female urinary microbiome: a comparison of 
women with and without urgency urinary incontinence. MBio 2014;5:e01283-14. 
166. Yuan S, Cohen DB, Ravel J, Abdo Z, Forney LJ. Evaluation of methods for the extraction and 
purification of DNA from the human microbiome. PloS one 2012;7:e33865. 
167. Schloss PD, Westcott SL, Ryabin T, et al. Introducing mothur: open-source, platform-
independent, community-supported software for describing and comparing microbial 
communities. Applied and environmental microbiology 2009;75:7537-41. 
168. Quast C, Pruesse E, Yilmaz P, et al. The SILVA ribosomal RNA gene database project: 
improved data processing and web-based tools. Nucleic acids research 2013;41:D590-6. 
169. Edgar RC, Haas BJ, Clemente JC, Quince C, Knight R. UCHIME improves sensitivity and 
speed of chimera detection. Bioinformatics 2011;27:2194-200. 
170. Arndt D, Xia J, Liu Y, et al. METAGENassist: a comprehensive web server for comparative 
metagenomics. Nucleic acids research 2012;40:W88-95. 
171. Dong Q, Nelson DE, Toh E, et al. The microbial communities in male first catch urine are 
highly similar to those in paired urethral swab specimens. PloS one 2011;6:e19709. 
172. Nelson DE, Dong Q, Van der Pol B, et al. Bacterial communities of the coronal sulcus and 
distal urethra of adolescent males. PloS one 2012;7:e36298. 
173. Nelson DE, Van Der Pol B, Dong Q, et al. Characteristic male urine microbiomes associate 
with asymptomatic sexually transmitted infection. PloS one 2010;5:e14116. 
174. Brubaker L, Nager CW, Richter HE, et al. Urinary bacteria in adult women with urgency 
urinary incontinence. International urogynecology journal 2014;25:1179-84. 
175. Riesenfeld CS, Schloss PD, Handelsman J. Metagenomics: genomic analysis of microbial 
communities. Annu Rev Genet 2004;38:525-52. 
- 421 - 
 
 
 
176. Nitti VW, Kopp Z, Lin AT, Moore KH, Oefelein M, Mills IW. Can we predict which patient 
will fail drug treatment for overactive bladder? A think tank discussion. Neurourology and 
urodynamics 2010;29:652-7. 
177. Hartmann KE, McPheeters ML, Biller DH, et al. Treatment of overactive bladder in women. 
Evidence report/technology assessment 2009:1-120, v. 
178. Haylen BT, de Ridder D, Freeman RM, et al. An International Urogynecological Association 
(IUGA)/International Continence Society (ICS) joint report on the terminology for female 
pelvic floor dysfunction. Neurourology and urodynamics 2010;29:4-20. 
179. Redondo-Lopez V, Cook RL, Sobel JD. Emerging role of lactobacilli in the control and 
maintenance of the vaginal bacterial microflora. Rev Infect Dis 1990;12:856-72. 
180. Kaewsrichan J, Peeyananjarassri K, Kongprasertkit J. Selection and identification of 
anaerobic lactobacilli producing inhibitory compounds against vaginal pathogens. FEMS 
Immunol Med Microbiol 2006;48:75-83. 
181. Hyman RW, Fukushima M, Diamond L, Kumm J, Giudice LC, Davis RW. Microbes on the 
human vaginal epithelium. Proc Natl Acad Sci U S A 2005;102:7952-7. 
182. Harwich MD, Jr., Alves JM, Buck GA, et al. Drawing the line between commensal and 
pathogenic Gardnerella vaginalis through genome analysis and virulence studies. BMC 
genomics 2010;11:375. 
183. Zimmermann P, Berlinger L, Liniger B, Grunt S, Agyeman P, Ritz N. Actinobaculum schaalii 
an emerging pediatric pathogen? BMC Infect Dis 2012;12:201. 
184. Bank S, Jensen A, Hansen TM, Soby KM, Prag J. Actinobaculum schaalii, a common 
uropathogen in elderly patients, Denmark. Emerg Infect Dis 2010;16:76-80. 
185. Rasmussen M. Aerococci and aerococcal infections. J Infect 2013;66:467-74. 
- 422 - 
 
 
 
186. Dabkowski J, Dodds P, Hughes K, Bush M. A persistent, symptomatic urinary tract 
infection with multiple "negative" urine cultures. Conn Med 2013;77:27-9. 
187. Funke G, Pagano-Niederer M, Sjoden B, Falsen E. Characteristics of Arthrobacter 
cumminsii, the most frequently encountered Arthrobacter species in human clinical 
specimens. J Clin Microbiol 1998;36:1539-43. 
188. O'Hara AM, Shanahan F. The gut flora as a forgotten organ. EMBO Rep 2006;7:688-93. 
189. Grice EA, Kong HH, Conlan S, et al. Topographical and temporal diversity of the human 
skin microbiome. Science 2009;324:1190-2. 
190. Chang JY, Antonopoulos DA, Kalra A, et al. Decreased diversity of the fecal Microbiome in 
recurrent Clostridium difficile-associated diarrhea. J Infect Dis 2008;197:435-8. 
191. Liu MB, Xu SR, He Y, et al. Diverse vaginal microbiomes in reproductive-age women with 
vulvovaginal candidiasis. PloS one 2013;8:e79812. 
192. Barber MD, Kuchibhatla MN, Pieper CF, Bump RC. Psychometric evaluation of 2 
comprehensive condition-specific quality of life instruments for women with pelvic floor 
disorders. Am J Obstet Gynecol 2001;185:1388-95. 
193. Uebersax JS, Wyman JF, Shumaker SA, McClish DK, Fantl JA. Short forms to assess life 
quality and symptom distress for urinary incontinence in women: the Incontinence Impact 
Questionnaire and the Urogenital Distress Inventory. Continence Program for Women 
Research Group. Neurourology and urodynamics 1995;14:131-9. 
194. Kozich JJ, Westcott SL, Baxter NT, Highlander SK, Schloss PD. Development of a dual-index 
sequencing strategy and curation pipeline for analyzing amplicon sequence data on the 
MiSeq Illumina sequencing platform. Appl Environ Microbiol 2013;79:5112-20. 
195. Wang Q, Garrity GM, Tiedje JM, Cole JR. Naive Bayesian classifier for rapid assignment of 
rRNA sequences into the new bacterial taxonomy. Applied and environmental 
microbiology 2007;73:5261-7. 
- 423 - 
 
 
 
196. Team RDC. R: a language and environment for statistical computing.  R Foundation for 
Statistical Computing2014. 
197. Hoffstetter S, Leong FC. Solifenacin succinate for the treatment of overactive bladder. 
Expert opinion on drug metabolism & toxicology 2009;5:345-50. 
198. Haab F, Cardozo L, Chapple C, Ridder AM, Solifenacin Study G. Long-term open-label 
solifenacin treatment associated with persistence with therapy in patients with overactive 
bladder syndrome. European urology 2005;47:376-84. 
199. Pelman RS, Capo JP, Jr., Forero-Schwanhaeuser S. Solifenacin at 3 years: a review of 
efficacy and safety. Postgraduate medicine 2008;120:85-91. 
200. Santos JC, Telo ER. Solifenacin: scientific evidence in the treatment of overactive bladder. 
Archivos espanoles de urologia 2010;63:197-213. 
201. Brubaker L, Wolfe AJ. The new world of the urinary microbiota in women. American 
journal of obstetrics and gynecology 2015. 
202. Wolfe AJ, Brubaker L. "Sterile Urine" and the Presence of Bacteria. European urology 
2015;68:173-4. 
203. Pearce MM, Hilt EE, Rosenfeld AB, et al. The Female Urinary Microbiome: A Comparison 
of Women With and Without Urgency Urinary Incontinence. mBio 2014;5. 
204. Siddiqui H, Nederbragt AJ, Lagesen K, Jeansson SL, Jakobsen KS. Assessing diversity of the 
female urine microbiota by high throughput sequencing of 16S rDNA amplicons. BMC 
microbiology 2011;11:244. 
205. Barber MD, Walters MD, Cundiff GW. Responsiveness of the Pelvic Floor Distress 
Inventory (PFDI) and Pelvic Floor Impact Questionnaire (PFIQ) in women undergoing 
vaginal surgery and pessary treatment for pelvic organ prolapse. Am J Obstet Gynecol 
2006;194:1492-8. 
- 424 - 
 
 
 
206. Landis JR, Koch GG. The measurement of observer agreement for categorical data. 
Biometrics 1977;33:159-74. 
207. Hooton TM, Roberts PL, Cox ME, Stapleton AE. Voided midstream urine culture and acute 
cystitis in premenopausal women. The New England journal of medicine 2013;369:1883-
91. 
208. Stamm WE, Counts GW, Running KR, Fihn S, Turck M, Holmes KK. Diagnosis of coliform 
infection in acutely dysuric women. The New England journal of medicine 1982;307:463-8. 
209. Stark RP, Maki DG. Bacteriuria in the catheterized patient. What quantitative level of 
bacteriuria is relevant? The New England journal of medicine 1984;311:560-4. 
210. Walsh CA, Siddins A, Parkin K, Mukerjee C, Moore KH. Prevalence of "low-count" 
bacteriuria in female urinary incontinence versus continent female controls: a cross-
sectional study. International urogynecology journal 2011;22:1267-72. 
211. Nager CW, Brubaker L, Daneshgari F, et al. Design of the Value of Urodynamic Evaluation 
(ValUE) trial: A non-inferiority randomized trial of preoperative urodynamic investigations. 
Contemp Clin Trials 2009;30:531-9. 
212. Reid G, Burton JP. Urinary incontinence: Making sense of the urinary microbiota in clinical 
urology. Nat Rev Urol 2016. 
213. Ghyselinck J, Pfeiffer S, Heylen K, Sessitsch A, De Vos P. The effect of primer choice and 
short read sequences on the outcome of 16S rRNA gene based diversity studies. PloS one 
2013;8:e71360. 
214. Cullen TW, Schofield WB, Barry NA, et al. Gut microbiota. Antimicrobial peptide resistance 
mediates resilience of prominent gut commensals during inflammation. Science 
2015;347:170-5. 
- 425 - 
 
 
 
215. Kubinak JL, Stephens WZ, Soto R, et al. MHC variation sculpts individualized microbial 
communities that control susceptibility to enteric infection. Nature communications 
2015;6:8642. 
216. Jari Oksanen FGB, Roeland Kindt, Pierre Legendre, RB O’Hara, Gavin L Simpson, Peter 
Solymos, M Henry H Stevens, Helene Wagner. Package ‘vegan’. Community Ecology 
Package, Version, , 2.2-2.1. 2008. 
217. Subak LL, Wing R, West DS, et al. Weight loss to treat urinary incontinence in overweight 
and obese women. The New England journal of medicine 2009;360:481-90. 
218. Tworoger SS, Eliassen AH, Missmer SA, et al. Birthweight and body size throughout life in 
relation to sex hormones and prolactin concentrations in premenopausal women. Cancer 
Epidemiol Biomarkers Prev 2006;15:2494-501. 
219. De Pergola G, Maldera S, Tartagni M, Pannacciulli N, Loverro G, Giorgino R. Inhibitory 
effect of obesity on gonadotropin, estradiol, and inhibin B levels in fertile women. Obesity 
(Silver Spring) 2006;14:1954-60. 
220. Cipullo LM, Cosimato C, Filippelli A, et al. Pharmacological approach to overactive bladder 
and urge urinary incontinence in women: an overview. European journal of obstetrics, 
gynecology, and reproductive biology 2014;174:27-34. 
221. Robinson D, Cardozo L, Milsom I, et al. Oestrogens and overactive bladder. Neurourology 
and urodynamics 2014;33:1086-91. 
222. Robinson D, Toozs-Hobson P, Cardozo L. The effect of hormones on the lower urinary 
tract. Menopause Int 2013;19:155-62. 
223. Rahn DD, Carberry C, Sanses TV, et al. Vaginal estrogen for genitourinary syndrome of 
menopause: a systematic review. Obstet Gynecol 2014;124:1147-56. 
224. Yu Y, Shen Z, Zhou X, Chen S. Effects of steroid hormones on morphology and vascular 
endothelial growth factor expression in female bladder. Urology 2009;73:1210-7. 
- 426 - 
 
 
 
225. Matsubara S, Okada H, Shirakawa T, Gotoh A, Kuno T, Kamidono S. Estrogen levels 
influence beta-3-adrenoceptor-mediated relaxation of the female rat detrusor muscle. 
Urology 2002;59:621-5. 
226. Pak CY. Kidney stones. Lancet 1998;351:1797-801. 
227. Lieske JC, Pena de la Vega LS, Slezak JM, et al. Renal stone epidemiology in Rochester, 
Minnesota: an update. Kidney Int 2006;69:760-4. 
228. Curhan GC, Willett WC, Speizer FE, Stampfer MJ. Twenty-four-hour urine chemistries and 
the risk of kidney stones among women and men. Kidney Int 2001;59:2290-8. 
229. Flannigan R, Choy WH, Chew B, Lange D. Renal struvite stones--pathogenesis, 
microbiology, and management strategies. Nat Rev Urol 2014;11:333-41. 
230. Hugosson J, Grenabo L, Hedelin H, Lincolon K, Pettersson S. Chronic urinary tract infection 
and renal stones. Scand J Urol Nephrol 1989;23:61-6. 
231. Holmgren K, Danielson BG, Fellstrom B, Ljunghall S, Niklasson F, Wikstrom B. The relation 
between urinary tract infections and stone composition in renal stone formers. Scand J 
Urol Nephrol 1989;23:131-6. 
232. Wang X, Krambeck AE, Williams JC, Jr., et al. Distinguishing characteristics of idiopathic 
calcium oxalate kidney stone formers with low amounts of Randall's plaque. Clin J Am Soc 
Nephrol 2014;9:1757-63. 
233. Tavichakorntrakool R, Prasongwattana V, Sungkeeree S, et al. Extensive characterizations 
of bacteria isolated from catheterized urine and stone matrices in patients with 
nephrolithiasis. Nephrol Dial Transplant 2012;27:4125-30. 
234. Grover RK, Cheng J, Peng Y, et al. The costimulatory immunogen LPS induces the B-Cell 
clones that infiltrate transplanted human kidneys. Proc Natl Acad Sci U S A 
2012;109:6036-41. 
- 427 - 
 
 
 
235. Kaijser B, Hanson LA, Jodal U, Lidin-Janson G, Robbins JB. Frequency of E. coli K antigens in 
urinary-tract infections in children. Lancet 1977;1:663-6. 
236. Srivastava T, Winston MJ, Auron A, Alon US. Urine calcium/citrate ratio in children with 
hypercalciuric stones. Pediatr Res 2009;66:85-90. 
237. Cameron MA, Sakhaee K, Moe OW. Nephrolithiasis in children. Pediatr Nephrol 
2005;20:1587-92. 
238. Grases F, Millan A, Conte A. Production of calcium oxalate monohydrate, dihydrate or 
trihydrate. A comparative study. Urol Res 1990;18:17-20. 
239. Flythe JE, Rueda JF, Riscoe MK, Watnick S. Silicate nephrolithiasis after ingestion of 
supplements containing silica dioxide. Am J Kidney Dis 2009;54:127-30. 
240. Osborne CA, Jacob F, Lulich JP, et al. Canine silica urolithiasis. Risk factors, detection, 
treatment, and prevention. Vet Clin North Am Small Anim Pract 1999;29:213-30, xiii. 
241. Okada A, Nomura S, Higashibata Y, et al. Successful formation of calcium oxalate crystal 
deposition in mouse kidney by intraabdominal glyoxylate injection. Urol Res 2007;35:89-
99. 
242. Tittel AP, Heuser C, Ohliger C, Knolle PA, Engel DR, Kurts C. Kidney dendritic cells induce 
innate immunity against bacterial pyelonephritis. J Am Soc Nephrol 2011;22:1435-41. 
243. Hains DS, Chen X, Saxena V, et al. Carbonic anhydrase 2 deficiency leads to increased 
pyelonephritis susceptibility. Am J Physiol Renal Physiol 2014;307:F869-80. 
244. Nacaroglu HT, Demircin G, Bulbul M, Erdogan O, Akyuz SG, Caltik A. The association 
between urinary tract infection and idiopathic hypercalciuria in children. Ren Fail 
2013;35:327-32. 
245. Balestracci A, Battaglia LM, Toledo I, Martin SM, Wainsztein RE. Idiopathic hypercalciuria 
in children with urinary tract infection. Arch Argent Pediatr 2014;112:428-33. 
- 428 - 
 
 
 
246. Dong Q, Brulc JM, Iovieno A, et al. Diversity of bacteria at healthy human conjunctiva. 
Invest Ophthalmol Vis Sci 2011;52:5408-13. 
247. Cisar JO, Xu DQ, Thompson J, Swaim W, Hu L, Kopecko DJ. An alternative interpretation of 
nanobacteria-induced biomineralization. Proc Natl Acad Sci U S A 2000;97:11511-5. 
248. Silva TM, Costa EA, Paixao TA, Tsolis RM, Santos RL. Laboratory animal models for 
brucellosis research. J Biomed Biotechnol 2011;2011:518323. 
249. Velasco J, Romero C, Lopez-Goni I, Leiva J, Diaz R, Moriyon I. Evaluation of the relatedness 
of Brucella spp. and Ochrobactrum anthropi and description of Ochrobactrum 
intermedium sp. nov., a new species with a closer relationship to Brucella spp. Int J Syst 
Bacteriol 1998;48 Pt 3:759-68. 
250. Qasimyar H, Hoffman MA, Simonsen KA. Late-onset Ochrobactrum anthropi sepsis in a 
preterm neonate with congenital urinary tract abnormalities. J Perinatol 2014;34:489-91. 
251. Wiessner JH, Henderson JD, Jr., Sohnle PG, Mandel NS, Mandel GS. The effect of crystal 
structure on mouse lung inflammation and fibrosis. Am Rev Respir Dis 1988;138:445-50. 
252. Fang HH, Chan KY, Xu LC. Quantification of bacterial adhesion forces using atomic force 
microscopy (AFM). J Microbiol Methods 2000;40:89-97. 
253. Chutipongtanate S, Sutthimethakorn S, Chiangjong W, Thongboonkerd V. Bacteria can 
promote calcium oxalate crystal growth and aggregation. J Biol Inorg Chem 2013;18:299-
308. 
254. De Ferrari ME, Macaluso M, Brunati C, Pozzoli R, Colussi G. Hypocitraturia and Ureaplasma 
urealyticum urinary tract infection in patients with idiopathic calcium nephrolithiasis. 
Nephrol Dial Transplant 1996;11:1185. 
255. Nilekani S, SivaRaman C. Purification and properties of citrate lyase from Escherichia coli. 
Biochemistry 1983;22:4657-63. 
- 429 - 
 
 
 
256. Ghazali A, Fuentes V, Desaint C, et al. Low bone mineral density and peripheral blood 
monocyte activation profile in calcium stone formers with idiopathic hypercalciuria. J Clin 
Endocrinol Metab 1997;82:32-8. 
257. Huang HS, Ma MC, Chen CF, Chen J. Lipid peroxidation and its correlations with urinary 
levels of oxalate, citric acid, and osteopontin in patients with renal calcium oxalate stones. 
Urology 2003;62:1123-8. 
258. Canales BK, Anderson L, Higgins L, et al. Proteome of human calcium kidney stones. 
Urology 2010;76:1017 e13-20. 
259. Mulay SR, Kulkarni OP, Rupanagudi KV, et al. Calcium oxalate crystals induce renal 
inflammation by NLRP3-mediated IL-1beta secretion. J Clin Invest 2013;123:236-46. 
260. Rhee E, Santiago L, Park E, Lad P, Bellman GC. Urinary IL-6 is elevated in patients with 
urolithiasis. J Urol 1998;160:2284-8. 
261. Suen JL, Liu CC, Lin YS, Tsai YF, Juo SH, Chou YH. Urinary chemokines/cytokines are 
elevated in patients with urolithiasis. Urol Res 2010;38:81-7. 
262. Mushtaq S, Siddiqui AA, Naqvi ZA, et al. Identification of myeloperoxidase, alpha-defensin 
and calgranulin in calcium oxalate renal stones. Clin Chim Acta 2007;384:41-7. 
263. Lanter BB, Sauer K, Davies DG. Bacteria present in carotid arterial plaques are found as 
biofilm deposits which may contribute to enhanced risk of plaque rupture. MBio 
2014;5:e01206-14. 
264. Gibson FC, 3rd, Hong C, Chou HH, et al. Innate immune recognition of invasive bacteria 
accelerates atherosclerosis in apolipoprotein E-deficient mice. Circulation 2004;109:2801-
6. 
265. Noviello S, Gallo R, Kelly M, et al. Laboratory-acquired brucellosis. Emerg Infect Dis 
2004;10:1848-50. 
- 430 - 
 
 
 
266. Olle-Goig JE, Canela-Soler J. An outbreak of Brucella melitensis infection by airborne 
transmission among laboratory workers. Am J Public Health 1987;77:335-8. 
267. Vila A, Pagella H, Vera Bello G, Vicente A. Brucella suis bacteremia misidentified as 
Ochrobactrum anthropi by the VITEK 2 system. J Infect Dev Ctries 2016;10:432-6. 
268. Ariza J, Pigrau C, Canas C, et al. Current understanding and management of chronic 
hepatosplenic suppurative brucellosis. Clin Infect Dis 2001;32:1024-33. 
269. D'Anastasio R, Zipfel B, Moggi-Cecchi J, Stanyon R, Capasso L. Possible brucellosis in an 
early hominin skeleton from sterkfontein, South Africa. PloS one 2009;4:e6439. 
270. Kay GL, Sergeant MJ, Giuffra V, et al. Recovery of a medieval Brucella melitensis genome 
using shotgun metagenomics. MBio 2014;5:e01337-14. 
271. Fredricks DN, Fiedler TL, Marrazzo JM. Molecular identification of bacteria associated with 
bacterial vaginosis. The New England journal of medicine 2005;353:1899-911. 
272. Srinivasan S, Hoffman NG, Morgan MT, et al. Bacterial communities in women with 
bacterial vaginosis: high resolution phylogenetic analyses reveal relationships of 
microbiota to clinical criteria. PloS one 2012;7:e37818. 
273. Turovskiy Y, Sutyak Noll K, Chikindas ML. The aetiology of bacterial vaginosis. J Appl 
Microbiol 2011;110:1105-28. 
274. Xu W, Yang L, Lee P, et al. Mini-review: perspective of the microbiome in the pathogenesis 
of urothelial carcinoma. Am J Clin Exp Urol 2014;2:57-61. 
275. Ahmed A, Earl J, Retchless A, et al. Comparative genomic analyses of 17 clinical isolates of 
Gardnerella vaginalis provide evidence of multiple genetically isolated clades consistent 
with subspeciation into genovars. J Bacteriol 2012;194:3922-37. 
- 431 - 
 
 
 
276. Lewis WG, Robinson LS, Gilbert NM, Perry JC, Lewis AL. Degradation, foraging, and 
depletion of mucus sialoglycans by the vagina-adapted Actinobacterium Gardnerella 
vaginalis. J Biol Chem 2013;288:12067-79. 
277. Oshima K, Hisamatsu S, Toh H, et al. Complete Genome Sequence of Gardnerella vaginalis 
Strain JCM 11026T, Isolated from Vaginal Tracts of Women. Genome Announc 2015;3. 
278. Schuyler JA, Chadwick SG, Mordechai E, Adelson ME, Gygax SE, Hilbert DW. Draft Genome 
Sequence of a Metronidazole-Resistant Gardnerella vaginalis Isolate. Genome Announc 
2015;3. 
279. Schuyler JA, Mordechai E, Adelson ME, Gygax SE, Hilbert DW. Draft Genome Sequence of 
a Metronidazole-Resistant Derivative of Gardnerella vaginalis Strain ATCC 14019. Genome 
Announc 2015;3. 
280. Yeoman CJ, Yildirim S, Thomas SM, et al. Comparative genomics of Gardnerella vaginalis 
strains reveals substantial differences in metabolic and virulence potential. PloS one 
2010;5:e12411. 
281. Pleckaityte M, Zilnyte M, Zvirbliene A. Insights into the CRISPR/Cas system of Gardnerella 
vaginalis. BMC microbiology 2012;12:301. 
282. Baugher JL, Durmaz E, Klaenhammer TR. Spontaneously induced prophages in 
Lactobacillus gasseri contribute to horizontal gene transfer. Applied and environmental 
microbiology 2014;80:3508-17. 
283. Ojala T, Kankainen M, Castro J, et al. Comparative genomics of Lactobacillus crispatus 
suggests novel mechanisms for the competitive exclusion of Gardnerella vaginalis. BMC 
genomics 2014;15:1070. 
284. Clokie MR, Millard AD, Letarov AV, Heaphy S. Phages in nature. Bacteriophage 2011;1:31-
45. 
- 432 - 
 
 
 
285. Roberts AP, Kreth J. The impact of horizontal gene transfer on the adaptive ability of the 
human oral microbiome. Frontiers in cellular and infection microbiology 2014;4:124. 
286. Martin R, Escobedo S, Suarez JE. Induction, structural characterization, and genome 
sequence of Lv1, a prophage from a human vaginal Lactobacillus jensenii strain. Int 
Microbiol 2010;13:113-21. 
287. Huddleston JR. Horizontal gene transfer in the human gastrointestinal tract: potential 
spread of antibiotic resistance genes. Infect Drug Resist 2014;7:167-76. 
288. Abeles SR, Pride DT. Molecular bases and role of viruses in the human microbiome. 
Journal of molecular biology 2014;426:3892-906. 
289. Hannigan GD, Meisel JS, Tyldsley AS, et al. The human skin double-stranded DNA virome: 
topographical and temporal diversity, genetic enrichment, and dynamic associations with 
the host microbiome. MBio 2015;6:e01578-15. 
290. Ogilvie LA, Jones BV. The human gut virome: a multifaceted majority. Front Microbiol 
2015;6:918. 
291. Overbeek R, Olson R, Pusch GD, et al. The SEED and the Rapid Annotation of microbial 
genomes using Subsystems Technology (RAST). Nucleic acids research 2014;42:D206-14. 
292. Van Domselaar GH, Stothard P, Shrivastava S, et al. BASys: a web server for automated 
bacterial genome annotation. Nucleic acids research 2005;33:W455-9. 
293. Grissa I, Vergnaud G, Pourcel C. The CRISPRdb database and tools to display CRISPRs and 
to generate dictionaries of spacers and repeats. BMC bioinformatics 2007;8:172. 
294. Jordan GE, Piel WH. PhyloWidget: web-based visualizations for the tree of life. 
Bioinformatics 2008;24:1641-2. 
295. Thompson JD, Gibson TJ, Higgins DG. Multiple sequence alignment using ClustalW and 
ClustalX. Curr Protoc Bioinformatics 2002;Chapter 2:Unit 2 3. 
- 433 - 
 
 
 
296. Beaulieu JO, JC. corHMM: hidden Markov models in R, version 1. 2012. 
297. Kumar S, Doerrler WT. Members of the conserved DedA family are likely membrane 
transporters and are required for drug resistance in Escherichia coli. Antimicrob Agents 
Chemother 2014;58:923-30. 
298. Gelber SE, Aguilar JL, Lewis KL, Ratner AJ. Functional and phylogenetic characterization of 
Vaginolysin, the human-specific cytolysin from Gardnerella vaginalis. J Bacteriol 
2008;190:3896-903. 
299. Wren BW, Stabler RA, Das SS, et al. Characterization of a haemolysin from Mycobacterium 
tuberculosis with homology to a virulence factor of Serpulina hyodysenteriae. 
Microbiology 1998;144 ( Pt 5):1205-11. 
300. Schellenberg JJ, Paramel Jayaprakash T, Withana Gamage N, Patterson MH, Vaneechoutte 
M, Hill JE. Gardnerella vaginalis Subgroups Defined by cpn60 Sequencing and Sialidase 
Activity in Isolates from Canada, Belgium and Kenya. PloS one 2016;11:e0146510. 
301. Castro J, Alves P, Sousa C, et al. Using an in-vitro biofilm model to assess the virulence 
potential of bacterial vaginosis or non-bacterial vaginosis Gardnerella vaginalis isolates. Sci 
Rep 2015;5:11640. 
302. Hickey RJ, Forney LJ. Gardnerella vaginalis does not always cause bacterial vaginosis. J 
Infect Dis 2014;210:1682-3. 
303. Zhou X, Brown CJ, Abdo Z, et al. Differences in the composition of vaginal microbial 
communities found in healthy Caucasian and black women. The ISME journal 2007;1:121-
33. 
304. Ma B, Forney LJ, Ravel J. Vaginal microbiome: rethinking health and disease. Annu Rev 
Microbiol 2012;66:371-89. 
305. Anukam KC, Macklaim JM, Gloor GB, et al. Genome sequence of Lactobacillus pentosus 
KCA1: vaginal isolate from a healthy premenopausal woman. PloS one 2013;8:e59239. 
- 434 - 
 
 
 
306. Garcia LS IH, ed. Clinical microbiology procedures handbook. 3rd ed. Washington, DC: 
ASM Press; 2010. 
307. Clayson D, Wild D, Doll H, Keating K, Gondek K. Validation of a patient-administered 
questionnaire to measure the severity and bothersomeness of lower urinary tract 
symptoms in uncomplicated urinary tract infection (UTI): the UTI Symptom Assessment 
questionnaire. BJU international 2005;96:350-9. 
308. Stein G, Funfstuck R. [Asymptomatic bacteriuria]. Med Klin (Munich) 2000;95:195-200. 
309. Whalley P. Bacteriuria of pregnancy. Am J Obstet Gynecol 1967;97:723-38. 
310. Hill JB, Sheffield JS, McIntire DD, Wendel GD, Jr. Acute pyelonephritis in pregnancy. Obstet 
Gynecol 2005;105:18-23. 
311. Fisher M. Guide to clinical preventive services. Baltimore, Maryland: Williams & Wilkins; 
1989. 
312. ACOG educational bulletin. Antimicrobial therapy for obstetric patients. Number 245, 
March 1998 (replaces no. 117, June 1988). American College of Obstetricians and 
Gynecologists. Int J Gynaecol Obstet 1998;61:299-308. 
313. Levinson WJ, Ernest Medical microbiology and immunology. New York: Lange Medical 
Books/McGraw-Hill; 2000. 
314. Madigan MTB, Thomas D Brock biology of microorganisms. San Francisco, CA Pearson 
Education; 2009. 
315. Lakeman MM, Roovers JP. Urinary tract infections in women with urogynaecological 
symptoms. Curr Opin Infect Dis 2016;29:92-7. 
316. Woese CR, Olsen GJ, Ibba M, Soll D. Aminoacyl-tRNA synthetases, the genetic code, and 
the evolutionary process. Microbiol Mol Biol Rev 2000;64:202-36. 
- 435 - 
 
 
 
317. Lotte R, Lotte L, Ruimy R. Actinotignum schaalii (formerly Actinobaculum schaalii): a newly 
recognized pathogen-review of the literature. Clin Microbiol Infect 2015. 
318. Romero R, Hassan SS, Gajer P, et al. The vaginal microbiota of pregnant women who 
subsequently have spontaneous preterm labor and delivery and those with a normal 
delivery at term. Microbiome 2014;2:18. 
319. Schieve LA, Handler A, Hershow R, Persky V, Davis F. Urinary tract infection during 
pregnancy: its association with maternal morbidity and perinatal outcome. Am J Public 
Health 1994;84:405-10. 
320. Karstens L, Asquith M, Davin S, et al. Does the Urinary Microbiome Play a Role in Urgency 
Urinary Incontinence and Its Severity? Frontiers in cellular and infection microbiology 
2016;6:78. 
321. Doherty GM. Chapter 5. Postoperative Complications. In: Doherty GM, ed. CURRENT 
Diagnosis &amp; Treatment: Surgery, 13e. New York, NY: The McGraw-Hill Companies; 
2010. 
322. Hooker EA. Chapter 90. Complications of General Surgical Procedures. In: Tintinalli JE, 
Stapczynski JS, Ma OJ, et al., eds. Tintinalli's Emergency Medicine: A Comprehensive Study 
Guide, 7e. New York, NY: The McGraw-Hill Companies; 2011. 
323. Weinstein RA. Chapter 131. Health Care–Associated Infections. In: Longo DL, Fauci AS, 
Kasper DL, Hauser SL, Jameson JL, Loscalzo J, eds. Harrison's Principles of Internal 
Medicine, 18e. New York, NY: The McGraw-Hill Companies; 2012. 
324. Wieslander CK, Marshall DD. Chapter 45. Perioperative, Intraoperative, &amp; 
Postoperative Complications in Gynecologic Surgery. In: DeCherney AH, Nathan L, Laufer 
N, Roman AS, eds. CURRENT Diagnosis &amp; Treatment: Obstetrics &amp; Gynecology, 
11e. New York, NY: The McGraw-Hill Companies; 2013. 
325. Leffler DA, Lamont JT. Clostridium difficile infection. The New England journal of medicine 
2015;372:1539-48. 
- 436 - 
 
 
 
326. Siddiqui H, Lagesen K, Nederbragt AJ, Jeansson SL, Jakobsen KS. Alterations of microbiota 
in urine from women with interstitial cystitis. BMC microbiology 2012;12:205. 
327. Willner D, Low S, Steen JA, et al. Single clinical isolates from acute uncomplicated urinary 
tract infections are representative of dominant in situ populations. mBio 2014;5:e01064-
13. 
328. Nasioudis D, Linhares IM, Ledger WJ, Witkin SS. Bacterial vaginosis: a critical analysis of 
current knowledge. BJOG 2017;124:61-9. 
329. Kitahara K, Miyazaki K. Revisiting bacterial phylogeny: Natural and experimental evidence 
for horizontal gene transfer of 16S rRNA. Mob Genet Elements 2013;3:e24210. 
330. Kumar N, Lad G, Giuntini E, et al. Bacterial genospecies that are not ecologically coherent: 
population genomics of Rhizobium leguminosarum. Open Biol 2015;5:140133. 
331. Martins GT. Computing and visualizing PCA in R. 2013. 
 
 
 
 
- 437 - 
 
 
VITA 
The author, Krystal Thomas-White, was born in Atascadero, CA on December 30, 1984 
to Kimber Hoey and Steven White, and grew up in Davis, CA with her mother and stepfather, 
Matt Hoey. In 2012, she married Patrick Thomas. She attended California Polytechnic State 
University in San Luis Obispo, California, where he earned a Bachelor’s of Science, Microbiology 
in June 2008. After graduation, Krystal trained in the human genetics laboratory of Dr. Pui Kwok 
at the University of California, San Francisco. In August 2011, Krystal joined the Department of 
Microbiology and Immunology’s Doctoral Program at the Loyola University Chicago Stritch 
School of Medicine in Maywood, Illinois.  
In 2012, Krystal joined the laboratory of Dr. Alan Wolfe, where she studied the 
microbiome of the female bladder. During her studies, she became a member of the Loyola 
Urinary Education and Research Collaborative (LUEREC), chaired by Drs. Wolfe, Brubaker (MD), 
and Mueller (MD). As part of her graduate work, she also studied comparative genomics at the 
Wellcome Trust Genome Campus (Hinxton, UK) in the lab of Dr. Trevor Lawley. Krystal’s 
research on the differences in microbial composition of the female urinary bladder and the 
vagina during urgency urinary incontinence was supported by the Arthur J. Schmitt Dissertation 
Fellowship and an investigator initiated grant from the Kimberly Clark Corporation. Krystal plans 
to continue pursuing research while living in Menlo Park, California.  
 
